Unnamed: 0 stringlengths 3 8 | Date stringlengths 23 23 | Article_title stringlengths 1 250 | Stock_symbol stringlengths 1 5 | Url stringlengths 44 135 | Publisher stringclasses 1 value | Author stringclasses 1 value | Article stringlengths 1 343k | Lsa_summary stringlengths 3 53.9k | Luhn_summary stringlengths 1 53.9k | Textrank_summary stringlengths 1 53.9k | Lexrank_summary stringlengths 1 53.9k |
|---|---|---|---|---|---|---|---|---|---|---|---|
24400.0 | 2020-09-11 00:00:00 UTC | Is AbbVie Stock a Buy? | ABBV | https://www.nasdaq.com/articles/is-abbvie-stock-a-buy-2020-09-11 | nan | nan | As the youngest of the pharma juggernauts, AbbVie (NYSE: ABBV) is an exciting company because of its impressive size and lineup of popular pharmaceutical and biological products. Since its spinoff from Abbott Laboratories (NYSE: ABT) in 2013, AbbVie has built an attractive portfolio of drugs while exploring promising programs in oncology, immunology, neuroscience, and more. AbbVie is also attractive to investors thanks to its profitability, consistently growing revenues, and a meaty trailing dividend yield of 5.1%.
But there are two issues which should give potential investors pause. First, AbbVie's $63 billion acquisition of Allergan was finalized in May, but the deal's impact on AbbVie's bottom line is far from clear. Second, there is the key question of how the company will replace flagging revenues from its best-selling drug Humira, which has faced increasing competition from biosimilar products since its patent protections expired in 2016. This question is of immediate concern to the company, as its international revenues from sales of the drug collapsed by 19.9% in the second quarter compared to 2019 on top of more modest declines in 2018.
In my view, the Allergan deal will be instrumental in addressing AbbVie's challenges with Humira. Let's investigate in closer detail how the merger could save AbbVie's day.
Image source: Getty Images.
Allergan is already boosting AbbVie's revenues
Before being acquired, Allergan produced profitable drugs like Botox as well as eye care and women's health products. AbbVie expects to make a total of $48 billion in total revenue this year, including sales from its new Allergan products. Of this $48 billion, the company expects that sales from its blockbuster biologic, Humira, will account for approximately 40%, which works out to be $19.2 billion, or around $4.8 billion per quarter. This is a drop from Humira's peak sales in 2018, when it brought in just over $19.9 billion over the entire year. Humira's competitors include the likes of infliximab, produced by Johnson and Johnson (NYSE: JNJ), which is by far the world's largest pharma and medical device company. But the real culprit for declining revenues is a bevy of off-patent biosimilars which undercut its price. From 2021 to 2026, Humira's revenues will shrink with a compound annual growth rate (CAGR) of negative 12.5%, according to Market Insight Reports .
How realistic is it for Allergan's sales to make up for Humira's decline? As it turns out, it's quite possible. According to AbbVie's second quarter earnings report, Allergan's portfolio brought in roughly $1.73 billion. This number is deceptively low, however, as the Allergan deal closed on May 8 and the quarter ended on June 30. In other words, Allergan's revenues are only reflected for about half of the quarter. If we double the $1.76 billion to estimate for a full quarter, AbbVie would be earning about $3.52 billion from Allergan.
We'll need to wait for the third quarter earnings report in late October to evaluate Allergan products' revenue contributions over a full quarter. Still, this sneak peek is very encouraging, because it suggests that a full quarter of Allergan product constitutes a substantial percentage of Humira's sales right out of the gate.
AbbVie's pipeline will make 2021 exciting for investors
Given that AbbVie is actively developing a plethora of new drugs while continuing development of Allergan's products, other streams of income will soon start to trickle in to make up for Humira's tapering. Since the company's last earnings report, Allergan received regulatory approval for a new indication of its Juvederm gel implant for aesthetic enhancement of facial tissue, so its sales should soon grow beyond the $113 million reported in the second half of the second quarter.
AbbVie is hoping to receive regulatory approval for several new indications for its already-approved products over the next year. In particular, AbbVie submitted the regulatory paperwork for three new indications for its arthritis therapeutic, Rinvoq, with the goal of offering the drug to a wider set of arthritis patients. The company is also seeking two approvals for a pair of new therapies created from a combination of its oncology drugs, Imbruvica and Venclexta. One of the regulatory submissions pertains to using the combination for mantle cell lymphoma (MCL) while the other aims to treat chronic lymphocytic leukemia (CLL). Although it might take a few years for these projects to eclipse Humira's present-day revenues, they should help ensure that the company's future is stable .
SPY data by YCharts
AbbVie is set up for success
In short, between the fruits of its Allergan acquisition and a substantial pipeline, AbbVie's stock is on track for modest growth. I think that AbbVie is worth buying if you're looking for a stalwart pharmaceutical company whose value will slowly appreciate thanks to its intelligently curated and growing sales base. Though there is no guarantee that the company will continue to increase its dividend over time, AbbVie's management has made it a priority so far.
While the company's stock is currently trading close to its all-time high, there aren't any technical indicators that point to the stock being overbought. On the basis of its trailing price to earnings (P/E) ratio of 20.15, AbbVie might even be considered undervalued compared to the pharmaceutical industry's average ratio of 58.18. Unless you're a diehard bargain hunter, now looks like a great time to buy.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of August 1, 2020
Alex Carchidi has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | As the youngest of the pharma juggernauts, AbbVie (NYSE: ABBV) is an exciting company because of its impressive size and lineup of popular pharmaceutical and biological products. Since its spinoff from Abbott Laboratories (NYSE: ABT) in 2013, AbbVie has built an attractive portfolio of drugs while exploring promising programs in oncology, immunology, neuroscience, and more. AbbVie is also attractive to investors thanks to its profitability, consistently growing revenues, and a meaty trailing dividend yield of 5.1%. | AbbVie expects to make a total of $48 billion in total revenue this year, including sales from its new Allergan products. According to AbbVie's second quarter earnings report, Allergan's portfolio brought in roughly $1.73 billion. As the youngest of the pharma juggernauts, AbbVie (NYSE: ABBV) is an exciting company because of its impressive size and lineup of popular pharmaceutical and biological products. | AbbVie expects to make a total of $48 billion in total revenue this year, including sales from its new Allergan products. AbbVie's pipeline will make 2021 exciting for investors Given that AbbVie is actively developing a plethora of new drugs while continuing development of Allergan's products, other streams of income will soon start to trickle in to make up for Humira's tapering. SPY data by YCharts AbbVie is set up for success In short, between the fruits of its Allergan acquisition and a substantial pipeline, AbbVie's stock is on track for modest growth. | First, AbbVie's $63 billion acquisition of Allergan was finalized in May, but the deal's impact on AbbVie's bottom line is far from clear. According to AbbVie's second quarter earnings report, Allergan's portfolio brought in roughly $1.73 billion. As the youngest of the pharma juggernauts, AbbVie (NYSE: ABBV) is an exciting company because of its impressive size and lineup of popular pharmaceutical and biological products. |
24401.0 | 2020-09-08 00:00:00 UTC | S.Korea's Celltrion to begin commercial production of COVID-19 antibody drug | ABBV | https://www.nasdaq.com/articles/s.koreas-celltrion-to-begin-commercial-production-of-covid-19-antibody-drug-2020-09-08 | nan | nan | By Sangmi Cha
SEOUL, Sept 8 (Reuters) - South Korea's Celltrion Inc 068270.KS will begin commercial production of its experimental treatment for COVID-19 this month, it said on Tuesday, as it pushes ahead with clinical trials of the antibody drug.
The company said it planned to make a request soon to regulators for emergency use authorisation of the drug, but that it would start mass production - likely to amount to around 1 million doses - before receiving that approval.
The treatment became the country's first COVID-19 antibody drug to be tested on humans after receiving regulatory approval in July for clinical trials.
"We have confirmed the safety of the antiviral antibody drug in the process of the local Phase I clinical trial," Kwon Ki-sung, head of Celltrion's R&D unit, told Reuters.
Celltrion completed a Phase I trial on 32 volunteers in the country and is enrolling an additional nine participants for another Phase I study before moving on to later stage trials, for which regulatory reviews are already underway.
The company is separately conducting overseas human trials of its treatment in the United Kingdom, which will be followed by global second and third stage trials in patients with mild and moderate symptoms.
Shares of Celltrion surged as much as 5.6% on Tuesday, while the broader KOSPI .KS11 gained 0.7%.
Other companies developing potential COVID-19 treatments include Eli Lilly and Co LLY.N, Regeneron Pharmaceuticals Inc REGN.O and AbbVie ABBV.N.
(Reporting by Sangmi Cha, Additional reporting by Joori Roh; Editing by Miyoung Kim and Mark Potter)
((Sangmi.Cha@thomsonreuters.com; +82 2 3704 5646; Reuters Messaging: sangmi.cha.thomsonreuters.com@reuters.net))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Other companies developing potential COVID-19 treatments include Eli Lilly and Co LLY.N, Regeneron Pharmaceuticals Inc REGN.O and AbbVie ABBV.N. By Sangmi Cha SEOUL, Sept 8 (Reuters) - South Korea's Celltrion Inc 068270.KS will begin commercial production of its experimental treatment for COVID-19 this month, it said on Tuesday, as it pushes ahead with clinical trials of the antibody drug. The company said it planned to make a request soon to regulators for emergency use authorisation of the drug, but that it would start mass production - likely to amount to around 1 million doses - before receiving that approval. | Other companies developing potential COVID-19 treatments include Eli Lilly and Co LLY.N, Regeneron Pharmaceuticals Inc REGN.O and AbbVie ABBV.N. By Sangmi Cha SEOUL, Sept 8 (Reuters) - South Korea's Celltrion Inc 068270.KS will begin commercial production of its experimental treatment for COVID-19 this month, it said on Tuesday, as it pushes ahead with clinical trials of the antibody drug. The treatment became the country's first COVID-19 antibody drug to be tested on humans after receiving regulatory approval in July for clinical trials. | Other companies developing potential COVID-19 treatments include Eli Lilly and Co LLY.N, Regeneron Pharmaceuticals Inc REGN.O and AbbVie ABBV.N. By Sangmi Cha SEOUL, Sept 8 (Reuters) - South Korea's Celltrion Inc 068270.KS will begin commercial production of its experimental treatment for COVID-19 this month, it said on Tuesday, as it pushes ahead with clinical trials of the antibody drug. "We have confirmed the safety of the antiviral antibody drug in the process of the local Phase I clinical trial," Kwon Ki-sung, head of Celltrion's R&D unit, told Reuters. | Other companies developing potential COVID-19 treatments include Eli Lilly and Co LLY.N, Regeneron Pharmaceuticals Inc REGN.O and AbbVie ABBV.N. The treatment became the country's first COVID-19 antibody drug to be tested on humans after receiving regulatory approval in July for clinical trials. "We have confirmed the safety of the antiviral antibody drug in the process of the local Phase I clinical trial," Kwon Ki-sung, head of Celltrion's R&D unit, told Reuters. |
24402.0 | 2020-09-04 00:00:00 UTC | AbbVie Partners With I-Mab for Cancer Drug | ABBV | https://www.nasdaq.com/articles/abbvie-partners-with-i-mab-for-cancer-drug-2020-09-04 | nan | nan | AbbVie (NYSE: ABBV) has signed a collaboration agreement with Chinese clinical-stage biotechnology company I-Mab (NASDAQ: IMAB) for the development and commercialization of lemzoparlimab, a monoclonal antibody in early-stage clinical testing that could be used to treat various cancers. The antibody targets CD47, a protein that is overexpressed on the surface of many types of cancer cells and delivers a "don't eat me" signal to the body's immune system.
Under the terms of the agreement, AbbVie will pay I-Mab $200 million now and up to $1.74 billion in milestone payments in the future. AbbVie will get an exclusive license to commercialize lemzoparlimab globally excluding greater China, paying tiered royalties in low- to mid-teen percentages of sales. I-Mab will have the right to commercialize the drug in mainland China, Hong Kong, and Macau.
Image source: Getty Images.
The collaboration potentially involves exploring the combination of lemzoparlimab with AbbVie's blood cancer drug Venclexta. On a conference call with analysts, I-Mab said that AbbVie will have the option of collaborating with the biotech on other CD47 antibody treatments, including two preclinical drug candidates in I-Mab's pipeline with potential deal value of another $1 billion. On the call, I-Mab said, "In terms of total deal value, we believe that this is the largest out-licensing and global partnership transaction ever executed by a Chinese biotech company."
Drugs targeting CD47 are a hot item in immuno-oncology now, with Gilead Sciences paying a stunning $4.9 billion to acquire small biotech Forty Seven earlier this year. I-Mab believes lemzoparlimab is superior to its competition because it minimizes binding to red blood cells, a problem with other CD47 antibodies. This may be the reason AbbVie passed up a deal with domestic biotech Trillium (NASDAQ: TRIL), whose shares fell on the news.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of August 1, 2020
Jim Crumly owns shares of AbbVie and Gilead Sciences. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie (NYSE: ABBV) has signed a collaboration agreement with Chinese clinical-stage biotechnology company I-Mab (NASDAQ: IMAB) for the development and commercialization of lemzoparlimab, a monoclonal antibody in early-stage clinical testing that could be used to treat various cancers. AbbVie will get an exclusive license to commercialize lemzoparlimab globally excluding greater China, paying tiered royalties in low- to mid-teen percentages of sales. Under the terms of the agreement, AbbVie will pay I-Mab $200 million now and up to $1.74 billion in milestone payments in the future. | AbbVie (NYSE: ABBV) has signed a collaboration agreement with Chinese clinical-stage biotechnology company I-Mab (NASDAQ: IMAB) for the development and commercialization of lemzoparlimab, a monoclonal antibody in early-stage clinical testing that could be used to treat various cancers. The collaboration potentially involves exploring the combination of lemzoparlimab with AbbVie's blood cancer drug Venclexta. Under the terms of the agreement, AbbVie will pay I-Mab $200 million now and up to $1.74 billion in milestone payments in the future. | AbbVie (NYSE: ABBV) has signed a collaboration agreement with Chinese clinical-stage biotechnology company I-Mab (NASDAQ: IMAB) for the development and commercialization of lemzoparlimab, a monoclonal antibody in early-stage clinical testing that could be used to treat various cancers. On a conference call with analysts, I-Mab said that AbbVie will have the option of collaborating with the biotech on other CD47 antibody treatments, including two preclinical drug candidates in I-Mab's pipeline with potential deal value of another $1 billion. See the 10 stocks *Stock Advisor returns as of August 1, 2020 Jim Crumly owns shares of AbbVie and Gilead Sciences. | The collaboration potentially involves exploring the combination of lemzoparlimab with AbbVie's blood cancer drug Venclexta. AbbVie (NYSE: ABBV) has signed a collaboration agreement with Chinese clinical-stage biotechnology company I-Mab (NASDAQ: IMAB) for the development and commercialization of lemzoparlimab, a monoclonal antibody in early-stage clinical testing that could be used to treat various cancers. Under the terms of the agreement, AbbVie will pay I-Mab $200 million now and up to $1.74 billion in milestone payments in the future. |
24403.0 | 2020-09-04 00:00:00 UTC | BUZZ-U.S. STOCKS ON THE MOVE-Domo Inc, CureVac NV, Cooper Companies, Wayfair Inc | ABBV | https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-domo-inc-curevac-nv-cooper-companies-wayfair-inc-2020-09-04 | nan | nan | Eikon search string for individual stock moves: STXBZ
The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi
The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh
Wall Street's main indexes extended declines on Friday, with the Nasdaq on track for its worst two-day fall since March as technology stocks sold off again, overshadowing data showing a steeper-than-expected drop in the August unemployment rate. .N
At 11:30 a.m. ET, the Dow Jones Industrial Average .DJI was down 1.92% at 27,749.53. The S&P 500 .SPX was down 2.24% at 3,377.83 and the Nasdaq Composite .IXIC was down 3.09% at 11,104.578. The top three S&P 500 .PG.INX percentage gainers: ** Cooper Companies Inc , up 5.1% ** Capital One Financial Corp , up 3.2% ** Coty Inc , up 2.9% The top three S&P 500 .PL.INX percentage losers: ** Paypal Holdings Inc , down 7.8% ** Abiomed Inc , down 7.1% ** Nvidia Corp , down 6.8% The top three NYSE .PG.N percentage gainers: ** Polymet Mining PLM.N, up 55.4% ** FBL Financial Group Inc , up 33.6% ** Flotek Industries Inc , up 12% The top three NYSE .PL.N percentage losers: ** Hovnanian Enterprises Inc , down 15.7% ** Garret Motion Inc , down 15.3% ** Oxford Industries Inc , down 14.7% The top three Nasdaq .PG.O percentage gainers: ** Vivopower International Plc , up 35.2% ** Addex Therapeutics Ltd , up 23% ** National Cine Media Inc , up 21.7% The top three Nasdaq .PL.O percentage losers: ** Syros Pharmaceuticals Inc SYRS.O, down 17.7% ** Fuwei Films Co Ltd FFHL.O, down 17.3% ** Heritage Global Inc , down 16.7% ** Broadcom Inc AVGO.O: up 2.0%
BUZZ-Street View: Broadcom shows 'meaningful' growth ahead of 5G ramp-up cycle ** I-Mab IMAB.O: up 4.4% BUZZ-I-Mab up on licensing deal with Chinese firm's lead cancer drug ** AnPac Bio-Medical Science Co Ltd ANPC.O: up 14.5%
BUZZ-Rises on positive data from cancer monitoring technology study ** DPW Holdings Inc DPW.A: up 17.2%
BUZZ-Gains as unit expects orders for EV charger products from Q4 ** PolyMet Mining Corp PLM.N: up 55.0%
BUZZ-Jumps as court finds no irregularities in NorthMet water permit issue ** Tesla Inc TSLA.O: down 4.2%
BUZZ-Set to fall for fourth straight session; insiders offload stake ** Kensington Capital Acquisition KCAC.N: up 11.8%
BUZZ-Jumps after huge gain on EV SPAC deal ** Apple Inc AAPL.O: down 3.9%
BUZZ-Slips as key supplier signals delay in iPhone launch ** Seelos Therapeutics Inc SEEL.O: down 29.6%
BUZZ-Plunges on stock-and-warrants offering ** CureVac NV CVAC.O: up 3.8%
BUZZ-Rises as Germany expected to give 252 mln euros for making COVID-19 vaccine ** Domo Inc DOMO.O: up 8.2%
BUZZ-Hits record high on upbeat forecast ** Cooper Companies Inc COO.N: up 5.8%
BUZZ-Top S&P performer after Q3 results, forecast beat ** Wayfair Inc W.N: down 7.9%
BUZZ-Falls as BofA downgrades on signs of sales deceleration ** Moderna Inc MRNA.O: down 4.2%
BUZZ-Falls on possibility of slowing COVID-19 trial enrollment
The 11 major S&P 500 sectors:
Communication Services
.SPLRCL
down 2.97%
Consumer Discretionary
.SPLRCD
down 2.67%
Consumer Staples
.SPLRCS
down 1.20%
Energy
.SPNY
down 1.28%
Financial
.SPSY
down 0.75%
Health
.SPXHC
down 1.76%
Industrial
.SPLRCI
down 0.90%
Information Technology
.SPLRCT
down 3.46%
Materials
.SPLRCM
down 1.26%
Real Estate
.SPLRCR
down 1.93%
Utilities
.SPLRCU
down 1.62%
(Compiled by Shivani Kumaresan in Bengaluru)
((Shivani.Kumaresan@thomsonreuters.com ; +1 646 223 8780))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh Wall Street's main indexes extended declines on Friday, with the Nasdaq on track for its worst two-day fall since March as technology stocks sold off again, overshadowing data showing a steeper-than-expected drop in the August unemployment rate. The top three S&P 500 .PG.INX percentage gainers: ** Cooper Companies Inc , up 5.1% ** Capital One Financial Corp , up 3.2% ** Coty Inc , up 2.9% The top three S&P 500 .PL.INX percentage losers: ** Paypal Holdings Inc , down 7.8% ** Abiomed Inc , down 7.1% ** Nvidia Corp , down 6.8% The top three NYSE .PG.N percentage gainers: ** Polymet Mining PLM.N, up 55.4% ** FBL Financial Group Inc , up 33.6% ** Flotek Industries Inc , up 12% The top three NYSE .PL.N percentage losers: ** Hovnanian Enterprises Inc , down 15.7% ** Garret Motion Inc , down 15.3% ** Oxford Industries Inc , down 14.7% The top three Nasdaq .PG.O percentage gainers: ** Vivopower International Plc , up 35.2% ** Addex Therapeutics Ltd , up 23% ** National Cine Media Inc , up 21.7% The top three Nasdaq .PL.O percentage losers: ** Syros Pharmaceuticals Inc SYRS.O, down 17.7% ** Fuwei Films Co Ltd FFHL.O, down 17.3% ** Heritage Global Inc , down 16.7% ** Broadcom Inc AVGO.O: up 2.0% BUZZ-Street View: Broadcom shows 'meaningful' growth ahead of 5G ramp-up cycle ** I-Mab IMAB.O: up 4.4% BUZZ-I-Mab up on licensing deal with Chinese firm's lead cancer drug ** AnPac Bio-Medical Science Co Ltd ANPC.O: up 14.5% BUZZ-Rises on positive data from cancer monitoring technology study ** DPW Holdings Inc DPW.A: up 17.2% BUZZ-Gains as unit expects orders for EV charger products from Q4 ** PolyMet Mining Corp PLM.N: up 55.0% BUZZ-Jumps as court finds no irregularities in NorthMet water permit issue ** Tesla Inc TSLA.O: down 4.2% BUZZ-Set to fall for fourth straight session; insiders offload stake ** Kensington Capital Acquisition KCAC.N: up 11.8% BUZZ-Jumps after huge gain on EV SPAC deal ** Apple Inc AAPL.O: down 3.9% BUZZ-Slips as key supplier signals delay in iPhone launch ** Seelos Therapeutics Inc SEEL.O: down 29.6% BUZZ-Plunges on stock-and-warrants offering ** CureVac NV CVAC.O: up 3.8% BUZZ-Rises as Germany expected to give 252 mln euros for making COVID-19 vaccine ** Domo Inc DOMO.O: up 8.2% BUZZ-Hits record high on upbeat forecast ** Cooper Companies Inc COO.N: up 5.8% BUZZ-Top S&P performer after Q3 results, forecast beat ** Wayfair Inc W.N: down 7.9% BUZZ-Falls as BofA downgrades on signs of sales deceleration ** Moderna Inc MRNA.O: down 4.2% BUZZ-Falls on possibility of slowing COVID-19 trial enrollment The 11 major S&P 500 sectors: Communication Services down 1.62% (Compiled by Shivani Kumaresan in Bengaluru) ((Shivani.Kumaresan@thomsonreuters.com ; +1 646 223 8780)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh Wall Street's main indexes extended declines on Friday, with the Nasdaq on track for its worst two-day fall since March as technology stocks sold off again, overshadowing data showing a steeper-than-expected drop in the August unemployment rate. The top three S&P 500 .PG.INX percentage gainers: ** Cooper Companies Inc , up 5.1% ** Capital One Financial Corp , up 3.2% ** Coty Inc , up 2.9% The top three S&P 500 .PL.INX percentage losers: ** Paypal Holdings Inc , down 7.8% ** Abiomed Inc , down 7.1% ** Nvidia Corp , down 6.8% The top three NYSE .PG.N percentage gainers: ** Polymet Mining PLM.N, up 55.4% ** FBL Financial Group Inc , up 33.6% ** Flotek Industries Inc , up 12% The top three NYSE .PL.N percentage losers: ** Hovnanian Enterprises Inc , down 15.7% ** Garret Motion Inc , down 15.3% ** Oxford Industries Inc , down 14.7% The top three Nasdaq .PG.O percentage gainers: ** Vivopower International Plc , up 35.2% ** Addex Therapeutics Ltd , up 23% ** National Cine Media Inc , up 21.7% The top three Nasdaq .PL.O percentage losers: ** Syros Pharmaceuticals Inc SYRS.O, down 17.7% ** Fuwei Films Co Ltd FFHL.O, down 17.3% ** Heritage Global Inc , down 16.7% ** Broadcom Inc AVGO.O: up 2.0% BUZZ-Street View: Broadcom shows 'meaningful' growth ahead of 5G ramp-up cycle ** I-Mab IMAB.O: up 4.4% BUZZ-I-Mab up on licensing deal with Chinese firm's lead cancer drug ** AnPac Bio-Medical Science Co Ltd ANPC.O: up 14.5% BUZZ-Rises on positive data from cancer monitoring technology study ** DPW Holdings Inc DPW.A: up 17.2% BUZZ-Gains as unit expects orders for EV charger products from Q4 ** PolyMet Mining Corp PLM.N: up 55.0% BUZZ-Jumps as court finds no irregularities in NorthMet water permit issue ** Tesla Inc TSLA.O: down 4.2% BUZZ-Set to fall for fourth straight session; insiders offload stake ** Kensington Capital Acquisition KCAC.N: up 11.8% BUZZ-Jumps after huge gain on EV SPAC deal ** Apple Inc AAPL.O: down 3.9% BUZZ-Slips as key supplier signals delay in iPhone launch ** Seelos Therapeutics Inc SEEL.O: down 29.6% BUZZ-Plunges on stock-and-warrants offering ** CureVac NV CVAC.O: up 3.8% BUZZ-Rises as Germany expected to give 252 mln euros for making COVID-19 vaccine ** Domo Inc DOMO.O: up 8.2% BUZZ-Hits record high on upbeat forecast ** Cooper Companies Inc COO.N: up 5.8% BUZZ-Top S&P performer after Q3 results, forecast beat ** Wayfair Inc W.N: down 7.9% BUZZ-Falls as BofA downgrades on signs of sales deceleration ** Moderna Inc MRNA.O: down 4.2% BUZZ-Falls on possibility of slowing COVID-19 trial enrollment The 11 major S&P 500 sectors: Communication Services down 1.62% (Compiled by Shivani Kumaresan in Bengaluru) ((Shivani.Kumaresan@thomsonreuters.com ; +1 646 223 8780)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh Wall Street's main indexes extended declines on Friday, with the Nasdaq on track for its worst two-day fall since March as technology stocks sold off again, overshadowing data showing a steeper-than-expected drop in the August unemployment rate. The top three S&P 500 .PG.INX percentage gainers: ** Cooper Companies Inc , up 5.1% ** Capital One Financial Corp , up 3.2% ** Coty Inc , up 2.9% The top three S&P 500 .PL.INX percentage losers: ** Paypal Holdings Inc , down 7.8% ** Abiomed Inc , down 7.1% ** Nvidia Corp , down 6.8% The top three NYSE .PG.N percentage gainers: ** Polymet Mining PLM.N, up 55.4% ** FBL Financial Group Inc , up 33.6% ** Flotek Industries Inc , up 12% The top three NYSE .PL.N percentage losers: ** Hovnanian Enterprises Inc , down 15.7% ** Garret Motion Inc , down 15.3% ** Oxford Industries Inc , down 14.7% The top three Nasdaq .PG.O percentage gainers: ** Vivopower International Plc , up 35.2% ** Addex Therapeutics Ltd , up 23% ** National Cine Media Inc , up 21.7% The top three Nasdaq .PL.O percentage losers: ** Syros Pharmaceuticals Inc SYRS.O, down 17.7% ** Fuwei Films Co Ltd FFHL.O, down 17.3% ** Heritage Global Inc , down 16.7% ** Broadcom Inc AVGO.O: up 2.0% BUZZ-Street View: Broadcom shows 'meaningful' growth ahead of 5G ramp-up cycle ** I-Mab IMAB.O: up 4.4% BUZZ-I-Mab up on licensing deal with Chinese firm's lead cancer drug ** AnPac Bio-Medical Science Co Ltd ANPC.O: up 14.5% BUZZ-Rises on positive data from cancer monitoring technology study ** DPW Holdings Inc DPW.A: up 17.2% BUZZ-Gains as unit expects orders for EV charger products from Q4 ** PolyMet Mining Corp PLM.N: up 55.0% BUZZ-Jumps as court finds no irregularities in NorthMet water permit issue ** Tesla Inc TSLA.O: down 4.2% BUZZ-Set to fall for fourth straight session; insiders offload stake ** Kensington Capital Acquisition KCAC.N: up 11.8% BUZZ-Jumps after huge gain on EV SPAC deal ** Apple Inc AAPL.O: down 3.9% BUZZ-Slips as key supplier signals delay in iPhone launch ** Seelos Therapeutics Inc SEEL.O: down 29.6% BUZZ-Plunges on stock-and-warrants offering ** CureVac NV CVAC.O: up 3.8% BUZZ-Rises as Germany expected to give 252 mln euros for making COVID-19 vaccine ** Domo Inc DOMO.O: up 8.2% BUZZ-Hits record high on upbeat forecast ** Cooper Companies Inc COO.N: up 5.8% BUZZ-Top S&P performer after Q3 results, forecast beat ** Wayfair Inc W.N: down 7.9% BUZZ-Falls as BofA downgrades on signs of sales deceleration ** Moderna Inc MRNA.O: down 4.2% BUZZ-Falls on possibility of slowing COVID-19 trial enrollment The 11 major S&P 500 sectors: Communication Services down 2.97% Consumer Discretionary | Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh Wall Street's main indexes extended declines on Friday, with the Nasdaq on track for its worst two-day fall since March as technology stocks sold off again, overshadowing data showing a steeper-than-expected drop in the August unemployment rate. ET, the Dow Jones Industrial Average .DJI was down 1.92% at 27,749.53. The S&P 500 .SPX was down 2.24% at 3,377.83 and the Nasdaq Composite .IXIC was down 3.09% at 11,104.578. |
24404.0 | 2020-09-04 00:00:00 UTC | BUZZ-U.S. STOCKS ON THE MOVE-Apple Inc, Tesla Inc, PolyMet Mining Corp, Seelos Therapeutics | ABBV | https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-apple-inc-tesla-inc-polymet-mining-corp-seelos-therapeutics | nan | nan | Eikon search string for individual stock moves: STXBZ
The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi
The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh
The S&P 500 rose shortly after the opening bell on Friday after a brutal selloff in the previous session as data showed U.S. unemployment rate dropped more than expected in August. .N
At 10:00 a.m. ET, the Dow Jones Industrial Average .DJI was up 0.23% at 28,357.93. The S&P 500 .SPX was down 0.57% at 3,435.2 and the Nasdaq Composite .IXIC was down 1.95% at 11,234.346. The top three S&P 500 .PG.INX percentage gainers: ** Cooper Companies Inc , up 8.8% ** Discover Financial Services , up 5.5% ** Broadcom Inc , up 5.5% The top three S&P 500 .PL.INX percentage losers: ** Nvidia Corp , down 5.8% ** Paypal Holdings Inc , down 5.4% ** Dexcom Inc , down 4.8% The top three NYSE .PG.N percentage gainers: ** FBL Financial Group Inc FFG.N, up 29.1% ** Independence Contract Drilling Inc , up 29.1% ** Kensington Capital Acquisition Corp , up 21% The top three NYSE .PL.N percentage losers: ** Oxford Industries Inc , down 14.3% ** Jumia Technologies AG , down 10.2% ** Garret Motion Inc , down 9% The top three Nasdaq .PG.O percentage gainers: ** Addex Therapeutics Ltd , up 18.5% ** Domo Inc , up 17.5% ** Precipio Inc , up 14.6% The top three Nasdaq .PL.O percentage losers: ** Vuzix Corp , down 20.6% ** Docusign Inc , down 11.8% ** Fulgent Genetics Inc , down 10.6% ** Broadcom Inc AVGO.O: up 5.4%
BUZZ-Street View: Broadcom shows 'meaningful' growth ahead of 5G ramp-up cycle ** I-Mab IMAB.O: up 9.3% ** Abbvie Inc ABBV.N: up 0.5%
BUZZ-I-Mab, AbbVie up on licensing deal with Chinese firm's lead cancer drug ** AnPac Bio-Medical Science Co Ltd ANPC.O: up 6.0%
BUZZ-Rises on positive data from cancer monitoring technology study ** DPW Holdings Inc DPW.A: up 25.2%
BUZZ-Gains as unit expects orders for EV charger products from Q4 ** PolyMet Mining Corp PLM.N: up 13.3%
BUZZ-Jumps as court finds no irregularities in NorthMet water permit issue ** Tesla Inc TSLA.O: down 3.7%
BUZZ-Set to fall for fourth straight session; insiders offload stake ** Kensington Capital Acquisition KCAC.N: up 21.5%
BUZZ-Jumping after huge gain on EV SPAC deal ** Apple Inc AAPL.O: down 4.1%
BUZZ-Slips as key supplier signals delay in iPhone launch ** Seelos Therapeutics Inc SEEL.O: down 22.4%
BUZZ-Plunges on stock-and-warrants offering
The 11 major S&P 500 sectors:
Communication Services
.SPLRCL
down 1.72%
Consumer Discretionary
.SPLRCD
down 1.34%
Consumer Staples
.SPLRCS
up 0.52%
Energy
.SPNY
up 1.10%
Financial
.SPSY
up 1.85%
Health
.SPXHC
up 0.05%
Industrial
.SPLRCI
up 1.28%
Information Technology
.SPLRCT
down 2.14%
Materials
.SPLRCM
up 0.40%
Real Estate
.SPLRCR
up 0.30%
Utilities
.SPLRCU
down 0.15%
(Compiled by Shivani Kumaresan in Bengaluru)
((Shivani.Kumaresan@thomsonreuters.com ; +1 646 223 8780))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The top three S&P 500 .PG.INX percentage gainers: ** Cooper Companies Inc , up 8.8% ** Discover Financial Services , up 5.5% ** Broadcom Inc , up 5.5% The top three S&P 500 .PL.INX percentage losers: ** Nvidia Corp , down 5.8% ** Paypal Holdings Inc , down 5.4% ** Dexcom Inc , down 4.8% The top three NYSE .PG.N percentage gainers: ** FBL Financial Group Inc FFG.N, up 29.1% ** Independence Contract Drilling Inc , up 29.1% ** Kensington Capital Acquisition Corp , up 21% The top three NYSE .PL.N percentage losers: ** Oxford Industries Inc , down 14.3% ** Jumia Technologies AG , down 10.2% ** Garret Motion Inc , down 9% The top three Nasdaq .PG.O percentage gainers: ** Addex Therapeutics Ltd , up 18.5% ** Domo Inc , up 17.5% ** Precipio Inc , up 14.6% The top three Nasdaq .PL.O percentage losers: ** Vuzix Corp , down 20.6% ** Docusign Inc , down 11.8% ** Fulgent Genetics Inc , down 10.6% ** Broadcom Inc AVGO.O: up 5.4% BUZZ-Street View: Broadcom shows 'meaningful' growth ahead of 5G ramp-up cycle ** I-Mab IMAB.O: up 9.3% ** Abbvie Inc ABBV.N: up 0.5% BUZZ-I-Mab, AbbVie up on licensing deal with Chinese firm's lead cancer drug ** AnPac Bio-Medical Science Co Ltd ANPC.O: up 6.0% BUZZ-Rises on positive data from cancer monitoring technology study ** DPW Holdings Inc DPW.A: up 25.2% BUZZ-Gains as unit expects orders for EV charger products from Q4 ** PolyMet Mining Corp PLM.N: up 13.3% BUZZ-Jumps as court finds no irregularities in NorthMet water permit issue ** Tesla Inc TSLA.O: down 3.7% BUZZ-Set to fall for fourth straight session; insiders offload stake ** Kensington Capital Acquisition KCAC.N: up 21.5% BUZZ-Jumping after huge gain on EV SPAC deal ** Apple Inc AAPL.O: down 4.1% BUZZ-Slips as key supplier signals delay in iPhone launch ** Seelos Therapeutics Inc SEEL.O: down 22.4% BUZZ-Plunges on stock-and-warrants offering The 11 major S&P 500 sectors: Communication Services Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh The S&P 500 rose shortly after the opening bell on Friday after a brutal selloff in the previous session as data showed U.S. unemployment rate dropped more than expected in August. down 0.15% (Compiled by Shivani Kumaresan in Bengaluru) ((Shivani.Kumaresan@thomsonreuters.com ; +1 646 223 8780)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The top three S&P 500 .PG.INX percentage gainers: ** Cooper Companies Inc , up 8.8% ** Discover Financial Services , up 5.5% ** Broadcom Inc , up 5.5% The top three S&P 500 .PL.INX percentage losers: ** Nvidia Corp , down 5.8% ** Paypal Holdings Inc , down 5.4% ** Dexcom Inc , down 4.8% The top three NYSE .PG.N percentage gainers: ** FBL Financial Group Inc FFG.N, up 29.1% ** Independence Contract Drilling Inc , up 29.1% ** Kensington Capital Acquisition Corp , up 21% The top three NYSE .PL.N percentage losers: ** Oxford Industries Inc , down 14.3% ** Jumia Technologies AG , down 10.2% ** Garret Motion Inc , down 9% The top three Nasdaq .PG.O percentage gainers: ** Addex Therapeutics Ltd , up 18.5% ** Domo Inc , up 17.5% ** Precipio Inc , up 14.6% The top three Nasdaq .PL.O percentage losers: ** Vuzix Corp , down 20.6% ** Docusign Inc , down 11.8% ** Fulgent Genetics Inc , down 10.6% ** Broadcom Inc AVGO.O: up 5.4% BUZZ-Street View: Broadcom shows 'meaningful' growth ahead of 5G ramp-up cycle ** I-Mab IMAB.O: up 9.3% ** Abbvie Inc ABBV.N: up 0.5% BUZZ-I-Mab, AbbVie up on licensing deal with Chinese firm's lead cancer drug ** AnPac Bio-Medical Science Co Ltd ANPC.O: up 6.0% BUZZ-Rises on positive data from cancer monitoring technology study ** DPW Holdings Inc DPW.A: up 25.2% BUZZ-Gains as unit expects orders for EV charger products from Q4 ** PolyMet Mining Corp PLM.N: up 13.3% BUZZ-Jumps as court finds no irregularities in NorthMet water permit issue ** Tesla Inc TSLA.O: down 3.7% BUZZ-Set to fall for fourth straight session; insiders offload stake ** Kensington Capital Acquisition KCAC.N: up 21.5% BUZZ-Jumping after huge gain on EV SPAC deal ** Apple Inc AAPL.O: down 4.1% BUZZ-Slips as key supplier signals delay in iPhone launch ** Seelos Therapeutics Inc SEEL.O: down 22.4% BUZZ-Plunges on stock-and-warrants offering The 11 major S&P 500 sectors: Communication Services Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh The S&P 500 rose shortly after the opening bell on Friday after a brutal selloff in the previous session as data showed U.S. unemployment rate dropped more than expected in August. down 0.15% (Compiled by Shivani Kumaresan in Bengaluru) ((Shivani.Kumaresan@thomsonreuters.com ; +1 646 223 8780)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The top three S&P 500 .PG.INX percentage gainers: ** Cooper Companies Inc , up 8.8% ** Discover Financial Services , up 5.5% ** Broadcom Inc , up 5.5% The top three S&P 500 .PL.INX percentage losers: ** Nvidia Corp , down 5.8% ** Paypal Holdings Inc , down 5.4% ** Dexcom Inc , down 4.8% The top three NYSE .PG.N percentage gainers: ** FBL Financial Group Inc FFG.N, up 29.1% ** Independence Contract Drilling Inc , up 29.1% ** Kensington Capital Acquisition Corp , up 21% The top three NYSE .PL.N percentage losers: ** Oxford Industries Inc , down 14.3% ** Jumia Technologies AG , down 10.2% ** Garret Motion Inc , down 9% The top three Nasdaq .PG.O percentage gainers: ** Addex Therapeutics Ltd , up 18.5% ** Domo Inc , up 17.5% ** Precipio Inc , up 14.6% The top three Nasdaq .PL.O percentage losers: ** Vuzix Corp , down 20.6% ** Docusign Inc , down 11.8% ** Fulgent Genetics Inc , down 10.6% ** Broadcom Inc AVGO.O: up 5.4% BUZZ-Street View: Broadcom shows 'meaningful' growth ahead of 5G ramp-up cycle ** I-Mab IMAB.O: up 9.3% ** Abbvie Inc ABBV.N: up 0.5% BUZZ-I-Mab, AbbVie up on licensing deal with Chinese firm's lead cancer drug ** AnPac Bio-Medical Science Co Ltd ANPC.O: up 6.0% BUZZ-Rises on positive data from cancer monitoring technology study ** DPW Holdings Inc DPW.A: up 25.2% BUZZ-Gains as unit expects orders for EV charger products from Q4 ** PolyMet Mining Corp PLM.N: up 13.3% BUZZ-Jumps as court finds no irregularities in NorthMet water permit issue ** Tesla Inc TSLA.O: down 3.7% BUZZ-Set to fall for fourth straight session; insiders offload stake ** Kensington Capital Acquisition KCAC.N: up 21.5% BUZZ-Jumping after huge gain on EV SPAC deal ** Apple Inc AAPL.O: down 4.1% BUZZ-Slips as key supplier signals delay in iPhone launch ** Seelos Therapeutics Inc SEEL.O: down 22.4% BUZZ-Plunges on stock-and-warrants offering The 11 major S&P 500 sectors: Communication Services down 1.72% Consumer Discretionary down 1.34% Consumer Staples | The top three S&P 500 .PG.INX percentage gainers: ** Cooper Companies Inc , up 8.8% ** Discover Financial Services , up 5.5% ** Broadcom Inc , up 5.5% The top three S&P 500 .PL.INX percentage losers: ** Nvidia Corp , down 5.8% ** Paypal Holdings Inc , down 5.4% ** Dexcom Inc , down 4.8% The top three NYSE .PG.N percentage gainers: ** FBL Financial Group Inc FFG.N, up 29.1% ** Independence Contract Drilling Inc , up 29.1% ** Kensington Capital Acquisition Corp , up 21% The top three NYSE .PL.N percentage losers: ** Oxford Industries Inc , down 14.3% ** Jumia Technologies AG , down 10.2% ** Garret Motion Inc , down 9% The top three Nasdaq .PG.O percentage gainers: ** Addex Therapeutics Ltd , up 18.5% ** Domo Inc , up 17.5% ** Precipio Inc , up 14.6% The top three Nasdaq .PL.O percentage losers: ** Vuzix Corp , down 20.6% ** Docusign Inc , down 11.8% ** Fulgent Genetics Inc , down 10.6% ** Broadcom Inc AVGO.O: up 5.4% BUZZ-Street View: Broadcom shows 'meaningful' growth ahead of 5G ramp-up cycle ** I-Mab IMAB.O: up 9.3% ** Abbvie Inc ABBV.N: up 0.5% BUZZ-I-Mab, AbbVie up on licensing deal with Chinese firm's lead cancer drug ** AnPac Bio-Medical Science Co Ltd ANPC.O: up 6.0% BUZZ-Rises on positive data from cancer monitoring technology study ** DPW Holdings Inc DPW.A: up 25.2% BUZZ-Gains as unit expects orders for EV charger products from Q4 ** PolyMet Mining Corp PLM.N: up 13.3% BUZZ-Jumps as court finds no irregularities in NorthMet water permit issue ** Tesla Inc TSLA.O: down 3.7% BUZZ-Set to fall for fourth straight session; insiders offload stake ** Kensington Capital Acquisition KCAC.N: up 21.5% BUZZ-Jumping after huge gain on EV SPAC deal ** Apple Inc AAPL.O: down 4.1% BUZZ-Slips as key supplier signals delay in iPhone launch ** Seelos Therapeutics Inc SEEL.O: down 22.4% BUZZ-Plunges on stock-and-warrants offering The 11 major S&P 500 sectors: Communication Services Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh The S&P 500 rose shortly after the opening bell on Friday after a brutal selloff in the previous session as data showed U.S. unemployment rate dropped more than expected in August. ET, the Dow Jones Industrial Average .DJI was up 0.23% at 28,357.93. |
24405.0 | 2020-09-04 00:00:00 UTC | BUZZ-U.S. STOCKS ON THE MOVE-I-Mab, AnPac Bio-Medical Science, DPW Holdings | ABBV | https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-i-mab-anpac-bio-medical-science-dpw-holdings-2020-09-04 | nan | nan | Eikon search string for individual stock moves: STXBZ
The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi
The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh
The S&P 500 was set for a higher open on Friday following a brutal selloff in the previous session as a drop in the unemployment rate offset a slide in technology stocks, while investors remained cautious about a patchy economic recovery. .N
At 8:30 a.m. ET, Dow e-minis 1YMc1 were up 0.34% at 28,447. S&P 500 e-minis ESc1 were down 0.13% at 3,457, while Nasdaq 100 e-minis NQc1 were down 1.24% at 11,654. The top three NYSE percentage gainers premarket .PRPG.NQ: ** Kensington Capital Acquisition Corp , up 16.9% ** Clearwater Paper Corp , up 15.0% ** Permianville Royalty Trust , up 11.1% The top three NYSE percentage losers premarket .PRPL.NQ: ** Tortoise Acquisition Corp SHLL.N, down 11.3% ** Global Blue Group Holding Ltd GB.N, down 9.7% ** American Realty Investors Inc ARL.N, down 8.1% The top three Nasdaq percentage gainers premarket .PRPG.O: ** I-Mab IMAB.O, up 27.9% ** Addex Therapeutics Ltd , up 27.9% ** Shiloh Industries Inc , up 15.5% The top three Nasdaq percentage losers premarket .PRPL.O: ** Savara Inc SVRA.O, down 13.7% ** Priority Technology Holdings Inc , down 11.7% ** Acorda Therapeutics Inc , down 10.3% ** Plug Power Inc PLUG.O: up 3.8% premarket BUZZ-Shares up after D.E. Shaw discloses passive stake ** BioNTech SE BNTX.O: up 0.5% premarket BUZZ-Up as co to begin human trial for fifth COVID-19 vaccine candidate ** Broadcom Inc AVGO.O: up 0.3% premarket BUZZ-Street View: Broadcom shows 'meaningful' growth ahead of 5G ramp-up cycle ** I-Mab IMAB.O: up 27.9% premarket BUZZ-I-Mab up on licensing deal with Chinese firm's lead cancer drug ** AnPac Bio-Medical Science Co Ltd ANPC.O: up 18.7% premarket BUZZ-Rises on positive data from cancer monitoring technology study ** DPW Holdings Inc DPW.A: UP 40.3% premarket BUZZ-Gains as unit expects orders for EV charger products from Q4
(Compiled by Shivani Kumaresan in Bengaluru)
((Shivani.Kumaresan@thomsonreuters.com ; +1 646 223 8780;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh The S&P 500 was set for a higher open on Friday following a brutal selloff in the previous session as a drop in the unemployment rate offset a slide in technology stocks, while investors remained cautious about a patchy economic recovery. The top three NYSE percentage gainers premarket .PRPG.NQ: ** Kensington Capital Acquisition Corp , up 16.9% ** Clearwater Paper Corp , up 15.0% ** Permianville Royalty Trust , up 11.1% The top three NYSE percentage losers premarket .PRPL.NQ: ** Tortoise Acquisition Corp SHLL.N, down 11.3% ** Global Blue Group Holding Ltd GB.N, down 9.7% ** American Realty Investors Inc ARL.N, down 8.1% The top three Nasdaq percentage gainers premarket .PRPG.O: ** I-Mab IMAB.O, up 27.9% ** Addex Therapeutics Ltd , up 27.9% ** Shiloh Industries Inc , up 15.5% The top three Nasdaq percentage losers premarket .PRPL.O: ** Savara Inc SVRA.O, down 13.7% ** Priority Technology Holdings Inc , down 11.7% ** Acorda Therapeutics Inc , down 10.3% ** Plug Power Inc PLUG.O: up 3.8% premarket BUZZ-Shares up after D.E. Shaw discloses passive stake ** BioNTech SE BNTX.O: up 0.5% premarket BUZZ-Up as co to begin human trial for fifth COVID-19 vaccine candidate ** Broadcom Inc AVGO.O: up 0.3% premarket BUZZ-Street View: Broadcom shows 'meaningful' growth ahead of 5G ramp-up cycle ** I-Mab IMAB.O: up 27.9% premarket BUZZ-I-Mab up on licensing deal with Chinese firm's lead cancer drug ** AnPac Bio-Medical Science Co Ltd ANPC.O: up 18.7% premarket BUZZ-Rises on positive data from cancer monitoring technology study ** DPW Holdings Inc DPW.A: UP 40.3% premarket BUZZ-Gains as unit expects orders for EV charger products from Q4 (Compiled by Shivani Kumaresan in Bengaluru) ((Shivani.Kumaresan@thomsonreuters.com ; +1 646 223 8780;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh The S&P 500 was set for a higher open on Friday following a brutal selloff in the previous session as a drop in the unemployment rate offset a slide in technology stocks, while investors remained cautious about a patchy economic recovery. The top three NYSE percentage gainers premarket .PRPG.NQ: ** Kensington Capital Acquisition Corp , up 16.9% ** Clearwater Paper Corp , up 15.0% ** Permianville Royalty Trust , up 11.1% The top three NYSE percentage losers premarket .PRPL.NQ: ** Tortoise Acquisition Corp SHLL.N, down 11.3% ** Global Blue Group Holding Ltd GB.N, down 9.7% ** American Realty Investors Inc ARL.N, down 8.1% The top three Nasdaq percentage gainers premarket .PRPG.O: ** I-Mab IMAB.O, up 27.9% ** Addex Therapeutics Ltd , up 27.9% ** Shiloh Industries Inc , up 15.5% The top three Nasdaq percentage losers premarket .PRPL.O: ** Savara Inc SVRA.O, down 13.7% ** Priority Technology Holdings Inc , down 11.7% ** Acorda Therapeutics Inc , down 10.3% ** Plug Power Inc PLUG.O: up 3.8% premarket BUZZ-Shares up after D.E. Shaw discloses passive stake ** BioNTech SE BNTX.O: up 0.5% premarket BUZZ-Up as co to begin human trial for fifth COVID-19 vaccine candidate ** Broadcom Inc AVGO.O: up 0.3% premarket BUZZ-Street View: Broadcom shows 'meaningful' growth ahead of 5G ramp-up cycle ** I-Mab IMAB.O: up 27.9% premarket BUZZ-I-Mab up on licensing deal with Chinese firm's lead cancer drug ** AnPac Bio-Medical Science Co Ltd ANPC.O: up 18.7% premarket BUZZ-Rises on positive data from cancer monitoring technology study ** DPW Holdings Inc DPW.A: UP 40.3% premarket BUZZ-Gains as unit expects orders for EV charger products from Q4 (Compiled by Shivani Kumaresan in Bengaluru) ((Shivani.Kumaresan@thomsonreuters.com ; +1 646 223 8780;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | S&P 500 e-minis ESc1 were down 0.13% at 3,457, while Nasdaq 100 e-minis NQc1 were down 1.24% at 11,654. The top three NYSE percentage gainers premarket .PRPG.NQ: ** Kensington Capital Acquisition Corp , up 16.9% ** Clearwater Paper Corp , up 15.0% ** Permianville Royalty Trust , up 11.1% The top three NYSE percentage losers premarket .PRPL.NQ: ** Tortoise Acquisition Corp SHLL.N, down 11.3% ** Global Blue Group Holding Ltd GB.N, down 9.7% ** American Realty Investors Inc ARL.N, down 8.1% The top three Nasdaq percentage gainers premarket .PRPG.O: ** I-Mab IMAB.O, up 27.9% ** Addex Therapeutics Ltd , up 27.9% ** Shiloh Industries Inc , up 15.5% The top three Nasdaq percentage losers premarket .PRPL.O: ** Savara Inc SVRA.O, down 13.7% ** Priority Technology Holdings Inc , down 11.7% ** Acorda Therapeutics Inc , down 10.3% ** Plug Power Inc PLUG.O: up 3.8% premarket BUZZ-Shares up after D.E. Shaw discloses passive stake ** BioNTech SE BNTX.O: up 0.5% premarket BUZZ-Up as co to begin human trial for fifth COVID-19 vaccine candidate ** Broadcom Inc AVGO.O: up 0.3% premarket BUZZ-Street View: Broadcom shows 'meaningful' growth ahead of 5G ramp-up cycle ** I-Mab IMAB.O: up 27.9% premarket BUZZ-I-Mab up on licensing deal with Chinese firm's lead cancer drug ** AnPac Bio-Medical Science Co Ltd ANPC.O: up 18.7% premarket BUZZ-Rises on positive data from cancer monitoring technology study ** DPW Holdings Inc DPW.A: UP 40.3% premarket BUZZ-Gains as unit expects orders for EV charger products from Q4 (Compiled by Shivani Kumaresan in Bengaluru) ((Shivani.Kumaresan@thomsonreuters.com ; +1 646 223 8780;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh The S&P 500 was set for a higher open on Friday following a brutal selloff in the previous session as a drop in the unemployment rate offset a slide in technology stocks, while investors remained cautious about a patchy economic recovery. ET, Dow e-minis 1YMc1 were up 0.34% at 28,447. S&P 500 e-minis ESc1 were down 0.13% at 3,457, while Nasdaq 100 e-minis NQc1 were down 1.24% at 11,654. |
24406.0 | 2020-09-04 00:00:00 UTC | AbbVie to develop and sell China-based I-Mab's cancer drug | ABBV | https://www.nasdaq.com/articles/abbvie-to-develop-and-sell-china-based-i-mabs-cancer-drug-2020-09-04 | nan | nan | Adds financial details, shares, background
Sept 4 (Reuters) - U.S. drugmaker AbbVie Inc ABBV.N will pay $180 million in upfront payment to develop and sell Chinese biotech company I-Mab's IMAB.O cancer drug, the companies said on Friday.
The U.S.-listed shares of I-Mab jumped 18.8% to $42.5 before the opening bell.
The agreement is the latest push by AbbVie into cancer therapies after its June collaboration with Denmark's biotech firm Genmab AS GMAB.CO to co-develop and market cancer drugs.
AbbVie will pay an additional $1.74 billion in milestone payments for lemzoparlimab, the companies said, adding that I-Mab will retain the rights to sell the drug in China.
I-Mab, which started trading on the Nasdaq at the start of the year, is a biotech company that develops treatments for immuno-oncology and autoimmune diseases.
The companies said they will also work together in future drug trials relating to multiple cancers.
(Reporting by Trisha Roy in Bengaluru; Editing by Arun Koyyur)
((Trisha.Roy@thomsonreuters.com; within U.S. +1 646 223 8780, outside U.S. +91 80 6182 3635;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Adds financial details, shares, background Sept 4 (Reuters) - U.S. drugmaker AbbVie Inc ABBV.N will pay $180 million in upfront payment to develop and sell Chinese biotech company I-Mab's IMAB.O cancer drug, the companies said on Friday. AbbVie will pay an additional $1.74 billion in milestone payments for lemzoparlimab, the companies said, adding that I-Mab will retain the rights to sell the drug in China. The agreement is the latest push by AbbVie into cancer therapies after its June collaboration with Denmark's biotech firm Genmab AS GMAB.CO to co-develop and market cancer drugs. | Adds financial details, shares, background Sept 4 (Reuters) - U.S. drugmaker AbbVie Inc ABBV.N will pay $180 million in upfront payment to develop and sell Chinese biotech company I-Mab's IMAB.O cancer drug, the companies said on Friday. The agreement is the latest push by AbbVie into cancer therapies after its June collaboration with Denmark's biotech firm Genmab AS GMAB.CO to co-develop and market cancer drugs. AbbVie will pay an additional $1.74 billion in milestone payments for lemzoparlimab, the companies said, adding that I-Mab will retain the rights to sell the drug in China. | Adds financial details, shares, background Sept 4 (Reuters) - U.S. drugmaker AbbVie Inc ABBV.N will pay $180 million in upfront payment to develop and sell Chinese biotech company I-Mab's IMAB.O cancer drug, the companies said on Friday. The agreement is the latest push by AbbVie into cancer therapies after its June collaboration with Denmark's biotech firm Genmab AS GMAB.CO to co-develop and market cancer drugs. AbbVie will pay an additional $1.74 billion in milestone payments for lemzoparlimab, the companies said, adding that I-Mab will retain the rights to sell the drug in China. | Adds financial details, shares, background Sept 4 (Reuters) - U.S. drugmaker AbbVie Inc ABBV.N will pay $180 million in upfront payment to develop and sell Chinese biotech company I-Mab's IMAB.O cancer drug, the companies said on Friday. The agreement is the latest push by AbbVie into cancer therapies after its June collaboration with Denmark's biotech firm Genmab AS GMAB.CO to co-develop and market cancer drugs. AbbVie will pay an additional $1.74 billion in milestone payments for lemzoparlimab, the companies said, adding that I-Mab will retain the rights to sell the drug in China. |
24407.0 | 2020-09-04 00:00:00 UTC | Like Dividends? I Bet You'll Love These 2 Stocks | ABBV | https://www.nasdaq.com/articles/like-dividends-i-bet-youll-love-these-2-stocks-2020-09-04 | nan | nan | The "Oracle of Omaha," Warren Buffett, has famously been quoted as saying, "Price is what you pay. Value is what you get." Dividend stocks are a tried-and-true way of adding value to your portfolio -- when a company pays a generous dividend, this can be a sign of its potential as a reliable long-term investment. High dividend yields inevitably draw investor cash, which may subsequently boost a stock's price and therefore the portfolios of existing shareholders.
These days, finding robust dividend stocks isn't a walk in the park. But plenty of highly profitable dividend stocks do exist even in the current volatile market. If you're actively searching for dividend stocks, you'll definitely want to add these two large-cap healthcare companies to your list of contenders.
Image source: Getty Images.
AbbVie
Biopharmaceutical giant AbbVie (NYSE: ABBV) is among the crème de la crème of stocks known as Dividend Aristocrats. To be listed on the S&P 500's Dividend Aristocrat index, a stock must boost its dividend every year for at least 25 years in a row; AbbVie's history as part of Abbott Laboratories (NYSE: ABT), from which it spun off in 2013, is included there. AbbVie currently pays out a mouth-watering dividend yield of 5%.
Although AbbVie stock fell in March with the rest of the market, it has more than recovered, and the stock is up about 5% year to date. The company has also maintained its high profitability, even during the darkest days of the pandemic. For first-quarter 2020, which ended March 31, the company reported net revenue of nearly $9 billion, up 10% over the first quarter of 2019. In the second quarter, which ended June 30, AbbVie's revenue reached $10.4 billion.
A few factors drove the company's exceptional performance during the first half of this year, and they're likely to play a vital role in the company's ongoing growth story. First, there was AbbVie's blockbuster immunosuppressive drug, Humira, which brought in $4.7 billion in Q1 and $4.8 billion in Q2. Then, there's the company's hugely profitable hematologic oncology (blood cancer) business, which brought in $1.5 billion in Q1 and $1.6 billion in Q2. AbbVie's acquisition of Allergan, which concluded in May, added considerable strength to its portfolio, including existing drugs and therapeutics as well as pipeline products.
The company announced Aug. 25 that it had submitted a regulatory application to the U.S. Food and Drug Administration (FDA) seeking a new label indication for Rinvoq, the rheumatoid arthritis drug it launched in August 2019. If the FDA grants the new indication, AbbVie could also market Rinvoq to treat patients with an inflammatory disease called ankylosing spondylitis. Such a new indication could expand Rinvoq's revenue potential -- the drug brought in $149 million in revenue in Q2 2020 alone.
The end to AbbVie's current momentum is nowhere in sight. Factoring in the Allergen acquisition, AbbVie anticipates diluted earnings per share (EPS) under generally accepted accounting principles (GAAP) to hit somewhere in the range of $4.12 to $4.22 for the whole of 2020.
GlaxoSmithKline
British pharmaceutical company GlaxoSmithKline (NYSE: GSK) closed at $39.90 per share on Wednesday, and its attractive yield of 6.41% is certainly a big draw for investors searching for dividend income.
GlaxoSmithKline's work on multiple concurrent COVID-19 vaccine candidates has been the most talked-about development in the company's pipeline lately. The company is contributing its pandemic adjuvant system to multiple vaccine collaborations with different companies. An adjuvant helps to elicit a more robust immune reaction in the subject. When someone is administered a vaccine that features an adjuvant, this aids the vaccine in being more effective. An adjuvant can also help to stimulate the development of antibodies in less potent vaccines and/or bring about the desired results with a more moderate dose, which can help to alleviate manufacturing constraints during the pandemic.
GlaxoSmithKline is collaborating with Clover Pharmaceuticals and Medicago on two separate vaccine candidates using its pandemic adjuvant system and vaccine technologies proffered by the respective companies. Both candidates from these collaborations are in phase 1 human trials.
But it's GlaxoSmithKline's third collaboration on a COVID-19 vaccine with French company Sanofi (NASDAQ: SNY) that may be the most compelling. A phase 1/2 study of the vaccine, which uses GlaxoSmithKline's pandemic adjuvant system and Sanofi's S-protein COVID-19 antigen (S-proteins help to elicit neutralizing antibodies) began this week. On July 31, the companies announced an agreement with the U.S. government to provide up to 600 million doses of the vaccine candidate, in return for which GlaxoSmithKline and Sanofi were awarded $2.1 billion in Operation Warp Speed funding. The companies plan to begin a phase 3 safety and efficacy study on the potential vaccine before the end of the year.
GlaxoSmithKline is also collaborating with Vir Biotechnology (NASDAQ: VIR) on potential antibody-based therapeutics. On Aug. 31, the the companies announced that their monoclonal antibody candidate, VIR-7831 -- designed to treat patients in the early stages of COVID-19 and prevent hospitalization -- had entered a phase 2/3 human trial. Initial data from the study could be released before the year is out.
GlaxoSmithKline has 35 medicines and 15 vaccines in its biopharma pipeline. The company reported second-quarter sales of $10.1 billion, a slight year-over-year decline attributable to the impact of COVID-19. Sales in GlaxoSmithKline's respiratory business were up 17% in the quarter, led by a 62% increase in sales of its chronic obstructive pulmonary disease (COPD) treatment, Trelegy, and a 24% boost in sales of Nucala, a treatment for eosinophilic asthma.
Investors analyzing GlaxoSmithKline's growth potential needn't (and shouldn't) pin their hopes on its role in the COVID-19 cure race. The company has stated emphatically that it "does not expect to profit from sales of its portfolio of collaborations for COVID-19 vaccines made during this pandemic phase, as profit generated will be invested in support of coronavirus related research and long-term pandemic preparedness."
In any case, the company has shown impressive resilience during highs and lows of 2020. The strength of its balance sheet, portfolio, and pipeline all paint a bright picture for its future beyond the pandemic.
10 stocks we like better than GlaxoSmithKline
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and GlaxoSmithKline wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of August 1, 2020
Rachel Warren has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Factoring in the Allergen acquisition, AbbVie anticipates diluted earnings per share (EPS) under generally accepted accounting principles (GAAP) to hit somewhere in the range of $4.12 to $4.22 for the whole of 2020. AbbVie Biopharmaceutical giant AbbVie (NYSE: ABBV) is among the crème de la crème of stocks known as Dividend Aristocrats. To be listed on the S&P 500's Dividend Aristocrat index, a stock must boost its dividend every year for at least 25 years in a row; AbbVie's history as part of Abbott Laboratories (NYSE: ABT), from which it spun off in 2013, is included there. | AbbVie Biopharmaceutical giant AbbVie (NYSE: ABBV) is among the crème de la crème of stocks known as Dividend Aristocrats. To be listed on the S&P 500's Dividend Aristocrat index, a stock must boost its dividend every year for at least 25 years in a row; AbbVie's history as part of Abbott Laboratories (NYSE: ABT), from which it spun off in 2013, is included there. AbbVie currently pays out a mouth-watering dividend yield of 5%. | AbbVie Biopharmaceutical giant AbbVie (NYSE: ABBV) is among the crème de la crème of stocks known as Dividend Aristocrats. To be listed on the S&P 500's Dividend Aristocrat index, a stock must boost its dividend every year for at least 25 years in a row; AbbVie's history as part of Abbott Laboratories (NYSE: ABT), from which it spun off in 2013, is included there. AbbVie currently pays out a mouth-watering dividend yield of 5%. | To be listed on the S&P 500's Dividend Aristocrat index, a stock must boost its dividend every year for at least 25 years in a row; AbbVie's history as part of Abbott Laboratories (NYSE: ABT), from which it spun off in 2013, is included there. AbbVie Biopharmaceutical giant AbbVie (NYSE: ABBV) is among the crème de la crème of stocks known as Dividend Aristocrats. AbbVie currently pays out a mouth-watering dividend yield of 5%. |
24408.0 | 2020-09-04 00:00:00 UTC | AbbVie To License I-Mab's Anti-CD47 Monoclonal Antibody Lemzoparlimab | ABBV | https://www.nasdaq.com/articles/abbvie-to-license-i-mabs-anti-cd47-monoclonal-antibody-lemzoparlimab-2020-09-04 | nan | nan | (RTTNews) - AbbVie (ABBV) and I-Mab (IMAB) have signed a global collaboration agreement for the development and commercialization of lemzoparlimab, an anti-CD47 monoclonal antibody internally discovered and developed by I-Mab for the treatment of multiple cancers. AbbVie will pay I-Mab $180 million in an upfront payment to exclusively license lemzoparlimab, along with $20 million in a milestone payment based on the Phase 1 results, for a total of $200 million.
Under the agreement, I-Mab will be eligible to receive up to $1.74 billion in success-based milestone payments for lemzoparlimab. Upon commercialization of lemzoparlimab, AbbVie will also pay tiered royalties from low-to-mid teen percentages on global net sales outside of greater China.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - AbbVie (ABBV) and I-Mab (IMAB) have signed a global collaboration agreement for the development and commercialization of lemzoparlimab, an anti-CD47 monoclonal antibody internally discovered and developed by I-Mab for the treatment of multiple cancers. Upon commercialization of lemzoparlimab, AbbVie will also pay tiered royalties from low-to-mid teen percentages on global net sales outside of greater China. AbbVie will pay I-Mab $180 million in an upfront payment to exclusively license lemzoparlimab, along with $20 million in a milestone payment based on the Phase 1 results, for a total of $200 million. | (RTTNews) - AbbVie (ABBV) and I-Mab (IMAB) have signed a global collaboration agreement for the development and commercialization of lemzoparlimab, an anti-CD47 monoclonal antibody internally discovered and developed by I-Mab for the treatment of multiple cancers. AbbVie will pay I-Mab $180 million in an upfront payment to exclusively license lemzoparlimab, along with $20 million in a milestone payment based on the Phase 1 results, for a total of $200 million. Upon commercialization of lemzoparlimab, AbbVie will also pay tiered royalties from low-to-mid teen percentages on global net sales outside of greater China. | (RTTNews) - AbbVie (ABBV) and I-Mab (IMAB) have signed a global collaboration agreement for the development and commercialization of lemzoparlimab, an anti-CD47 monoclonal antibody internally discovered and developed by I-Mab for the treatment of multiple cancers. AbbVie will pay I-Mab $180 million in an upfront payment to exclusively license lemzoparlimab, along with $20 million in a milestone payment based on the Phase 1 results, for a total of $200 million. Upon commercialization of lemzoparlimab, AbbVie will also pay tiered royalties from low-to-mid teen percentages on global net sales outside of greater China. | (RTTNews) - AbbVie (ABBV) and I-Mab (IMAB) have signed a global collaboration agreement for the development and commercialization of lemzoparlimab, an anti-CD47 monoclonal antibody internally discovered and developed by I-Mab for the treatment of multiple cancers. AbbVie will pay I-Mab $180 million in an upfront payment to exclusively license lemzoparlimab, along with $20 million in a milestone payment based on the Phase 1 results, for a total of $200 million. Upon commercialization of lemzoparlimab, AbbVie will also pay tiered royalties from low-to-mid teen percentages on global net sales outside of greater China. |
24409.0 | 2020-09-01 00:00:00 UTC | BUZZ-U.S. STOCKS ON THE MOVE-Quest Diagnostics, Murphy USA Inc, Intercept Pharmaceuticals | ABBV | https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-quest-diagnostics-murphy-usa-inc-intercept-pharmaceuticals | nan | nan | Eikon search string for individual stock moves: STXBZ
The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi
The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh
The S&P 500 and the Nasdaq hit new highs on Tuesday with the tech-heavy index boosted by Apple and Zoom Video, while better-than-expected U.S. manufacturing sector data fueled optimism around a post-pandemic economic recovery. .N
At 13:00 p.m. ET, the Dow Jones Industrial Average .DJI was up 0.28% at 28,509.12. The S&P 500 .SPX was up 0.36% at 3,513.06 and the Nasdaq Composite .IXIC was up 1.02% at 11,895.958. The top three S&P 500 .PG.INX percentage gainers: ** Walmart Inc , up 6.2% ** L Brands Inc , up 5.2% ** Albemarle Corp , up 4.7% The top three S&P 500 .PL.INX percentage losers: ** Mylan Nv , down 4.8% ** Regeneron Pharmaceuticals Inc , down 4.5% ** Abbvie Inc , down 4.3% The top three NYSE .PG.N percentage gainers: ** Liberty Oilfield Services Inc , up 35% ** Eastman Kodak Co , up 26.8% ** At Home Group Inc , up 19.7% The top three NYSE .PL.N percentage losers: ** Global Blue Group Holding Ltd , down 11.9% ** Polymet Mining Corp , down 10.8% ** Retractable Technologies Inc , down 10.4% The top three Nasdaq .PG.O percentage gainers: ** Jounce Therapeutics Inc , up 50.4% ** Zoom Video Communications , up 36.6% ** Gogo Inc , up 33.2% The top three Nasdaq .PL.O percentage losers: ** Applied UV Inc Ord , down 22.9% ** PainReform Ltd , down 20% ** Neuronetics Inc , down 17.4% ** Zoom Video Communications Inc ZM.O: up 36.6%
BUZZ-Zoom soars after blowout report, defies Wall Street warnings ** Walmart Inc WMT.N: up 6.2%
BUZZ-Rises as retailer unveils 'Amazon Prime rival' ** Eastman Kodak Co KODK.N: up 26.7%
BUZZ-Kodak shares soar after D.E. Shaw discloses 5% stake ** T2 Biosystems Inc TTOO.O: up 7.7%
BUZZ-Up on U.S. FDA authorization for COVID-19 test ** Apple Inc AAPL.O: up 3.6%
BUZZ-Apple now has bigger market cap than Russell 2000 after stock split ** Zosano Pharma Corp ZSAN.O: down 7.1%
BUZZ-Drops on equity offering ** Bloomin' Brands Inc BLMN.O: up 9.4%
BUZZ-Jumps as Deutsche Bank sees sales rebound, upgrades ** Plus Therapeutics Inc PSTV.O: up 1.6%
BUZZ-Rises on FDA orphan drug tag for cancer treatment ** MediciNova Inc MNOV.O: up 3.8%
BUZZ-Jumps after progress on COVID-19 vaccine candidate ** Build-A-Bear Workshop BBW.N: up 15.5%
BUZZ-Up on 4x e-commerce boost, revenue beat ** Rackspace Technology Inc RXT.O: up 1.1%
BUZZ-Up after bookings more than double ** Tesla Inc TSLA.O: down 3.6%
BUZZ-Pares gains on $5 bln stock offering ** Aemetis Inc AMTX.O: up 33.1%
BUZZ-Rises on FDA registration for OTC sanitizer products ** Athenex Inc ANTX.O: up 9.8%
BUZZ-Jumps after FDA grants priority review for breast cancer treatment ** Renewable Energy Group Inc REGI.O: up 13.4%
BUZZ-CS starts with 'outperform' on 'attractive' M&A value ** Liberty Oilfield Services Inc LBRT.N: up 34.9%
BUZZ-Jumps on deal to buy Schlumberger's fracking unit ** J.Jill Inc JILL.N: up 81.4%
BUZZ-Soars as some lenders agree to restructuring deal ** Jounce Therapeutics Inc JNCE.O: up 50.4%
BUZZ-More than doubles on cancer therapy deal with Gilead ** INmune Bio Inc INMB.O: up 2.1%
BUZZ-Gains after FDA nod for drug trial in patients with COVID-19 complications ** Atossa Genetics Inc ATOS.O: up 0.3%
BUZZ-Up on safety data from early stage trial of COVID-19 nasal spray ** Hawaiian Holdings Inc HA.O: down 1.0%
BUZZ-Plans to cut over 400 jobs, shares down ** Abbvie Inc ABBV.N: down 4.3%
BUZZ-Slips on U.S. house panel subpoena in drug-pricing probe ** Quest Diagnostics Inc DGX.N: down 2.3%
BUZZ-Falls after Florida cuts ties on delayed COVID-19 test results ** Murphy USA Inc MUSA.N: up 1.5%
BUZZ-Rises on participating in Walmart Plus program ** Intercept Pharmaceuticals Inc ICPT.O: down 8.9%
BUZZ-To cut 25% jobs, shares drop
The 11 major S&P 500 sectors:
Communication Services
.SPLRCL
up 0.92%
Consumer Discretionary
.SPLRCD
up 0.85%
Consumer Staples
.SPLRCS
down 0.17%
Energy
.SPNY
down 0.84%
Financial
.SPSY
down 0.21%
Health
.SPXHC
down 1.35%
Industrial
.SPLRCI
up 0.75%
Information Technology
.SPLRCT
up 1.19%
Materials
.SPLRCM
up 1.42%
Real Estate
.SPLRCR
down 0.08%
Utilities
.SPLRCU
down 1.13%
(Compiled by Shivani Kumaresan in Bengaluru)
((Shivani.Kumaresan@thomsonreuters.com ; +1 646 223 8780))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The top three S&P 500 .PG.INX percentage gainers: ** Walmart Inc , up 6.2% ** L Brands Inc , up 5.2% ** Albemarle Corp , up 4.7% The top three S&P 500 .PL.INX percentage losers: ** Mylan Nv , down 4.8% ** Regeneron Pharmaceuticals Inc , down 4.5% ** Abbvie Inc , down 4.3% The top three NYSE .PG.N percentage gainers: ** Liberty Oilfield Services Inc , up 35% ** Eastman Kodak Co , up 26.8% ** At Home Group Inc , up 19.7% The top three NYSE .PL.N percentage losers: ** Global Blue Group Holding Ltd , down 11.9% ** Polymet Mining Corp , down 10.8% ** Retractable Technologies Inc , down 10.4% The top three Nasdaq .PG.O percentage gainers: ** Jounce Therapeutics Inc , up 50.4% ** Zoom Video Communications , up 36.6% ** Gogo Inc , up 33.2% The top three Nasdaq .PL.O percentage losers: ** Applied UV Inc Ord , down 22.9% ** PainReform Ltd , down 20% ** Neuronetics Inc , down 17.4% ** Zoom Video Communications Inc ZM.O: up 36.6% BUZZ-Zoom soars after blowout report, defies Wall Street warnings ** Walmart Inc WMT.N: up 6.2% BUZZ-Rises as retailer unveils 'Amazon Prime rival' ** Eastman Kodak Co KODK.N: up 26.7% BUZZ-Kodak shares soar after D.E. Shaw discloses 5% stake ** T2 Biosystems Inc TTOO.O: up 7.7% BUZZ-Up on U.S. FDA authorization for COVID-19 test ** Apple Inc AAPL.O: up 3.6% BUZZ-Apple now has bigger market cap than Russell 2000 after stock split ** Zosano Pharma Corp ZSAN.O: down 7.1% BUZZ-Drops on equity offering ** Bloomin' Brands Inc BLMN.O: up 9.4% BUZZ-Jumps as Deutsche Bank sees sales rebound, upgrades ** Plus Therapeutics Inc PSTV.O: up 1.6% BUZZ-Rises on FDA orphan drug tag for cancer treatment ** MediciNova Inc MNOV.O: up 3.8% BUZZ-Jumps after progress on COVID-19 vaccine candidate ** Build-A-Bear Workshop BBW.N: up 15.5% BUZZ-Up on 4x e-commerce boost, revenue beat ** Rackspace Technology Inc RXT.O: up 1.1% BUZZ-Up after bookings more than double ** Tesla Inc TSLA.O: down 3.6% BUZZ-Pares gains on $5 bln stock offering ** Aemetis Inc AMTX.O: up 33.1% BUZZ-Rises on FDA registration for OTC sanitizer products ** Athenex Inc ANTX.O: up 9.8% BUZZ-Jumps after FDA grants priority review for breast cancer treatment ** Renewable Energy Group Inc REGI.O: up 13.4% BUZZ-CS starts with 'outperform' on 'attractive' M&A value ** Liberty Oilfield Services Inc LBRT.N: up 34.9% BUZZ-Jumps on deal to buy Schlumberger's fracking unit ** J.Jill Inc JILL.N: up 81.4% BUZZ-Soars as some lenders agree to restructuring deal ** Jounce Therapeutics Inc JNCE.O: up 50.4% BUZZ-More than doubles on cancer therapy deal with Gilead ** INmune Bio Inc INMB.O: up 2.1% BUZZ-Gains after FDA nod for drug trial in patients with COVID-19 complications ** Atossa Genetics Inc ATOS.O: up 0.3% BUZZ-Up on safety data from early stage trial of COVID-19 nasal spray ** Hawaiian Holdings Inc HA.O: down 1.0% BUZZ-Plans to cut over 400 jobs, shares down ** Abbvie Inc ABBV.N: down 4.3% BUZZ-Slips on U.S. house panel subpoena in drug-pricing probe ** Quest Diagnostics Inc DGX.N: down 2.3% BUZZ-Falls after Florida cuts ties on delayed COVID-19 test results ** Murphy USA Inc MUSA.N: up 1.5% BUZZ-Rises on participating in Walmart Plus program ** Intercept Pharmaceuticals Inc ICPT.O: down 8.9% BUZZ-To cut 25% jobs, shares drop The 11 major S&P 500 sectors: Communication Services Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh The S&P 500 and the Nasdaq hit new highs on Tuesday with the tech-heavy index boosted by Apple and Zoom Video, while better-than-expected U.S. manufacturing sector data fueled optimism around a post-pandemic economic recovery. | The top three S&P 500 .PG.INX percentage gainers: ** Walmart Inc , up 6.2% ** L Brands Inc , up 5.2% ** Albemarle Corp , up 4.7% The top three S&P 500 .PL.INX percentage losers: ** Mylan Nv , down 4.8% ** Regeneron Pharmaceuticals Inc , down 4.5% ** Abbvie Inc , down 4.3% The top three NYSE .PG.N percentage gainers: ** Liberty Oilfield Services Inc , up 35% ** Eastman Kodak Co , up 26.8% ** At Home Group Inc , up 19.7% The top three NYSE .PL.N percentage losers: ** Global Blue Group Holding Ltd , down 11.9% ** Polymet Mining Corp , down 10.8% ** Retractable Technologies Inc , down 10.4% The top three Nasdaq .PG.O percentage gainers: ** Jounce Therapeutics Inc , up 50.4% ** Zoom Video Communications , up 36.6% ** Gogo Inc , up 33.2% The top three Nasdaq .PL.O percentage losers: ** Applied UV Inc Ord , down 22.9% ** PainReform Ltd , down 20% ** Neuronetics Inc , down 17.4% ** Zoom Video Communications Inc ZM.O: up 36.6% BUZZ-Zoom soars after blowout report, defies Wall Street warnings ** Walmart Inc WMT.N: up 6.2% BUZZ-Rises as retailer unveils 'Amazon Prime rival' ** Eastman Kodak Co KODK.N: up 26.7% BUZZ-Kodak shares soar after D.E. Shaw discloses 5% stake ** T2 Biosystems Inc TTOO.O: up 7.7% BUZZ-Up on U.S. FDA authorization for COVID-19 test ** Apple Inc AAPL.O: up 3.6% BUZZ-Apple now has bigger market cap than Russell 2000 after stock split ** Zosano Pharma Corp ZSAN.O: down 7.1% BUZZ-Drops on equity offering ** Bloomin' Brands Inc BLMN.O: up 9.4% BUZZ-Jumps as Deutsche Bank sees sales rebound, upgrades ** Plus Therapeutics Inc PSTV.O: up 1.6% BUZZ-Rises on FDA orphan drug tag for cancer treatment ** MediciNova Inc MNOV.O: up 3.8% BUZZ-Jumps after progress on COVID-19 vaccine candidate ** Build-A-Bear Workshop BBW.N: up 15.5% BUZZ-Up on 4x e-commerce boost, revenue beat ** Rackspace Technology Inc RXT.O: up 1.1% BUZZ-Up after bookings more than double ** Tesla Inc TSLA.O: down 3.6% BUZZ-Pares gains on $5 bln stock offering ** Aemetis Inc AMTX.O: up 33.1% BUZZ-Rises on FDA registration for OTC sanitizer products ** Athenex Inc ANTX.O: up 9.8% BUZZ-Jumps after FDA grants priority review for breast cancer treatment ** Renewable Energy Group Inc REGI.O: up 13.4% BUZZ-CS starts with 'outperform' on 'attractive' M&A value ** Liberty Oilfield Services Inc LBRT.N: up 34.9% BUZZ-Jumps on deal to buy Schlumberger's fracking unit ** J.Jill Inc JILL.N: up 81.4% BUZZ-Soars as some lenders agree to restructuring deal ** Jounce Therapeutics Inc JNCE.O: up 50.4% BUZZ-More than doubles on cancer therapy deal with Gilead ** INmune Bio Inc INMB.O: up 2.1% BUZZ-Gains after FDA nod for drug trial in patients with COVID-19 complications ** Atossa Genetics Inc ATOS.O: up 0.3% BUZZ-Up on safety data from early stage trial of COVID-19 nasal spray ** Hawaiian Holdings Inc HA.O: down 1.0% BUZZ-Plans to cut over 400 jobs, shares down ** Abbvie Inc ABBV.N: down 4.3% BUZZ-Slips on U.S. house panel subpoena in drug-pricing probe ** Quest Diagnostics Inc DGX.N: down 2.3% BUZZ-Falls after Florida cuts ties on delayed COVID-19 test results ** Murphy USA Inc MUSA.N: up 1.5% BUZZ-Rises on participating in Walmart Plus program ** Intercept Pharmaceuticals Inc ICPT.O: down 8.9% BUZZ-To cut 25% jobs, shares drop The 11 major S&P 500 sectors: Communication Services Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh The S&P 500 and the Nasdaq hit new highs on Tuesday with the tech-heavy index boosted by Apple and Zoom Video, while better-than-expected U.S. manufacturing sector data fueled optimism around a post-pandemic economic recovery. | The top three S&P 500 .PG.INX percentage gainers: ** Walmart Inc , up 6.2% ** L Brands Inc , up 5.2% ** Albemarle Corp , up 4.7% The top three S&P 500 .PL.INX percentage losers: ** Mylan Nv , down 4.8% ** Regeneron Pharmaceuticals Inc , down 4.5% ** Abbvie Inc , down 4.3% The top three NYSE .PG.N percentage gainers: ** Liberty Oilfield Services Inc , up 35% ** Eastman Kodak Co , up 26.8% ** At Home Group Inc , up 19.7% The top three NYSE .PL.N percentage losers: ** Global Blue Group Holding Ltd , down 11.9% ** Polymet Mining Corp , down 10.8% ** Retractable Technologies Inc , down 10.4% The top three Nasdaq .PG.O percentage gainers: ** Jounce Therapeutics Inc , up 50.4% ** Zoom Video Communications , up 36.6% ** Gogo Inc , up 33.2% The top three Nasdaq .PL.O percentage losers: ** Applied UV Inc Ord , down 22.9% ** PainReform Ltd , down 20% ** Neuronetics Inc , down 17.4% ** Zoom Video Communications Inc ZM.O: up 36.6% BUZZ-Zoom soars after blowout report, defies Wall Street warnings ** Walmart Inc WMT.N: up 6.2% BUZZ-Rises as retailer unveils 'Amazon Prime rival' ** Eastman Kodak Co KODK.N: up 26.7% BUZZ-Kodak shares soar after D.E. Shaw discloses 5% stake ** T2 Biosystems Inc TTOO.O: up 7.7% BUZZ-Up on U.S. FDA authorization for COVID-19 test ** Apple Inc AAPL.O: up 3.6% BUZZ-Apple now has bigger market cap than Russell 2000 after stock split ** Zosano Pharma Corp ZSAN.O: down 7.1% BUZZ-Drops on equity offering ** Bloomin' Brands Inc BLMN.O: up 9.4% BUZZ-Jumps as Deutsche Bank sees sales rebound, upgrades ** Plus Therapeutics Inc PSTV.O: up 1.6% BUZZ-Rises on FDA orphan drug tag for cancer treatment ** MediciNova Inc MNOV.O: up 3.8% BUZZ-Jumps after progress on COVID-19 vaccine candidate ** Build-A-Bear Workshop BBW.N: up 15.5% BUZZ-Up on 4x e-commerce boost, revenue beat ** Rackspace Technology Inc RXT.O: up 1.1% BUZZ-Up after bookings more than double ** Tesla Inc TSLA.O: down 3.6% BUZZ-Pares gains on $5 bln stock offering ** Aemetis Inc AMTX.O: up 33.1% BUZZ-Rises on FDA registration for OTC sanitizer products ** Athenex Inc ANTX.O: up 9.8% BUZZ-Jumps after FDA grants priority review for breast cancer treatment ** Renewable Energy Group Inc REGI.O: up 13.4% BUZZ-CS starts with 'outperform' on 'attractive' M&A value ** Liberty Oilfield Services Inc LBRT.N: up 34.9% BUZZ-Jumps on deal to buy Schlumberger's fracking unit ** J.Jill Inc JILL.N: up 81.4% BUZZ-Soars as some lenders agree to restructuring deal ** Jounce Therapeutics Inc JNCE.O: up 50.4% BUZZ-More than doubles on cancer therapy deal with Gilead ** INmune Bio Inc INMB.O: up 2.1% BUZZ-Gains after FDA nod for drug trial in patients with COVID-19 complications ** Atossa Genetics Inc ATOS.O: up 0.3% BUZZ-Up on safety data from early stage trial of COVID-19 nasal spray ** Hawaiian Holdings Inc HA.O: down 1.0% BUZZ-Plans to cut over 400 jobs, shares down ** Abbvie Inc ABBV.N: down 4.3% BUZZ-Slips on U.S. house panel subpoena in drug-pricing probe ** Quest Diagnostics Inc DGX.N: down 2.3% BUZZ-Falls after Florida cuts ties on delayed COVID-19 test results ** Murphy USA Inc MUSA.N: up 1.5% BUZZ-Rises on participating in Walmart Plus program ** Intercept Pharmaceuticals Inc ICPT.O: down 8.9% BUZZ-To cut 25% jobs, shares drop The 11 major S&P 500 sectors: Communication Services ET, the Dow Jones Industrial Average .DJI was up 0.28% at 28,509.12. | The top three S&P 500 .PG.INX percentage gainers: ** Walmart Inc , up 6.2% ** L Brands Inc , up 5.2% ** Albemarle Corp , up 4.7% The top three S&P 500 .PL.INX percentage losers: ** Mylan Nv , down 4.8% ** Regeneron Pharmaceuticals Inc , down 4.5% ** Abbvie Inc , down 4.3% The top three NYSE .PG.N percentage gainers: ** Liberty Oilfield Services Inc , up 35% ** Eastman Kodak Co , up 26.8% ** At Home Group Inc , up 19.7% The top three NYSE .PL.N percentage losers: ** Global Blue Group Holding Ltd , down 11.9% ** Polymet Mining Corp , down 10.8% ** Retractable Technologies Inc , down 10.4% The top three Nasdaq .PG.O percentage gainers: ** Jounce Therapeutics Inc , up 50.4% ** Zoom Video Communications , up 36.6% ** Gogo Inc , up 33.2% The top three Nasdaq .PL.O percentage losers: ** Applied UV Inc Ord , down 22.9% ** PainReform Ltd , down 20% ** Neuronetics Inc , down 17.4% ** Zoom Video Communications Inc ZM.O: up 36.6% BUZZ-Zoom soars after blowout report, defies Wall Street warnings ** Walmart Inc WMT.N: up 6.2% BUZZ-Rises as retailer unveils 'Amazon Prime rival' ** Eastman Kodak Co KODK.N: up 26.7% BUZZ-Kodak shares soar after D.E. Shaw discloses 5% stake ** T2 Biosystems Inc TTOO.O: up 7.7% BUZZ-Up on U.S. FDA authorization for COVID-19 test ** Apple Inc AAPL.O: up 3.6% BUZZ-Apple now has bigger market cap than Russell 2000 after stock split ** Zosano Pharma Corp ZSAN.O: down 7.1% BUZZ-Drops on equity offering ** Bloomin' Brands Inc BLMN.O: up 9.4% BUZZ-Jumps as Deutsche Bank sees sales rebound, upgrades ** Plus Therapeutics Inc PSTV.O: up 1.6% BUZZ-Rises on FDA orphan drug tag for cancer treatment ** MediciNova Inc MNOV.O: up 3.8% BUZZ-Jumps after progress on COVID-19 vaccine candidate ** Build-A-Bear Workshop BBW.N: up 15.5% BUZZ-Up on 4x e-commerce boost, revenue beat ** Rackspace Technology Inc RXT.O: up 1.1% BUZZ-Up after bookings more than double ** Tesla Inc TSLA.O: down 3.6% BUZZ-Pares gains on $5 bln stock offering ** Aemetis Inc AMTX.O: up 33.1% BUZZ-Rises on FDA registration for OTC sanitizer products ** Athenex Inc ANTX.O: up 9.8% BUZZ-Jumps after FDA grants priority review for breast cancer treatment ** Renewable Energy Group Inc REGI.O: up 13.4% BUZZ-CS starts with 'outperform' on 'attractive' M&A value ** Liberty Oilfield Services Inc LBRT.N: up 34.9% BUZZ-Jumps on deal to buy Schlumberger's fracking unit ** J.Jill Inc JILL.N: up 81.4% BUZZ-Soars as some lenders agree to restructuring deal ** Jounce Therapeutics Inc JNCE.O: up 50.4% BUZZ-More than doubles on cancer therapy deal with Gilead ** INmune Bio Inc INMB.O: up 2.1% BUZZ-Gains after FDA nod for drug trial in patients with COVID-19 complications ** Atossa Genetics Inc ATOS.O: up 0.3% BUZZ-Up on safety data from early stage trial of COVID-19 nasal spray ** Hawaiian Holdings Inc HA.O: down 1.0% BUZZ-Plans to cut over 400 jobs, shares down ** Abbvie Inc ABBV.N: down 4.3% BUZZ-Slips on U.S. house panel subpoena in drug-pricing probe ** Quest Diagnostics Inc DGX.N: down 2.3% BUZZ-Falls after Florida cuts ties on delayed COVID-19 test results ** Murphy USA Inc MUSA.N: up 1.5% BUZZ-Rises on participating in Walmart Plus program ** Intercept Pharmaceuticals Inc ICPT.O: down 8.9% BUZZ-To cut 25% jobs, shares drop The 11 major S&P 500 sectors: Communication Services Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh The S&P 500 and the Nasdaq hit new highs on Tuesday with the tech-heavy index boosted by Apple and Zoom Video, while better-than-expected U.S. manufacturing sector data fueled optimism around a post-pandemic economic recovery. |
24410.0 | 2020-09-01 00:00:00 UTC | Notable Tuesday Option Activity: CSCO, ABBV, MA | ABBV | https://www.nasdaq.com/articles/notable-tuesday-option-activity%3A-csco-abbv-ma-2020-09-01 | nan | nan | Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in Cisco Systems Inc (Symbol: CSCO), where a total of 150,103 contracts have traded so far, representing approximately 15.0 million underlying shares. That amounts to about 64.2% of CSCO's average daily trading volume over the past month of 23.4 million shares. Especially high volume was seen for the $44 strike call option expiring November 20, 2020, with 23,667 contracts trading so far today, representing approximately 2.4 million underlying shares of CSCO. Below is a chart showing CSCO's trailing twelve month trading history, with the $44 strike highlighted in orange:
AbbVie Inc (Symbol: ABBV) options are showing a volume of 31,758 contracts thus far today. That number of contracts represents approximately 3.2 million underlying shares, working out to a sizeable 49% of ABBV's average daily trading volume over the past month, of 6.5 million shares. Especially high volume was seen for the $95 strike call option expiring September 18, 2020, with 4,570 contracts trading so far today, representing approximately 457,000 underlying shares of ABBV. Below is a chart showing ABBV's trailing twelve month trading history, with the $95 strike highlighted in orange:
And Mastercard Inc (Symbol: MA) options are showing a volume of 16,307 contracts thus far today. That number of contracts represents approximately 1.6 million underlying shares, working out to a sizeable 47.1% of MA's average daily trading volume over the past month, of 3.5 million shares. Particularly high volume was seen for the $360 strike call option expiring September 18, 2020, with 951 contracts trading so far today, representing approximately 95,100 underlying shares of MA. Below is a chart showing MA's trailing twelve month trading history, with the $360 strike highlighted in orange:
For the various different available expirations for CSCO options, ABBV options, or MA options, visit StockOptionsChannel.com.
Today's Most Active Call & Put Options of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Especially high volume was seen for the $95 strike call option expiring September 18, 2020, with 4,570 contracts trading so far today, representing approximately 457,000 underlying shares of ABBV. Below is a chart showing CSCO's trailing twelve month trading history, with the $44 strike highlighted in orange: AbbVie Inc (Symbol: ABBV) options are showing a volume of 31,758 contracts thus far today. That number of contracts represents approximately 3.2 million underlying shares, working out to a sizeable 49% of ABBV's average daily trading volume over the past month, of 6.5 million shares. | Below is a chart showing CSCO's trailing twelve month trading history, with the $44 strike highlighted in orange: AbbVie Inc (Symbol: ABBV) options are showing a volume of 31,758 contracts thus far today. That number of contracts represents approximately 3.2 million underlying shares, working out to a sizeable 49% of ABBV's average daily trading volume over the past month, of 6.5 million shares. Especially high volume was seen for the $95 strike call option expiring September 18, 2020, with 4,570 contracts trading so far today, representing approximately 457,000 underlying shares of ABBV. | Below is a chart showing CSCO's trailing twelve month trading history, with the $44 strike highlighted in orange: AbbVie Inc (Symbol: ABBV) options are showing a volume of 31,758 contracts thus far today. That number of contracts represents approximately 3.2 million underlying shares, working out to a sizeable 49% of ABBV's average daily trading volume over the past month, of 6.5 million shares. Especially high volume was seen for the $95 strike call option expiring September 18, 2020, with 4,570 contracts trading so far today, representing approximately 457,000 underlying shares of ABBV. | Below is a chart showing MA's trailing twelve month trading history, with the $360 strike highlighted in orange: For the various different available expirations for CSCO options, ABBV options, or MA options, visit StockOptionsChannel.com. Below is a chart showing CSCO's trailing twelve month trading history, with the $44 strike highlighted in orange: AbbVie Inc (Symbol: ABBV) options are showing a volume of 31,758 contracts thus far today. That number of contracts represents approximately 3.2 million underlying shares, working out to a sizeable 49% of ABBV's average daily trading volume over the past month, of 6.5 million shares. |
24411.0 | 2020-09-01 00:00:00 UTC | Tuesday's ETF with Unusual Volume: IWX | ABBV | https://www.nasdaq.com/articles/tuesdays-etf-with-unusual-volume%3A-iwx-2020-09-01 | nan | nan | The iShares Russell Top 200 Value ETF is seeing unusually high volume in afternoon trading Tuesday, with over 185,000 shares traded versus three month average volume of about 93,000. Shares of IWX were down about 0.2% on the day.
Components of that ETF with the highest volume on Tuesday were General Electric, trading down about 0.2% with over 36.4 million shares changing hands so far this session, and Advanced Micro Devices, up about 0.1% on volume of over 27.0 million shares. Walmart is the component faring the best Tuesday, higher by about 6% on the day, while Abbvie is lagging other components of the iShares Russell Top 200 Value ETF, trading lower by about 4.6%.
VIDEO: Tuesday's ETF with Unusual Volume: IWX
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Walmart is the component faring the best Tuesday, higher by about 6% on the day, while Abbvie is lagging other components of the iShares Russell Top 200 Value ETF, trading lower by about 4.6%. The iShares Russell Top 200 Value ETF is seeing unusually high volume in afternoon trading Tuesday, with over 185,000 shares traded versus three month average volume of about 93,000. Components of that ETF with the highest volume on Tuesday were General Electric, trading down about 0.2% with over 36.4 million shares changing hands so far this session, and Advanced Micro Devices, up about 0.1% on volume of over 27.0 million shares. | Walmart is the component faring the best Tuesday, higher by about 6% on the day, while Abbvie is lagging other components of the iShares Russell Top 200 Value ETF, trading lower by about 4.6%. The iShares Russell Top 200 Value ETF is seeing unusually high volume in afternoon trading Tuesday, with over 185,000 shares traded versus three month average volume of about 93,000. VIDEO: Tuesday's ETF with Unusual Volume: IWX The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Walmart is the component faring the best Tuesday, higher by about 6% on the day, while Abbvie is lagging other components of the iShares Russell Top 200 Value ETF, trading lower by about 4.6%. The iShares Russell Top 200 Value ETF is seeing unusually high volume in afternoon trading Tuesday, with over 185,000 shares traded versus three month average volume of about 93,000. Components of that ETF with the highest volume on Tuesday were General Electric, trading down about 0.2% with over 36.4 million shares changing hands so far this session, and Advanced Micro Devices, up about 0.1% on volume of over 27.0 million shares. | Walmart is the component faring the best Tuesday, higher by about 6% on the day, while Abbvie is lagging other components of the iShares Russell Top 200 Value ETF, trading lower by about 4.6%. Components of that ETF with the highest volume on Tuesday were General Electric, trading down about 0.2% with over 36.4 million shares changing hands so far this session, and Advanced Micro Devices, up about 0.1% on volume of over 27.0 million shares. VIDEO: Tuesday's ETF with Unusual Volume: IWX The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. |
24412.0 | 2020-09-01 00:00:00 UTC | BUZZ-U.S. STOCKS ON THE MOVE-Abbvie Inc, Hawaiian Holdings, Zoom Video Communications | ABBV | https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-abbvie-inc-hawaiian-holdings-zoom-video-communications-2020 | nan | nan | Eikon search string for individual stock moves: STXBZ
The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi
The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh
Wall Street climbed on Tuesday as gains in Apple and Zoom Video shares propelled the tech-heavy Nasdaq to record highs, while better-than-expected U.S. manufacturing sector data fueled optimism around a post-pandemic economic recovery. .N
At 11:30 a.m. ET, the Dow Jones Industrial Average .DJI was up 0.25% at 28,500.66. The S&P 500 .SPX was up 0.27% at 3,509.93 and the Nasdaq Composite .IXIC was up 0.87% at 11,877.867. The top three S&P 500 .PG.INX percentage gainers: ** Walmart Inc , up 6.2% ** L Brands Inc , up 4.1% ** Broadcom Inc , up 3.8% The top three S&P 500 .PL.INX percentage losers: ** Mylan Nv , down 5% ** Abbvie Inc , down 4.2% ** Regeneron Pharmaceuticals Inc , down 4.2% The top three NYSE .PG.N percentage gainers: ** Liberty Oilfield Services Inc , up 34.9% ** Eastman Kodak Co , up 31% ** At Home Group Inc , up 23% The top three NYSE .PL.N percentage losers: ** Global Blue Group Holding Inc , down 10.1% ** CorMedix Inc , down 9.6% ** Cypress Environmental Partners LP , down 8.7% The top three Nasdaq .PG.O percentage gainers: ** Aemetis Inc , up 49% ** Jounce Therapeutics Inc , up 43.2% ** Zoom Video Communications Inc , up 33.6% The top three Nasdaq .PL.O percentage losers: ** Appld UV Inc , down 19.4% ** I-Mab , down 15.1% ** Greenpower Motor Company Inc , down 14.3% ** Zoom Video Communications Inc ZM.O: up 33.6%
BUZZ-Zoom soars after blowout report, defies Wall Street warnings ** Walmart Inc WMT.N: up 6.2%
BUZZ-Rises as retailer unveils 'Amazon Prime rival' ** Eastman Kodak Co KODK.N: up 30.9%
BUZZ-Kodak shares soar after D.E. Shaw discloses 5% stake ** T2 Biosystems Inc TTOO.O: up 6.1%
BUZZ-Up on U.S. FDA authorization for COVID-19 test ** Apple Inc AAPL.O: up 2.5%
BUZZ-Apple now has bigger market cap than Russell 2000 after stock split ** Zosano Pharma Corp ZSAN.O: down 9.7%
BUZZ-Drops on equity offering ** Bloomin' Brands Inc BLMN.O: up 8.2%
BUZZ-Jumps as Deutsche Bank sees sales rebound, upgrades ** Plus Therapeutics Inc PSTV.O: up 1.6%
BUZZ-Rises on FDA orphan drug tag for cancer treatment ** MediciNova Inc MNOV.O: up 4.0%
BUZZ-Jumps after progress on COVID-19 vaccine candidate ** Build-A-Bear Workshop BBW.N: up 17.2%
BUZZ-Up on 4x e-commerce boost, revenue beat ** Rackspace Technology Inc RXT.O: up 4.1%
BUZZ-Up after bookings more than double ** Tesla Inc TSLA.O: down 2.4%
BUZZ-Pares gains on $5 bln stock offering ** Aemetis Inc AMTX.O: up 49.0%
BUZZ-Rises on FDA registration for OTC sanitizer products ** Athenex Inc ANTX.O: up 9.5%
BUZZ-Jumps after FDA grants priority review for breast cancer treatment ** Renewable Energy Group Inc REGI.O: up 12.7%
BUZZ-CS starts with 'outperform' on 'attractive' M&A value ** Liberty Oilfield Services Inc LBRT.N: up 35.3%
BUZZ-Jumps on deal to buy Schlumberger's fracking unit ** J.Jill Inc JILL.N: up 97.1%
BUZZ-Soars as some lenders agree to restructuring deal ** Jounce Therapeutics Inc JNCE.O: up 43.2%
BUZZ-More than doubles on cancer therapy deal with Gilead ** Hawaiian Holdings Inc HA.O: down 1.1%
BUZZ-Plans to cut over 400 jobs, shares down ** Abbvie Inc ABBV.N: down 4.2%
BUZZ-Slips on U.S. house panel subpoena in drug-pricing probe
The 11 major S&P 500 sectors:
Communication Services
.SPLRCL
up 0.52%
Consumer Discretionary
.SPLRCD
up 0.74%
Consumer Staples
.SPLRCS
down 0.06%
Energy
.SPNY
down 0.92%
Financial
.SPSY
up 0.16%
Health
.SPXHC
down 1.17%
Industrial
.SPLRCI
up 0.45%
Information Technology
.SPLRCT
up 1.06%
Materials
.SPLRCM
up 0.77%
Real Estate
.SPLRCR
down 0.34%
Utilities
.SPLRCU
down 1.47%
(Compiled by Shivani Kumaresan in Bengaluru)
((Shivani.Kumaresan@thomsonreuters.com ; +1 646 223 8780))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The top three S&P 500 .PG.INX percentage gainers: ** Walmart Inc , up 6.2% ** L Brands Inc , up 4.1% ** Broadcom Inc , up 3.8% The top three S&P 500 .PL.INX percentage losers: ** Mylan Nv , down 5% ** Abbvie Inc , down 4.2% ** Regeneron Pharmaceuticals Inc , down 4.2% The top three NYSE .PG.N percentage gainers: ** Liberty Oilfield Services Inc , up 34.9% ** Eastman Kodak Co , up 31% ** At Home Group Inc , up 23% The top three NYSE .PL.N percentage losers: ** Global Blue Group Holding Inc , down 10.1% ** CorMedix Inc , down 9.6% ** Cypress Environmental Partners LP , down 8.7% The top three Nasdaq .PG.O percentage gainers: ** Aemetis Inc , up 49% ** Jounce Therapeutics Inc , up 43.2% ** Zoom Video Communications Inc , up 33.6% The top three Nasdaq .PL.O percentage losers: ** Appld UV Inc , down 19.4% ** I-Mab , down 15.1% ** Greenpower Motor Company Inc , down 14.3% ** Zoom Video Communications Inc ZM.O: up 33.6% BUZZ-Zoom soars after blowout report, defies Wall Street warnings ** Walmart Inc WMT.N: up 6.2% BUZZ-Rises as retailer unveils 'Amazon Prime rival' ** Eastman Kodak Co KODK.N: up 30.9% BUZZ-Kodak shares soar after D.E. Shaw discloses 5% stake ** T2 Biosystems Inc TTOO.O: up 6.1% BUZZ-Up on U.S. FDA authorization for COVID-19 test ** Apple Inc AAPL.O: up 2.5% BUZZ-Apple now has bigger market cap than Russell 2000 after stock split ** Zosano Pharma Corp ZSAN.O: down 9.7% BUZZ-Drops on equity offering ** Bloomin' Brands Inc BLMN.O: up 8.2% BUZZ-Jumps as Deutsche Bank sees sales rebound, upgrades ** Plus Therapeutics Inc PSTV.O: up 1.6% BUZZ-Rises on FDA orphan drug tag for cancer treatment ** MediciNova Inc MNOV.O: up 4.0% BUZZ-Jumps after progress on COVID-19 vaccine candidate ** Build-A-Bear Workshop BBW.N: up 17.2% BUZZ-Up on 4x e-commerce boost, revenue beat ** Rackspace Technology Inc RXT.O: up 4.1% BUZZ-Up after bookings more than double ** Tesla Inc TSLA.O: down 2.4% BUZZ-Pares gains on $5 bln stock offering ** Aemetis Inc AMTX.O: up 49.0% BUZZ-Rises on FDA registration for OTC sanitizer products ** Athenex Inc ANTX.O: up 9.5% BUZZ-Jumps after FDA grants priority review for breast cancer treatment ** Renewable Energy Group Inc REGI.O: up 12.7% BUZZ-CS starts with 'outperform' on 'attractive' M&A value ** Liberty Oilfield Services Inc LBRT.N: up 35.3% BUZZ-Jumps on deal to buy Schlumberger's fracking unit ** J.Jill Inc JILL.N: up 97.1% BUZZ-Soars as some lenders agree to restructuring deal ** Jounce Therapeutics Inc JNCE.O: up 43.2% BUZZ-More than doubles on cancer therapy deal with Gilead ** Hawaiian Holdings Inc HA.O: down 1.1% BUZZ-Plans to cut over 400 jobs, shares down ** Abbvie Inc ABBV.N: down 4.2% BUZZ-Slips on U.S. house panel subpoena in drug-pricing probe The 11 major S&P 500 sectors: Communication Services Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh Wall Street climbed on Tuesday as gains in Apple and Zoom Video shares propelled the tech-heavy Nasdaq to record highs, while better-than-expected U.S. manufacturing sector data fueled optimism around a post-pandemic economic recovery. | The top three S&P 500 .PG.INX percentage gainers: ** Walmart Inc , up 6.2% ** L Brands Inc , up 4.1% ** Broadcom Inc , up 3.8% The top three S&P 500 .PL.INX percentage losers: ** Mylan Nv , down 5% ** Abbvie Inc , down 4.2% ** Regeneron Pharmaceuticals Inc , down 4.2% The top three NYSE .PG.N percentage gainers: ** Liberty Oilfield Services Inc , up 34.9% ** Eastman Kodak Co , up 31% ** At Home Group Inc , up 23% The top three NYSE .PL.N percentage losers: ** Global Blue Group Holding Inc , down 10.1% ** CorMedix Inc , down 9.6% ** Cypress Environmental Partners LP , down 8.7% The top three Nasdaq .PG.O percentage gainers: ** Aemetis Inc , up 49% ** Jounce Therapeutics Inc , up 43.2% ** Zoom Video Communications Inc , up 33.6% The top three Nasdaq .PL.O percentage losers: ** Appld UV Inc , down 19.4% ** I-Mab , down 15.1% ** Greenpower Motor Company Inc , down 14.3% ** Zoom Video Communications Inc ZM.O: up 33.6% BUZZ-Zoom soars after blowout report, defies Wall Street warnings ** Walmart Inc WMT.N: up 6.2% BUZZ-Rises as retailer unveils 'Amazon Prime rival' ** Eastman Kodak Co KODK.N: up 30.9% BUZZ-Kodak shares soar after D.E. Shaw discloses 5% stake ** T2 Biosystems Inc TTOO.O: up 6.1% BUZZ-Up on U.S. FDA authorization for COVID-19 test ** Apple Inc AAPL.O: up 2.5% BUZZ-Apple now has bigger market cap than Russell 2000 after stock split ** Zosano Pharma Corp ZSAN.O: down 9.7% BUZZ-Drops on equity offering ** Bloomin' Brands Inc BLMN.O: up 8.2% BUZZ-Jumps as Deutsche Bank sees sales rebound, upgrades ** Plus Therapeutics Inc PSTV.O: up 1.6% BUZZ-Rises on FDA orphan drug tag for cancer treatment ** MediciNova Inc MNOV.O: up 4.0% BUZZ-Jumps after progress on COVID-19 vaccine candidate ** Build-A-Bear Workshop BBW.N: up 17.2% BUZZ-Up on 4x e-commerce boost, revenue beat ** Rackspace Technology Inc RXT.O: up 4.1% BUZZ-Up after bookings more than double ** Tesla Inc TSLA.O: down 2.4% BUZZ-Pares gains on $5 bln stock offering ** Aemetis Inc AMTX.O: up 49.0% BUZZ-Rises on FDA registration for OTC sanitizer products ** Athenex Inc ANTX.O: up 9.5% BUZZ-Jumps after FDA grants priority review for breast cancer treatment ** Renewable Energy Group Inc REGI.O: up 12.7% BUZZ-CS starts with 'outperform' on 'attractive' M&A value ** Liberty Oilfield Services Inc LBRT.N: up 35.3% BUZZ-Jumps on deal to buy Schlumberger's fracking unit ** J.Jill Inc JILL.N: up 97.1% BUZZ-Soars as some lenders agree to restructuring deal ** Jounce Therapeutics Inc JNCE.O: up 43.2% BUZZ-More than doubles on cancer therapy deal with Gilead ** Hawaiian Holdings Inc HA.O: down 1.1% BUZZ-Plans to cut over 400 jobs, shares down ** Abbvie Inc ABBV.N: down 4.2% BUZZ-Slips on U.S. house panel subpoena in drug-pricing probe The 11 major S&P 500 sectors: Communication Services Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh Wall Street climbed on Tuesday as gains in Apple and Zoom Video shares propelled the tech-heavy Nasdaq to record highs, while better-than-expected U.S. manufacturing sector data fueled optimism around a post-pandemic economic recovery. | The top three S&P 500 .PG.INX percentage gainers: ** Walmart Inc , up 6.2% ** L Brands Inc , up 4.1% ** Broadcom Inc , up 3.8% The top three S&P 500 .PL.INX percentage losers: ** Mylan Nv , down 5% ** Abbvie Inc , down 4.2% ** Regeneron Pharmaceuticals Inc , down 4.2% The top three NYSE .PG.N percentage gainers: ** Liberty Oilfield Services Inc , up 34.9% ** Eastman Kodak Co , up 31% ** At Home Group Inc , up 23% The top three NYSE .PL.N percentage losers: ** Global Blue Group Holding Inc , down 10.1% ** CorMedix Inc , down 9.6% ** Cypress Environmental Partners LP , down 8.7% The top three Nasdaq .PG.O percentage gainers: ** Aemetis Inc , up 49% ** Jounce Therapeutics Inc , up 43.2% ** Zoom Video Communications Inc , up 33.6% The top three Nasdaq .PL.O percentage losers: ** Appld UV Inc , down 19.4% ** I-Mab , down 15.1% ** Greenpower Motor Company Inc , down 14.3% ** Zoom Video Communications Inc ZM.O: up 33.6% BUZZ-Zoom soars after blowout report, defies Wall Street warnings ** Walmart Inc WMT.N: up 6.2% BUZZ-Rises as retailer unveils 'Amazon Prime rival' ** Eastman Kodak Co KODK.N: up 30.9% BUZZ-Kodak shares soar after D.E. Shaw discloses 5% stake ** T2 Biosystems Inc TTOO.O: up 6.1% BUZZ-Up on U.S. FDA authorization for COVID-19 test ** Apple Inc AAPL.O: up 2.5% BUZZ-Apple now has bigger market cap than Russell 2000 after stock split ** Zosano Pharma Corp ZSAN.O: down 9.7% BUZZ-Drops on equity offering ** Bloomin' Brands Inc BLMN.O: up 8.2% BUZZ-Jumps as Deutsche Bank sees sales rebound, upgrades ** Plus Therapeutics Inc PSTV.O: up 1.6% BUZZ-Rises on FDA orphan drug tag for cancer treatment ** MediciNova Inc MNOV.O: up 4.0% BUZZ-Jumps after progress on COVID-19 vaccine candidate ** Build-A-Bear Workshop BBW.N: up 17.2% BUZZ-Up on 4x e-commerce boost, revenue beat ** Rackspace Technology Inc RXT.O: up 4.1% BUZZ-Up after bookings more than double ** Tesla Inc TSLA.O: down 2.4% BUZZ-Pares gains on $5 bln stock offering ** Aemetis Inc AMTX.O: up 49.0% BUZZ-Rises on FDA registration for OTC sanitizer products ** Athenex Inc ANTX.O: up 9.5% BUZZ-Jumps after FDA grants priority review for breast cancer treatment ** Renewable Energy Group Inc REGI.O: up 12.7% BUZZ-CS starts with 'outperform' on 'attractive' M&A value ** Liberty Oilfield Services Inc LBRT.N: up 35.3% BUZZ-Jumps on deal to buy Schlumberger's fracking unit ** J.Jill Inc JILL.N: up 97.1% BUZZ-Soars as some lenders agree to restructuring deal ** Jounce Therapeutics Inc JNCE.O: up 43.2% BUZZ-More than doubles on cancer therapy deal with Gilead ** Hawaiian Holdings Inc HA.O: down 1.1% BUZZ-Plans to cut over 400 jobs, shares down ** Abbvie Inc ABBV.N: down 4.2% BUZZ-Slips on U.S. house panel subpoena in drug-pricing probe The 11 major S&P 500 sectors: Communication Services ET, the Dow Jones Industrial Average .DJI was up 0.25% at 28,500.66. | The top three S&P 500 .PG.INX percentage gainers: ** Walmart Inc , up 6.2% ** L Brands Inc , up 4.1% ** Broadcom Inc , up 3.8% The top three S&P 500 .PL.INX percentage losers: ** Mylan Nv , down 5% ** Abbvie Inc , down 4.2% ** Regeneron Pharmaceuticals Inc , down 4.2% The top three NYSE .PG.N percentage gainers: ** Liberty Oilfield Services Inc , up 34.9% ** Eastman Kodak Co , up 31% ** At Home Group Inc , up 23% The top three NYSE .PL.N percentage losers: ** Global Blue Group Holding Inc , down 10.1% ** CorMedix Inc , down 9.6% ** Cypress Environmental Partners LP , down 8.7% The top three Nasdaq .PG.O percentage gainers: ** Aemetis Inc , up 49% ** Jounce Therapeutics Inc , up 43.2% ** Zoom Video Communications Inc , up 33.6% The top three Nasdaq .PL.O percentage losers: ** Appld UV Inc , down 19.4% ** I-Mab , down 15.1% ** Greenpower Motor Company Inc , down 14.3% ** Zoom Video Communications Inc ZM.O: up 33.6% BUZZ-Zoom soars after blowout report, defies Wall Street warnings ** Walmart Inc WMT.N: up 6.2% BUZZ-Rises as retailer unveils 'Amazon Prime rival' ** Eastman Kodak Co KODK.N: up 30.9% BUZZ-Kodak shares soar after D.E. Shaw discloses 5% stake ** T2 Biosystems Inc TTOO.O: up 6.1% BUZZ-Up on U.S. FDA authorization for COVID-19 test ** Apple Inc AAPL.O: up 2.5% BUZZ-Apple now has bigger market cap than Russell 2000 after stock split ** Zosano Pharma Corp ZSAN.O: down 9.7% BUZZ-Drops on equity offering ** Bloomin' Brands Inc BLMN.O: up 8.2% BUZZ-Jumps as Deutsche Bank sees sales rebound, upgrades ** Plus Therapeutics Inc PSTV.O: up 1.6% BUZZ-Rises on FDA orphan drug tag for cancer treatment ** MediciNova Inc MNOV.O: up 4.0% BUZZ-Jumps after progress on COVID-19 vaccine candidate ** Build-A-Bear Workshop BBW.N: up 17.2% BUZZ-Up on 4x e-commerce boost, revenue beat ** Rackspace Technology Inc RXT.O: up 4.1% BUZZ-Up after bookings more than double ** Tesla Inc TSLA.O: down 2.4% BUZZ-Pares gains on $5 bln stock offering ** Aemetis Inc AMTX.O: up 49.0% BUZZ-Rises on FDA registration for OTC sanitizer products ** Athenex Inc ANTX.O: up 9.5% BUZZ-Jumps after FDA grants priority review for breast cancer treatment ** Renewable Energy Group Inc REGI.O: up 12.7% BUZZ-CS starts with 'outperform' on 'attractive' M&A value ** Liberty Oilfield Services Inc LBRT.N: up 35.3% BUZZ-Jumps on deal to buy Schlumberger's fracking unit ** J.Jill Inc JILL.N: up 97.1% BUZZ-Soars as some lenders agree to restructuring deal ** Jounce Therapeutics Inc JNCE.O: up 43.2% BUZZ-More than doubles on cancer therapy deal with Gilead ** Hawaiian Holdings Inc HA.O: down 1.1% BUZZ-Plans to cut over 400 jobs, shares down ** Abbvie Inc ABBV.N: down 4.2% BUZZ-Slips on U.S. house panel subpoena in drug-pricing probe The 11 major S&P 500 sectors: Communication Services Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh Wall Street climbed on Tuesday as gains in Apple and Zoom Video shares propelled the tech-heavy Nasdaq to record highs, while better-than-expected U.S. manufacturing sector data fueled optimism around a post-pandemic economic recovery. |
24413.0 | 2020-09-01 00:00:00 UTC | U.S. House Oversight Committee to subpoena AbbVie in drug-pricing probe | ABBV | https://www.nasdaq.com/articles/u.s.-house-oversight-committee-to-subpoena-abbvie-in-drug-pricing-probe-2020-09-01 | nan | nan | Adds AbbVie comment
Sept 1 (Reuters) - The U.S. House Oversight Committee on Tuesday decided to subpoena AbbVie Inc ABBV.N to seek documents on the drugmaker's blockbuster treatments, Humira and Imbruvica, as part of its investigation into drug-pricing practices.
The committee began the probe last year and had sought information from 12 drugmakers on price increases, corporate strategies to preserve market share and pricing power.
"After more than 18 months, AbbVie has demonstrated its unwillingness to comply voluntarily with the committee's investigation," Representative Carolyn Maloney, the Chairwoman of the committee, wrote in a memo.
"Although most of the drug companies we are examining have cooperated with the committee's investigation, AbbVie's noncompliance stands out as particularly egregious, which is why I am issuing this subpoena."
AbbVie said it has been cooperating with the committee since it received their initial letter in January 2019.
"While we are surprised and disappointed the committee chose to take this action, we will continue to work in good faith with them on this important subject," the drugmaker said in a statement.
AbbVie shares fell nearly 3% to $93.10 on Tuesday.
(Reporting by Ankur Banerjee in Bengaluru; Editing by Arun Koyyur)
((ankur.banerjee@thomsonreuters.com;; within U.S. +1 646 223 8780, outside U.S. +91 80 6749 6132; Twitter: @AnkurBanerjee17;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Adds AbbVie comment Sept 1 (Reuters) - The U.S. House Oversight Committee on Tuesday decided to subpoena AbbVie Inc ABBV.N to seek documents on the drugmaker's blockbuster treatments, Humira and Imbruvica, as part of its investigation into drug-pricing practices. "Although most of the drug companies we are examining have cooperated with the committee's investigation, AbbVie's noncompliance stands out as particularly egregious, which is why I am issuing this subpoena." "After more than 18 months, AbbVie has demonstrated its unwillingness to comply voluntarily with the committee's investigation," Representative Carolyn Maloney, the Chairwoman of the committee, wrote in a memo. | Adds AbbVie comment Sept 1 (Reuters) - The U.S. House Oversight Committee on Tuesday decided to subpoena AbbVie Inc ABBV.N to seek documents on the drugmaker's blockbuster treatments, Humira and Imbruvica, as part of its investigation into drug-pricing practices. "After more than 18 months, AbbVie has demonstrated its unwillingness to comply voluntarily with the committee's investigation," Representative Carolyn Maloney, the Chairwoman of the committee, wrote in a memo. "Although most of the drug companies we are examining have cooperated with the committee's investigation, AbbVie's noncompliance stands out as particularly egregious, which is why I am issuing this subpoena." | Adds AbbVie comment Sept 1 (Reuters) - The U.S. House Oversight Committee on Tuesday decided to subpoena AbbVie Inc ABBV.N to seek documents on the drugmaker's blockbuster treatments, Humira and Imbruvica, as part of its investigation into drug-pricing practices. "After more than 18 months, AbbVie has demonstrated its unwillingness to comply voluntarily with the committee's investigation," Representative Carolyn Maloney, the Chairwoman of the committee, wrote in a memo. "Although most of the drug companies we are examining have cooperated with the committee's investigation, AbbVie's noncompliance stands out as particularly egregious, which is why I am issuing this subpoena." | Adds AbbVie comment Sept 1 (Reuters) - The U.S. House Oversight Committee on Tuesday decided to subpoena AbbVie Inc ABBV.N to seek documents on the drugmaker's blockbuster treatments, Humira and Imbruvica, as part of its investigation into drug-pricing practices. "After more than 18 months, AbbVie has demonstrated its unwillingness to comply voluntarily with the committee's investigation," Representative Carolyn Maloney, the Chairwoman of the committee, wrote in a memo. "Although most of the drug companies we are examining have cooperated with the committee's investigation, AbbVie's noncompliance stands out as particularly egregious, which is why I am issuing this subpoena." |
24414.0 | 2020-09-01 00:00:00 UTC | 2 Embarrassingly Cheap Dividend Stocks | ABBV | https://www.nasdaq.com/articles/2-embarrassingly-cheap-dividend-stocks-2020-09-01 | nan | nan | Investing in sturdy dividend stocks is a fantastic way to diversify your portfolio and collect some extra cash. If you invest in companies with a historically robust (and growing) dividend and stable balance sheet, you could enjoy a stream of secondary income that can be used to buy additional shares, save, or put toward retirement.
Before you invest in these types of stocks, however, it's important to separate the dividend champions from the duds. Although biopharmaceutical leader Gilead Sciences (NASDAQ: GILD) only started paying a dividend in the last several years, it has consistently raised its payouts since that time. And over the last three years in particular, the company has grown its dividend by nearly 37%. Large-cap pharmaceutical company Bristol Myers Squibb (NYSE: BMY) started paying shareholders a dividend 40 years ago, and has raised its dividend by more than 90% over the past 20 years alone. Gilead is currently trading at about $66 per share while Bristol Myers' stock sits around $62. Regularly buying and holding some of these inexpensive shares could spell major gains in the long run. Here's what you need to know before you scoop up Bristol Myers and Gilead Sciences.
Image source: Getty Images.
1. Gilead Sciences
Gilead Sciences' dividend yields 4.13%, far higher than the S&P 500 average of 2%. Although the company's share price has fluctuated since the beginning of the year, the stock is still an affordable option for dividend investors willing to ride short term dips. Its forward P/E ratio sits just under 10, suggesting that the discounted stock has more growth ahead and is inexpensive at its going rate.
But don't get me wrong. A cheap stock price doesn't make a company a buy. Some investors have been on the fence about Gilead's prospects since the U.S. Food and Drug Administration (FDA) denied its new drug approval application. Gilead had hoped that its potential rheumatoid arthritis (RA) treatment, filgotinib, and its unique profile would provide RA patients better results than some of the bigger drugs on the market, which include Johnson & Johnson's Remicade, AbbVie's Humira, and Amgen's Enbrel. The market for RA treatments is a highly profitable space, expected to reach a value of more than $9 billion this year.
Another recent issue for Gilead has been mixed findings on the safety and effectiveness of remdesivir, also known by the brand name Veklury, which the company marketed as a treatment for patients with severe cases of COVID-19. An Aug. 28 expanded emergency use authorization (EUA) from the FDA has since quelled some worries. Phase 3 SIMPLE trials showed that remdesivir produced favorable results in hospitalized patients with moderate cases of COVID-19. Before this use expansion, Veklury was only authorized for severely ill individuals hospitalized with the disease. Now, the drug can be administered to any patient hospitalized with COVID-19. Considering that Gilead is already planning to produce millions of courses of Veklury at a price tag of up to $3,120 per treatment, the expansion could have an extremely favorable impact on the company's balance sheet.
Speaking of Gilead's balance sheet, the company managed to deliver strong financial results in first half of 2020, with just a 3% decline in total product sales. The company's product sales in the first six months of 2020 came to $10.5 billion, bolstered mostly by its HIV product segment, up 6% year over year to $8.1 billion. Gilead's large B-cell lymphoma treatment, Yescarta, also demonstrated 37% sales growth in the first six months, amassing $296 billion. Even though product sales in the U.S. and Europe were down in the first half of 2020, international product sales were up by 12%. It's been a year of ups and downs for Gilead Sciences, but that doesn't mean this cheap stock won't come out on top in the long term, as I believe it can.
2. Bristol Myers Squibb
Closing at around $62, Bristol Myers Squibb stock price has proven relatively resilient this year, declining by 3% since Jan. 1. The company consistently pays a dividend of just under 3%, and has increased its per share payments every year since 1999. Shares have risen 29% over the trailing 12 months, but Bristol Myers still looks undervalued, trading at just 11 times earnings.
The company's saw 82% revenue growth in the first quarter of 2020 and 61% growth in the second quarter that ended June 30. In Q2 2020, Bristol Myers reported a gross margin of 73.4%, with cash flow of $22.2 billion. The company's purchase of Celgene contributed significantly to Bristol Myers' success at the height of the pandemic, although the acquisition dented its bottom line. The fact that Bristol Myers' portfolio contains a variety of medicines in high demand during any market climate also boosted performance. For example, the chemotherapy drug Revlimid, which Bristol Myers gained through Celgene, hit $2.9 billion in sales in Q2 2020. The blockbuster cancer drug Opdivo amassed $1.7 billion in revenue during the second quarter, up 9% from Q2 2019.
On Aug. 11, Bristol Myers reported that a phase 3 trial studying Opdivo as an adjuvant treatment for patients with gastroesophageal junction or resected esophageal cancer achieved its primary endpoint. Opdivo is already approved to treat other diseases including non-small cell lung cancer, Hodgkin's lymphoma, and colorectal cancer.
The company has a pipeline with more than 50 compounds in development involving over 40 disease areas. Its robust portfolio and the strength of its balance sheet have revealed Bristol Myers' resilience in the face of six months of volatility. The combination of its cheap price, strong indicators for future growth, and consistent payouts make this dividend stock a compelling choice to buy and hold for the next decade and beyond.
10 stocks we like better than Gilead Sciences
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Gilead Sciences wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of August 1, 2020
Rachel Warren has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Bristol Myers Squibb and Gilead Sciences. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Gilead had hoped that its potential rheumatoid arthritis (RA) treatment, filgotinib, and its unique profile would provide RA patients better results than some of the bigger drugs on the market, which include Johnson & Johnson's Remicade, AbbVie's Humira, and Amgen's Enbrel. If you invest in companies with a historically robust (and growing) dividend and stable balance sheet, you could enjoy a stream of secondary income that can be used to buy additional shares, save, or put toward retirement. On Aug. 11, Bristol Myers reported that a phase 3 trial studying Opdivo as an adjuvant treatment for patients with gastroesophageal junction or resected esophageal cancer achieved its primary endpoint. | Gilead had hoped that its potential rheumatoid arthritis (RA) treatment, filgotinib, and its unique profile would provide RA patients better results than some of the bigger drugs on the market, which include Johnson & Johnson's Remicade, AbbVie's Humira, and Amgen's Enbrel. Although biopharmaceutical leader Gilead Sciences (NASDAQ: GILD) only started paying a dividend in the last several years, it has consistently raised its payouts since that time. Bristol Myers Squibb Closing at around $62, Bristol Myers Squibb stock price has proven relatively resilient this year, declining by 3% since Jan. 1. | Gilead had hoped that its potential rheumatoid arthritis (RA) treatment, filgotinib, and its unique profile would provide RA patients better results than some of the bigger drugs on the market, which include Johnson & Johnson's Remicade, AbbVie's Humira, and Amgen's Enbrel. Large-cap pharmaceutical company Bristol Myers Squibb (NYSE: BMY) started paying shareholders a dividend 40 years ago, and has raised its dividend by more than 90% over the past 20 years alone. Gilead is currently trading at about $66 per share while Bristol Myers' stock sits around $62. | Gilead had hoped that its potential rheumatoid arthritis (RA) treatment, filgotinib, and its unique profile would provide RA patients better results than some of the bigger drugs on the market, which include Johnson & Johnson's Remicade, AbbVie's Humira, and Amgen's Enbrel. Before this use expansion, Veklury was only authorized for severely ill individuals hospitalized with the disease. For example, the chemotherapy drug Revlimid, which Bristol Myers gained through Celgene, hit $2.9 billion in sales in Q2 2020. |
24415.0 | 2020-09-01 00:00:00 UTC | Forget Johnson & Johnson, AbbVie Is a Better Dividend Stock | ABBV | https://www.nasdaq.com/articles/forget-johnson-johnson-abbvie-is-a-better-dividend-stock-2020-09-01 | nan | nan | Dividend stocks are great for long-term investors who want to sit back and watch secondary income accumulate. Dividend investing can be a great way to supplement returns, especially over longer periods of time once you've accumulated a nice number of paying stocks in your portfolio. In the midst of the biggest recession since 2008, it's more important than ever to load up on safe and reliable stocks that will stand the test of time. A dividend is just one signal of a company's longevity and future value.
One healthcare stock that dividend investors gravitate toward is Johnson & Johnson (NYSE: JNJ). The big-name drugmaker pays a decent and regular yield: It's been growing payouts for decades and its drug pipeline and consumer goods businesses are solid. But perhaps there's an even better option for dividend investors in pharmaceutical company AbbVie (NYSE: ABBV). Here's why:
AbbVie's dividend yield is much higher -- and likely to stay that way
Today, J&J pays its shareholders a quarterly dividend of $1.01 for an annual yield of 2.6%, which is well above the S&P 500 average of 2%. AbbVie, however, pays a quarterly dividend of $1.18, which annually yields over 5% at current share prices. This is significantly higher than J&J's yield, such that if you were to invest $10,000 in both stocks, AbbVie's annual payouts would be $240 higher. Even if you factor in each company's historical dividend growth, that gap isn't likely to narrow.
Image source: Getty Images.
Unless J&J's share price falls sharply to where its dividend yield increases significantly (or the reverse happens to AbbVie), it's unlikely that J&J's dividend will bridge the gap. Both of these companies have long histories of paying dividends. J&J is a Dividend King, having raised payouts for 58 years in a row. AbbVie is still a Dividend Aristocrat, having increased dividend payments for more than 40 straight years if you include its time as a part of Abbott Labs.
J&J has increased its dividend payments by 34.7% from the $0.75 it was distributing to shareholders five years ago. Its rise averages to a compound annual growth rate (CAGR) of 6.1%. In contrast, AbbVie's payouts are more than double the $0.51 it was paying in 2015, and sport a CAGR of 18.3%.
AbbVie's most recent payout increase was a modest 10.3%, though still higher than the 6.3% that J&J hiked its payouts by earlier this year. Unless there's a significant change in dividend policies from either of these two companies, it is unlikely that J&J's dividend and yield will best AbbVie's anytime soon.
AbbVie's dividend is at less risk in the long-term
Another reason income investors should opt for AbbVie's dividend? It's growing, and not really at risk of slowing down.
On May 8, the company completed a $63 billion acquisition of Botox-maker Allergan. The move leaves AbbVie a more reliable long-term buy, as the deal diversified the pharma company's business. Currently, AbbVie relies on Humira, a biologic used to treat arthritis, psoriasis, and Crohn's disease for 50% of its sales. The deal with Allergan renders AbbVie's business opportunities safer, and makes room for the company to continue growing its dividend payouts at a high rate.
Even without the new acquisition, an ability to increase its dividend probably would not be a huge concern for AbbVie. The company has reported positive free cash flow in each of the past 10 quarters in amounts far higher than the sum paid out in dividends. Last year, dividend payments amounted to about 47% of its total operating cash flow.
This is not to say that J&J has had trouble maintaining its dividend either. It's also generated positive free cash flow in each of the past 10 quarters, and has had more than enough to cover its dividend payments, which amount to about $9.9 billion annually. In 2019, J&J's dividend payments comprised about 42% of its own operating cash flow.
One of the biggest concerns that investors have with J&J is the company's legal turmoil. Over the past few years, it has faced lawsuits surrounding the antipsychotic drug Risperdal, talc baby powder, and most notably, its role in the opioid crisis. In 2019, the company incurred $5.1 billion in litigation expenses, more than double the $2 billion it recorded in the previous year. While its dividend remains safe today, future litigation could become a problem for the New Jersey-based company, especially if expenses continue to rise and new suits are filed. If J&J is consistently spending billions in court, keeping up its dividend payments at its current rate could be a challenge.
Both of these companies are in similar boats due to COVID-19. In J&J's second-quarter results, released on July 16 for the period ended June 28, sales of $18.3 billion were down by 10.8% year over year. Earnings per share (EPS) of $1.36 also declined by 34.6% from the year-prior period.
AbbVie released its second-quarter results on July 31 for the period ended June 30. Its sales of $10.4 billion were down 5.3% on a comparable operational basis. Sales were technically up 26.3%, but that was largely due to the integration of Allergan into the results. EPS was negative $0.46, compared to positive $0.49 for the same period last year. The company incurred $777 million in acquisition-related expenses during the quarter, which weighed on its bottom line.
AbbVie is the way forward for income investors
Although J&J is a Dividend King, that's not enough for it to prove the better buy when compared to AbbVie. An investor's job is made trickier by the fact that both of these healthcare stocks appear similar in their returns this year:
ABBV data by YCharts
Neither company has quite outperformed the S&P 500, although both are stable, value investments. But with a better payout and a strong, perhaps less perilous future, AbbVie looks to be the better immediate option for dividend investors.
10 stocks we like better than Johnson & Johnson
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Johnson & Johnson wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of August 1, 2020
David Jagielski has no position in any of the stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The deal with Allergan renders AbbVie's business opportunities safer, and makes room for the company to continue growing its dividend payouts at a high rate. An investor's job is made trickier by the fact that both of these healthcare stocks appear similar in their returns this year: ABBV data by YCharts Neither company has quite outperformed the S&P 500, although both are stable, value investments. But perhaps there's an even better option for dividend investors in pharmaceutical company AbbVie (NYSE: ABBV). | AbbVie, however, pays a quarterly dividend of $1.18, which annually yields over 5% at current share prices. AbbVie released its second-quarter results on July 31 for the period ended June 30. But perhaps there's an even better option for dividend investors in pharmaceutical company AbbVie (NYSE: ABBV). | Here's why: AbbVie's dividend yield is much higher -- and likely to stay that way Today, J&J pays its shareholders a quarterly dividend of $1.01 for an annual yield of 2.6%, which is well above the S&P 500 average of 2%. Unless there's a significant change in dividend policies from either of these two companies, it is unlikely that J&J's dividend and yield will best AbbVie's anytime soon. AbbVie's dividend is at less risk in the long-term Another reason income investors should opt for AbbVie's dividend? | Here's why: AbbVie's dividend yield is much higher -- and likely to stay that way Today, J&J pays its shareholders a quarterly dividend of $1.01 for an annual yield of 2.6%, which is well above the S&P 500 average of 2%. AbbVie, however, pays a quarterly dividend of $1.18, which annually yields over 5% at current share prices. But perhaps there's an even better option for dividend investors in pharmaceutical company AbbVie (NYSE: ABBV). |
24416.0 | 2020-08-28 00:00:00 UTC | These 3 Dividend Stocks Could Bring You an Extra $100 a Month | ABBV | https://www.nasdaq.com/articles/these-3-dividend-stocks-could-bring-you-an-extra-%24100-a-month-2020-08-28 | nan | nan | One of the benefits of investing in dividend stocks it that they can generate recurring income. Whether it's to help pay bills or boost your savings, it's not hard to find a use for some extra cash. But many dividend stocks pay on a quarterly basis, meaning you'll need to wait three months for each payout to flow through to your portfolio.
However, I'll show you how investing in three dividend stocks, all with different payment schedules, can allow you to earn $100 per month. They're all quality dividend stocks that you can hold in your portfolio for the long term, and all yield more than the S&P 500 average of just 2%.
1. AbbVie
Drug manufacturer AbbVie (NYSE: ABBV) is known for its blockbuster, Humira, which treats rheumatoid arthritis and Crohn's disease among other conditions. With profit margins of at least 17% in each of the past five years and annual revenue rising from $20 billion in 2014 to $33.3 billion in 2019, AbbVie's business was already looking strong. But the Illinois-based healthcare company became an even better investment when it acquired Allergan, which makes Botox, in a massive $63 billion deal. AbbVie announced the closing of the acquisition, which greatly expands its portfolio of products, on May 8.
Image source: Getty Images.
A stronger and more diverse business model helps make prospects for its dividend even better. And that's key for a Dividend Aristocrat that's known for growing its payments over the years. Since spinning off from Abbott Labs in 2013, AbbVie has increased its dividend payments by 195%.
Today, it pays investors a quarterly dividend of $1.18, for a yield of 5% annually. An $8,000 investment in AbbVie would bring investors $400 for the year, or $100 every three months. Its quarterly payments come every February, May, August, and November.
Year to date, shares of AbbVie are up 6%, right in line with the S&P 500's returns.
2. Unilever
Dutch company Unilever (NYSE: UL) is another Dividend Aristocrat that's well diversified. From its food and refreshment products to home care to beauty and personal care, Unilever sells a wide range of goods to consumers. The company estimates that 2.5 billion people use its products every day. Some of its better-known brands include Ben & Jerry's, Knorr, Lipton, and Dove.
In each of the past five years, Unilever's sales totaled more than 50 million euros, while its profit margin has held steady at 9% or better. The business is stable, and that's what makes it a reliable dividend stock to hang on to for years and years. Even during a recession or pandemic, consumers are going to continue buying Unilever products because they're essential to their day-to-day lives.
However, because the company issues dividends in euros, there are some fluctuations for U.S. investors collecting a payout as a result of foreign exchange. Today, the stock is yielding 3.1%, meaning investors will need to spend about $12,900 to earn $400 in recurring income every year. Unilever makes payments every March, June, September, and December.
Shares of Unilever are up by more than 4% in 2020.
3. JPMorgan
Bank stocks are always great sources of dividend income, and that's why JPMorgan Chase (NYSE: JPM) makes this list. The New York-based company and many of its peers are facing some challenges right now amid a recession and the COVID-19 pandemic. But over the long term, bank stocks are safe bets to continue doing well as long as the economy is strong. And that's what makes a top bank like JPMorgan a fairly safe investment to hold on to.
In each of the past five years, JPMorgan has recorded a solid profit margin of at least 24%; on revenue of more than $93 million in each of those years, that's a lot of cash on a regular basis. Although JPMorgan's not an Aristocrat, it's been increasing its dividend payments regularly since the end of the previous financial crisis. Annual payments of $3.30 in 2019 were more than six times the $0.53 that it paid out in 2009.
With JPMorgan's stock down more than 25% year to date and its yield pushed up, now could be an opportune time to invest in one of the top financial companies in the country. Today the bank pays out $0.90 every quarter to its shareholders, which on an annual basis yields 3.6%. An investment of $11,100 would earn you $100 in quarterly payments. JPMorgan pays investors a dividend every January, April, July, and October.
The breakdown
Here's a summary of what the investments would look like:
COMPANY CURRENT YIELD INVESTMENT QUARTERLY PAYMENT PAYMENT SCHEDULE
AbbVie 5% $8,000 $100 February, May, August, November
Unilever 3.1% $12,900 $100 March, June, September, December
JPMorgan Chase 3.6% $11,100 $100 January, April, July, October
Data source: AbbVie, Unilever, JPMorgan Chase.
The total investment needed across these three stocks would be $32,000, and the individual investments would not only bring you $100 a month, they'd also diversify your portfolio. With strong businesses and great dividend payments, these are all solid buy-and-forget stocks that you can safely hang on to for years, possibly even decades.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of August 1, 2020
David Jagielski has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie Drug manufacturer AbbVie (NYSE: ABBV) is known for its blockbuster, Humira, which treats rheumatoid arthritis and Crohn's disease among other conditions. With profit margins of at least 17% in each of the past five years and annual revenue rising from $20 billion in 2014 to $33.3 billion in 2019, AbbVie's business was already looking strong. AbbVie announced the closing of the acquisition, which greatly expands its portfolio of products, on May 8. | AbbVie 5% $8,000 $100 February, May, August, November Unilever 3.1% $12,900 $100 March, June, September, December JPMorgan Chase 3.6% $11,100 $100 January, April, July, October Data source: AbbVie, Unilever, JPMorgan Chase. AbbVie Drug manufacturer AbbVie (NYSE: ABBV) is known for its blockbuster, Humira, which treats rheumatoid arthritis and Crohn's disease among other conditions. With profit margins of at least 17% in each of the past five years and annual revenue rising from $20 billion in 2014 to $33.3 billion in 2019, AbbVie's business was already looking strong. | AbbVie 5% $8,000 $100 February, May, August, November Unilever 3.1% $12,900 $100 March, June, September, December JPMorgan Chase 3.6% $11,100 $100 January, April, July, October Data source: AbbVie, Unilever, JPMorgan Chase. 10 stocks we like better than AbbVie When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. AbbVie Drug manufacturer AbbVie (NYSE: ABBV) is known for its blockbuster, Humira, which treats rheumatoid arthritis and Crohn's disease among other conditions. | An $8,000 investment in AbbVie would bring investors $400 for the year, or $100 every three months. AbbVie Drug manufacturer AbbVie (NYSE: ABBV) is known for its blockbuster, Humira, which treats rheumatoid arthritis and Crohn's disease among other conditions. With profit margins of at least 17% in each of the past five years and annual revenue rising from $20 billion in 2014 to $33.3 billion in 2019, AbbVie's business was already looking strong. |
24417.0 | 2020-08-27 00:00:00 UTC | UroGen Pharma: Phase 2 APOLLO Clinical Trial Did Not Meet Primary Endpoint | ABBV | https://www.nasdaq.com/articles/urogen-pharma%3A-phase-2-apollo-clinical-trial-did-not-meet-primary-endpoint-2020-08-27 | nan | nan | (RTTNews) - Biopharmaceutical company UroGen Pharma Ltd. (URGN) said Thursday that the Phase 2 APOLLO clinical trial of a RTGel hydrogel formulation in combination with Botox (onabotulinumtoxinA) intravesical instillation in patients with overactive bladder (OAB) and urinary incontinence did not meet the primary endpoint of the trial.
The primary endpoint is the improvement of overactive bladder symptoms, as measured by the reduction in urinary incontinence episodes per day.
According to UroGen Pharma, data from the trial suggested this result may have been due to Botox not effectively permeating the urothelium.
The company added that safety and tolerability were evaluated compared to placebo, as well as the dwell time manifested by hydrogel excretion. The combination was reported to be safe and well tolerated compared to placebo, with extended dwell time for up to 10 hours following initial instillation.
In addition, patients also reported satisfaction with the ease of hydrogel administration which is performed through a standard urinary catheter.
"While we were disappointed with the results of the APOLLO trial, the data are very informative and provide important learnings for future experiments. The topline data from this trial reinforces that our RTGel technology could be combined with a substantial library of molecules to deliver therapy where dwell time may improve outcomes and we look forward to our continued collaboration with AbbVie as they develop their portfolio of toxin proteins," said Dr. Mark Schoenberg, Chief Medical Officer at UroGen.
The Phase 2 trial was conducted by AbbVie under the license agreement entered into with UroGen in October 2016. The agreement granted an exclusive worldwide license to Allergan plc, now an AbbVie company, to research, manufacture and commercialize pharmaceutical products formulated with an RTGel hydrogel formulation and clostridial toxins, including Botox.
The license agreement enables the companies to continue exploration of the RTGel hydrogel formulation in combination with AbbVie's portfolio of clostridial toxins in OAB and other patient populations.
UroGen noted that it is eligible to receive payments from AbbVie on the achievement of certain development, regulatory and commercial milestones, in addition to royalties on potential net sales.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The topline data from this trial reinforces that our RTGel technology could be combined with a substantial library of molecules to deliver therapy where dwell time may improve outcomes and we look forward to our continued collaboration with AbbVie as they develop their portfolio of toxin proteins," said Dr. Mark Schoenberg, Chief Medical Officer at UroGen. The license agreement enables the companies to continue exploration of the RTGel hydrogel formulation in combination with AbbVie's portfolio of clostridial toxins in OAB and other patient populations. UroGen noted that it is eligible to receive payments from AbbVie on the achievement of certain development, regulatory and commercial milestones, in addition to royalties on potential net sales. | The agreement granted an exclusive worldwide license to Allergan plc, now an AbbVie company, to research, manufacture and commercialize pharmaceutical products formulated with an RTGel hydrogel formulation and clostridial toxins, including Botox. The license agreement enables the companies to continue exploration of the RTGel hydrogel formulation in combination with AbbVie's portfolio of clostridial toxins in OAB and other patient populations. The topline data from this trial reinforces that our RTGel technology could be combined with a substantial library of molecules to deliver therapy where dwell time may improve outcomes and we look forward to our continued collaboration with AbbVie as they develop their portfolio of toxin proteins," said Dr. Mark Schoenberg, Chief Medical Officer at UroGen. | The topline data from this trial reinforces that our RTGel technology could be combined with a substantial library of molecules to deliver therapy where dwell time may improve outcomes and we look forward to our continued collaboration with AbbVie as they develop their portfolio of toxin proteins," said Dr. Mark Schoenberg, Chief Medical Officer at UroGen. The agreement granted an exclusive worldwide license to Allergan plc, now an AbbVie company, to research, manufacture and commercialize pharmaceutical products formulated with an RTGel hydrogel formulation and clostridial toxins, including Botox. The Phase 2 trial was conducted by AbbVie under the license agreement entered into with UroGen in October 2016. | The license agreement enables the companies to continue exploration of the RTGel hydrogel formulation in combination with AbbVie's portfolio of clostridial toxins in OAB and other patient populations. The topline data from this trial reinforces that our RTGel technology could be combined with a substantial library of molecules to deliver therapy where dwell time may improve outcomes and we look forward to our continued collaboration with AbbVie as they develop their portfolio of toxin proteins," said Dr. Mark Schoenberg, Chief Medical Officer at UroGen. The Phase 2 trial was conducted by AbbVie under the license agreement entered into with UroGen in October 2016. |
24418.0 | 2020-08-26 00:00:00 UTC | Is Gilead Sciences a Buy After Its Most Recent Roadblock? | ABBV | https://www.nasdaq.com/articles/is-gilead-sciences-a-buy-after-its-most-recent-roadblock-2020-08-26 | nan | nan | Gilead Sciences (NASDAQ: GILD) navigated the coronavirus market crash better than most. At one point, the biotech's antiviral drug, Veklury (remdesivir), was considered one of the most promising potential treatments for COVID-19. In May, the U.S. Food and Drug Administration (FDA) granted Veklury an Emergency Use Authorization (EUA), which allowed the drug to be administered to patients with serious cases of COVID-19. As a result, enthusiastic investors bid up shares of the company. However, the healthcare giant lost some momentum after the FDA warned about potentially harmful drug interactions involving remdesivir, and consumers realized the treatment was just that -- a treatment -- not a fail-proof cure for the virus.
While the stock market has recovered since its low in March, Gilead Sciences has been moving in the opposite direction. Overall, the company's stock is up by 1.66% year to date, while the S&P 500 is up by over 6% in the same period. What's more, Gilead and its shareholders just received some discouraging news. The FDA denied the approval of the company's treatment candidate, filgotinib, as a therapy for rheumatoid arthritis (RA). Let's see why this rejection was significant and what it means for Gilead Sciences moving forward.
GILD data by YCharts
A potential blockbuster drug
The market for RA drugs is competitive. Some of the top-selling products that treat the condition include AbbVie's Humira, Johnson & Johnson's Remicade, and Amgen's Enbrel, among others. Athough the field is crowded, Gilead Sciences had high hopes for filgotinib. Only one out of five RA patients achieves complete remission, a period in which symptoms are under control, after a year of treatment. That's despite the widespread availability of therapy options, according to the company's chief commercial officer, Johanna Mercier.
In their Q4 2019earnings callearlier this year, Mercier went on to say that filgotinib had a "compelling and differentiated clinical profile" suited to send more patients into remission at a faster pace. Gilead is also investigating the candidate as a treatment for Crohn's disease, ulcerative colitis, psoriatic arthritis, and other conditions. The company originally hoped it would earn would earn five new indications for filgotinib over the next four years. But since the FDA's rejection, the future of the drug is uncertain.
What's next for Gilead Sciences?
Filgotinib could still go on to be approved by the FDA. The regulator has requested data from studies on whether the drug has an impact on sperm parameters, such as concentration and mobility, before it can move forward in the approvals process. Gilead expects preliminary results from these studies in the first half of 2021, which means filgotinib won't earn regulatory approval until sometime next year at best. How will the company fare in the meantime? Note that during its second quarter, which ended on June 30, Gilead's sales declined by roughly 10% year over year to $5.1 billion.
Image source: Getty Images.
The decrease in the company's top line was due in part to sales of its hepatitis C virus (HCV) products plunging by 47% year over year to $448 million. While the company blamed the COVID-19 crisis for its slumping HCV business, its struggles predate the pandemic. During the fiscal year 2019, revenue from this segment came in at $2.9 billion, compared to $3.7 billion during the fiscal year 2018. The decline was due to lower average net selling prices, according to the company.
Gilead's human immunodeficiency virus (HIV) therapy business is starting to close the gap, however. During the first quarter, sales from this unit decreased by only 1%, to $4 billion. This is good news, considering sales from the segment make of 79% of current revenue. Gilead's HIV business also gained some market share during the quarter. Biktarvy, one of Gilead's top products, is now used to treat 50% of patients new to HIV therapy and the majority of those switching their HIV therapy.
Gilead expects to continue its reliance on these HCV and HIV drugs, but also hopes that Veklury sales will accelerate internationally. The COVID-19 treatment has received regulatory approval in Japan and earned conditional marketing authorization in Europe. The company said it expects to sell between 1 million and 1.5 million treatment courses by the end of the year. Gilead revised its fiscal 2020 guidance with this market in mind. The biotech previously expected sales to come in between $21.8 billion and $22.2 billion. Now, it thinks it will be able to generate sales between $23 billion and $25 billion. Thanks to its thriving HIV business and the potential market for Veklury, the company should be able to keep its revenue and earnings afloat.
Is now a good time to buy?
Gilead Sciences still aims to introduce 10 new therapies over the next decade. The company has been collaborating with other biotechs, including Galapagos, to achieve this goal. Per their July 2019 agreement, Galapagos received an upfront payment of $3.95 billion and a $1.1 billion equity investment from Gilead Sciences. In return, Gilead acquired the option to develop any of Galapagos' pipeline candidates and to commercialize them outside of Europe.
One of the candidates Gilead got its hands on through the deal is GLPG-1690, a potential treatment for idiopathic pulmonary fibrosis, a fibrotic disease that leads to scarring of the lungs. The treatment is currently in phase 3 testing. In other words, filgotinib wasn't Gilead Sciences' last hope. Despite the FDA's recent rejection, the company has found other avenues for sales growth and hasn't given up on the RA treatment's possible approval. In short, I think Gilead Sciences is worth buying, and given its recent woes, it seems like a great time to initiate a position in this biotech stock.
10 stocks we like better than Gilead Sciences
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Gilead Sciences wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of August 1, 2020
Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool recommends Amgen and Johnson & Johnson. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some of the top-selling products that treat the condition include AbbVie's Humira, Johnson & Johnson's Remicade, and Amgen's Enbrel, among others. Gilead expects preliminary results from these studies in the first half of 2021, which means filgotinib won't earn regulatory approval until sometime next year at best. One of the candidates Gilead got its hands on through the deal is GLPG-1690, a potential treatment for idiopathic pulmonary fibrosis, a fibrotic disease that leads to scarring of the lungs. | Some of the top-selling products that treat the condition include AbbVie's Humira, Johnson & Johnson's Remicade, and Amgen's Enbrel, among others. The FDA denied the approval of the company's treatment candidate, filgotinib, as a therapy for rheumatoid arthritis (RA). The COVID-19 treatment has received regulatory approval in Japan and earned conditional marketing authorization in Europe. | Some of the top-selling products that treat the condition include AbbVie's Humira, Johnson & Johnson's Remicade, and Amgen's Enbrel, among others. Gilead expects preliminary results from these studies in the first half of 2021, which means filgotinib won't earn regulatory approval until sometime next year at best. Note that during its second quarter, which ended on June 30, Gilead's sales declined by roughly 10% year over year to $5.1 billion. | Some of the top-selling products that treat the condition include AbbVie's Humira, Johnson & Johnson's Remicade, and Amgen's Enbrel, among others. What's next for Gilead Sciences? During the fiscal year 2019, revenue from this segment came in at $2.9 billion, compared to $3.7 billion during the fiscal year 2018. |
24419.0 | 2020-08-25 00:00:00 UTC | 6 Marijuana Stocks to Buy That Are Sticking In the Green | ABBV | https://www.nasdaq.com/articles/6-marijuana-stocks-to-buy-that-are-sticking-in-the-green-2020-08-25 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Investors searching for marijuana stocks to buy are looking to get green. So how can investors identify stocks that will “get green?” From investors’ perspective this should likely relate to price appreciation. However, there is no exact formula for price appreciation. But there are fundamental, technical and other indicators which catalyze stocks to rise in price. From my perspective that means sales, deal making and execution of strategic vision are the factors which most strongly predict success.
10 Growth Stocks That Could Seriously Double
Investors looking for marijuana opportunities ultimately want to know which stocks have those proper factors for success in place. So the marijuana stocks to buy listed here will have one or more of the factors which predict success above.
AbbVie (NYSE:ABBV)
GW Pharmaceuticals (NASDAQ:GWPH)
Cresco Labs (OTCMKTS:CRLBF)
GrowGeneration (NASDAQ:GRWG)
Green Thumb Industries (OTCMKTS:GTBIF)
Village Farms International (NASDAQ:VFF)
Let’s take a closer look at what makes each of these stocks worth your consideration.
Marijuana Stocks to Buy: AbbVie (ABBV)
ABBV) website and logo on mobile phone" width="300" height="169">
Source: Piotr Swat / Shutterstock.com
AbbVie is no longer producing cannabis-derived synthetic drugs after having sold Marinol in late 2019. However, the company held 59 medical cannabis patents as of 2019. AbbVie is the No.1 holder of such patents.
So, while AbbVie is not a marijuana producer, nor would it be considered a marijuana stock, it’s in the space. ABBV stock is well-regarded itself. InvestorPlace writer Mark R. Hake, CFA makes an excellent case as to why it is a worthwhile investment in his article. With its dividend and well-run operations, ABBV stock is an excellent choice for investors looking to avoid volatile pure cannabis plays.
GW Pharmaceuticals (GWPH)
GWPH)" width="300" height="165">
Source: GW Pharmaceuticals
GW Pharmaceuticals is an established cannabis pharmaceutical company. On Aug. 3 the company received Food and Drug Administration approval for its cannabidiol drug Epidiolex. Epidiolex treats tuberous sclerosis complex (TSC) and Lennox-Gastaut syndrome (LSG). There are 50,000 patients with TSC worldwide, 85% of whom develop seizures which Epidiolex is indicated for. With a maintenance dose of 25 mg/kg/day for TSC patients, and a cost of $1,377/100ml (3) revenues should remain strong. Q2 ‘20 U.S. revenues for Epidiolex were $111 million.
7 Value Stocks to Buy For Growth and Peace of Mind
GW Pharmaceuticals also has a strong pipeline of cannabinoid drugs in development. Although GW has not received FDA approval for these, their potential is clear. GWPH stock is in a strong position to make money for investors.
Cresco Labs (CRLBF)
Source: Shutterstock
Investors who know the name Cresco Labs are bullish on it currently. And they should be. It just reported record revenues of $94.3 million equating to 42% growth quarter-over-quarter. Further, the company is a vertically integrated multi-state U.S. cannabis operator. Of the 13 analysts covering CRLBF stock, 12 rate it a buy.
The company’s operations looked really strong. This company is not simply a cannabis hype story. However, the industry as a whole has not lived up to the hype because many operators were not doing what Cresco has: run a tight operation.
Although Cresco Labs still has room for improvement and reported a net loss, revenue should encourage investors looking for marijuana stocks to buy.
GrowGeneration (GRWG)
Source: Shutterstock
GRWG stock recently spiked after having traded flat for the previous few years. The firm has 28 locations in 10 states. Moreover, it is the largest hydroponic equipment supplier in the U.S. GrowGeneration had a strong quarter. It posted record revenues of $43.5 million, EBITDA of $4.6 million, and $2.6 million in net income.
7 Earnings Reports to Watch Next Week
GrowGeneration increased guidance for 2020 revenue to between $170-$175 million. It set 2021 revenue guidance between $245-$260 million. Investors know that these metrics indicate a company worth investing in. GrowGeneration’s strategy of selling shovels to the gold miner certainly seems to be paying off so far. Many companies have exploded utilizing this strategy. GRGW stock could well be another.
Green Thumb Industries (GTBIF)
Source: Shutterstock
Investors could be forgiven for guessing it operates in a similar niche with GrowGeneration based on its name. However, it is a cannabis CPG company, and not an equipment supplier.
Again, investors should concern themselves with revenue when considering marijuana stocks. The cannabis/marijuana space is volatile because there have been so many operators pumped up on hype alone. Now that the industry is cooling, real operators are starting to emerge. And real operators are going to show strong sales and revenue growth.
Fortunately, Green Thumb Industries looks to be one of them. Its recent earnings were strong. Year-over-year revenues increased by 167.5% to $119 million. Further, Green Thumb Industries’ first half 2020 revenues exceed 2019’s total revenues.
Analysts are bullish on GTBIF stock with 15 rating it a buy, and 2 having it overweight.
Village Farms International (VFF)
Source: Shutterstock
Village Farms is primarily a greenhouse produce grower. It is a large vertically integrated company with a 9 million square foot greenhouse footprint in British Columbia, Ontario, Mexico, and Texas. The company is leveraging 3 decades of experience in greenhouse produce production and expanding into cannabis and hemp.
The company has a majority ownership position in British Columbia cannabis grower Pure Sunfarms. It has also established several joint ventures for CBD and hemp production across the U.S. Analysts are bullish on VFF stock, with five rating it a buy and one rating it overweight.
10 Growth Stocks That Could Seriously Double
Much like ABBV, VFF stock is not a pure marijuana play. Clearly its greenhouse produce experience is a very short pivot. Further, its logistics network should be a benefit as well. The company’s investor presentation should give investors a good idea of its scale and operations. The company has many assets across the industry which it will be able to leverage.
Alex Sirois is a freelance contributor to InvestorPlace whose personal stock investing style is focused on long-term, buy-and-hold, wealth-building stock picks. Having worked in several industries from e-commerce to translation to education and utilizing his MBA from George Washington University, he brings a diverse set of skills through which he filters his writing. Alex Sirois did not hold any shares of stocks mentioned in this article as of writing.
The post 6 Marijuana Stocks to Buy That Are Sticking In the Green appeared first on InvestorPlace.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | With its dividend and well-run operations, ABBV stock is an excellent choice for investors looking to avoid volatile pure cannabis plays. AbbVie (NYSE:ABBV) GW Pharmaceuticals (NASDAQ:GWPH) Cresco Labs (OTCMKTS:CRLBF) GrowGeneration (NASDAQ:GRWG) Green Thumb Industries (OTCMKTS:GTBIF) Village Farms International (NASDAQ:VFF) Let’s take a closer look at what makes each of these stocks worth your consideration. Marijuana Stocks to Buy: AbbVie (ABBV) ABBV) website and logo on mobile phone" width="300" height="169"> Source: Piotr Swat / Shutterstock.com AbbVie is no longer producing cannabis-derived synthetic drugs after having sold Marinol in late 2019. | AbbVie (NYSE:ABBV) GW Pharmaceuticals (NASDAQ:GWPH) Cresco Labs (OTCMKTS:CRLBF) GrowGeneration (NASDAQ:GRWG) Green Thumb Industries (OTCMKTS:GTBIF) Village Farms International (NASDAQ:VFF) Let’s take a closer look at what makes each of these stocks worth your consideration. Marijuana Stocks to Buy: AbbVie (ABBV) ABBV) website and logo on mobile phone" width="300" height="169"> Source: Piotr Swat / Shutterstock.com AbbVie is no longer producing cannabis-derived synthetic drugs after having sold Marinol in late 2019. AbbVie is the No.1 holder of such patents. | AbbVie (NYSE:ABBV) GW Pharmaceuticals (NASDAQ:GWPH) Cresco Labs (OTCMKTS:CRLBF) GrowGeneration (NASDAQ:GRWG) Green Thumb Industries (OTCMKTS:GTBIF) Village Farms International (NASDAQ:VFF) Let’s take a closer look at what makes each of these stocks worth your consideration. Marijuana Stocks to Buy: AbbVie (ABBV) ABBV) website and logo on mobile phone" width="300" height="169"> Source: Piotr Swat / Shutterstock.com AbbVie is no longer producing cannabis-derived synthetic drugs after having sold Marinol in late 2019. AbbVie is the No.1 holder of such patents. | 10 Growth Stocks That Could Seriously Double Much like ABBV, VFF stock is not a pure marijuana play. AbbVie (NYSE:ABBV) GW Pharmaceuticals (NASDAQ:GWPH) Cresco Labs (OTCMKTS:CRLBF) GrowGeneration (NASDAQ:GRWG) Green Thumb Industries (OTCMKTS:GTBIF) Village Farms International (NASDAQ:VFF) Let’s take a closer look at what makes each of these stocks worth your consideration. Marijuana Stocks to Buy: AbbVie (ABBV) ABBV) website and logo on mobile phone" width="300" height="169"> Source: Piotr Swat / Shutterstock.com AbbVie is no longer producing cannabis-derived synthetic drugs after having sold Marinol in late 2019. |
24420.0 | 2020-08-20 00:00:00 UTC | Investing in These Stocks Now Could Make You a Millionaire Retiree | ABBV | https://www.nasdaq.com/articles/investing-in-these-stocks-now-could-make-you-a-millionaire-retiree-2020-08-20 | nan | nan | We all would like to be millionaires by the time we retire. With Social Security income likely to provide only a modest fraction of the income we need, most of us will have to come up with the rest of our needed cash flows on our own.
Fortunately, if you invest regularly and effectively for a long time, you can achieve a comfortable retirement. The stock market is hard to beat for that -- but which stocks should you invest in? Here are some categories to consider.
Image source: Getty Images.
Some preliminary math
Let's start with a little math, though, to help you see how you can become a millionaire. It takes time and diligence, and much will depend on how much you can sock away each year and how quickly it grows.
The table below shows how much you might amass over various periods, investing various amounts:
GROWING AT 8% FOR
$10,000 INVESTED ANNUALLY
$15,000 INVESTED ANNUALLY
$20,000 INVESTED ANNUALLY
5 years
$63,359
$95,039
$126,718
10 years
$156,455
$234,683
$312,910
15 years
$293,243
$439,865
$586,486
20 years
$494,229
$741,344
$988,458
25 years
$789,544
$1,184,316
$1,579,088
30 years
$1,223,459
$1,835,189
$2,446,918
Data source: Calculations by author.
The overall stock market has averaged annual returns close to 10% over long periods, but you may average more or less during your investment time frame. So the table above uses 8% to be a bit conservative.
Now let's move on to what kinds of stocks can make you a millionaire.
Boring stocks
You might assume that you'll need to get lucky and invest in companies that end up turning in amazing performances over long periods -- such as Amazon.com or Netflix. That's not true, though. Many boring companies can build wealth for you at a good clip, too. Check out the examples below:
COMPANY
20-YEAR AVERAGE ANNUAL RETURN*
Sherwin-Williams
20%
United Pacific
17.8%
Nike
17%
Public Storage
15.1%
Altria
14.8%
Clorox
12.6%
Home Depot
11.1%
Toronto-Dominion Bank
10.8%
Procter & Gamble
10.6%
General Mills
10.1%
United Parcel Service
8%
CVS Health
7.8%
S&P 500
6%
Source: Theonlineinvestor.com. *With dividends reinvested.
Those companies are focused on exciting businesses such as paint, railroad transport, shoes, storage units, tobacco products, cleaning products, home improvement supplies, banking, shampoos, cereal, parcel delivery, and health supplies. Yawn! But all of them outperformed the S&P 500's performance, and most exhibited fairly rapid growth, far exceeding the 8% example in the table up top.
Dividend stocks
Next up are dividend-paying stocks, which you might assume are also boring. Not so! (After all, even Apple and Microsoft pay dividends these days.) More than one study has found dividend stocks outperforming non-dividend payers. For example, when researchers Eugene Fama and Kenneth French examined stock-performance data from 1927 to 2014, they found that dividend payers outperformed non-payers, averaging 10.4% annual growth vs. 8.5%.
The beauty of a portfolio full of dividend payers is that it will generate income regularly, without your having to sell any of your holdings. If your portfolio is worth, say, $500,000 and it has an overall dividend yield of, say, 4%, you're looking at $20,000 in income annually just from dividends -- which would complement your Social Security benefits nicely. Even better, healthy and growing companies tend to increase their payouts each year, which means increasing dividend income each year -- and that can help you keep up with inflation.
It's not hard to find some solid dividend yields, either. Here are some recent yields from some familiar companies:
STOCK
RECENT DIVIDEND YIELD
AT&T
6.9%
Chevron
5.7%
AbbVie
5%
MetLife
4.7%
Duke Energy
4.7%
Walgreens Boots Alliance
4.5%
Verizon Communications
4.2%
Citigroup
3.9%
3M
3.5%
Kellogg
3.3%
PepsiCo
3%
Source: Yahoo! Financial.
Growth and value stocks
Two other classifications of stocks are growth stocks and value stocks -- in other words, ones that growth investors or value investors would seek. Growth investors chase companies that are growing rapidly and aren't afraid to pay rich prices for them. Amazon.com, for example, has usually looked rather overvalued, but then has kept rising over many years, albeit in a jagged line. Not all growth stocks keep growing rapidly, though, and some are so overvalued that they pull back, hurting investors.
Value investors, on the other hand, seek a margin of safety by favoring stocks that seem significantly undervalued relative to their intrinsic worth. These companies can be less exciting than high-flying market darlings, but value investors tend to do quite well, and their ranks include Warren Buffett.
Fortunately, you don't necessarily have to choose between value and growth stocks. After all, the best investments should be both growing at a good clip and also be undervalued.
Most or all stocks
Finally, if you're going to study stocks and choose which individual ones to invest in and when to do so, that will take a lot of time and skill -- which many of us don't have enough of. Fortunately, you can also become a millionaire simply by investing in low-fee, broad-market index funds, such as those that track the S&P 500 or the overall market. If the stock market averages 9% or 6% growth during your investment period, an index fund that tracks it will also return roughly 9% or 6%.
There's no shame or compromise in opting for index funds. If you're diligent and determined and have some years ahead of you, you can become an index fund millionaire, too.
10 stocks we like better than Walmart
When investing geniuses David and Tom Gardner have an investing tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Walmart wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
Stock Advisor returns as of 2/1/20
John Mackey, CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Teresa Kersten, an employee of LinkedIn, a Microsoft subsidiary, is a member of The Motley Fool's board of directors. Selena Maranjian owns shares of AbbVie, Amazon, Apple, AT&T, Microsoft, Netflix, Procter & Gamble, and Verizon Communications. The Motley Fool owns shares of and recommends Amazon, Apple, Home Depot, Microsoft, Netflix, and Nike. The Motley Fool recommends 3M, CVS Health, Duke Energy, Sherwin-Williams, Union Pacific, and Verizon Communications and recommends the following options: long January 2022 $1920 calls on Amazon, short January 2022 $1940 calls on Amazon, long January 2021 $85 calls on Microsoft, long January 2021 $120 calls on Home Depot, short January 2021 $115 calls on Microsoft, and short January 2021 $210 calls on Home Depot. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Selena Maranjian owns shares of AbbVie, Amazon, Apple, AT&T, Microsoft, Netflix, Procter & Gamble, and Verizon Communications. 6.9% Chevron 5.7% AbbVie 5% MetLife 4.7% Duke Energy 4.7% Walgreens Boots Alliance 4.5% Verizon Communications 4.2% Citigroup 3.9% Boring stocks You might assume that you'll need to get lucky and invest in companies that end up turning in amazing performances over long periods -- such as Amazon.com or Netflix. | 6.9% Chevron 5.7% AbbVie 5% MetLife 4.7% Duke Energy 4.7% Walgreens Boots Alliance 4.5% Verizon Communications 4.2% Citigroup 3.9% Selena Maranjian owns shares of AbbVie, Amazon, Apple, AT&T, Microsoft, Netflix, Procter & Gamble, and Verizon Communications. Sherwin-Williams 20% United Pacific 17.8% Nike 17% Public Storage 15.1% Altria 14.8% Clorox 12.6% Home Depot 11.1% Toronto-Dominion Bank 10.8% Procter & Gamble 10.6% General Mills 10.1% United Parcel Service 8% CVS Health 7.8% | 6.9% Chevron 5.7% AbbVie 5% MetLife 4.7% Duke Energy 4.7% Walgreens Boots Alliance 4.5% Verizon Communications 4.2% Citigroup 3.9% Selena Maranjian owns shares of AbbVie, Amazon, Apple, AT&T, Microsoft, Netflix, Procter & Gamble, and Verizon Communications. 5 years $63,359 $95,039 $126,718 10 years $156,455 $234,683 $312,910 15 years $293,243 $439,865 $586,486 20 years $494,229 $741,344 $988,458 25 years $789,544 $1,184,316 $1,579,088 30 years $1,223,459 $1,835,189 $2,446,918 Data source: Calculations by author. | 6.9% Chevron 5.7% AbbVie 5% MetLife 4.7% Duke Energy 4.7% Walgreens Boots Alliance 4.5% Verizon Communications 4.2% Citigroup 3.9% Selena Maranjian owns shares of AbbVie, Amazon, Apple, AT&T, Microsoft, Netflix, Procter & Gamble, and Verizon Communications. We all would like to be millionaires by the time we retire. |
24421.0 | 2020-08-19 00:00:00 UTC | FDA Denies Approval for Gilead Sciences' Potential Blockbuster Arthritis Drug | ABBV | https://www.nasdaq.com/articles/fda-denies-approval-for-gilead-sciences-potential-blockbuster-arthritis-drug-2020-08-19 | nan | nan | The space for oral rheumatoid arthritis treatments won't be getting crowded quite as quickly as some might have been expecting. Gilead Sciences (NASDAQ: GILD) told investors on Tuesday that the FDA has issued a complete response letter (CRL) denying approval for its drug candidate filgotinib -- for now -- and dealing a huge blow to the company's cash flow projections.
An FDA approval for filgotinib had been widely expected, and forecasts of its market potential suggested it would likely become a blockbuster. Sales had been expected to exceed $1 billion in 2022 and peak above $4 billion annually.
This setback for Gilead's drug will give recently launched oral rheumatoid arthritis (RA) treatments from AbbVie (NYSE: ABBV) and Eli Lily (NYSE: LLY) more time to establish their footholds in the highly lucrative market for immune system suppressants that safely prevent the disease from progressing.
Image source: Getty Images.
AbbVie's injectable RA treatment, Humira is the world's top-selling drug; its annual sales peaked at $19.9 billion in 2018. In 2019, AbbVie launched Rinvoq, an oral RA treatment similar to filgotinib that generated an annualized $596 million during the second quarter.
Rinvoq and a similar RA treatment from Eli Lilly called Olumiant have both been associated with life-threatening blood clots, though that side effect has been extremely uncommon. Because it has exhibited fewer serious side effects during clinical trials, filgotinib was expected to give Rinvoq and Olumiant fierce competition.
According to Gilead Sciences, the FDA wants to see data from ongoing studies designed to measure whether or not filgotinib impacts sperm counts. An ongoing study to assess testicular safety that began in 2017 isn't expected to produce preliminary results until January 2021, which means it's going to be at least another year before the FDA takes another look at filgotinib.
10 stocks we like better than Gilead Sciences
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Gilead Sciences wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of August 1, 2020
Cory Renauer owns shares of Gilead Sciences. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | This setback for Gilead's drug will give recently launched oral rheumatoid arthritis (RA) treatments from AbbVie (NYSE: ABBV) and Eli Lily (NYSE: LLY) more time to establish their footholds in the highly lucrative market for immune system suppressants that safely prevent the disease from progressing. AbbVie's injectable RA treatment, Humira is the world's top-selling drug; its annual sales peaked at $19.9 billion in 2018. In 2019, AbbVie launched Rinvoq, an oral RA treatment similar to filgotinib that generated an annualized $596 million during the second quarter. | This setback for Gilead's drug will give recently launched oral rheumatoid arthritis (RA) treatments from AbbVie (NYSE: ABBV) and Eli Lily (NYSE: LLY) more time to establish their footholds in the highly lucrative market for immune system suppressants that safely prevent the disease from progressing. In 2019, AbbVie launched Rinvoq, an oral RA treatment similar to filgotinib that generated an annualized $596 million during the second quarter. AbbVie's injectable RA treatment, Humira is the world's top-selling drug; its annual sales peaked at $19.9 billion in 2018. | This setback for Gilead's drug will give recently launched oral rheumatoid arthritis (RA) treatments from AbbVie (NYSE: ABBV) and Eli Lily (NYSE: LLY) more time to establish their footholds in the highly lucrative market for immune system suppressants that safely prevent the disease from progressing. AbbVie's injectable RA treatment, Humira is the world's top-selling drug; its annual sales peaked at $19.9 billion in 2018. In 2019, AbbVie launched Rinvoq, an oral RA treatment similar to filgotinib that generated an annualized $596 million during the second quarter. | AbbVie's injectable RA treatment, Humira is the world's top-selling drug; its annual sales peaked at $19.9 billion in 2018. In 2019, AbbVie launched Rinvoq, an oral RA treatment similar to filgotinib that generated an annualized $596 million during the second quarter. This setback for Gilead's drug will give recently launched oral rheumatoid arthritis (RA) treatments from AbbVie (NYSE: ABBV) and Eli Lily (NYSE: LLY) more time to establish their footholds in the highly lucrative market for immune system suppressants that safely prevent the disease from progressing. |
24422.0 | 2020-08-19 00:00:00 UTC | Validea John Neff Strategy Daily Upgrade Report - 8/19/2020 | ABBV | https://www.nasdaq.com/articles/validea-john-neff-strategy-daily-upgrade-report-8-19-2020-2020-08-19 | nan | nan | The following are today's upgrades for Validea's Low PE Investor model based on the published strategy of John Neff. This strategy looks for firms with persistent earnings growth that trade at a discount relative to their earnings growth and dividend yield.
LEIDOS HOLDINGS INC (LDOS) is a large-cap growth stock in the Computer Services industry. The rating according to our strategy based on John Neff changed from 62% to 81% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Leidos Holdings, Inc. is a global science and technology company. The Company provides technology and engineering services and solutions in the defense, intelligence, civil and health markets. Its segments include National Security Solutions (NSS), Information Systems & Global Solutions (IS&GS), Health and Infrastructure (HIS), and Corporate and Other. The NSS segment provides a portfolio of national security solutions and systems. The IS&GS segment focuses on providing information technology, management and engineering services to civil, defense and intelligence agencies of the United States government. HIS segment serves customers, including the United States federal government, state and local governmental agencies, foreign governments, healthcare providers and commercial enterprises. Its infrastructure business is focused on integrating and protecting physical, digital and data domains. The Corporate and Other segment includes the operations of various corporate activities.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: FAIL
EPS GROWTH: PASS
FUTURE EPS GROWTH: PASS
SALES GROWTH: PASS
TOTAL RETURN/PE: FAIL
FREE CASH FLOW: PASS
EPS PERSISTENCE: PASS
Detailed Analysis of LEIDOS HOLDINGS INC
Full Guru Analysis for LDOS
Full Factor Report for LDOS
ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on John Neff changed from 60% to 79% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions. It offers products in various categories, including HUMIRA (adalimumab), Oncology products, Virology Products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products, which include Duopa and Duodopa (carbidopa and levodopa), Anesthesia products and ZINBRYTA (daclizumab).
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: FAIL
EPS GROWTH: FAIL
FUTURE EPS GROWTH: PASS
SALES GROWTH: PASS
TOTAL RETURN/PE: PASS
FREE CASH FLOW: PASS
EPS PERSISTENCE: FAIL
Detailed Analysis of ABBVIE INC
Full Guru Analysis for ABBV
Full Factor Report for ABBV
ASGN INC (ASGN) is a mid-cap growth stock in the Software & Programming industry. The rating according to our strategy based on John Neff changed from 62% to 81% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: ASGN Incorporated is engaged in providing information technology (IT) and professional services in the technology, digital, creative, healthcare technology, engineering, life sciences, and government sectors. Its operating segments are Apex, Oxford and ECS segments. It helps corporate enterprises and government organizations to develop, implement and operate critical IT and business solutions through its integrated offering of professional staffing and IT solutions. The Apex Segment provides technical, scientific, digital and creative services and solutions to Fortune 1000 and mid-market clients. The Oxford Segment provides technical, engineering and Life Sciences services and solutions in select skill and geographic markets. The ECS Segment delivers advanced solutions in the cloud, cybersecurity, artificial intelligence, machine learning, software development, IT modernization, and science and engineering and is primarily focused on Federal Government activities.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: FAIL
EPS GROWTH: FAIL
FUTURE EPS GROWTH: PASS
SALES GROWTH: PASS
TOTAL RETURN/PE: PASS
FREE CASH FLOW: PASS
EPS PERSISTENCE: PASS
Detailed Analysis of ASGN INC
Full Guru Analysis for ASGN
Full Factor Report for ASGN
More details on Validea's John Neff strategy
About John Neff: While known as the manager with whom many top managers entrusted their own money, Neff was far from the smooth-talking, high-profile Wall Streeter you might expect. He was mild-mannered and low-key, and the same might be said of the Windsor Fund that he managed for more than three decades. In fact, Neff himself described the fund as "relatively prosaic, dull, [and] conservative." There was nothing dull about his results, however. From 1964 to 1995, Neff guided Windsor to a 13.7 percent average annual return, easily outpacing the S&P 500's 10.6 percent return during that time. That 3.1 percentage point difference is huge over time -- a $10,000 investment in Windsor (with dividends reinvested) at the start of Neff's tenure would have ended up as more than $564,000 by the time he retired, more than twice what the same investment in the S&P would have yielded (about $233,000). Considering the length of his tenure, that track record may be the best ever for a manager of such a large fund.
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Detailed Analysis of LEIDOS HOLDINGS INC Full Guru Analysis for LDOS Full Factor Report for LDOS ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. Detailed Analysis of ABBVIE INC Full Guru Analysis for ABBV Full Factor Report for ABBV ASGN INC (ASGN) is a mid-cap growth stock in the Software & Programming industry. | Detailed Analysis of LEIDOS HOLDINGS INC Full Guru Analysis for LDOS Full Factor Report for LDOS ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. Detailed Analysis of ABBVIE INC Full Guru Analysis for ABBV Full Factor Report for ABBV ASGN INC (ASGN) is a mid-cap growth stock in the Software & Programming industry. | Detailed Analysis of LEIDOS HOLDINGS INC Full Guru Analysis for LDOS Full Factor Report for LDOS ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. Detailed Analysis of ABBVIE INC Full Guru Analysis for ABBV Full Factor Report for ABBV ASGN INC (ASGN) is a mid-cap growth stock in the Software & Programming industry. | Detailed Analysis of LEIDOS HOLDINGS INC Full Guru Analysis for LDOS Full Factor Report for LDOS ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. Detailed Analysis of ABBVIE INC Full Guru Analysis for ABBV Full Factor Report for ABBV ASGN INC (ASGN) is a mid-cap growth stock in the Software & Programming industry. |
24423.0 | 2020-08-18 00:00:00 UTC | New York charges Teva, Allergan with insurance fraud over opioid claims | ABBV | https://www.nasdaq.com/articles/new-york-charges-teva-allergan-with-insurance-fraud-over-opioid-claims-2020-08-18 | nan | nan | By Jonathan Stempel and Mrinalika Roy
NEW YORK, Aug 18 (Reuters) - New York state filed civil charges on Tuesday accusing Teva Pharmaceutical Industries Ltd TEVA.TA and Allergan Plc with insurance fraud for downplaying the risks of their opioid painkillers to patients and doctors.
Governor Andrew Cuomo said the charges by New York's Department of Financial Services are the third this year in that regulator's opioid industry probe, following charges against Endo International Plc ENDP.O and Mallinckrodt Plc MNK.N.
Teva denied the allegations. Abbvie Inc ABBV.N, which bought Allergan in May, did not immediately respond to requests for comment.
New York said Teva, which made 20% of opioids distributed from 2006 to 2014 in the state, intentionally marketed opioids such as Actiq for off-label use, and drafted form "letters of medical necessity" for doctors to boost prescriptions and insurer reimbursements.
It said Allergan misrepresented the safety of its drugs in marketing materials, citing a 2010 U.S. Food and Drug Administration warning letter over its Kadian pain treatment.
New York also accused Teva and Allergan of using "front groups" and doctors known as "key opinion leaders" to mislead people about the safety and effectiveness of opioids.
It cited the 2012 annual meeting of the New York Pain Society in White Plains, New York, where Allergan was a exhibitor. The state said a key opinion leader present downplayed addiction signs by promoting the concept of "pseudoaddiction."
Opioids have contributed to more than 400,000 deaths since 1997, according to the U.S. Centers for Disease Control and Prevention.
Cuomo called the nation's opioid crisis "an American tragedy that has taken too many lives and caused irrevocable harm to communities," and he pledged to hold drugmakers accountable.
New York charged Teva and Allergan with violating two state insurance laws, with civil penalties of up to $5,000 per violation.
A hearing was scheduled for Oct. 26 at the financial services department's offices in Albany, New York.
(Reporting By Mrinalika Roy in Bengaluru and Jonathan Stempel in New York; Editing by Anil D'Silva and Aurora Ellis)
((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223 8780, outside U.S. +91 806749 8325;))(c) Copyright Thomson Reuters 2020. Click For Restrictions - https://agency.reuters.com/en/copyright.html))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbvie Inc ABBV.N, which bought Allergan in May, did not immediately respond to requests for comment. New York also accused Teva and Allergan of using "front groups" and doctors known as "key opinion leaders" to mislead people about the safety and effectiveness of opioids. Cuomo called the nation's opioid crisis "an American tragedy that has taken too many lives and caused irrevocable harm to communities," and he pledged to hold drugmakers accountable. | Abbvie Inc ABBV.N, which bought Allergan in May, did not immediately respond to requests for comment. By Jonathan Stempel and Mrinalika Roy NEW YORK, Aug 18 (Reuters) - New York state filed civil charges on Tuesday accusing Teva Pharmaceutical Industries Ltd TEVA.TA and Allergan Plc with insurance fraud for downplaying the risks of their opioid painkillers to patients and doctors. Governor Andrew Cuomo said the charges by New York's Department of Financial Services are the third this year in that regulator's opioid industry probe, following charges against Endo International Plc ENDP.O and Mallinckrodt Plc MNK.N. | Abbvie Inc ABBV.N, which bought Allergan in May, did not immediately respond to requests for comment. By Jonathan Stempel and Mrinalika Roy NEW YORK, Aug 18 (Reuters) - New York state filed civil charges on Tuesday accusing Teva Pharmaceutical Industries Ltd TEVA.TA and Allergan Plc with insurance fraud for downplaying the risks of their opioid painkillers to patients and doctors. New York said Teva, which made 20% of opioids distributed from 2006 to 2014 in the state, intentionally marketed opioids such as Actiq for off-label use, and drafted form "letters of medical necessity" for doctors to boost prescriptions and insurer reimbursements. | Abbvie Inc ABBV.N, which bought Allergan in May, did not immediately respond to requests for comment. By Jonathan Stempel and Mrinalika Roy NEW YORK, Aug 18 (Reuters) - New York state filed civil charges on Tuesday accusing Teva Pharmaceutical Industries Ltd TEVA.TA and Allergan Plc with insurance fraud for downplaying the risks of their opioid painkillers to patients and doctors. Teva denied the allegations. |
24424.0 | 2020-08-18 00:00:00 UTC | ANALYSIS-U.S. activists complain that virtual shareholder meetings let companies silence them | ABBV | https://www.nasdaq.com/articles/analysis-u.s.-activists-complain-that-virtual-shareholder-meetings-let-companies-silence | nan | nan | By Jessica DiNapoli and Ross Kerber
NEW YORK/BOSTON, Aug 18 (Reuters) - Justin Danhof has used annual shareholder meetings to question companies on social issues for the last nine years.
His conservative think tank, the National Center for Public Policy Research, owns just a few shares in each of about 150 companies and takes advantage of its shareholder status to grill executives on issues ranging from gay rights to boardroom diversity.
This year, Danhof often found himself ignored, as companies held their shareholder meetings remotely during the COVID-19 pandemic, and asked investors to submit their questions online.
Danhof said his questions on topics such as companies' dealings with China or restrictions on financing gun makers were answered in only 13 of the 27 virtual shareholder meetings he and his representatives attended.
"Companies used the crisis to set up question-and-answer sessions that are a joke," Danhof said. His success rate was much higher when he could sit near a microphone or in a CEO's line of sight during in-person gatherings, he added.
Danhof is not alone. Investors faced obstacles, such as not being able to ask questions or not having their inquiries addressed, about 55% of the time in a sample of 88 virtual shareholder meetings held this year and reviewed in a Hebrew University of Jerusalem study published this month.
The researchers did not provide such figures for in-person shareholder gatherings in previous years but estimated that this year's virtual meetings had significantly increased the number of dodged questions.
To be sure, virtual shareholder meetings have been welcomed by many mom-and-pop investors, who would have otherwise had to travel to a company's headquarters to attend amid the pandemic.
Broadridge Financial Solutions Inc, BR.N the top technology vendor to companies for these events, said it helped run 1,494 virtual shareholder meetings this year, up from 326 last year, preserving a key ritual in the corporate calendar.
Yet many activists focused on environmental, social and corporate governance issues say the digital format can make it hard for them to hold companies accountable, given that Wall Street's big institutional investors get access to top executives all year long.
"Companies should not use the pandemic as a cover for silencing their investors," New York State Comptroller Thomas DiNapoli, who administers the state's roughly $194 billion pension fund, said in a statement to Reuters. He said he wanted companies to use virtual meetings as a supplement to in-person shareholder gatherings, not a replacement.
Questions avoided this year ranged from online auctioneer eBay Inc EBAY.O declining to name directors who did not attend its online meeting to drug maker AbbVie Inc ABBV.N avoiding an inquiry on whether it would raise the cost of drugs during the pandemic.
"As long-term investors, we were disappointed our question wasn't answered by AbbVie," said Kate Monahan, shareholder engagement manager at the Friends Fiduciary Corporation, which invests roughly $480 million based on religious Quaker values.
She said she also posted her question on social media to attract attention but has yet to receive an answer from AbbVie.
Abbvie did not respond to a request for comment. An eBay spokeswoman said the company's shareholder meeting was well attended by its board, and that it focused on questions more relevant to its business "out of fairness to other shareholders."
Shareholder advocacy groups, including the Council of Institutional Investors (CII), last month asked the U.S. Securities and Exchange Commission (SEC) to look into the issue, including companies avoiding questions or not allowing shareholders to speak during virtual meetings.
An SEC spokesman declined to comment. The securities regulator issued guidance in April instructing companies to be clear about how shareholders "can remotely access, participate in, and vote" in online meetings.
The New York State Common Retirement Fund, overseen by DiNapoli, voted against the re-election of directors sitting on the governance committees of AT&T Inc T.N and Berkshire Hathaway Inc's BRKa.N boards this year for restricting investor participation at their virtual meetings.
Berkshire Hathaway did not respond to requests for comment. An AT&T spokeswoman said via e-mail that its decision this year to tweak the format of its shareholder meeting, allowing the company to read comments on proxy proponents' behalf, "lets us efficiently address the matters to be voted and then move on to additional content."
A spokesman for the fund said it will vote against directors of companies that do not meet CII's standards for virtual shareholder meetings.
Proxy advisory firm Glass, Lewis & Co, which many funds turn to for advice on how to cast their shareholder votes, is considering recommending against directors at companies that ran this year's virtual meetings poorly, its head of research and engagement Aaron Bertinetti said.
TECHNICAL GLITCHES
The snubbing of the activists has not always been intentional. As the pandemic spread in the spring, some companies had to switch to virtual meetings with little notice, resulting in technical glitches.
"The technology is just catching up with the need to make virtual meetings the best in class," said Lawrence Elbaum, a partner at law firm Vinson & Elkins LLP, who often works with companies challenged by activists. He added that investors can also contact companies through investor relations and by writing letters any day of the year.
Some activists argued, however, that public pressure on companies at shareholder meetings is more successful in triggering change. They pointed to oil major ExxonMobil Corp’s XOM.N move in 2018 to provide investors with a report on the impact of climate change after shareholders won a high-profile vote at its annual meeting the previous year.
"Virtual meetings provide another tool for companies who don't like dissent to shut it down," said Doug Chia, the president of corporate governance consulting firm Soundboard Governance LLC.
(Reporting by Jessica DiNapoli in New York and Ross Kerber in Boston Additional reporting by Svea Herbst-Bayliss in Boston Editing by Greg Roumeliotis and Cynthia Osterman)
((Jessica.DiNapoli@thomsonreuters.com; 646-223-4678;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Questions avoided this year ranged from online auctioneer eBay Inc EBAY.O declining to name directors who did not attend its online meeting to drug maker AbbVie Inc ABBV.N avoiding an inquiry on whether it would raise the cost of drugs during the pandemic. "As long-term investors, we were disappointed our question wasn't answered by AbbVie," said Kate Monahan, shareholder engagement manager at the Friends Fiduciary Corporation, which invests roughly $480 million based on religious Quaker values. She said she also posted her question on social media to attract attention but has yet to receive an answer from AbbVie. | Questions avoided this year ranged from online auctioneer eBay Inc EBAY.O declining to name directors who did not attend its online meeting to drug maker AbbVie Inc ABBV.N avoiding an inquiry on whether it would raise the cost of drugs during the pandemic. "As long-term investors, we were disappointed our question wasn't answered by AbbVie," said Kate Monahan, shareholder engagement manager at the Friends Fiduciary Corporation, which invests roughly $480 million based on religious Quaker values. She said she also posted her question on social media to attract attention but has yet to receive an answer from AbbVie. | Questions avoided this year ranged from online auctioneer eBay Inc EBAY.O declining to name directors who did not attend its online meeting to drug maker AbbVie Inc ABBV.N avoiding an inquiry on whether it would raise the cost of drugs during the pandemic. "As long-term investors, we were disappointed our question wasn't answered by AbbVie," said Kate Monahan, shareholder engagement manager at the Friends Fiduciary Corporation, which invests roughly $480 million based on religious Quaker values. She said she also posted her question on social media to attract attention but has yet to receive an answer from AbbVie. | Questions avoided this year ranged from online auctioneer eBay Inc EBAY.O declining to name directors who did not attend its online meeting to drug maker AbbVie Inc ABBV.N avoiding an inquiry on whether it would raise the cost of drugs during the pandemic. "As long-term investors, we were disappointed our question wasn't answered by AbbVie," said Kate Monahan, shareholder engagement manager at the Friends Fiduciary Corporation, which invests roughly $480 million based on religious Quaker values. She said she also posted her question on social media to attract attention but has yet to receive an answer from AbbVie. |
24425.0 | 2020-08-16 00:00:00 UTC | Pfizer's Unheralded Franchise That's Worth Billions of Dollars | ABBV | https://www.nasdaq.com/articles/pfizers-unheralded-franchise-thats-worth-billions-of-dollars-2020-08-16 | nan | nan | Which of Pfizer's (NYSE: PFE) products grab investors' attention the most? I'd put BNT162b2, the COVID-19 vaccine candidate that Pfizer is developing with BioNTech, high on the list. The company's top-selling drugs Ibrance and Eliquis would also certainly make the cut. Pneumococcal vaccine Prevnar 13 might be worthy of inclusion as well.
There's another franchise in Pfizer's lineup, though, that doesn't get a spot in the limelight often. But it could be on track to generate annual sales of more than $3 billion. What is this unheralded franchise that's worth billions of dollars to Pfizer? The big pharma company's biosimilars.
Image source: Getty Images.
Quietly gaining ground
You can think of biosimilars as kind of the generic versions of biologic drugs. These biologic drugs are made within living organisms and tend to be super-complicated to manufacture. Because of this complexity, there aren't nearly as many companies that make biosimilars compares to those that make generic drugs.
Pfizer jumped into the biosimilar business with its 2015 acquisition of Hospira. When the giant drugmaker closed the deal, Hospira hadn't yet won U.S. approvals for any of its biosimilars (although it had received European approvals for three biosimilars.)
Today, Pfizer claims five biosimilars on the market in the U.S. Its biggest winner so far is Inflectra/Remsima, a biosimilar to Johnson & Johnson's blockbuster autoimmune-disease drug Remicade. Inflectra/Remsima raked in $308 million in the first half of 2020, up 6% year over year.
Retacrit stands out as the only other biosimilar in Pfizer's lineup other than Inflectra/Remsima that gets a line item in the company's quarterly earnings release. The biosimilar to Amgen's Epogen, a biologic used to treat anemia in patients with chronic kidney disease, made $176 million in the first half of 2020, more than double its total in the prior-year period.
But Pfizer launched three biosimilars to top-selling cancer drugs sold by Roche earlier this year. Zirabev is Pfizer's biosimilar to Avastin. Ruxience is a biosimilar to Rituxan. Trazimera, a biosimilar to Herceptin, received a special mention by Pfizer CEO Albert Bourla in the company's Q2 conference call. Bourla said that Trazimera led the company's international biosimilar sales growth in the second quarter.
More on the way
Pfizer will soon have another biosimilar competing in the U.S. market. In June, the company won FDA approval for Nyvepria. It's a biosimilar to Amgen's Neulasta, a bone marrow stimulant used to prevent infection in patients on chemotherapy. Pfizer plans to launch Nyvepria in the U.S. later in 2020. The drugmaker has also filed for European approval of its Neulasta biosimilar.
In addition, Pfizer won FDA approval in November 2019 for Abrilada, a biosimilar to AbbVie's autoimmune-disease drug Humira. However, the company hasn't launched Abrilada yet. Why? AbbVie built up a strong set of patents that protect its top-selling drug for a few more years. It reached agreements with Pfizer and other potential biosimilar rivals to hold off on their launches until early 2023.
A billion here, a billion there
Based on Pfizer's results in the first half of 2020, the company appears to be on track to generate more than $1.1 billion from its biosimilars franchise. However, the actual total could be well above that figure since Ruxience, Trazimera, and Zirabev should pick up more momentum in the coming months.
Bernstein analyst Ronny Gal thinks that biosimilars are entering a "golden age." He projects that Pfizer could be on course to make around $3 billion per year from its biosimilars down the road. That estimate seems realistic considering the growth for the company's current biosimilars plus the potential for its biosimilar to Humira, which ranks as the No. 1 best-selling drug in the world right now.
The late Illinois Senator Everett Dirksen reportedly once said, "A billion here, a billion there, and pretty soon you're talking real money." Pfizer's biosimilars franchise seems destined to produce plenty of "real money" over the long run. That's great news for the pharma stock on top of its strong prospects for Ibrance, Eliquis, BNT162b2, and other drugs and pipeline candidates.
10 stocks we like better than Pfizer
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Pfizer wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of August 1, 2020
Keith Speights owns shares of AbbVie and Pfizer. The Motley Fool recommends Amgen and Johnson & Johnson. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In addition, Pfizer won FDA approval in November 2019 for Abrilada, a biosimilar to AbbVie's autoimmune-disease drug Humira. AbbVie built up a strong set of patents that protect its top-selling drug for a few more years. See the 10 stocks *Stock Advisor returns as of August 1, 2020 Keith Speights owns shares of AbbVie and Pfizer. | In addition, Pfizer won FDA approval in November 2019 for Abrilada, a biosimilar to AbbVie's autoimmune-disease drug Humira. AbbVie built up a strong set of patents that protect its top-selling drug for a few more years. See the 10 stocks *Stock Advisor returns as of August 1, 2020 Keith Speights owns shares of AbbVie and Pfizer. | In addition, Pfizer won FDA approval in November 2019 for Abrilada, a biosimilar to AbbVie's autoimmune-disease drug Humira. AbbVie built up a strong set of patents that protect its top-selling drug for a few more years. See the 10 stocks *Stock Advisor returns as of August 1, 2020 Keith Speights owns shares of AbbVie and Pfizer. | In addition, Pfizer won FDA approval in November 2019 for Abrilada, a biosimilar to AbbVie's autoimmune-disease drug Humira. AbbVie built up a strong set of patents that protect its top-selling drug for a few more years. See the 10 stocks *Stock Advisor returns as of August 1, 2020 Keith Speights owns shares of AbbVie and Pfizer. |
24426.0 | 2020-08-16 00:00:00 UTC | 3 Dividend Stocks Yielding More Than 4% That Are Safe Buys Right Now | ABBV | https://www.nasdaq.com/articles/3-dividend-stocks-yielding-more-than-4-that-are-safe-buys-right-now-2020-08-16 | nan | nan | If you're retired (or close to that point), there are typically two main things you'll look for in stocks. First, the stock should pay an attractive dividend. Second, the underlying business should be solid and reliable.
Once you find stocks that check off these boxes, you can buy and hold without losing any sleep at night. Your retirement should be relatively secure, with dividends rolling in regularly.
But what stocks meet both of these criteria? Here are three dividend stocks yielding more than 4% that are safe buys right now.
Image source: Getty Images.
1. Brookfield Infrastructure Partners
Brookfield Infrastructure Partners' (NYSE: BIP) dividend currently yields 4.4%. The company has consistently distributed a dividend to unitholders since it went public in 2008. It has also increased its distribution by an average of 10% annually over the last 10 years.
The company's business is about as steady as they come. Brookfield Infrastructure, as its name indicates, owns and manages infrastructure assets. These assets include electricity distribution and transmission systems, railroads, ports, toll roads, natural gas pipelines, communications towers, and data centers.
As you would expect, these are the kinds of infrastructure assets that provide a stable revenue stream month in and month out. In fact, roughly 95% of Brookfield Infrastructure's adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) are either regulated or locked into long-term contracts. It's also helpful that the company's assets are well diversified geographically across five continents, with no region generating more than 30% of total cash flows. .
Brookfield Infrastructure expects to deliver organic funds from operations (FFO) growth of between 6% and 9% each year and could boost that level with acquisitions. The company targets distributing between 60% and 70% of its FFO to unitholders.
2. Duke Energy
Duke Energy (NYSE: DUK) offers a dividend yield of nearly 4.7%. It has consistently paid a dividend every quarter for decades. However, Duke's dividend payout didn't increase during the latter part of the 1990s and the early years of the 21st century. The company also reduced its dividend in 2007. Since then, though, Duke Energy has increased its dividend every year.
Thanks to some acquisitions and mergers through the years, Duke Energy now ranks as one of the largest utilities in the U.S. It provides electricity to around 7.7 million customers in six states and natural gas to more than 1.6 million customers in five states. In addition, Duke operates solar and wind power facilities in 14 states.
The good news for investors is that Duke can count on generating a stable cash flow. Utilities are highly regulated, but they also enjoy monopolies. Duke's markets include fast-growing areas such as Florida and North Carolina that will likely need more electric power in the future.
Granted, Duke's business could be viewed as boring. The stock isn't going to deliver soaring growth. But for dividend-seeking investors, that's not a problem at all.
3. AbbVie
AbbVie (NYSE: ABBV) pays the most attractive dividend of the three, with a juicy yield of close to 5%. The big pharma company also belongs to the elite group of stocks known as Dividend Aristocrats, members of the S&P 500 index that have increased their dividends for at least 25 consecutive years.
The company's top-selling drug Humira faces biosimilar rivals in the U.S. beginning in 2023. Is that something for dividend investors to worry about, considering that Humira generated nearly 58% of AbbVie's total revenue last year? I don't think so.
For one thing, Humira is now a smaller (although still important) part of AbbVie's portfolio now that the company has completed its acquisition of Allergan. Also, AbbVie's lineup and pipeline include fast-rising stars that should further reduce its dependence on Humira.
AbbVie's blood cancer drugs Imbruvica and Venclexta rank at the top of that list. It also has two new immunology drugs, Rinvoq and Skyrizi, that will take the baton from Humira. These and other drugs should enable AbbVie's dividends to keep flowing and growing for a long time to come.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of August 1, 2020
Keith Speights owns shares of AbbVie and Brookfield Infrastructure Partners. The Motley Fool recommends Brookfield Infrastructure Partners and Duke Energy. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie AbbVie (NYSE: ABBV) pays the most attractive dividend of the three, with a juicy yield of close to 5%. Is that something for dividend investors to worry about, considering that Humira generated nearly 58% of AbbVie's total revenue last year? For one thing, Humira is now a smaller (although still important) part of AbbVie's portfolio now that the company has completed its acquisition of Allergan. | AbbVie AbbVie (NYSE: ABBV) pays the most attractive dividend of the three, with a juicy yield of close to 5%. Is that something for dividend investors to worry about, considering that Humira generated nearly 58% of AbbVie's total revenue last year? For one thing, Humira is now a smaller (although still important) part of AbbVie's portfolio now that the company has completed its acquisition of Allergan. | See the 10 stocks *Stock Advisor returns as of August 1, 2020 Keith Speights owns shares of AbbVie and Brookfield Infrastructure Partners. AbbVie AbbVie (NYSE: ABBV) pays the most attractive dividend of the three, with a juicy yield of close to 5%. Is that something for dividend investors to worry about, considering that Humira generated nearly 58% of AbbVie's total revenue last year? | Is that something for dividend investors to worry about, considering that Humira generated nearly 58% of AbbVie's total revenue last year? * David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! AbbVie AbbVie (NYSE: ABBV) pays the most attractive dividend of the three, with a juicy yield of close to 5%. |
24427.0 | 2020-08-13 00:00:00 UTC | Peek Under The Hood: SPYD Has 11% Upside | ABBV | https://www.nasdaq.com/articles/peek-under-the-hood%3A-spyd-has-11-upside-2020-08-13 | nan | nan | Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR— Portfolio S&P 500— High Dividend ETF (Symbol: SPYD), we found that the implied analyst target price for the ETF based upon its underlying holdings is $32.41 per unit.
With SPYD trading at a recent price near $29.31 per unit, that means that analysts see 10.59% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of SPYD's underlying holdings with notable upside to their analyst target prices are AbbVie Inc (Symbol: ABBV), Philip Morris International Inc (Symbol: PM), and Altria Group Inc (Symbol: MO). Although ABBV has traded at a recent price of $95.51/share, the average analyst target is 12.38% higher at $107.33/share. Similarly, PM has 11.34% upside from the recent share price of $79.69 if the average analyst target price of $88.73/share is reached, and analysts on average are expecting MO to reach a target price of $47.67/share, which is 10.95% above the recent price of $42.96. Below is a twelve month price history chart comparing the stock performance of ABBV, PM, and MO:
Below is a summary table of the current analyst target prices discussed above:
NAME SYMBOL RECENT PRICE AVG. ANALYST 12-MO. TARGET % UPSIDE TO TARGET
SPDR— Portfolio S&P 500— High Dividend ETF SPYD $29.31 $32.41 10.59%
AbbVie Inc ABBV $95.51 $107.33 12.38%
Philip Morris International Inc PM $79.69 $88.73 11.34%
Altria Group Inc MO $42.96 $47.67 10.95%
Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research.
10 ETFs With Most Upside To Analyst Targets »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Although ABBV has traded at a recent price of $95.51/share, the average analyst target is 12.38% higher at $107.33/share. SPDR— Portfolio S&P 500— High Dividend ETF SPYD $29.31 $32.41 10.59% AbbVie Inc ABBV $95.51 $107.33 12.38% Philip Morris International Inc PM $79.69 $88.73 11.34% Altria Group Inc MO $42.96 $47.67 10.95% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of SPYD's underlying holdings with notable upside to their analyst target prices are AbbVie Inc (Symbol: ABBV), Philip Morris International Inc (Symbol: PM), and Altria Group Inc (Symbol: MO). | Three of SPYD's underlying holdings with notable upside to their analyst target prices are AbbVie Inc (Symbol: ABBV), Philip Morris International Inc (Symbol: PM), and Altria Group Inc (Symbol: MO). SPDR— Portfolio S&P 500— High Dividend ETF SPYD $29.31 $32.41 10.59% AbbVie Inc ABBV $95.51 $107.33 12.38% Philip Morris International Inc PM $79.69 $88.73 11.34% Altria Group Inc MO $42.96 $47.67 10.95% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Although ABBV has traded at a recent price of $95.51/share, the average analyst target is 12.38% higher at $107.33/share. | Three of SPYD's underlying holdings with notable upside to their analyst target prices are AbbVie Inc (Symbol: ABBV), Philip Morris International Inc (Symbol: PM), and Altria Group Inc (Symbol: MO). Although ABBV has traded at a recent price of $95.51/share, the average analyst target is 12.38% higher at $107.33/share. Below is a twelve month price history chart comparing the stock performance of ABBV, PM, and MO: Below is a summary table of the current analyst target prices discussed above: | SPDR— Portfolio S&P 500— High Dividend ETF SPYD $29.31 $32.41 10.59% AbbVie Inc ABBV $95.51 $107.33 12.38% Philip Morris International Inc PM $79.69 $88.73 11.34% Altria Group Inc MO $42.96 $47.67 10.95% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of SPYD's underlying holdings with notable upside to their analyst target prices are AbbVie Inc (Symbol: ABBV), Philip Morris International Inc (Symbol: PM), and Altria Group Inc (Symbol: MO). Although ABBV has traded at a recent price of $95.51/share, the average analyst target is 12.38% higher at $107.33/share. |
24428.0 | 2020-08-12 00:00:00 UTC | Notable Wednesday Option Activity: ABBV, GPRE, AMGN | ABBV | https://www.nasdaq.com/articles/notable-wednesday-option-activity%3A-abbv-gpre-amgn-2020-08-12 | nan | nan | Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in AbbVie Inc (Symbol: ABBV), where a total of 29,353 contracts have traded so far, representing approximately 2.9 million underlying shares. That amounts to about 44.8% of ABBV's average daily trading volume over the past month of 6.6 million shares. Particularly high volume was seen for the $82.50 strike put option expiring September 18, 2020, with 1,125 contracts trading so far today, representing approximately 112,500 underlying shares of ABBV. Below is a chart showing ABBV's trailing twelve month trading history, with the $82.50 strike highlighted in orange:
Green Plains Inc. (Symbol: GPRE) options are showing a volume of 2,402 contracts thus far today. That number of contracts represents approximately 240,200 underlying shares, working out to a sizeable 42.7% of GPRE's average daily trading volume over the past month, of 562,580 shares. Especially high volume was seen for the $17 strike put option expiring September 18, 2020, with 500 contracts trading so far today, representing approximately 50,000 underlying shares of GPRE. Below is a chart showing GPRE's trailing twelve month trading history, with the $17 strike highlighted in orange:
And Amgen Inc (Symbol: AMGN) options are showing a volume of 8,473 contracts thus far today. That number of contracts represents approximately 847,300 underlying shares, working out to a sizeable 42.6% of AMGN's average daily trading volume over the past month, of 2.0 million shares. Especially high volume was seen for the $275 strike call option expiring September 18, 2020, with 1,676 contracts trading so far today, representing approximately 167,600 underlying shares of AMGN. Below is a chart showing AMGN's trailing twelve month trading history, with the $275 strike highlighted in orange:
For the various different available expirations for ABBV options, GPRE options, or AMGN options, visit StockOptionsChannel.com.
Today's Most Active Call & Put Options of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Particularly high volume was seen for the $82.50 strike put option expiring September 18, 2020, with 1,125 contracts trading so far today, representing approximately 112,500 underlying shares of ABBV. Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in AbbVie Inc (Symbol: ABBV), where a total of 29,353 contracts have traded so far, representing approximately 2.9 million underlying shares. That amounts to about 44.8% of ABBV's average daily trading volume over the past month of 6.6 million shares. | Below is a chart showing ABBV's trailing twelve month trading history, with the $82.50 strike highlighted in orange: Green Plains Inc. (Symbol: GPRE) options are showing a volume of 2,402 contracts thus far today. Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in AbbVie Inc (Symbol: ABBV), where a total of 29,353 contracts have traded so far, representing approximately 2.9 million underlying shares. That amounts to about 44.8% of ABBV's average daily trading volume over the past month of 6.6 million shares. | Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in AbbVie Inc (Symbol: ABBV), where a total of 29,353 contracts have traded so far, representing approximately 2.9 million underlying shares. Particularly high volume was seen for the $82.50 strike put option expiring September 18, 2020, with 1,125 contracts trading so far today, representing approximately 112,500 underlying shares of ABBV. That amounts to about 44.8% of ABBV's average daily trading volume over the past month of 6.6 million shares. | Below is a chart showing AMGN's trailing twelve month trading history, with the $275 strike highlighted in orange: For the various different available expirations for ABBV options, GPRE options, or AMGN options, visit StockOptionsChannel.com. Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in AbbVie Inc (Symbol: ABBV), where a total of 29,353 contracts have traded so far, representing approximately 2.9 million underlying shares. That amounts to about 44.8% of ABBV's average daily trading volume over the past month of 6.6 million shares. |
24429.0 | 2020-08-11 00:00:00 UTC | 5 Dividend Aristocrats Where Analysts See Capital Gains | ABBV | https://www.nasdaq.com/articles/5-dividend-aristocrats-where-analysts-see-capital-gains-2020-08-11 | nan | nan | To become a "Dividend Aristocrat," a dividend paying company must accomplish an incredible feat: consistently increase shareholder dividends every year for at least 20 consecutive years. Companies with this kind of track record tend to attract a lot of investor attention — and furthermore, "tracking" funds that follow the Dividend Aristocrats Index must own them. With all of this demand for shares, dividend growth stocks can sometimes become "fully priced," where there isn't much upside to analyst targets.
But we here at ETF Channel have looked through the underlying holdings of the SPDR S&P Dividend ETF (which tracks the S&P High Yield Dividend Aristocrats Index), and found these five dividend growth stocks that actually still have fairly substantial upside to the average analyst target price 12 months out. Which means, if the analysts are correct, these are five dividend growth stocks that could produce capital gains in addition to their growing dividend payments.
In the first table below, we present the five stocks. The recent share price, average analyst 12-month target price, and percentage upside to reach the analyst target are presented.
STOCK RECENT PRICE AVG. ANALYST 12-MO. TARGET % UPSIDE TO TARGET
AbbVie Inc (Symbol: ABBV) $92.38 $104.50 13.12%
Cincinnati Financial Corp. (Symbol: CINF) $83.42 $92.00 10.29%
Becton, Dickinson & Co (Symbol: BDX) $256.75 $280.62 9.30%
Stanley Black & Decker Inc (Symbol: SWK) $159.97 $172.00 7.52%
S&P Global Inc (Symbol: SPGI) $344.07 $367.38 6.77%
The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period — so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. To ballpark that total return potential, we have added the current yield to the analyst target price upside, in order to arrive at the 12-month total return potential:
STOCK DIVIDEND YIELD % UPSIDE TO ANALYST TARGET IMPLIED TOTAL RETURN POTENTIAL
AbbVie Inc (Symbol: ABBV) 5.11% 13.12% 18.23%
Cincinnati Financial Corp. (Symbol: CINF) 2.88% 10.29% 13.17%
Becton, Dickinson & Co (Symbol: BDX) 1.23% 9.30% 10.53%
Stanley Black & Decker Inc (Symbol: SWK) 1.75% 7.52% 9.27%
S&P Global Inc (Symbol: SPGI) 0.78% 6.77% 7.55%
Another consideration with dividend growth stocks is just how much the dividend is growing. We looked up the trailing twelve months worth of dividends shareholders of each of the above five companies have collected, and then also looked up the same number for the prior trailing twelve months. This gives us a rough yardstick to see how much the dividend has grown, from one trailing twelve month period to another.
STOCK PRIOR TTM DIVIDEND TTM DIVIDEND % GROWTH
AbbVie Inc (Symbol: ABBV) $4.17 $4.61 10.55%
Cincinnati Financial Corp. (Symbol: CINF) $2.18 $2.32 6.42%
Becton, Dickinson & Co (Symbol: BDX) $3.06 $3.14 2.61%
Stanley Black & Decker Inc (Symbol: SWK) $2.64 $2.76 4.55%
S&P Global Inc (Symbol: SPGI) $2.14 $2.48 15.89%
These five stocks are part of our full Dividend Aristocrats List. The average analyst target price data upon which this article was based, is courtesy of data provided by Zacks Investment Research via Quandl.com.
Get the latest Zacks research report on SWK — FREE
Get the latest Zacks research report on SPGI — FREE
Dividend Growth Stocks: 25 Aristocrats »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie Inc (Symbol: ABBV) $92.38 $104.50 13.12% Cincinnati Financial Corp. (Symbol: CINF) $83.42 $92.00 10.29% Becton, Dickinson & Co (Symbol: BDX) $256.75 $280.62 9.30% Stanley Black & Decker Inc (Symbol: SWK) $159.97 $172.00 7.52% S&P Global Inc (Symbol: SPGI) $344.07 $367.38 6.77% The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period — so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. AbbVie Inc (Symbol: ABBV) 5.11% 13.12% 18.23% Cincinnati Financial Corp. (Symbol: CINF) 2.88% 10.29% 13.17% Becton, Dickinson & Co (Symbol: BDX) 1.23% 9.30% 10.53% Stanley Black & Decker Inc (Symbol: SWK) 1.75% 7.52% 9.27% S&P Global Inc (Symbol: SPGI) 0.78% 6.77% 7.55% Another consideration with dividend growth stocks is just how much the dividend is growing. AbbVie Inc (Symbol: ABBV) $4.17 $4.61 10.55% Cincinnati Financial Corp. (Symbol: CINF) $2.18 $2.32 6.42% Becton, Dickinson & Co (Symbol: BDX) $3.06 $3.14 2.61% Stanley Black & Decker Inc (Symbol: SWK) $2.64 $2.76 4.55% S&P Global Inc (Symbol: SPGI) $2.14 $2.48 15.89% These five stocks are part of our full Dividend Aristocrats List. | AbbVie Inc (Symbol: ABBV) $92.38 $104.50 13.12% Cincinnati Financial Corp. (Symbol: CINF) $83.42 $92.00 10.29% Becton, Dickinson & Co (Symbol: BDX) $256.75 $280.62 9.30% Stanley Black & Decker Inc (Symbol: SWK) $159.97 $172.00 7.52% S&P Global Inc (Symbol: SPGI) $344.07 $367.38 6.77% The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period — so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. AbbVie Inc (Symbol: ABBV) 5.11% 13.12% 18.23% Cincinnati Financial Corp. (Symbol: CINF) 2.88% 10.29% 13.17% Becton, Dickinson & Co (Symbol: BDX) 1.23% 9.30% 10.53% Stanley Black & Decker Inc (Symbol: SWK) 1.75% 7.52% 9.27% S&P Global Inc (Symbol: SPGI) 0.78% 6.77% 7.55% Another consideration with dividend growth stocks is just how much the dividend is growing. AbbVie Inc (Symbol: ABBV) $4.17 $4.61 10.55% Cincinnati Financial Corp. (Symbol: CINF) $2.18 $2.32 6.42% Becton, Dickinson & Co (Symbol: BDX) $3.06 $3.14 2.61% Stanley Black & Decker Inc (Symbol: SWK) $2.64 $2.76 4.55% S&P Global Inc (Symbol: SPGI) $2.14 $2.48 15.89% These five stocks are part of our full Dividend Aristocrats List. | AbbVie Inc (Symbol: ABBV) $92.38 $104.50 13.12% Cincinnati Financial Corp. (Symbol: CINF) $83.42 $92.00 10.29% Becton, Dickinson & Co (Symbol: BDX) $256.75 $280.62 9.30% Stanley Black & Decker Inc (Symbol: SWK) $159.97 $172.00 7.52% S&P Global Inc (Symbol: SPGI) $344.07 $367.38 6.77% The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period — so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. AbbVie Inc (Symbol: ABBV) 5.11% 13.12% 18.23% Cincinnati Financial Corp. (Symbol: CINF) 2.88% 10.29% 13.17% Becton, Dickinson & Co (Symbol: BDX) 1.23% 9.30% 10.53% Stanley Black & Decker Inc (Symbol: SWK) 1.75% 7.52% 9.27% S&P Global Inc (Symbol: SPGI) 0.78% 6.77% 7.55% Another consideration with dividend growth stocks is just how much the dividend is growing. AbbVie Inc (Symbol: ABBV) $4.17 $4.61 10.55% Cincinnati Financial Corp. (Symbol: CINF) $2.18 $2.32 6.42% Becton, Dickinson & Co (Symbol: BDX) $3.06 $3.14 2.61% Stanley Black & Decker Inc (Symbol: SWK) $2.64 $2.76 4.55% S&P Global Inc (Symbol: SPGI) $2.14 $2.48 15.89% These five stocks are part of our full Dividend Aristocrats List. | AbbVie Inc (Symbol: ABBV) $92.38 $104.50 13.12% Cincinnati Financial Corp. (Symbol: CINF) $83.42 $92.00 10.29% Becton, Dickinson & Co (Symbol: BDX) $256.75 $280.62 9.30% Stanley Black & Decker Inc (Symbol: SWK) $159.97 $172.00 7.52% S&P Global Inc (Symbol: SPGI) $344.07 $367.38 6.77% The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period — so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. AbbVie Inc (Symbol: ABBV) 5.11% 13.12% 18.23% Cincinnati Financial Corp. (Symbol: CINF) 2.88% 10.29% 13.17% Becton, Dickinson & Co (Symbol: BDX) 1.23% 9.30% 10.53% Stanley Black & Decker Inc (Symbol: SWK) 1.75% 7.52% 9.27% S&P Global Inc (Symbol: SPGI) 0.78% 6.77% 7.55% Another consideration with dividend growth stocks is just how much the dividend is growing. AbbVie Inc (Symbol: ABBV) $4.17 $4.61 10.55% Cincinnati Financial Corp. (Symbol: CINF) $2.18 $2.32 6.42% Becton, Dickinson & Co (Symbol: BDX) $3.06 $3.14 2.61% Stanley Black & Decker Inc (Symbol: SWK) $2.64 $2.76 4.55% S&P Global Inc (Symbol: SPGI) $2.14 $2.48 15.89% These five stocks are part of our full Dividend Aristocrats List. |
24430.0 | 2020-08-08 00:00:00 UTC | 3 Big Pharma Stocks With Surprising Cannabis Connections | ABBV | https://www.nasdaq.com/articles/3-big-pharma-stocks-with-surprising-cannabis-connections-2020-08-08 | nan | nan | While smaller drugmakers such as GW Pharmaceuticals (NASDAQ: GWPH) and Corbus Pharmaceuticals (NASDAQ: CRBP) have plowed headlong into medical marijuana research, most of the largest pharmaceutical companies have stayed on the sidelines. Most -- but not all. A few of the top names in the sector have recognized the potential of cannabis. The rise in opioid lawsuits may lead drug companies to cannabinoids in the search for less-addictive pain relievers. It doesn't hurt that the compound annual growth rate (CAGR) of theglobal marketfor medical marijuana, according to one study, is estimated to be 24% over the next four years. This could considerably rise if federal laws around medical marijuana loosen. The reticence of those who have stayed out of this emerging business may not last long, especially with the share prices of the aforementioned stocks rising quickly. Johnson & Johnson (NYSE: JNJ), AbbVie (NYSE: ABBV), and Teva Pharmaceutical (NYSE: TEVA) are huge pharmaceutical companies that are less likely to see that same type of explosive growth in share price, but all three are establishing, at a distance, connections to medical marijuana.
CRBP data by YCharts
GW Pharmaceuticals made big news Monday when the U.S. Food and Drug Administration expanded its approval for the oral form of Epidiolex to treat seizures from tuberous sclerosis complex, a leading cause of genetic epilepsy that often produces benign tumors. Epidiolex, the only FDA-approved cannabidiol (CBD) treatment, was initially approved in 2018 for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) and Dravet syndrome, two types of childhood epilepsy.
Given the possibility of massiveglobal marketgrowth over the next decade and the successes of small companies like GW Pharmaceuticals, it's not a surprise that three of the biggest drug companies in the world are quietly testing the waters on cannabis and preparing themselves for the possibility of medical marijuana legalization in the U.S.
Image source: Getty Images
Johnson & Johnson's cannabis association
Johnson & Johnson topped all pharmaceutical companies for revenue last year, and while you won't find the words "marijuana" or "cannabis" anywhere in its annual report, it is well-positioned to jump into the market.
Start with Avicanna, a biopharmaceutical company with facilities in Colombia that is focusing on commercializing cannabinoids for medical and wellness use. Avicanna is headquartered at Johnson & Johnson's JLABS, a medical and science incubator in Toronto, which provides Johnson & Johnson mentors and access to the company's labs and technology. Johnson & Johnson doesn't have an ownership stake in Avicanna, but it frequently initiates partnerships with other companies engaged in research at the JLABS campus. Another company working at JLABS is Vapium, which is developing dose-control technology for Grenco Science's cannabis products.
The Food and Drug Administration places tight restrictions on studying cannabis in the United States. For example, research on any Schedule I drug, including cannabis, must be done under the auspices of a site-specific DEA investigator.
Because of the regulatory limitations on studying cannabis in the United States, it makes sense that Johnson & Johnson would bolster studies in Canada, where medical marijuana has been legal nationwide since 2001. Johnson & Johnson did $82.1 billion in sales last year, a rise of 3.7% over the previous year, and it is constantly looking for ways to increase its sales and profit margin. Cannabinoid-related medicine could be a way for the pharma giant to boost sales in the future.
AbbVie has been applying for cannabis-related patents
AbbVie, known as Abbott Labs before its spin-off as a branded pharmaceutical business, had produced and sold the anti-nausea drug, Marinol, for 35 years before selling it to Alkem Labs in late 2019. Marinol's active ingredient, dronabinol, is a synthetic form of tetrahydrocannabinol (THC). It has been prescribed to chemotherapy patients with nausea, and to induce appetite in patients with anorexia and AIDS. While AbbVie, the ninth-largest pharmaceutical company in the world by revenue, doesn't currently have any cannabis-related drugs in its catalog, it has filed for at least 59 cannabis-related patents in the United States, more than any other company, according to a 2019 report.
While 14 states and the District of Columbia have legalized marijuana for recreational use and 33 have approved it for medical use, it's still labeled as a Schedule I drug. Despite the federal government's history of restricting marijuana distribution and use, the U.S. Patent and Trademark Office has issued cannabis-related patents since 1942. AbbVie's active patents involving cannabinoids include a cancer treatment, a treatment for juvenile idiopathic arthritis, and cannabis as a treatment for skin disorders.
Teva is marketing cannabis in Israel
Teva Pharmaceutical is the largest supplier of generic drugs in the U.S. It's also quite active in the cannabis sector, although not in this country. In September, Salomon, Levin, Elstein (SLE), a subsidiary of the Israel-based pharmaceutical giant, announced that it would handle distribution of the products of Canndoc, a subsidiary of InterCure that specializes in medical marijuana. InterCure's CEO is former Israeli Prime Minister Ehud Barak.
This isn't Teva's first foray into marketing cannabis-related products. Last year, it agreed to market and distribute an inhaler from Syqe, another Israel-based pharmaceutical company. The Syqe is a dosing device for medical marijuana that comes with pre-loaded, cannabis-containing cartridges.
Teva earned $16.8 billion in revenue last year, down from $18.2 billion in 2018. In its annual report, the company talked of an effort to diversify its income. One way to do that could be to strengthen its reach into cannabis. For now, though, its cannabis-related business is pretty quiet. Its deal with Syqe wasn't referenced in the annual report, and its connection to SLE only earned a brief mention.
The tip of the iceberg
There are still plenty of roadblocks keeping these and other major pharmaceutical companies from diving into the cannabis business. A complicated patchwork of state and federal regulations and a wide spectrum of public perception are a few factors that have kept these players from going all in.
While some may see cannabis as a competitor to pharmaceuticals, if medical marijuana is legalized nationwide, it won't take long for pharmaceutical companies to establish a foothold in the sector, either by buying up cannabis companies or by expanding on the plans they're already making. Investors who realize this now may find themselves enjoying the benefits in the long term, when these big companies get even bigger.
Here's The Marijuana Stock You've Been Waiting For
A little-known Canadian company just unlocked what some experts think could be the key to profiting off the coming marijuana boom.
And make no mistake – it is coming.
Cannabis legalization is sweeping over North America – 11 states plus Washington, D.C., have all legalized recreational marijuana over the last few years, and full legalization came to Canada in October 2018.
And one under-the-radar Canadian company is poised to explode from this coming marijuana revolution.
Because a game-changing deal just went down between the Ontario government and this powerhouse company...and you need to hear this story today if you have even considered investing in pot stocks.
Simply click here to get the full story now.
Learn more
Jim Halley owns shares of AbbVie and Johnson & Johnson. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Johnson & Johnson (NYSE: JNJ), AbbVie (NYSE: ABBV), and Teva Pharmaceutical (NYSE: TEVA) are huge pharmaceutical companies that are less likely to see that same type of explosive growth in share price, but all three are establishing, at a distance, connections to medical marijuana. AbbVie has been applying for cannabis-related patents AbbVie, known as Abbott Labs before its spin-off as a branded pharmaceutical business, had produced and sold the anti-nausea drug, Marinol, for 35 years before selling it to Alkem Labs in late 2019. While AbbVie, the ninth-largest pharmaceutical company in the world by revenue, doesn't currently have any cannabis-related drugs in its catalog, it has filed for at least 59 cannabis-related patents in the United States, more than any other company, according to a 2019 report. | Johnson & Johnson (NYSE: JNJ), AbbVie (NYSE: ABBV), and Teva Pharmaceutical (NYSE: TEVA) are huge pharmaceutical companies that are less likely to see that same type of explosive growth in share price, but all three are establishing, at a distance, connections to medical marijuana. AbbVie has been applying for cannabis-related patents AbbVie, known as Abbott Labs before its spin-off as a branded pharmaceutical business, had produced and sold the anti-nausea drug, Marinol, for 35 years before selling it to Alkem Labs in late 2019. While AbbVie, the ninth-largest pharmaceutical company in the world by revenue, doesn't currently have any cannabis-related drugs in its catalog, it has filed for at least 59 cannabis-related patents in the United States, more than any other company, according to a 2019 report. | Johnson & Johnson (NYSE: JNJ), AbbVie (NYSE: ABBV), and Teva Pharmaceutical (NYSE: TEVA) are huge pharmaceutical companies that are less likely to see that same type of explosive growth in share price, but all three are establishing, at a distance, connections to medical marijuana. AbbVie has been applying for cannabis-related patents AbbVie, known as Abbott Labs before its spin-off as a branded pharmaceutical business, had produced and sold the anti-nausea drug, Marinol, for 35 years before selling it to Alkem Labs in late 2019. While AbbVie, the ninth-largest pharmaceutical company in the world by revenue, doesn't currently have any cannabis-related drugs in its catalog, it has filed for at least 59 cannabis-related patents in the United States, more than any other company, according to a 2019 report. | While AbbVie, the ninth-largest pharmaceutical company in the world by revenue, doesn't currently have any cannabis-related drugs in its catalog, it has filed for at least 59 cannabis-related patents in the United States, more than any other company, according to a 2019 report. Johnson & Johnson (NYSE: JNJ), AbbVie (NYSE: ABBV), and Teva Pharmaceutical (NYSE: TEVA) are huge pharmaceutical companies that are less likely to see that same type of explosive growth in share price, but all three are establishing, at a distance, connections to medical marijuana. AbbVie has been applying for cannabis-related patents AbbVie, known as Abbott Labs before its spin-off as a branded pharmaceutical business, had produced and sold the anti-nausea drug, Marinol, for 35 years before selling it to Alkem Labs in late 2019. |
24431.0 | 2020-08-07 00:00:00 UTC | AbbVie a Top Ranked SAFE Dividend Stock With 5.1% Yield (ABBV) | ABBV | https://www.nasdaq.com/articles/abbvie-a-top-ranked-safe-dividend-stock-with-5.1-yield-abbv-2020-08-07 | nan | nan | AbbVie Inc (Symbol: ABBV) has been named to the Dividend Channel ''S.A.F.E. 25'' list, signifying a stock with above-average ''DividendRank'' statistics including a strong 5.1% yield, as well as a superb track record of at least two decades of dividend growth, according to the most recent ''DividendRank'' report.
According to the ETF Finder at ETF Channel, AbbVie Inc is a member of the iShares S&P 1500 Index ETF (ITOT), and is also an underlying holding representing 1.74% of the SPDR S&P Dividend ETF (SDY), which holds $291,848,191 worth of ABBV shares.
AbbVie Inc (Symbol: ABBV) made the "Dividend Channel S.A.F.E. 25" list because of these qualities: S. Solid return — hefty yield and strong DividendRank characteristics; A. Accelerating amount — consistent dividend increases over time; F. Flawless history — never a missed or lowered dividend; E. Enduring — at least two decades of dividend payments.
The annualized dividend paid by AbbVie Inc is $4.72/share, currently paid in quarterly installments, and its most recent dividend ex-date was on 07/14/2020. Below is a long-term dividend history chart for ABBV, which the report stressed as being of key importance.
ABBV operates in the Drugs & Pharmaceuticals sector, among companies like Johnson & Johnson (JNJ), and Novartis (NVS).
Top 25 S.A.F.E. Dividend Stocks Increasing Payments For Decades »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Below is a long-term dividend history chart for ABBV, which the report stressed as being of key importance. AbbVie Inc (Symbol: ABBV) has been named to the Dividend Channel ''S.A.F.E. According to the ETF Finder at ETF Channel, AbbVie Inc is a member of the iShares S&P 1500 Index ETF (ITOT), and is also an underlying holding representing 1.74% of the SPDR S&P Dividend ETF (SDY), which holds $291,848,191 worth of ABBV shares. | AbbVie Inc (Symbol: ABBV) made the "Dividend Channel S.A.F.E. AbbVie Inc (Symbol: ABBV) has been named to the Dividend Channel ''S.A.F.E. According to the ETF Finder at ETF Channel, AbbVie Inc is a member of the iShares S&P 1500 Index ETF (ITOT), and is also an underlying holding representing 1.74% of the SPDR S&P Dividend ETF (SDY), which holds $291,848,191 worth of ABBV shares. | According to the ETF Finder at ETF Channel, AbbVie Inc is a member of the iShares S&P 1500 Index ETF (ITOT), and is also an underlying holding representing 1.74% of the SPDR S&P Dividend ETF (SDY), which holds $291,848,191 worth of ABBV shares. AbbVie Inc (Symbol: ABBV) has been named to the Dividend Channel ''S.A.F.E. AbbVie Inc (Symbol: ABBV) made the "Dividend Channel S.A.F.E. | AbbVie Inc (Symbol: ABBV) has been named to the Dividend Channel ''S.A.F.E. According to the ETF Finder at ETF Channel, AbbVie Inc is a member of the iShares S&P 1500 Index ETF (ITOT), and is also an underlying holding representing 1.74% of the SPDR S&P Dividend ETF (SDY), which holds $291,848,191 worth of ABBV shares. AbbVie Inc (Symbol: ABBV) made the "Dividend Channel S.A.F.E. |
24432.0 | 2020-08-07 00:00:00 UTC | 2 Coronavirus Stocks Robinhood Investors Love. Should You? | ABBV | https://www.nasdaq.com/articles/2-coronavirus-stocks-robinhood-investors-love.-should-you-2020-08-07 | nan | nan | Robinhood Markets is a financial services company that owns the stock-trading app Robinhood, which is highly popular among millennials. The company has made a habit of maintaining an updated list of the 100 most popular stocks on its platform.
A peek at the stocks in the most recent ranking (as of this writing) reveals that Robinhood investors have been busy buying shares of companies that are involved in the development of vaccines or treatments for the coronavirus. In particular, Gilead Sciences (NASDAQ: GILD) and Sorrento Therapeutics (NASDAQ: SRNE) both feature on the list.
Gilead Sciences is the biotech behind remdesivir, an antiviral drug that could be our best shot at a treatment for COVID-19. Meanwhile, Sorrento Therapeutics boasts several coronavirus-related products in its pipeline. Both of these companies have handily outperformed the market of late, but will they continue to do so? Let's look at each and figure out whether they deserve a place in your portfolio.
GILD data by YCharts.
Gilead Sciences is more than just remdesivir
Gilead failed to impress investors with its latest earnings report. During the second quarter, the company's revenue of about $5.1 billion was down by about 10.6% year over year, while its adjusted earnings per share were $1.11, down from $1.72 in the prior-year quarter. The company blamed the pandemic, which hurt some of its products' sales, for its poor performance. But long-term investors should look beyond these disappointing results for a few reasons.
First, the U.S. Food and Drug Administration (FDA) issued an emergency use authorization for remdesivir back in May, and the drug was also given the green light in Europe in June. The company should be able to generate some sales from this drug in the coming months.
Second, Gilead remains one of the leaders in the HIV market. The company's HIV and HIV prep products performed comparatively well during the second quarter. Sales in the segment, which made up roughly 79% of the company's revenue during the quarter, declined by 1% to $4 billion. While sales of its hepatitis C products plunged by 47% to $448 million, this segment accounted for just 9% of the company's revenue.
Image source: Getty Images.
During Gilead Sciences' second-quarterearnings call CEO Daniel O'Day said that the company's Biktarvy drug has become the "gold standard in HIV treatment." The company boasts other top-performing products in this segment as well.
Lastly, Gilead Sciences boasts a rich pipeline; in particular, it is awaiting a decision from regulators in the U.S. and Europe on filgotinib, a potential treatment for rheumatoid arthritis (RA).
I think it's likely that this drug will be approved and will go on to become a key growth driver for the company, especially considering its edge over its competitors, including AbbVie's (NYSE: ABBV) Humira and Johnson & Johnson's (NYSE: JNJ) Remicade. As Gilead's chief commercial officer, Johanna Mercier, said: "Despite currently available treatment options, many patients are still living with symptoms of inadequately controlled RA around the world. In fact, only one out of five patients living with RA achieve complete remission at year one, which means four to five do not. Filgotinib has a compelling and differentiated clinical profile that we believe may uniquely address the significant unmet need for patients with RA."
For all these reasons, and given that Gilead Sciences is currently trading at just 9.9 times future earnings, I think this healthcare stock is a buy.
Sorrento Therapeutics' hopes hang on its COVID-19 programs
Sorrento Therapeutics is attacking COVID-19 from all fronts. The company boasts potential vaccines, treatments, and diagnostic tests for the disease. Let's go through several of these.
First, the company has developed a neutralizing antibody called COVI-GUARD (also known as STI-1499), which management claimed in May had demonstrated the ability to completely neutralize the SARS-CoV-2 virus that causes COVID-19 in pre-clinical trials.
Second, there's abivertinib, which the company is testing in a phase 2 clinical trial for COVID-19 patients with moderate to severe manifestations of the disease. It is investigating the efficacy of abivertinib on hospitalized patients who have suffered a cytokine storm, a potentially deadly immune reaction that some COVID-19 patients experience.
Third, Sorrento Therapeutics has developed COVI-TRACK, a diagnostic test that it says can detect antibodies to the SARS-CoV-2 virus in eight minutes or less. The FDA is currently reviewing the company's application for an emergency use authorization for this test.
Sorrento doesn't have much going on outside its COVID-19 programs, however. And while the company's coronavirus-related work may seem impressive at first glance, let's not forget that it faces stiff competition across the range of the products it is working on.
Notable companies that have already developed successful tests for COVID-19 include Abbott Laboratories (NYSE: ABT) and Roche Holdings (OTC: RHHBY). While no vaccines for the disease have been approved yet, such biotechs as Moderna (NASDAQ: MRNA), Novavax (NASDAQ: NVAX), and Pfizer (NYSE: PFE) are much further along with their efforts.
What will matter at the end is which products are most effective, so even if Sorrento is behind right now, things could change quickly in its favor. But given what we know now, that outcome seems very optimistic. Investors looking at coronavirus stocks should look elsewhere, since Sorrento Therapeutics seems too risky at the moment.
10 stocks we like better than Gilead Sciences
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Gilead Sciences wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of June 2, 2020
Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | I think it's likely that this drug will be approved and will go on to become a key growth driver for the company, especially considering its edge over its competitors, including AbbVie's (NYSE: ABBV) Humira and Johnson & Johnson's (NYSE: JNJ) Remicade. A peek at the stocks in the most recent ranking (as of this writing) reveals that Robinhood investors have been busy buying shares of companies that are involved in the development of vaccines or treatments for the coronavirus. Lastly, Gilead Sciences boasts a rich pipeline; in particular, it is awaiting a decision from regulators in the U.S. and Europe on filgotinib, a potential treatment for rheumatoid arthritis (RA). | I think it's likely that this drug will be approved and will go on to become a key growth driver for the company, especially considering its edge over its competitors, including AbbVie's (NYSE: ABBV) Humira and Johnson & Johnson's (NYSE: JNJ) Remicade. In particular, Gilead Sciences (NASDAQ: GILD) and Sorrento Therapeutics (NASDAQ: SRNE) both feature on the list. The company boasts potential vaccines, treatments, and diagnostic tests for the disease. | I think it's likely that this drug will be approved and will go on to become a key growth driver for the company, especially considering its edge over its competitors, including AbbVie's (NYSE: ABBV) Humira and Johnson & Johnson's (NYSE: JNJ) Remicade. A peek at the stocks in the most recent ranking (as of this writing) reveals that Robinhood investors have been busy buying shares of companies that are involved in the development of vaccines or treatments for the coronavirus. In particular, Gilead Sciences (NASDAQ: GILD) and Sorrento Therapeutics (NASDAQ: SRNE) both feature on the list. | I think it's likely that this drug will be approved and will go on to become a key growth driver for the company, especially considering its edge over its competitors, including AbbVie's (NYSE: ABBV) Humira and Johnson & Johnson's (NYSE: JNJ) Remicade. In particular, Gilead Sciences (NASDAQ: GILD) and Sorrento Therapeutics (NASDAQ: SRNE) both feature on the list. Meanwhile, Sorrento Therapeutics boasts several coronavirus-related products in its pipeline. |
24433.0 | 2020-08-06 00:00:00 UTC | AbbVie agrees to pay $24 mln to resolve Humira California lawsuit | ABBV | https://www.nasdaq.com/articles/abbvie-agrees-to-pay-%2424-mln-to-resolve-humira-california-lawsuit-2020-08-06-0 | nan | nan | Adds statement from AbbVie
Aug 6 (Reuters) - AbbVie Inc ABBV.N has agreed to pay $24 million to settle a lawsuit that alleged insurance fraud by the drugmaker in promoting its blockbuster drug Humira, California's insurance regulator said on Thursday.
AbbVie denied the allegations, but agreed to look into how Humira is marketed to health care providers in the state, the regulator said
The Insurance Commissioner of California said the company also agreed to disclose that AbbVie, and not a medical provider, paid the registered nurses who are employed as so-called AbbVie Ambassadors to interact with patients about Humira.
Insurance Commissioner Ricardo Lara said AbbVie has paid $24 million to California and the whistleblower, a registered nurse who brought the case to the department's attention in October 2016.
AbbVie said in a statement it was glad the settlement allows its nurse ambassador program to continue with no significant changes and noted that some parallel cases have been dismissed in other courts.
Humira, the company's flagship arthritis treatment, brought in sales of $3.97 billion in the latest quarter. It has been the major driver of AbbVie's growth in recent years but faces expirations of its patents in U.S. in 2023.
Among other things, the regulator had alleged AbbVie violated California's Insurance Frauds Prevention Act by unlawfully providing free and valuable professional goods and services to physicians to induce and reward Humira prescriptions.
(Reporting by Vishwadha Chander in Bengaluru; Editing by Shailesh Kuber)
((Vishwadha.Chander@thomsonreuters.com; within U.S. +1 646 223 8780, outside U.S. +91 80 6749 6132;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Insurance Commissioner Ricardo Lara said AbbVie has paid $24 million to California and the whistleblower, a registered nurse who brought the case to the department's attention in October 2016. AbbVie said in a statement it was glad the settlement allows its nurse ambassador program to continue with no significant changes and noted that some parallel cases have been dismissed in other courts. Among other things, the regulator had alleged AbbVie violated California's Insurance Frauds Prevention Act by unlawfully providing free and valuable professional goods and services to physicians to induce and reward Humira prescriptions. | Adds statement from AbbVie Aug 6 (Reuters) - AbbVie Inc ABBV.N has agreed to pay $24 million to settle a lawsuit that alleged insurance fraud by the drugmaker in promoting its blockbuster drug Humira, California's insurance regulator said on Thursday. Insurance Commissioner Ricardo Lara said AbbVie has paid $24 million to California and the whistleblower, a registered nurse who brought the case to the department's attention in October 2016. Among other things, the regulator had alleged AbbVie violated California's Insurance Frauds Prevention Act by unlawfully providing free and valuable professional goods and services to physicians to induce and reward Humira prescriptions. | Adds statement from AbbVie Aug 6 (Reuters) - AbbVie Inc ABBV.N has agreed to pay $24 million to settle a lawsuit that alleged insurance fraud by the drugmaker in promoting its blockbuster drug Humira, California's insurance regulator said on Thursday. AbbVie denied the allegations, but agreed to look into how Humira is marketed to health care providers in the state, the regulator said The Insurance Commissioner of California said the company also agreed to disclose that AbbVie, and not a medical provider, paid the registered nurses who are employed as so-called AbbVie Ambassadors to interact with patients about Humira. Among other things, the regulator had alleged AbbVie violated California's Insurance Frauds Prevention Act by unlawfully providing free and valuable professional goods and services to physicians to induce and reward Humira prescriptions. | AbbVie denied the allegations, but agreed to look into how Humira is marketed to health care providers in the state, the regulator said The Insurance Commissioner of California said the company also agreed to disclose that AbbVie, and not a medical provider, paid the registered nurses who are employed as so-called AbbVie Ambassadors to interact with patients about Humira. AbbVie said in a statement it was glad the settlement allows its nurse ambassador program to continue with no significant changes and noted that some parallel cases have been dismissed in other courts. Adds statement from AbbVie Aug 6 (Reuters) - AbbVie Inc ABBV.N has agreed to pay $24 million to settle a lawsuit that alleged insurance fraud by the drugmaker in promoting its blockbuster drug Humira, California's insurance regulator said on Thursday. |
24434.0 | 2020-08-06 00:00:00 UTC | AbbVie agrees to pay $24 mln to resolve Humira California lawsuit | ABBV | https://www.nasdaq.com/articles/abbvie-agrees-to-pay-%2424-mln-to-resolve-humira-california-lawsuit-2020-08-06 | nan | nan | Aug 6 (Reuters) - AbbVie Inc ABBV.N has agreed to pay $24 million to settle a lawsuit that alleged insurance fraud by the drugmaker in promoting its blockbuster drug Humira, California's insurance regulator said on Thursday.
AbbVie denied the allegations, but agreed to look into how Humira is marketed to health care providers in the state, the regulator said
The Insurance Commissioner of California said the company also agreed to disclose that AbbVie, and not a medical provider, paid the registered nurses who are employed as so-called AbbVie Ambassadors to interact with patients about Humira.
Insurance Commissioner Ricardo Lara said AbbVie has paid $24 million to California and the whistleblower, a registered nurse who brought the case to the department's attention in October 2016.
AbbVie did not immediately respond to Reuters request for comment.
Humira, the company's flagship arthritis treatment, brought in sales of $3.97 billion in the latest quarter. It has been the major driver of AbbVie's growth in the recent years but faces expirations of its patents in U.S. in 2023.
Among other things, the department alleged AbbVie violated California's Insurance Frauds Prevention Act by unlawfully providing free and valuable professional goods and services to physicians to induce and reward Humira prescriptions.
(Reporting by Vishwadha Chander in Bengaluru; Editing by Shailesh Kuber)
((Vishwadha.Chander@thomsonreuters.com; within U.S. +1 646 223 8780, outside U.S. +91 80 6749 6132;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Insurance Commissioner Ricardo Lara said AbbVie has paid $24 million to California and the whistleblower, a registered nurse who brought the case to the department's attention in October 2016. Among other things, the department alleged AbbVie violated California's Insurance Frauds Prevention Act by unlawfully providing free and valuable professional goods and services to physicians to induce and reward Humira prescriptions. Aug 6 (Reuters) - AbbVie Inc ABBV.N has agreed to pay $24 million to settle a lawsuit that alleged insurance fraud by the drugmaker in promoting its blockbuster drug Humira, California's insurance regulator said on Thursday. | Aug 6 (Reuters) - AbbVie Inc ABBV.N has agreed to pay $24 million to settle a lawsuit that alleged insurance fraud by the drugmaker in promoting its blockbuster drug Humira, California's insurance regulator said on Thursday. Insurance Commissioner Ricardo Lara said AbbVie has paid $24 million to California and the whistleblower, a registered nurse who brought the case to the department's attention in October 2016. Among other things, the department alleged AbbVie violated California's Insurance Frauds Prevention Act by unlawfully providing free and valuable professional goods and services to physicians to induce and reward Humira prescriptions. | Aug 6 (Reuters) - AbbVie Inc ABBV.N has agreed to pay $24 million to settle a lawsuit that alleged insurance fraud by the drugmaker in promoting its blockbuster drug Humira, California's insurance regulator said on Thursday. AbbVie denied the allegations, but agreed to look into how Humira is marketed to health care providers in the state, the regulator said The Insurance Commissioner of California said the company also agreed to disclose that AbbVie, and not a medical provider, paid the registered nurses who are employed as so-called AbbVie Ambassadors to interact with patients about Humira. Among other things, the department alleged AbbVie violated California's Insurance Frauds Prevention Act by unlawfully providing free and valuable professional goods and services to physicians to induce and reward Humira prescriptions. | AbbVie denied the allegations, but agreed to look into how Humira is marketed to health care providers in the state, the regulator said The Insurance Commissioner of California said the company also agreed to disclose that AbbVie, and not a medical provider, paid the registered nurses who are employed as so-called AbbVie Ambassadors to interact with patients about Humira. AbbVie did not immediately respond to Reuters request for comment. Aug 6 (Reuters) - AbbVie Inc ABBV.N has agreed to pay $24 million to settle a lawsuit that alleged insurance fraud by the drugmaker in promoting its blockbuster drug Humira, California's insurance regulator said on Thursday. |
24435.0 | 2020-08-06 00:00:00 UTC | ABBV Named A Top Socially Responsible Dividend Stock | ABBV | https://www.nasdaq.com/articles/abbv-named-a-top-socially-responsible-dividend-stock-2020-08-06 | nan | nan | AbbVie Inc (Symbol: ABBV) has been named a Top Socially Responsible Dividend Stock by Dividend Channel, signifying a stock with above-average ''DividendRank'' statistics including a strong 5.1% yield, as well as being recognized by prominent asset managers as being a socially responsible investment, through analysis of social and environmental criteria. Environmental criteria include considerations like the environmental impact of the company's products and services, as well as the company's efficiency in terms of its use of energy and resources. Social criteria include elements such as human rights, child labor, corporate diversity, and the company's impact on society — for instance, taken into consideration would be business activities tied to weapons, gambling, tobacco, and alcohol.
According to the ETF Finder at ETF Channel, AbbVie Inc is a member of both the iShares MSCI USA ESG Select ETF (SUSA), making up 0.56% of the underlying holdings of the fund, as well as the iShares MSCI KLD 400 Social Index Fund ETF (DSI), where ABBV makes up 1.10% of the underlying holdings of the fund.
The annualized dividend paid by AbbVie Inc is $4.72/share, currently paid in quarterly installments, and its most recent dividend ex-date was on 07/14/2020. Below is a long-term dividend history chart for ABBV, which the DividendRank report stressed as being of key importance. Indeed, studying a company's past dividend history can be of good help in judging whether the most recent dividend is likely to continue.
ABBV operates in the Drugs & Pharmaceuticals sector, among companies like Johnson & Johnson (JNJ), and Novartis (NVS).
Top 25 Socially Responsible Dividend Stocks — Income To Feel Good About »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie Inc (Symbol: ABBV) has been named a Top Socially Responsible Dividend Stock by Dividend Channel, signifying a stock with above-average ''DividendRank'' statistics including a strong 5.1% yield, as well as being recognized by prominent asset managers as being a socially responsible investment, through analysis of social and environmental criteria. Below is a long-term dividend history chart for ABBV, which the DividendRank report stressed as being of key importance. According to the ETF Finder at ETF Channel, AbbVie Inc is a member of both the iShares MSCI USA ESG Select ETF (SUSA), making up 0.56% of the underlying holdings of the fund, as well as the iShares MSCI KLD 400 Social Index Fund ETF (DSI), where ABBV makes up 1.10% of the underlying holdings of the fund. | AbbVie Inc (Symbol: ABBV) has been named a Top Socially Responsible Dividend Stock by Dividend Channel, signifying a stock with above-average ''DividendRank'' statistics including a strong 5.1% yield, as well as being recognized by prominent asset managers as being a socially responsible investment, through analysis of social and environmental criteria. According to the ETF Finder at ETF Channel, AbbVie Inc is a member of both the iShares MSCI USA ESG Select ETF (SUSA), making up 0.56% of the underlying holdings of the fund, as well as the iShares MSCI KLD 400 Social Index Fund ETF (DSI), where ABBV makes up 1.10% of the underlying holdings of the fund. The annualized dividend paid by AbbVie Inc is $4.72/share, currently paid in quarterly installments, and its most recent dividend ex-date was on 07/14/2020. | AbbVie Inc (Symbol: ABBV) has been named a Top Socially Responsible Dividend Stock by Dividend Channel, signifying a stock with above-average ''DividendRank'' statistics including a strong 5.1% yield, as well as being recognized by prominent asset managers as being a socially responsible investment, through analysis of social and environmental criteria. According to the ETF Finder at ETF Channel, AbbVie Inc is a member of both the iShares MSCI USA ESG Select ETF (SUSA), making up 0.56% of the underlying holdings of the fund, as well as the iShares MSCI KLD 400 Social Index Fund ETF (DSI), where ABBV makes up 1.10% of the underlying holdings of the fund. The annualized dividend paid by AbbVie Inc is $4.72/share, currently paid in quarterly installments, and its most recent dividend ex-date was on 07/14/2020. | AbbVie Inc (Symbol: ABBV) has been named a Top Socially Responsible Dividend Stock by Dividend Channel, signifying a stock with above-average ''DividendRank'' statistics including a strong 5.1% yield, as well as being recognized by prominent asset managers as being a socially responsible investment, through analysis of social and environmental criteria. According to the ETF Finder at ETF Channel, AbbVie Inc is a member of both the iShares MSCI USA ESG Select ETF (SUSA), making up 0.56% of the underlying holdings of the fund, as well as the iShares MSCI KLD 400 Social Index Fund ETF (DSI), where ABBV makes up 1.10% of the underlying holdings of the fund. The annualized dividend paid by AbbVie Inc is $4.72/share, currently paid in quarterly installments, and its most recent dividend ex-date was on 07/14/2020. |
24436.0 | 2020-08-04 00:00:00 UTC | How Neurocrine Biosciences Crushed It in Q2 | ABBV | https://www.nasdaq.com/articles/how-neurocrine-biosciences-crushed-it-in-q2-2020-08-04 | nan | nan | Neurocrine Biosciences' (NASDAQ: NBIX) 30% plunge earlier this year during the coronavirus-fueled market meltdown is practically all but forgotten now. The stock was up around 15% as of the market close on Monday.
But Neurocrine's shares are now likely to go even higher. The biotech announced its second-quarter results after the market closed on Monday. Here's what you need to know about Neurocrine's impressive Q2 update.
Image source: Getty Images.
By the numbers
Neurocrine reported revenue of $302.4 million in the second quarter, a 65% increase from the $183.5 million reported in the prior-year period. This result also blew past the average analysts' revenue estimate of $260.5 million.
The company announced Q2 net income of $80 million, or $0.81 per share, based on generally accepted accounting principles (GAAP). This marked a significant improvement from Neurocrine's GAAP earnings of $51 million, or $0.54 per share, in the same period in 2019.
Neurocrine recorded adjusted net income in the second quarter of $139 million, or $1.42 per share. This doubled the company's adjusted earnings of $67 million, or $0.71 per share, posted in the second quarter of last year. It also trounced the consensus Wall Street adjusted earnings estimate of $0.73 per share.
Behind the numbers
Most of Neurocrine's impressive revenue growth in Q2 was driven by Ingrezza. Sales of the drug, which treats neurological disorder tardive dyskinesia, soared 48% year over year to $267.6 million.
Neurocrine also reported $34.8 million in collaboration revenue in the second quarter. In the prior-year period, the company's collaboration revenue totaled only $3 million. Most of the increase stemmed from a $30 million milestone payment from AbbVie associated with FDA approval for Oriahnn (elagolix) in treating uterine fibroids.
In addition to its stellar financial results, Neurocrine also made significant progress that should boost its revenue going forward. The company won FDA approval for Ongentys in treating Parkinson's disease in April. In May, Neurocrine exercised its option with Iorsia Pharmaceuticals to license the global rights to NBI-827104, which is a potential treatment for a rare type of pediatric epilepsy. It also licensed several of Takeda's schizophrenia, depression, and anhedonia candidates in early to-mid-stage testing.
Looking ahead
Neurocrine didn't provide revenue guidance for full-year 2020. However, it seems realistic to expect continued momentum for Ingrezza in the second half of the year. The company could also begin to see small initial royalties from AbbVie's sales of Oriahnn that grow over time.
On the other hand, Neurocrine did give a revised outlook related to its full-year 2020 expenses. It now anticipates combined GAAP research and development (R&D) and selling, general, and administrative (SG&A) expenses will be between $850 million and $900 million, up from its previous guidance range of $675 million to $725 million. The company also projects full-year 2020 non-GAAP R&D and SG&A expenses will be between $570 million and $610 million, compared to the range of $550 million to $600 million provided in its previous outlook.
One of the most important things to watch with the biotech stock in the next few quarters is the impact of sales of Ongentys. Neurocrine expects to launch the drug later this year.
10 stocks we like better than Neurocrine Biosciences
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Neurocrine Biosciences wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of June 2, 2020
Keith Speights owns shares of AbbVie. The Motley Fool recommends Neurocrine Biosciences. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Most of the increase stemmed from a $30 million milestone payment from AbbVie associated with FDA approval for Oriahnn (elagolix) in treating uterine fibroids. The company could also begin to see small initial royalties from AbbVie's sales of Oriahnn that grow over time. See the 10 stocks *Stock Advisor returns as of June 2, 2020 Keith Speights owns shares of AbbVie. | Most of the increase stemmed from a $30 million milestone payment from AbbVie associated with FDA approval for Oriahnn (elagolix) in treating uterine fibroids. The company could also begin to see small initial royalties from AbbVie's sales of Oriahnn that grow over time. See the 10 stocks *Stock Advisor returns as of June 2, 2020 Keith Speights owns shares of AbbVie. | Most of the increase stemmed from a $30 million milestone payment from AbbVie associated with FDA approval for Oriahnn (elagolix) in treating uterine fibroids. The company could also begin to see small initial royalties from AbbVie's sales of Oriahnn that grow over time. See the 10 stocks *Stock Advisor returns as of June 2, 2020 Keith Speights owns shares of AbbVie. | Most of the increase stemmed from a $30 million milestone payment from AbbVie associated with FDA approval for Oriahnn (elagolix) in treating uterine fibroids. The company could also begin to see small initial royalties from AbbVie's sales of Oriahnn that grow over time. See the 10 stocks *Stock Advisor returns as of June 2, 2020 Keith Speights owns shares of AbbVie. |
24437.0 | 2020-08-03 00:00:00 UTC | BUZZ-U.S. STOCKS ON THE MOVE-Microsoft, Dynatrace, Carnival Corp, Atossa Therapeutics | ABBV | https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-microsoft-dynatrace-carnival-corp-atossa-therapeutics-2020-08 | nan | nan | Eikon search string for individual stock moves: STXBZ
The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi
The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh
Wall Street's main indexes rose on Monday as a rebound in multi-billion dollar deals, including Microsoft's pursuit of TikTok's U.S. operations, lifted sentiment in the absence of a fiscal coronavirus relief bill. .N
At 11:30 a.m. ET, the Dow Jones Industrial Average .DJI was up 0.95% at 26,679.21. The S&P 500 .SPX was up 0.77% at 3,296.35 and the Nasdaq Composite .IXIC was up 1.32% at 10,887.181. The top three S&P 500 .PG.INX percentage gainers: ** Varian Medical Systems Inc , up 21.9% ** Cardinal Health Inc , up 5.2% ** Mckesson Corp , up 4.9% The top three S&P 500 .PL.INX percentage losers: ** Under Armour Inc , down 6.8% ** Norwegian Cruise Line Holdings Ltd NCLH.N, down 6.6% ** Carnival Corp , down 5.7% The top three NYSE .PG.N percentage gainers: ** ADT Inc , up 65.2% ** Ambow Education Holding Ltd , up 41.9% ** Pitney Bowes Inc , up 31.3% The top three NYSE .PL.N percentage losers: ** Resideo Technologies Inc REZI.N, down 19.3% ** Eastman Kodak Co KODK.N, down 18.6% ** Tupperware Brands Corporation , down 17.6% The top three Nasdaq .PG.O percentage gainers: ** Datasea Inc , up 99.5% ** Marathon Patent Group Inc , up 78.3% ** Cymabay Therapeutics Inc , up 36.3% The top three Nasdaq .PL.O percentage losers: ** Tiziana Life Sciences PLC , down 21% ** Alarm.com Holdings Inc , down 19.7% ** Mid-Con Energy Partners LP , down 15.3% ** AbbVie Inc ABBV.N: up 2.2%
BUZZ-Street View: AbbVie in good stead to tackle Humira competition ** Varian Medical Systems Inc VAR.N: up 21.9%
BUZZ-Jumps on Siemens Healthineers' $16.4 bln buyout deal ** Pinterest Inc PINS.N: up 5.5%
BUZZ-Up as brokerage raises rating on growth prospects ** Colgate-Palmolive CO CL.N: down 0.4%
BUZZ-Street View: Colgate-Palmolive's H2 growth could slow down in emerging markets ** Chevron Corp CVX.N: up 0.5%
BUZZ-Street View: Chevron has strong balance sheet despite challenging quarter ** Marathon Petroleum Corp MPC.N: up 0.3%
BUZZ-Rises on $21 bln Speedway sale to 7-Eleven owner ** ADT Inc ADT.N: up 65.3%
BUZZ-Surges on $450 mln Google investment in home security partnership ** Charter Communications Inc CHTR.O: up 1.4%
BUZZ-Street View: Charter Communications waltzes into Q3 after impressive results ** Merck & Co Inc MRK.N: up 3.9%
BUZZ-Street View: Merck's late launch of COVID-19 vaccines may be advantageous ** VistaGen Therapeutics Inc VTGN.O: down 16.1%
BUZZ-Plunges on discounted share sale offer ** Co-Diagnostics Inc CODX.O: up 19.2%
BUZZ-Co-Diagnostics tech to be used in FDA-authorized COVID-19 test, shares up ** Eli Lilly & Co LLY.N: up 2.1%
BUZZ-Up on starting late-stage trial of COVID-19 drug in nursing homes ** Exxon Mobil Corp XOM.N: up 0.1%
BUZZ-Street View: Exxon Mobil's reduced capex improves near-term cash burn ** McKesson Corp MCK.N: up 4.8%
BUZZ-Rises on higher 2021 forecast, profit beat ** BioCryst Pharmaceuticals Inc BCRX.O: up 4.4%
BUZZ-Rises on 'Fast Track' tag for potential blood disorder treatment ** Keurig Dr Pepper Inc KDP.N: down 2.1%
BUZZ-Down as Goldman shops large block ** Spirit AeroSystems Holdings Inc SPR.N: down 2.5%
BUZZ-Falls as co cuts production of 737 MAX jet parts ** Tyme Technologies Inc TYME.O: up 12.6%
BUZZ-Surges as cancer treatment gets 'orphan drug' status ** Jernigan Capital Inc JCAP.N: up 23.8%
BUZZ-To be acquired by NexPoint; shares rise ** Moderna Inc MRNA.O: up 1.4%
BUZZ-Potential COVID-19 vaccine can generate $5 bln in annual sales -Jefferies ** CymaBay Therapeutics Inc CBAY.O: up 36.3%
BUZZ-Jumps on positive data from liver disease drug ** Jacobs Engineering Group Inc J.N: up 5.0%
BUZZ-Gains after raising FY profit forecast; tops Q3 est ** Carnival Corp CCL.N: down 5.3%
BUZZ-Cruise stocks down after Carnival cancels AIDA restart ** Ferrari NV RACE.N: up 3.8%
BUZZ-Accelerates as orders rise "significantly" ** Atossa Therapeutics Inc ATOS.O: up 6.9%
BUZZ-Jumps as co to start study of nasal spray against COVID-19 ** Dynatrace Inc DT.N: down 3.0%
BUZZ-Drops as sponsor Thoma Bravo carves stake ** Microsoft Corp MSFT.O: up 4.2%
BUZZ-Rises on proposed TikTok deal ** Kansas City Southern KSU.N: up 1.2%
BUZZ-Up on report of possible takeover bid ** Marvell Technology Group Ltd MRVL.O: up 2.9%
BUZZ-Up as BofA Securities raises PT on growth prospects ** Marathon Petroleum Corp MPC.N: up 0.3%
BUZZ-Street View: Marathon-Speedway deal to aid refineries in low-demand periods ** Clorox Co CLX.N: down 1.9%
BUZZ-Falls on 'conservative' fiscal 2021 forecast ** Snap Inc SNAP.N: down 7.4%
BUZZ-Falls as Microsoft looks to go viral with TikTok ** SunCoke Energy Inc SXC.N: up 0.6%
BUZZ-High on surprise Q2 profit
The 11 major S&P 500 sectors:
Communication Services
.SPLRCL
up 0.10%
Consumer Discretionary
.SPLRCD
down 0.33%
Consumer Staples
.SPLRCS
down 0.15%
Energy
.SPNY
up 0.09%
Financial
.SPSY
up 0.77%
Health
.SPXHC
up 1.21%
Industrial
.SPLRCI
up 0.52%
Information Technology
.SPLRCT
up 2.17%
Materials
.SPLRCM
up 0.03%
Real Estate
.SPLRCR
down 1.71%
Utilities
.SPLRCU
down 1.09%
(Compiled by Shivani Kumaresan in Bengaluru)
((Shivani.Kumaresan@thomsonreuters.com ; +1 646 223 8780))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The top three S&P 500 .PG.INX percentage gainers: ** Varian Medical Systems Inc , up 21.9% ** Cardinal Health Inc , up 5.2% ** Mckesson Corp , up 4.9% The top three S&P 500 .PL.INX percentage losers: ** Under Armour Inc , down 6.8% ** Norwegian Cruise Line Holdings Ltd NCLH.N, down 6.6% ** Carnival Corp , down 5.7% The top three NYSE .PG.N percentage gainers: ** ADT Inc , up 65.2% ** Ambow Education Holding Ltd , up 41.9% ** Pitney Bowes Inc , up 31.3% The top three NYSE .PL.N percentage losers: ** Resideo Technologies Inc REZI.N, down 19.3% ** Eastman Kodak Co KODK.N, down 18.6% ** Tupperware Brands Corporation , down 17.6% The top three Nasdaq .PG.O percentage gainers: ** Datasea Inc , up 99.5% ** Marathon Patent Group Inc , up 78.3% ** Cymabay Therapeutics Inc , up 36.3% The top three Nasdaq .PL.O percentage losers: ** Tiziana Life Sciences PLC , down 21% ** Alarm.com Holdings Inc , down 19.7% ** Mid-Con Energy Partners LP , down 15.3% ** AbbVie Inc ABBV.N: up 2.2% BUZZ-Street View: AbbVie in good stead to tackle Humira competition ** Varian Medical Systems Inc VAR.N: up 21.9% BUZZ-Jumps on Siemens Healthineers' $16.4 bln buyout deal ** Pinterest Inc PINS.N: up 5.5% BUZZ-Up as brokerage raises rating on growth prospects ** Colgate-Palmolive CO CL.N: down 0.4% BUZZ-Street View: Colgate-Palmolive's H2 growth could slow down in emerging markets ** Chevron Corp CVX.N: up 0.5% BUZZ-Street View: Chevron has strong balance sheet despite challenging quarter ** Marathon Petroleum Corp MPC.N: up 0.3% BUZZ-Rises on $21 bln Speedway sale to 7-Eleven owner ** ADT Inc ADT.N: up 65.3% BUZZ-Surges on $450 mln Google investment in home security partnership ** Charter Communications Inc CHTR.O: up 1.4% BUZZ-Street View: Charter Communications waltzes into Q3 after impressive results ** Merck & Co Inc MRK.N: up 3.9% BUZZ-Street View: Merck's late launch of COVID-19 vaccines may be advantageous ** VistaGen Therapeutics Inc VTGN.O: down 16.1% BUZZ-Plunges on discounted share sale offer ** Co-Diagnostics Inc CODX.O: up 19.2% BUZZ-Co-Diagnostics tech to be used in FDA-authorized COVID-19 test, shares up ** Eli Lilly & Co LLY.N: up 2.1% BUZZ-Up on starting late-stage trial of COVID-19 drug in nursing homes ** Exxon Mobil Corp XOM.N: up 0.1% BUZZ-Street View: Exxon Mobil's reduced capex improves near-term cash burn ** McKesson Corp MCK.N: up 4.8% BUZZ-Rises on higher 2021 forecast, profit beat ** BioCryst Pharmaceuticals Inc BCRX.O: up 4.4% BUZZ-Rises on 'Fast Track' tag for potential blood disorder treatment ** Keurig Dr Pepper Inc KDP.N: down 2.1% BUZZ-Down as Goldman shops large block ** Spirit AeroSystems Holdings Inc SPR.N: down 2.5% BUZZ-Falls as co cuts production of 737 MAX jet parts ** Tyme Technologies Inc TYME.O: up 12.6% BUZZ-Surges as cancer treatment gets 'orphan drug' status ** Jernigan Capital Inc JCAP.N: up 23.8% BUZZ-To be acquired by NexPoint; shares rise ** Moderna Inc MRNA.O: up 1.4% BUZZ-Potential COVID-19 vaccine can generate $5 bln in annual sales -Jefferies ** CymaBay Therapeutics Inc CBAY.O: up 36.3% BUZZ-Jumps on positive data from liver disease drug ** Jacobs Engineering Group Inc J.N: up 5.0% BUZZ-Gains after raising FY profit forecast; tops Q3 est ** Carnival Corp CCL.N: down 5.3% BUZZ-Cruise stocks down after Carnival cancels AIDA restart ** Ferrari NV RACE.N: up 3.8% BUZZ-Accelerates as orders rise "significantly" ** Atossa Therapeutics Inc ATOS.O: up 6.9% BUZZ-Jumps as co to start study of nasal spray against COVID-19 ** Dynatrace Inc DT.N: down 3.0% BUZZ-Drops as sponsor Thoma Bravo carves stake ** Microsoft Corp MSFT.O: up 4.2% BUZZ-Rises on proposed TikTok deal ** Kansas City Southern KSU.N: up 1.2% BUZZ-Up on report of possible takeover bid ** Marvell Technology Group Ltd MRVL.O: up 2.9% BUZZ-Up as BofA Securities raises PT on growth prospects ** Marathon Petroleum Corp MPC.N: up 0.3% BUZZ-Street View: Marathon-Speedway deal to aid refineries in low-demand periods ** Clorox Co CLX.N: down 1.9% BUZZ-Falls on 'conservative' fiscal 2021 forecast ** Snap Inc SNAP.N: down 7.4% BUZZ-Falls as Microsoft looks to go viral with TikTok ** SunCoke Energy Inc SXC.N: up 0.6% BUZZ-High on surprise Q2 profit The 11 major S&P 500 sectors: Communication Services Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh Wall Street's main indexes rose on Monday as a rebound in multi-billion dollar deals, including Microsoft's pursuit of TikTok's U.S. operations, lifted sentiment in the absence of a fiscal coronavirus relief bill. down 1.09% (Compiled by Shivani Kumaresan in Bengaluru) ((Shivani.Kumaresan@thomsonreuters.com ; +1 646 223 8780)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The top three S&P 500 .PG.INX percentage gainers: ** Varian Medical Systems Inc , up 21.9% ** Cardinal Health Inc , up 5.2% ** Mckesson Corp , up 4.9% The top three S&P 500 .PL.INX percentage losers: ** Under Armour Inc , down 6.8% ** Norwegian Cruise Line Holdings Ltd NCLH.N, down 6.6% ** Carnival Corp , down 5.7% The top three NYSE .PG.N percentage gainers: ** ADT Inc , up 65.2% ** Ambow Education Holding Ltd , up 41.9% ** Pitney Bowes Inc , up 31.3% The top three NYSE .PL.N percentage losers: ** Resideo Technologies Inc REZI.N, down 19.3% ** Eastman Kodak Co KODK.N, down 18.6% ** Tupperware Brands Corporation , down 17.6% The top three Nasdaq .PG.O percentage gainers: ** Datasea Inc , up 99.5% ** Marathon Patent Group Inc , up 78.3% ** Cymabay Therapeutics Inc , up 36.3% The top three Nasdaq .PL.O percentage losers: ** Tiziana Life Sciences PLC , down 21% ** Alarm.com Holdings Inc , down 19.7% ** Mid-Con Energy Partners LP , down 15.3% ** AbbVie Inc ABBV.N: up 2.2% BUZZ-Street View: AbbVie in good stead to tackle Humira competition ** Varian Medical Systems Inc VAR.N: up 21.9% BUZZ-Jumps on Siemens Healthineers' $16.4 bln buyout deal ** Pinterest Inc PINS.N: up 5.5% BUZZ-Up as brokerage raises rating on growth prospects ** Colgate-Palmolive CO CL.N: down 0.4% BUZZ-Street View: Colgate-Palmolive's H2 growth could slow down in emerging markets ** Chevron Corp CVX.N: up 0.5% BUZZ-Street View: Chevron has strong balance sheet despite challenging quarter ** Marathon Petroleum Corp MPC.N: up 0.3% BUZZ-Rises on $21 bln Speedway sale to 7-Eleven owner ** ADT Inc ADT.N: up 65.3% BUZZ-Surges on $450 mln Google investment in home security partnership ** Charter Communications Inc CHTR.O: up 1.4% BUZZ-Street View: Charter Communications waltzes into Q3 after impressive results ** Merck & Co Inc MRK.N: up 3.9% BUZZ-Street View: Merck's late launch of COVID-19 vaccines may be advantageous ** VistaGen Therapeutics Inc VTGN.O: down 16.1% BUZZ-Plunges on discounted share sale offer ** Co-Diagnostics Inc CODX.O: up 19.2% BUZZ-Co-Diagnostics tech to be used in FDA-authorized COVID-19 test, shares up ** Eli Lilly & Co LLY.N: up 2.1% BUZZ-Up on starting late-stage trial of COVID-19 drug in nursing homes ** Exxon Mobil Corp XOM.N: up 0.1% BUZZ-Street View: Exxon Mobil's reduced capex improves near-term cash burn ** McKesson Corp MCK.N: up 4.8% BUZZ-Rises on higher 2021 forecast, profit beat ** BioCryst Pharmaceuticals Inc BCRX.O: up 4.4% BUZZ-Rises on 'Fast Track' tag for potential blood disorder treatment ** Keurig Dr Pepper Inc KDP.N: down 2.1% BUZZ-Down as Goldman shops large block ** Spirit AeroSystems Holdings Inc SPR.N: down 2.5% BUZZ-Falls as co cuts production of 737 MAX jet parts ** Tyme Technologies Inc TYME.O: up 12.6% BUZZ-Surges as cancer treatment gets 'orphan drug' status ** Jernigan Capital Inc JCAP.N: up 23.8% BUZZ-To be acquired by NexPoint; shares rise ** Moderna Inc MRNA.O: up 1.4% BUZZ-Potential COVID-19 vaccine can generate $5 bln in annual sales -Jefferies ** CymaBay Therapeutics Inc CBAY.O: up 36.3% BUZZ-Jumps on positive data from liver disease drug ** Jacobs Engineering Group Inc J.N: up 5.0% BUZZ-Gains after raising FY profit forecast; tops Q3 est ** Carnival Corp CCL.N: down 5.3% BUZZ-Cruise stocks down after Carnival cancels AIDA restart ** Ferrari NV RACE.N: up 3.8% BUZZ-Accelerates as orders rise "significantly" ** Atossa Therapeutics Inc ATOS.O: up 6.9% BUZZ-Jumps as co to start study of nasal spray against COVID-19 ** Dynatrace Inc DT.N: down 3.0% BUZZ-Drops as sponsor Thoma Bravo carves stake ** Microsoft Corp MSFT.O: up 4.2% BUZZ-Rises on proposed TikTok deal ** Kansas City Southern KSU.N: up 1.2% BUZZ-Up on report of possible takeover bid ** Marvell Technology Group Ltd MRVL.O: up 2.9% BUZZ-Up as BofA Securities raises PT on growth prospects ** Marathon Petroleum Corp MPC.N: up 0.3% BUZZ-Street View: Marathon-Speedway deal to aid refineries in low-demand periods ** Clorox Co CLX.N: down 1.9% BUZZ-Falls on 'conservative' fiscal 2021 forecast ** Snap Inc SNAP.N: down 7.4% BUZZ-Falls as Microsoft looks to go viral with TikTok ** SunCoke Energy Inc SXC.N: up 0.6% BUZZ-High on surprise Q2 profit The 11 major S&P 500 sectors: Communication Services Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh Wall Street's main indexes rose on Monday as a rebound in multi-billion dollar deals, including Microsoft's pursuit of TikTok's U.S. operations, lifted sentiment in the absence of a fiscal coronavirus relief bill. down 1.09% (Compiled by Shivani Kumaresan in Bengaluru) ((Shivani.Kumaresan@thomsonreuters.com ; +1 646 223 8780)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The top three S&P 500 .PG.INX percentage gainers: ** Varian Medical Systems Inc , up 21.9% ** Cardinal Health Inc , up 5.2% ** Mckesson Corp , up 4.9% The top three S&P 500 .PL.INX percentage losers: ** Under Armour Inc , down 6.8% ** Norwegian Cruise Line Holdings Ltd NCLH.N, down 6.6% ** Carnival Corp , down 5.7% The top three NYSE .PG.N percentage gainers: ** ADT Inc , up 65.2% ** Ambow Education Holding Ltd , up 41.9% ** Pitney Bowes Inc , up 31.3% The top three NYSE .PL.N percentage losers: ** Resideo Technologies Inc REZI.N, down 19.3% ** Eastman Kodak Co KODK.N, down 18.6% ** Tupperware Brands Corporation , down 17.6% The top three Nasdaq .PG.O percentage gainers: ** Datasea Inc , up 99.5% ** Marathon Patent Group Inc , up 78.3% ** Cymabay Therapeutics Inc , up 36.3% The top three Nasdaq .PL.O percentage losers: ** Tiziana Life Sciences PLC , down 21% ** Alarm.com Holdings Inc , down 19.7% ** Mid-Con Energy Partners LP , down 15.3% ** AbbVie Inc ABBV.N: up 2.2% BUZZ-Street View: AbbVie in good stead to tackle Humira competition ** Varian Medical Systems Inc VAR.N: up 21.9% BUZZ-Jumps on Siemens Healthineers' $16.4 bln buyout deal ** Pinterest Inc PINS.N: up 5.5% BUZZ-Up as brokerage raises rating on growth prospects ** Colgate-Palmolive CO CL.N: down 0.4% BUZZ-Street View: Colgate-Palmolive's H2 growth could slow down in emerging markets ** Chevron Corp CVX.N: up 0.5% BUZZ-Street View: Chevron has strong balance sheet despite challenging quarter ** Marathon Petroleum Corp MPC.N: up 0.3% BUZZ-Rises on $21 bln Speedway sale to 7-Eleven owner ** ADT Inc ADT.N: up 65.3% BUZZ-Surges on $450 mln Google investment in home security partnership ** Charter Communications Inc CHTR.O: up 1.4% BUZZ-Street View: Charter Communications waltzes into Q3 after impressive results ** Merck & Co Inc MRK.N: up 3.9% BUZZ-Street View: Merck's late launch of COVID-19 vaccines may be advantageous ** VistaGen Therapeutics Inc VTGN.O: down 16.1% BUZZ-Plunges on discounted share sale offer ** Co-Diagnostics Inc CODX.O: up 19.2% BUZZ-Co-Diagnostics tech to be used in FDA-authorized COVID-19 test, shares up ** Eli Lilly & Co LLY.N: up 2.1% BUZZ-Up on starting late-stage trial of COVID-19 drug in nursing homes ** Exxon Mobil Corp XOM.N: up 0.1% BUZZ-Street View: Exxon Mobil's reduced capex improves near-term cash burn ** McKesson Corp MCK.N: up 4.8% BUZZ-Rises on higher 2021 forecast, profit beat ** BioCryst Pharmaceuticals Inc BCRX.O: up 4.4% BUZZ-Rises on 'Fast Track' tag for potential blood disorder treatment ** Keurig Dr Pepper Inc KDP.N: down 2.1% BUZZ-Down as Goldman shops large block ** Spirit AeroSystems Holdings Inc SPR.N: down 2.5% BUZZ-Falls as co cuts production of 737 MAX jet parts ** Tyme Technologies Inc TYME.O: up 12.6% BUZZ-Surges as cancer treatment gets 'orphan drug' status ** Jernigan Capital Inc JCAP.N: up 23.8% BUZZ-To be acquired by NexPoint; shares rise ** Moderna Inc MRNA.O: up 1.4% BUZZ-Potential COVID-19 vaccine can generate $5 bln in annual sales -Jefferies ** CymaBay Therapeutics Inc CBAY.O: up 36.3% BUZZ-Jumps on positive data from liver disease drug ** Jacobs Engineering Group Inc J.N: up 5.0% BUZZ-Gains after raising FY profit forecast; tops Q3 est ** Carnival Corp CCL.N: down 5.3% BUZZ-Cruise stocks down after Carnival cancels AIDA restart ** Ferrari NV RACE.N: up 3.8% BUZZ-Accelerates as orders rise "significantly" ** Atossa Therapeutics Inc ATOS.O: up 6.9% BUZZ-Jumps as co to start study of nasal spray against COVID-19 ** Dynatrace Inc DT.N: down 3.0% BUZZ-Drops as sponsor Thoma Bravo carves stake ** Microsoft Corp MSFT.O: up 4.2% BUZZ-Rises on proposed TikTok deal ** Kansas City Southern KSU.N: up 1.2% BUZZ-Up on report of possible takeover bid ** Marvell Technology Group Ltd MRVL.O: up 2.9% BUZZ-Up as BofA Securities raises PT on growth prospects ** Marathon Petroleum Corp MPC.N: up 0.3% BUZZ-Street View: Marathon-Speedway deal to aid refineries in low-demand periods ** Clorox Co CLX.N: down 1.9% BUZZ-Falls on 'conservative' fiscal 2021 forecast ** Snap Inc SNAP.N: down 7.4% BUZZ-Falls as Microsoft looks to go viral with TikTok ** SunCoke Energy Inc SXC.N: up 0.6% BUZZ-High on surprise Q2 profit The 11 major S&P 500 sectors: Communication Services ET, the Dow Jones Industrial Average .DJI was up 0.95% at 26,679.21. up 0.10% Consumer Discretionary | The top three S&P 500 .PG.INX percentage gainers: ** Varian Medical Systems Inc , up 21.9% ** Cardinal Health Inc , up 5.2% ** Mckesson Corp , up 4.9% The top three S&P 500 .PL.INX percentage losers: ** Under Armour Inc , down 6.8% ** Norwegian Cruise Line Holdings Ltd NCLH.N, down 6.6% ** Carnival Corp , down 5.7% The top three NYSE .PG.N percentage gainers: ** ADT Inc , up 65.2% ** Ambow Education Holding Ltd , up 41.9% ** Pitney Bowes Inc , up 31.3% The top three NYSE .PL.N percentage losers: ** Resideo Technologies Inc REZI.N, down 19.3% ** Eastman Kodak Co KODK.N, down 18.6% ** Tupperware Brands Corporation , down 17.6% The top three Nasdaq .PG.O percentage gainers: ** Datasea Inc , up 99.5% ** Marathon Patent Group Inc , up 78.3% ** Cymabay Therapeutics Inc , up 36.3% The top three Nasdaq .PL.O percentage losers: ** Tiziana Life Sciences PLC , down 21% ** Alarm.com Holdings Inc , down 19.7% ** Mid-Con Energy Partners LP , down 15.3% ** AbbVie Inc ABBV.N: up 2.2% BUZZ-Street View: AbbVie in good stead to tackle Humira competition ** Varian Medical Systems Inc VAR.N: up 21.9% BUZZ-Jumps on Siemens Healthineers' $16.4 bln buyout deal ** Pinterest Inc PINS.N: up 5.5% BUZZ-Up as brokerage raises rating on growth prospects ** Colgate-Palmolive CO CL.N: down 0.4% BUZZ-Street View: Colgate-Palmolive's H2 growth could slow down in emerging markets ** Chevron Corp CVX.N: up 0.5% BUZZ-Street View: Chevron has strong balance sheet despite challenging quarter ** Marathon Petroleum Corp MPC.N: up 0.3% BUZZ-Rises on $21 bln Speedway sale to 7-Eleven owner ** ADT Inc ADT.N: up 65.3% BUZZ-Surges on $450 mln Google investment in home security partnership ** Charter Communications Inc CHTR.O: up 1.4% BUZZ-Street View: Charter Communications waltzes into Q3 after impressive results ** Merck & Co Inc MRK.N: up 3.9% BUZZ-Street View: Merck's late launch of COVID-19 vaccines may be advantageous ** VistaGen Therapeutics Inc VTGN.O: down 16.1% BUZZ-Plunges on discounted share sale offer ** Co-Diagnostics Inc CODX.O: up 19.2% BUZZ-Co-Diagnostics tech to be used in FDA-authorized COVID-19 test, shares up ** Eli Lilly & Co LLY.N: up 2.1% BUZZ-Up on starting late-stage trial of COVID-19 drug in nursing homes ** Exxon Mobil Corp XOM.N: up 0.1% BUZZ-Street View: Exxon Mobil's reduced capex improves near-term cash burn ** McKesson Corp MCK.N: up 4.8% BUZZ-Rises on higher 2021 forecast, profit beat ** BioCryst Pharmaceuticals Inc BCRX.O: up 4.4% BUZZ-Rises on 'Fast Track' tag for potential blood disorder treatment ** Keurig Dr Pepper Inc KDP.N: down 2.1% BUZZ-Down as Goldman shops large block ** Spirit AeroSystems Holdings Inc SPR.N: down 2.5% BUZZ-Falls as co cuts production of 737 MAX jet parts ** Tyme Technologies Inc TYME.O: up 12.6% BUZZ-Surges as cancer treatment gets 'orphan drug' status ** Jernigan Capital Inc JCAP.N: up 23.8% BUZZ-To be acquired by NexPoint; shares rise ** Moderna Inc MRNA.O: up 1.4% BUZZ-Potential COVID-19 vaccine can generate $5 bln in annual sales -Jefferies ** CymaBay Therapeutics Inc CBAY.O: up 36.3% BUZZ-Jumps on positive data from liver disease drug ** Jacobs Engineering Group Inc J.N: up 5.0% BUZZ-Gains after raising FY profit forecast; tops Q3 est ** Carnival Corp CCL.N: down 5.3% BUZZ-Cruise stocks down after Carnival cancels AIDA restart ** Ferrari NV RACE.N: up 3.8% BUZZ-Accelerates as orders rise "significantly" ** Atossa Therapeutics Inc ATOS.O: up 6.9% BUZZ-Jumps as co to start study of nasal spray against COVID-19 ** Dynatrace Inc DT.N: down 3.0% BUZZ-Drops as sponsor Thoma Bravo carves stake ** Microsoft Corp MSFT.O: up 4.2% BUZZ-Rises on proposed TikTok deal ** Kansas City Southern KSU.N: up 1.2% BUZZ-Up on report of possible takeover bid ** Marvell Technology Group Ltd MRVL.O: up 2.9% BUZZ-Up as BofA Securities raises PT on growth prospects ** Marathon Petroleum Corp MPC.N: up 0.3% BUZZ-Street View: Marathon-Speedway deal to aid refineries in low-demand periods ** Clorox Co CLX.N: down 1.9% BUZZ-Falls on 'conservative' fiscal 2021 forecast ** Snap Inc SNAP.N: down 7.4% BUZZ-Falls as Microsoft looks to go viral with TikTok ** SunCoke Energy Inc SXC.N: up 0.6% BUZZ-High on surprise Q2 profit The 11 major S&P 500 sectors: Communication Services Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh Wall Street's main indexes rose on Monday as a rebound in multi-billion dollar deals, including Microsoft's pursuit of TikTok's U.S. operations, lifted sentiment in the absence of a fiscal coronavirus relief bill. ET, the Dow Jones Industrial Average .DJI was up 0.95% at 26,679.21. |
24438.0 | 2020-08-03 00:00:00 UTC | BUZZ-U.S. STOCKS ON THE MOVE-Zovio, Tyson Foods, Mack-Cali Realty, Xerox | ABBV | https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-zovio-tyson-foods-mack-cali-realty-xerox-2020-08-03 | nan | nan | Eikon search string for individual stock moves: STXBZ
The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi
The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh
Wall Street's main indexes rose on Monday as a rebound in multi-billion dollar deals, including Microsoft's pursuit of TikTok's U.S. operations, lifted sentiment as efforts to hammer out a coronavirus relief bill resumed. .N
At 13:00 ET, the Dow Jones Industrial Average .DJI was up 0.84% at 26,649.58. The S&P 500 .SPX was up 0.73% at 3,294.89 and the Nasdaq Composite .IXIC was up 1.41% at 10,897.258. The top three S&P 500 .PG.INX percentage gainers: ** Varian Medical Systems Inc , up 21.6% ** Jacobs Engineering Group Inc , up 6.5% ** Cardinal Health Inc , up 5.9% The top three S&P 500 .PL.INX percentage losers: ** Under Armour Inc , down 6.2% ** Carnival Corp CCL.N, down 4.9% ** Norwegian Cruise Line Holdings Ltd , down 4.2% The top three NYSE .PG.N percentage gainers: ** ADT Inc , up 60.3% ** Pitney Bowes Inc , up 44.6% ** Ambow Education Holding Ltd , up 34.7% The top three NYSE .PL.N percentage losers: ** Eastman Kodak Co KODK.N, down 24.8% ** Resideo Technologies Inc , down 16.1% ** Tupperware Brands Corp , down 12.8% The top three Nasdaq .PG.O percentage gainers: ** Marathon Patent Group Inc , up 103.7% ** Datasea Inc , up 71.9% ** Cymabay Therapeutics Inc , up 40.6% The top three Nasdaq .PL.O percentage losers: ** Tiziana Life Sciences PLC , down 22.6% ** Alarm.com Holdings Inc , down 18.8% ** Sonnet Biotherapeutics Holdings Inc , down 17.6% ** AbbVie Inc ABBV.N: up 1.7%
BUZZ-Street View: AbbVie in good stead to tackle Humira competition ** Varian Medical Systems Inc VAR.N: up 21.6%
BUZZ-Jumps on Siemens Healthineers' $16.4 bln buyout deal ** Pinterest Inc PINS.N: up 7.1%
BUZZ-Up as brokerage raises rating on growth prospects ** Colgate-Palmolive CO CL.N: down 0.6%
BUZZ-Street View: Colgate-Palmolive's H2 growth could slow down in emerging markets ** Chevron Corp CVX.N: up 0.2%
BUZZ-Street View: Chevron has strong balance sheet despite challenging quarter ** Marathon Petroleum Corp MPC.N: up 0.2%
BUZZ-Rises on $21 bln Speedway sale to 7-Eleven owner ** ADT Inc ADT.N: up 60.2%
BUZZ-Surges on $450 mln Google investment in home security partnership ** Charter Communications Inc CHTR.O: up 1.7%
BUZZ-Street View: Charter Communications waltzes into Q3 after impressive results ** Merck & Co Inc MRK.N: up 2.9%
BUZZ-Street View: Merck's late launch of COVID-19 vaccines may be advantageous ** VistaGen Therapeutics Inc VTGN.O: down 15.2%
BUZZ-Plunges on discounted share sale offer ** Co-Diagnostics Inc CODX.O: up 22.3%
BUZZ-Co-Diagnostics tech to be used in FDA-authorized COVID-19 test, shares up ** Eli Lilly & Co LLY.N: up 1.6%
BUZZ-Up on starting late-stage trial of COVID-19 drug in nursing homes ** McKesson Corp MCK.N: up 5.8%
BUZZ-Rises on higher 2021 forecast, profit beat ** BioCryst Pharmaceuticals Inc BCRX.O: up 6.0%
BUZZ-Rises on 'Fast Track' tag for potential blood disorder treatment ** Keurig Dr Pepper Inc KDP.N: down 2.4%
BUZZ-Down as Goldman shops large block ** Spirit AeroSystems Holdings Inc SPR.N: down 1.7%
BUZZ-Falls as co cuts production of 737 MAX jet parts ** Tyme Technologies Inc TYME.O: up 10.1%
BUZZ-Surges as cancer treatment gets 'orphan drug' status ** Jernigan Capital Inc JCAP.N: up 22.4%
BUZZ-To be acquired by NexPoint; shares rise ** Moderna Inc MRNA.O: up 2.9%
BUZZ-Potential COVID-19 vaccine can generate $5 bln in annual sales - Jefferies ** CymaBay Therapeutics Inc CBAY.O: up 40.6%
BUZZ-Jumps on positive data from liver disease drug ** Jacobs Engineering Group Inc J.N: up 6.4%
BUZZ-Gains after raising FY profit forecast; tops Q3 est ** Carnival Corp CCL.N: down 4.8%
BUZZ-Cruise stocks down after Carnival cancels AIDA restart ** Ferrari NV RACE.N: up 3.8%
BUZZ-Accelerates as orders rise 'significantly' ** Atossa Therapeutics Inc ATOS.O: up 5.5%
BUZZ-Jumps as co to start study of nasal spray against COVID-19 ** Dynatrace Inc DT.N: down 2.4%
BUZZ-Drops as sponsor Thoma Bravo carves stake ** Microsoft Corp MSFT.O: up 4.3%
BUZZ-Rises on proposed TikTok deal ** Kansas City Southern KSU.N: up 2.5%
BUZZ-Up on report of possible takeover bid ** Marvell Technology Group Ltd MRVL.O: up 2.5%
BUZZ-Up as BofA Securities raises PT on growth prospects ** Marathon Petroleum Corp MPC.N: up 0.2%
BUZZ-Street View: Marathon-Speedway deal to aid refineries in low-demand periods ** Clorox Co CLX.N: down 2.6%
BUZZ-Falls on 'conservative' fiscal 2021 forecast ** Snap Inc SNAP.N: down 5.5%
BUZZ-Falls as Microsoft looks to go viral with TikTok ** SunCoke Energy Inc SXC.N: up 3.9%
BUZZ-High on surprise Q2 profit ** Mack-Cali Realty Corp CLI.N: down 8.1%
BUZZ-Drops as Q2 results disappoint ** Tyson Foods Inc TSN.N: up 0.9%
BUZZ-Rises on profit beat, new CEO announcement ** World Wrestling Entertainment Inc WWE.N: down 5%
BUZZ-Falls as group, including The Rock, wins bid for XFL parent's assets ** Zovio Inc ZVO.O: up 23.4%
BUZZ-Jumps on profit beat as e-learning subscribers grow ** Xerox Holdings Corp XRX.N: down 4.2%
BUZZ-Set to snap 3-day winning streak; plans senior note offerings
The 11 major S&P 500 sectors:
Communication Services
.SPLRCL
up 0.13%
Consumer Discretionary
.SPLRCD
down 0.39%
Consumer Staples
.SPLRCS
down 0.29%
Energy
.SPNY
up 0.01%
Financial
.SPSY
up 0.67%
Health
.SPXHC
up 1.07%
Industrial
.SPLRCI
up 0.48%
Information Technology
.SPLRCT
up 2.29%
Materials
.SPLRCM
up 0.03%
Real Estate
.SPLRCR
down 1.54%
Utilities
.SPLRCU
down 1.40%
(Compiled by Shivani Kumaresan in Bengaluru)
((Shivani.Kumaresan@thomsonreuters.com ; +1 646 223 8780))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The top three S&P 500 .PG.INX percentage gainers: ** Varian Medical Systems Inc , up 21.6% ** Jacobs Engineering Group Inc , up 6.5% ** Cardinal Health Inc , up 5.9% The top three S&P 500 .PL.INX percentage losers: ** Under Armour Inc , down 6.2% ** Carnival Corp CCL.N, down 4.9% ** Norwegian Cruise Line Holdings Ltd , down 4.2% The top three NYSE .PG.N percentage gainers: ** ADT Inc , up 60.3% ** Pitney Bowes Inc , up 44.6% ** Ambow Education Holding Ltd , up 34.7% The top three NYSE .PL.N percentage losers: ** Eastman Kodak Co KODK.N, down 24.8% ** Resideo Technologies Inc , down 16.1% ** Tupperware Brands Corp , down 12.8% The top three Nasdaq .PG.O percentage gainers: ** Marathon Patent Group Inc , up 103.7% ** Datasea Inc , up 71.9% ** Cymabay Therapeutics Inc , up 40.6% The top three Nasdaq .PL.O percentage losers: ** Tiziana Life Sciences PLC , down 22.6% ** Alarm.com Holdings Inc , down 18.8% ** Sonnet Biotherapeutics Holdings Inc , down 17.6% ** AbbVie Inc ABBV.N: up 1.7% BUZZ-Street View: AbbVie in good stead to tackle Humira competition ** Varian Medical Systems Inc VAR.N: up 21.6% BUZZ-Jumps on Siemens Healthineers' $16.4 bln buyout deal ** Pinterest Inc PINS.N: up 7.1% BUZZ-Up as brokerage raises rating on growth prospects ** Colgate-Palmolive CO CL.N: down 0.6% BUZZ-Street View: Colgate-Palmolive's H2 growth could slow down in emerging markets ** Chevron Corp CVX.N: up 0.2% BUZZ-Street View: Chevron has strong balance sheet despite challenging quarter ** Marathon Petroleum Corp MPC.N: up 0.2% BUZZ-Rises on $21 bln Speedway sale to 7-Eleven owner ** ADT Inc ADT.N: up 60.2% BUZZ-Surges on $450 mln Google investment in home security partnership ** Charter Communications Inc CHTR.O: up 1.7% BUZZ-Street View: Charter Communications waltzes into Q3 after impressive results ** Merck & Co Inc MRK.N: up 2.9% BUZZ-Street View: Merck's late launch of COVID-19 vaccines may be advantageous ** VistaGen Therapeutics Inc VTGN.O: down 15.2% BUZZ-Plunges on discounted share sale offer ** Co-Diagnostics Inc CODX.O: up 22.3% BUZZ-Co-Diagnostics tech to be used in FDA-authorized COVID-19 test, shares up ** Eli Lilly & Co LLY.N: up 1.6% BUZZ-Up on starting late-stage trial of COVID-19 drug in nursing homes ** McKesson Corp MCK.N: up 5.8% BUZZ-Rises on higher 2021 forecast, profit beat ** BioCryst Pharmaceuticals Inc BCRX.O: up 6.0% BUZZ-Rises on 'Fast Track' tag for potential blood disorder treatment ** Keurig Dr Pepper Inc KDP.N: down 2.4% BUZZ-Down as Goldman shops large block ** Spirit AeroSystems Holdings Inc SPR.N: down 1.7% BUZZ-Falls as co cuts production of 737 MAX jet parts ** Tyme Technologies Inc TYME.O: up 10.1% BUZZ-Surges as cancer treatment gets 'orphan drug' status ** Jernigan Capital Inc JCAP.N: up 22.4% BUZZ-To be acquired by NexPoint; shares rise ** Moderna Inc MRNA.O: up 2.9% BUZZ-Potential COVID-19 vaccine can generate $5 bln in annual sales - Jefferies ** CymaBay Therapeutics Inc CBAY.O: up 40.6% BUZZ-Jumps on positive data from liver disease drug ** Jacobs Engineering Group Inc J.N: up 6.4% BUZZ-Gains after raising FY profit forecast; tops Q3 est ** Carnival Corp CCL.N: down 4.8% BUZZ-Cruise stocks down after Carnival cancels AIDA restart ** Ferrari NV RACE.N: up 3.8% BUZZ-Accelerates as orders rise 'significantly' ** Atossa Therapeutics Inc ATOS.O: up 5.5% BUZZ-Jumps as co to start study of nasal spray against COVID-19 ** Dynatrace Inc DT.N: down 2.4% BUZZ-Drops as sponsor Thoma Bravo carves stake ** Microsoft Corp MSFT.O: up 4.3% BUZZ-Rises on proposed TikTok deal ** Kansas City Southern KSU.N: up 2.5% BUZZ-Up on report of possible takeover bid ** Marvell Technology Group Ltd MRVL.O: up 2.5% BUZZ-Up as BofA Securities raises PT on growth prospects ** Marathon Petroleum Corp MPC.N: up 0.2% BUZZ-Street View: Marathon-Speedway deal to aid refineries in low-demand periods ** Clorox Co CLX.N: down 2.6% BUZZ-Falls on 'conservative' fiscal 2021 forecast ** Snap Inc SNAP.N: down 5.5% BUZZ-Falls as Microsoft looks to go viral with TikTok ** SunCoke Energy Inc SXC.N: up 3.9% BUZZ-High on surprise Q2 profit ** Mack-Cali Realty Corp CLI.N: down 8.1% BUZZ-Drops as Q2 results disappoint ** Tyson Foods Inc TSN.N: up 0.9% BUZZ-Rises on profit beat, new CEO announcement ** World Wrestling Entertainment Inc WWE.N: down 5% BUZZ-Falls as group, including The Rock, wins bid for XFL parent's assets ** Zovio Inc ZVO.O: up 23.4% BUZZ-Jumps on profit beat as e-learning subscribers grow ** Xerox Holdings Corp XRX.N: down 4.2% BUZZ-Set to snap 3-day winning streak; plans senior note offerings The 11 major S&P 500 sectors: Communication Services Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh Wall Street's main indexes rose on Monday as a rebound in multi-billion dollar deals, including Microsoft's pursuit of TikTok's U.S. operations, lifted sentiment as efforts to hammer out a coronavirus relief bill resumed. down 1.40% (Compiled by Shivani Kumaresan in Bengaluru) ((Shivani.Kumaresan@thomsonreuters.com ; +1 646 223 8780)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The top three S&P 500 .PG.INX percentage gainers: ** Varian Medical Systems Inc , up 21.6% ** Jacobs Engineering Group Inc , up 6.5% ** Cardinal Health Inc , up 5.9% The top three S&P 500 .PL.INX percentage losers: ** Under Armour Inc , down 6.2% ** Carnival Corp CCL.N, down 4.9% ** Norwegian Cruise Line Holdings Ltd , down 4.2% The top three NYSE .PG.N percentage gainers: ** ADT Inc , up 60.3% ** Pitney Bowes Inc , up 44.6% ** Ambow Education Holding Ltd , up 34.7% The top three NYSE .PL.N percentage losers: ** Eastman Kodak Co KODK.N, down 24.8% ** Resideo Technologies Inc , down 16.1% ** Tupperware Brands Corp , down 12.8% The top three Nasdaq .PG.O percentage gainers: ** Marathon Patent Group Inc , up 103.7% ** Datasea Inc , up 71.9% ** Cymabay Therapeutics Inc , up 40.6% The top three Nasdaq .PL.O percentage losers: ** Tiziana Life Sciences PLC , down 22.6% ** Alarm.com Holdings Inc , down 18.8% ** Sonnet Biotherapeutics Holdings Inc , down 17.6% ** AbbVie Inc ABBV.N: up 1.7% BUZZ-Street View: AbbVie in good stead to tackle Humira competition ** Varian Medical Systems Inc VAR.N: up 21.6% BUZZ-Jumps on Siemens Healthineers' $16.4 bln buyout deal ** Pinterest Inc PINS.N: up 7.1% BUZZ-Up as brokerage raises rating on growth prospects ** Colgate-Palmolive CO CL.N: down 0.6% BUZZ-Street View: Colgate-Palmolive's H2 growth could slow down in emerging markets ** Chevron Corp CVX.N: up 0.2% BUZZ-Street View: Chevron has strong balance sheet despite challenging quarter ** Marathon Petroleum Corp MPC.N: up 0.2% BUZZ-Rises on $21 bln Speedway sale to 7-Eleven owner ** ADT Inc ADT.N: up 60.2% BUZZ-Surges on $450 mln Google investment in home security partnership ** Charter Communications Inc CHTR.O: up 1.7% BUZZ-Street View: Charter Communications waltzes into Q3 after impressive results ** Merck & Co Inc MRK.N: up 2.9% BUZZ-Street View: Merck's late launch of COVID-19 vaccines may be advantageous ** VistaGen Therapeutics Inc VTGN.O: down 15.2% BUZZ-Plunges on discounted share sale offer ** Co-Diagnostics Inc CODX.O: up 22.3% BUZZ-Co-Diagnostics tech to be used in FDA-authorized COVID-19 test, shares up ** Eli Lilly & Co LLY.N: up 1.6% BUZZ-Up on starting late-stage trial of COVID-19 drug in nursing homes ** McKesson Corp MCK.N: up 5.8% BUZZ-Rises on higher 2021 forecast, profit beat ** BioCryst Pharmaceuticals Inc BCRX.O: up 6.0% BUZZ-Rises on 'Fast Track' tag for potential blood disorder treatment ** Keurig Dr Pepper Inc KDP.N: down 2.4% BUZZ-Down as Goldman shops large block ** Spirit AeroSystems Holdings Inc SPR.N: down 1.7% BUZZ-Falls as co cuts production of 737 MAX jet parts ** Tyme Technologies Inc TYME.O: up 10.1% BUZZ-Surges as cancer treatment gets 'orphan drug' status ** Jernigan Capital Inc JCAP.N: up 22.4% BUZZ-To be acquired by NexPoint; shares rise ** Moderna Inc MRNA.O: up 2.9% BUZZ-Potential COVID-19 vaccine can generate $5 bln in annual sales - Jefferies ** CymaBay Therapeutics Inc CBAY.O: up 40.6% BUZZ-Jumps on positive data from liver disease drug ** Jacobs Engineering Group Inc J.N: up 6.4% BUZZ-Gains after raising FY profit forecast; tops Q3 est ** Carnival Corp CCL.N: down 4.8% BUZZ-Cruise stocks down after Carnival cancels AIDA restart ** Ferrari NV RACE.N: up 3.8% BUZZ-Accelerates as orders rise 'significantly' ** Atossa Therapeutics Inc ATOS.O: up 5.5% BUZZ-Jumps as co to start study of nasal spray against COVID-19 ** Dynatrace Inc DT.N: down 2.4% BUZZ-Drops as sponsor Thoma Bravo carves stake ** Microsoft Corp MSFT.O: up 4.3% BUZZ-Rises on proposed TikTok deal ** Kansas City Southern KSU.N: up 2.5% BUZZ-Up on report of possible takeover bid ** Marvell Technology Group Ltd MRVL.O: up 2.5% BUZZ-Up as BofA Securities raises PT on growth prospects ** Marathon Petroleum Corp MPC.N: up 0.2% BUZZ-Street View: Marathon-Speedway deal to aid refineries in low-demand periods ** Clorox Co CLX.N: down 2.6% BUZZ-Falls on 'conservative' fiscal 2021 forecast ** Snap Inc SNAP.N: down 5.5% BUZZ-Falls as Microsoft looks to go viral with TikTok ** SunCoke Energy Inc SXC.N: up 3.9% BUZZ-High on surprise Q2 profit ** Mack-Cali Realty Corp CLI.N: down 8.1% BUZZ-Drops as Q2 results disappoint ** Tyson Foods Inc TSN.N: up 0.9% BUZZ-Rises on profit beat, new CEO announcement ** World Wrestling Entertainment Inc WWE.N: down 5% BUZZ-Falls as group, including The Rock, wins bid for XFL parent's assets ** Zovio Inc ZVO.O: up 23.4% BUZZ-Jumps on profit beat as e-learning subscribers grow ** Xerox Holdings Corp XRX.N: down 4.2% BUZZ-Set to snap 3-day winning streak; plans senior note offerings The 11 major S&P 500 sectors: Communication Services Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh Wall Street's main indexes rose on Monday as a rebound in multi-billion dollar deals, including Microsoft's pursuit of TikTok's U.S. operations, lifted sentiment as efforts to hammer out a coronavirus relief bill resumed. down 1.40% (Compiled by Shivani Kumaresan in Bengaluru) ((Shivani.Kumaresan@thomsonreuters.com ; +1 646 223 8780)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The top three S&P 500 .PG.INX percentage gainers: ** Varian Medical Systems Inc , up 21.6% ** Jacobs Engineering Group Inc , up 6.5% ** Cardinal Health Inc , up 5.9% The top three S&P 500 .PL.INX percentage losers: ** Under Armour Inc , down 6.2% ** Carnival Corp CCL.N, down 4.9% ** Norwegian Cruise Line Holdings Ltd , down 4.2% The top three NYSE .PG.N percentage gainers: ** ADT Inc , up 60.3% ** Pitney Bowes Inc , up 44.6% ** Ambow Education Holding Ltd , up 34.7% The top three NYSE .PL.N percentage losers: ** Eastman Kodak Co KODK.N, down 24.8% ** Resideo Technologies Inc , down 16.1% ** Tupperware Brands Corp , down 12.8% The top three Nasdaq .PG.O percentage gainers: ** Marathon Patent Group Inc , up 103.7% ** Datasea Inc , up 71.9% ** Cymabay Therapeutics Inc , up 40.6% The top three Nasdaq .PL.O percentage losers: ** Tiziana Life Sciences PLC , down 22.6% ** Alarm.com Holdings Inc , down 18.8% ** Sonnet Biotherapeutics Holdings Inc , down 17.6% ** AbbVie Inc ABBV.N: up 1.7% BUZZ-Street View: AbbVie in good stead to tackle Humira competition ** Varian Medical Systems Inc VAR.N: up 21.6% BUZZ-Jumps on Siemens Healthineers' $16.4 bln buyout deal ** Pinterest Inc PINS.N: up 7.1% BUZZ-Up as brokerage raises rating on growth prospects ** Colgate-Palmolive CO CL.N: down 0.6% BUZZ-Street View: Colgate-Palmolive's H2 growth could slow down in emerging markets ** Chevron Corp CVX.N: up 0.2% BUZZ-Street View: Chevron has strong balance sheet despite challenging quarter ** Marathon Petroleum Corp MPC.N: up 0.2% BUZZ-Rises on $21 bln Speedway sale to 7-Eleven owner ** ADT Inc ADT.N: up 60.2% BUZZ-Surges on $450 mln Google investment in home security partnership ** Charter Communications Inc CHTR.O: up 1.7% BUZZ-Street View: Charter Communications waltzes into Q3 after impressive results ** Merck & Co Inc MRK.N: up 2.9% BUZZ-Street View: Merck's late launch of COVID-19 vaccines may be advantageous ** VistaGen Therapeutics Inc VTGN.O: down 15.2% BUZZ-Plunges on discounted share sale offer ** Co-Diagnostics Inc CODX.O: up 22.3% BUZZ-Co-Diagnostics tech to be used in FDA-authorized COVID-19 test, shares up ** Eli Lilly & Co LLY.N: up 1.6% BUZZ-Up on starting late-stage trial of COVID-19 drug in nursing homes ** McKesson Corp MCK.N: up 5.8% BUZZ-Rises on higher 2021 forecast, profit beat ** BioCryst Pharmaceuticals Inc BCRX.O: up 6.0% BUZZ-Rises on 'Fast Track' tag for potential blood disorder treatment ** Keurig Dr Pepper Inc KDP.N: down 2.4% BUZZ-Down as Goldman shops large block ** Spirit AeroSystems Holdings Inc SPR.N: down 1.7% BUZZ-Falls as co cuts production of 737 MAX jet parts ** Tyme Technologies Inc TYME.O: up 10.1% BUZZ-Surges as cancer treatment gets 'orphan drug' status ** Jernigan Capital Inc JCAP.N: up 22.4% BUZZ-To be acquired by NexPoint; shares rise ** Moderna Inc MRNA.O: up 2.9% BUZZ-Potential COVID-19 vaccine can generate $5 bln in annual sales - Jefferies ** CymaBay Therapeutics Inc CBAY.O: up 40.6% BUZZ-Jumps on positive data from liver disease drug ** Jacobs Engineering Group Inc J.N: up 6.4% BUZZ-Gains after raising FY profit forecast; tops Q3 est ** Carnival Corp CCL.N: down 4.8% BUZZ-Cruise stocks down after Carnival cancels AIDA restart ** Ferrari NV RACE.N: up 3.8% BUZZ-Accelerates as orders rise 'significantly' ** Atossa Therapeutics Inc ATOS.O: up 5.5% BUZZ-Jumps as co to start study of nasal spray against COVID-19 ** Dynatrace Inc DT.N: down 2.4% BUZZ-Drops as sponsor Thoma Bravo carves stake ** Microsoft Corp MSFT.O: up 4.3% BUZZ-Rises on proposed TikTok deal ** Kansas City Southern KSU.N: up 2.5% BUZZ-Up on report of possible takeover bid ** Marvell Technology Group Ltd MRVL.O: up 2.5% BUZZ-Up as BofA Securities raises PT on growth prospects ** Marathon Petroleum Corp MPC.N: up 0.2% BUZZ-Street View: Marathon-Speedway deal to aid refineries in low-demand periods ** Clorox Co CLX.N: down 2.6% BUZZ-Falls on 'conservative' fiscal 2021 forecast ** Snap Inc SNAP.N: down 5.5% BUZZ-Falls as Microsoft looks to go viral with TikTok ** SunCoke Energy Inc SXC.N: up 3.9% BUZZ-High on surprise Q2 profit ** Mack-Cali Realty Corp CLI.N: down 8.1% BUZZ-Drops as Q2 results disappoint ** Tyson Foods Inc TSN.N: up 0.9% BUZZ-Rises on profit beat, new CEO announcement ** World Wrestling Entertainment Inc WWE.N: down 5% BUZZ-Falls as group, including The Rock, wins bid for XFL parent's assets ** Zovio Inc ZVO.O: up 23.4% BUZZ-Jumps on profit beat as e-learning subscribers grow ** Xerox Holdings Corp XRX.N: down 4.2% BUZZ-Set to snap 3-day winning streak; plans senior note offerings The 11 major S&P 500 sectors: Communication Services .N At 13:00 ET, the Dow Jones Industrial Average .DJI was up 0.84% at 26,649.58. up 0.13% Consumer Discretionary | The top three S&P 500 .PG.INX percentage gainers: ** Varian Medical Systems Inc , up 21.6% ** Jacobs Engineering Group Inc , up 6.5% ** Cardinal Health Inc , up 5.9% The top three S&P 500 .PL.INX percentage losers: ** Under Armour Inc , down 6.2% ** Carnival Corp CCL.N, down 4.9% ** Norwegian Cruise Line Holdings Ltd , down 4.2% The top three NYSE .PG.N percentage gainers: ** ADT Inc , up 60.3% ** Pitney Bowes Inc , up 44.6% ** Ambow Education Holding Ltd , up 34.7% The top three NYSE .PL.N percentage losers: ** Eastman Kodak Co KODK.N, down 24.8% ** Resideo Technologies Inc , down 16.1% ** Tupperware Brands Corp , down 12.8% The top three Nasdaq .PG.O percentage gainers: ** Marathon Patent Group Inc , up 103.7% ** Datasea Inc , up 71.9% ** Cymabay Therapeutics Inc , up 40.6% The top three Nasdaq .PL.O percentage losers: ** Tiziana Life Sciences PLC , down 22.6% ** Alarm.com Holdings Inc , down 18.8% ** Sonnet Biotherapeutics Holdings Inc , down 17.6% ** AbbVie Inc ABBV.N: up 1.7% BUZZ-Street View: AbbVie in good stead to tackle Humira competition ** Varian Medical Systems Inc VAR.N: up 21.6% BUZZ-Jumps on Siemens Healthineers' $16.4 bln buyout deal ** Pinterest Inc PINS.N: up 7.1% BUZZ-Up as brokerage raises rating on growth prospects ** Colgate-Palmolive CO CL.N: down 0.6% BUZZ-Street View: Colgate-Palmolive's H2 growth could slow down in emerging markets ** Chevron Corp CVX.N: up 0.2% BUZZ-Street View: Chevron has strong balance sheet despite challenging quarter ** Marathon Petroleum Corp MPC.N: up 0.2% BUZZ-Rises on $21 bln Speedway sale to 7-Eleven owner ** ADT Inc ADT.N: up 60.2% BUZZ-Surges on $450 mln Google investment in home security partnership ** Charter Communications Inc CHTR.O: up 1.7% BUZZ-Street View: Charter Communications waltzes into Q3 after impressive results ** Merck & Co Inc MRK.N: up 2.9% BUZZ-Street View: Merck's late launch of COVID-19 vaccines may be advantageous ** VistaGen Therapeutics Inc VTGN.O: down 15.2% BUZZ-Plunges on discounted share sale offer ** Co-Diagnostics Inc CODX.O: up 22.3% BUZZ-Co-Diagnostics tech to be used in FDA-authorized COVID-19 test, shares up ** Eli Lilly & Co LLY.N: up 1.6% BUZZ-Up on starting late-stage trial of COVID-19 drug in nursing homes ** McKesson Corp MCK.N: up 5.8% BUZZ-Rises on higher 2021 forecast, profit beat ** BioCryst Pharmaceuticals Inc BCRX.O: up 6.0% BUZZ-Rises on 'Fast Track' tag for potential blood disorder treatment ** Keurig Dr Pepper Inc KDP.N: down 2.4% BUZZ-Down as Goldman shops large block ** Spirit AeroSystems Holdings Inc SPR.N: down 1.7% BUZZ-Falls as co cuts production of 737 MAX jet parts ** Tyme Technologies Inc TYME.O: up 10.1% BUZZ-Surges as cancer treatment gets 'orphan drug' status ** Jernigan Capital Inc JCAP.N: up 22.4% BUZZ-To be acquired by NexPoint; shares rise ** Moderna Inc MRNA.O: up 2.9% BUZZ-Potential COVID-19 vaccine can generate $5 bln in annual sales - Jefferies ** CymaBay Therapeutics Inc CBAY.O: up 40.6% BUZZ-Jumps on positive data from liver disease drug ** Jacobs Engineering Group Inc J.N: up 6.4% BUZZ-Gains after raising FY profit forecast; tops Q3 est ** Carnival Corp CCL.N: down 4.8% BUZZ-Cruise stocks down after Carnival cancels AIDA restart ** Ferrari NV RACE.N: up 3.8% BUZZ-Accelerates as orders rise 'significantly' ** Atossa Therapeutics Inc ATOS.O: up 5.5% BUZZ-Jumps as co to start study of nasal spray against COVID-19 ** Dynatrace Inc DT.N: down 2.4% BUZZ-Drops as sponsor Thoma Bravo carves stake ** Microsoft Corp MSFT.O: up 4.3% BUZZ-Rises on proposed TikTok deal ** Kansas City Southern KSU.N: up 2.5% BUZZ-Up on report of possible takeover bid ** Marvell Technology Group Ltd MRVL.O: up 2.5% BUZZ-Up as BofA Securities raises PT on growth prospects ** Marathon Petroleum Corp MPC.N: up 0.2% BUZZ-Street View: Marathon-Speedway deal to aid refineries in low-demand periods ** Clorox Co CLX.N: down 2.6% BUZZ-Falls on 'conservative' fiscal 2021 forecast ** Snap Inc SNAP.N: down 5.5% BUZZ-Falls as Microsoft looks to go viral with TikTok ** SunCoke Energy Inc SXC.N: up 3.9% BUZZ-High on surprise Q2 profit ** Mack-Cali Realty Corp CLI.N: down 8.1% BUZZ-Drops as Q2 results disappoint ** Tyson Foods Inc TSN.N: up 0.9% BUZZ-Rises on profit beat, new CEO announcement ** World Wrestling Entertainment Inc WWE.N: down 5% BUZZ-Falls as group, including The Rock, wins bid for XFL parent's assets ** Zovio Inc ZVO.O: up 23.4% BUZZ-Jumps on profit beat as e-learning subscribers grow ** Xerox Holdings Corp XRX.N: down 4.2% BUZZ-Set to snap 3-day winning streak; plans senior note offerings The 11 major S&P 500 sectors: Communication Services Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh Wall Street's main indexes rose on Monday as a rebound in multi-billion dollar deals, including Microsoft's pursuit of TikTok's U.S. operations, lifted sentiment as efforts to hammer out a coronavirus relief bill resumed. .N At 13:00 ET, the Dow Jones Industrial Average .DJI was up 0.84% at 26,649.58. |
24439.0 | 2020-08-03 00:00:00 UTC | AbbVie, Amgen, Takeda Pharma Enroll First Patients In I-SPY COVID Trial | ABBV | https://www.nasdaq.com/articles/abbvie-amgen-takeda-pharma-enroll-first-patients-in-i-spy-covid-trial-2020-08-03 | nan | nan | (RTTNews) - AbbVie, Inc. (ABBV), Amgen Inc. (AMGN), and Takeda Pharmaceutical Co. Ltd. (TAK) said Monday that they have enrolled the first patients in the I-SPY COVID Trial (Investigation of Serial Studies to Predict Your COVID Therapeutic Response with Biomarker Integration and Adaptive Learning) clinical trial.
The three companies are members of the COVID R&D Alliance, a group of more than 20 of the world's biopharmaceutical and life science companies working to speed the development of novel antibodies, potential therapies and anti-viral therapies for COVID-19.
The I-SPY COVID Trial is a collaboration between members of the COVID R&D Alliance, Quantum Leap, and the U.S. Food and Drug Administration or FDA. The trial is sponsored and managed by Quantum Leap Healthcare Collaborative.
The trial will evaluate the efficacy of cenicriviroc, a chemokine (CCR2 and CCR5) dual-receptor antagonist; Otezla (apremilast), a PDE4 inhibitor; and Firazyr (icatibant injection), a bradykinin B2 receptor antagonist in severely ill, hospitalized COVID-19 patients who require high-flow oxygen.
The I-SPY COVID Trial utilizes Quantum Leap Healthcare Collaborative's adaptive platform trial design, which is intended to increase trial efficiency by minimizing the number of participants and time required to evaluate potential treatments.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - AbbVie, Inc. (ABBV), Amgen Inc. (AMGN), and Takeda Pharmaceutical Co. Ltd. (TAK) said Monday that they have enrolled the first patients in the I-SPY COVID Trial (Investigation of Serial Studies to Predict Your COVID Therapeutic Response with Biomarker Integration and Adaptive Learning) clinical trial. The three companies are members of the COVID R&D Alliance, a group of more than 20 of the world's biopharmaceutical and life science companies working to speed the development of novel antibodies, potential therapies and anti-viral therapies for COVID-19. The trial will evaluate the efficacy of cenicriviroc, a chemokine (CCR2 and CCR5) dual-receptor antagonist; Otezla (apremilast), a PDE4 inhibitor; and Firazyr (icatibant injection), a bradykinin B2 receptor antagonist in severely ill, hospitalized COVID-19 patients who require high-flow oxygen. | (RTTNews) - AbbVie, Inc. (ABBV), Amgen Inc. (AMGN), and Takeda Pharmaceutical Co. Ltd. (TAK) said Monday that they have enrolled the first patients in the I-SPY COVID Trial (Investigation of Serial Studies to Predict Your COVID Therapeutic Response with Biomarker Integration and Adaptive Learning) clinical trial. The I-SPY COVID Trial is a collaboration between members of the COVID R&D Alliance, Quantum Leap, and the U.S. Food and Drug Administration or FDA. The trial is sponsored and managed by Quantum Leap Healthcare Collaborative. | (RTTNews) - AbbVie, Inc. (ABBV), Amgen Inc. (AMGN), and Takeda Pharmaceutical Co. Ltd. (TAK) said Monday that they have enrolled the first patients in the I-SPY COVID Trial (Investigation of Serial Studies to Predict Your COVID Therapeutic Response with Biomarker Integration and Adaptive Learning) clinical trial. The I-SPY COVID Trial is a collaboration between members of the COVID R&D Alliance, Quantum Leap, and the U.S. Food and Drug Administration or FDA. The I-SPY COVID Trial utilizes Quantum Leap Healthcare Collaborative's adaptive platform trial design, which is intended to increase trial efficiency by minimizing the number of participants and time required to evaluate potential treatments. | (RTTNews) - AbbVie, Inc. (ABBV), Amgen Inc. (AMGN), and Takeda Pharmaceutical Co. Ltd. (TAK) said Monday that they have enrolled the first patients in the I-SPY COVID Trial (Investigation of Serial Studies to Predict Your COVID Therapeutic Response with Biomarker Integration and Adaptive Learning) clinical trial. The three companies are members of the COVID R&D Alliance, a group of more than 20 of the world's biopharmaceutical and life science companies working to speed the development of novel antibodies, potential therapies and anti-viral therapies for COVID-19. The I-SPY COVID Trial is a collaboration between members of the COVID R&D Alliance, Quantum Leap, and the U.S. Food and Drug Administration or FDA. |
24440.0 | 2020-08-03 00:00:00 UTC | BUZZ-U.S. STOCKS ON THE MOVE-Jernigan Capital, Keurig Dr Pepper, Spirit AeroSystems, Tyme Tech | ABBV | https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-jernigan-capital-keurig-dr-pepper-spirit-aerosystems-tyme | nan | nan | Eikon search string for individual stock moves: STXBZ
The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi
The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh
Wall Street's main indexes opened higher on Monday as Microsoft's pursuit of TikTok's U.S. operations and a clutch of upbeat quarterly earnings reports lifted sentiment in the absence of a fiscal coronavirus relief deal. .N
At 09:30 a.m. ET, the Dow Jones Industrial Average .DJI was up 0.50% at 26,559.83. The S&P 500 .SPX was unchanged at 0 and the Nasdaq Composite .IXIC was up 0.87% at 10,838.94. The top three S&P 500 .PG.INX percentage gainers: ** Varian Medical Systems Inc , up 23% ** Kansas City So , up 4% ** Microsoft Corp , up 2.9% The top three S&P 500 .PL.INX percentage losers: ** Loews Corp , down 6.1% ** Carnival Corp , down 3.6% ** Royal Caribbean Cruises Ltd , down 3.2% The top three NYSE .PG.N percentage gainers: ** ADT Inc , up 55.2% ** Varian Medical Systems Inc , up 23% ** Jernigan Capital Inc , up 22% The top three NYSE .PL.N percentage losers: ** Companhia Energetica de Minas Gerais , down 7.9% ** Resideo Technologies Inc , down 6.5% ** Loews Corp , down 6.1% The top three Nasdaq .PG.O percentage gainers: ** Datasea Inc , up 180.4% ** Highway Holdings Ltd , up 56.7% ** Marathon Patent Group Inc , up 63% The top three Nasdaq .PL.O percentage losers: ** Tiziana Life Sciences PLC , down 15.2% ** Mid-Con Energy Partners LP , down 11.5% ** Sonnet Biotherapeutics Holdings Inc , down 10.3% ** AbbVie Inc ABBV.N: up 0.5%
BUZZ-Street View: AbbVie in good stead to tackle Humira competition ** Varian Medical Systems Inc VAR.N: up 23.0%
BUZZ-Jumps on Siemens Healthineers' $16.4 bln buyout deal ** Pinterest Inc PINS.N: up 1.5%
BUZZ-Up as brokerage raises rating on growth prospects ** Chevron Corp CVX.N: up 0.9%
BUZZ-Street View: Chevron has strong balance sheet despite challenging quarter ** Expedia Group Inc EXPE.O: up 0.3%
BUZZ-Up after Susquehanna hikes PT on recovery hopes ** Marathon Petroleum Corp MPC.N: up 2.1%
BUZZ-Rises on $21 bln Speedway sale to 7-Eleven owner ** ADT Inc ADT.N: up 55.1%
BUZZ-surges on $450 mln Google investment in home security partnership ** Charter Communications Inc CHTR.O: up 0.8%
BUZZ-Street View: Charter Communications waltzes into Q3 after impressive results ** Merck & Co Inc MRK.N: up 2.5%
BUZZ-Street View: Merck's late launch of COVID-19 vaccines may be advantageous ** VistaGen Therapeutics Inc VTGN.O: down 17.1%
BUZZ-Plunges on discounted share sale offer ** Co-Diagnostics Inc CODX.O: up 7.7%
BUZZ-Co-Diagnostics tech to be used in FDA-authorized COVID-19 test, shares up ** Eli Lilly & Co LLY.N: up 1.6%
BUZZ-Up on starting late-stage trial of COVID-19 drug in nursing homes ** McKesson Corp MCK.N: up 3.6%
BUZZ-Rises on higher 2021 forecast, profit beat ** BioCryst Pharmaceuticals Inc BCRX.O: up 9.3%
BUZZ-Rises on 'Fast Track' tag for potential blood disorder treatment ** Ontonomy Inc OTIC.O: up 1.1%
BUZZ-Rises on deal to develop hearing loss treatment compound ** Keurig Dr Pepper Inc KDP.N: down 2.0%
BUZZ-Down as Goldman shops large block ** Spirit AeroSystems Holdings Inc SPR.N: down 3.9%
BUZZ-Falls as co cuts production of 737 MAX jet parts ** Tyme Technologies Inc TYME.O: up 20.2%
BUZZ-Surges as cancer treatment gets 'orphan drug' status ** Jernigan Capital Inc JCAP.N: up 22.9%
BUZZ-To be acquired by NexPoint; shares rise
The 11 major S&P 500 sectors:
Communication Services
.SPLRCL
up 0.31%
Consumer Discretionary
.SPLRCD
up 0.21%
Consumer Staples
.SPLRCS
down 0.02%
Energy
.SPNY
flat
Financial
.SPSY
up 0.17%
Health
.SPXHC
up 0.80%
Industrial
.SPLRCI
up 0.15%
Information Technology
.SPLRCT
up 1.42%
Materials
.SPLRCM
up 0.40%
Real Estate
.SPLRCR
down 0.76%
Utilities
.SPLRCU
down 0.34%
(Compiled by Shivani Kumaresan in Bengaluru)
((Shivani.Kumaresan@thomsonreuters.com ; +1 646 223 8780))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The top three S&P 500 .PG.INX percentage gainers: ** Varian Medical Systems Inc , up 23% ** Kansas City So , up 4% ** Microsoft Corp , up 2.9% The top three S&P 500 .PL.INX percentage losers: ** Loews Corp , down 6.1% ** Carnival Corp , down 3.6% ** Royal Caribbean Cruises Ltd , down 3.2% The top three NYSE .PG.N percentage gainers: ** ADT Inc , up 55.2% ** Varian Medical Systems Inc , up 23% ** Jernigan Capital Inc , up 22% The top three NYSE .PL.N percentage losers: ** Companhia Energetica de Minas Gerais , down 7.9% ** Resideo Technologies Inc , down 6.5% ** Loews Corp , down 6.1% The top three Nasdaq .PG.O percentage gainers: ** Datasea Inc , up 180.4% ** Highway Holdings Ltd , up 56.7% ** Marathon Patent Group Inc , up 63% The top three Nasdaq .PL.O percentage losers: ** Tiziana Life Sciences PLC , down 15.2% ** Mid-Con Energy Partners LP , down 11.5% ** Sonnet Biotherapeutics Holdings Inc , down 10.3% ** AbbVie Inc ABBV.N: up 0.5% BUZZ-Street View: AbbVie in good stead to tackle Humira competition ** Varian Medical Systems Inc VAR.N: up 23.0% BUZZ-Jumps on Siemens Healthineers' $16.4 bln buyout deal ** Pinterest Inc PINS.N: up 1.5% BUZZ-Up as brokerage raises rating on growth prospects ** Chevron Corp CVX.N: up 0.9% BUZZ-Street View: Chevron has strong balance sheet despite challenging quarter ** Expedia Group Inc EXPE.O: up 0.3% BUZZ-Up after Susquehanna hikes PT on recovery hopes ** Marathon Petroleum Corp MPC.N: up 2.1% BUZZ-Rises on $21 bln Speedway sale to 7-Eleven owner ** ADT Inc ADT.N: up 55.1% BUZZ-surges on $450 mln Google investment in home security partnership ** Charter Communications Inc CHTR.O: up 0.8% BUZZ-Street View: Charter Communications waltzes into Q3 after impressive results ** Merck & Co Inc MRK.N: up 2.5% BUZZ-Street View: Merck's late launch of COVID-19 vaccines may be advantageous ** VistaGen Therapeutics Inc VTGN.O: down 17.1% BUZZ-Plunges on discounted share sale offer ** Co-Diagnostics Inc CODX.O: up 7.7% BUZZ-Co-Diagnostics tech to be used in FDA-authorized COVID-19 test, shares up ** Eli Lilly & Co LLY.N: up 1.6% BUZZ-Up on starting late-stage trial of COVID-19 drug in nursing homes ** McKesson Corp MCK.N: up 3.6% BUZZ-Rises on higher 2021 forecast, profit beat ** BioCryst Pharmaceuticals Inc BCRX.O: up 9.3% BUZZ-Rises on 'Fast Track' tag for potential blood disorder treatment ** Ontonomy Inc OTIC.O: up 1.1% BUZZ-Rises on deal to develop hearing loss treatment compound ** Keurig Dr Pepper Inc KDP.N: down 2.0% BUZZ-Down as Goldman shops large block ** Spirit AeroSystems Holdings Inc SPR.N: down 3.9% BUZZ-Falls as co cuts production of 737 MAX jet parts ** Tyme Technologies Inc TYME.O: up 20.2% BUZZ-Surges as cancer treatment gets 'orphan drug' status ** Jernigan Capital Inc JCAP.N: up 22.9% BUZZ-To be acquired by NexPoint; shares rise The 11 major S&P 500 sectors: Communication Services Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh Wall Street's main indexes opened higher on Monday as Microsoft's pursuit of TikTok's U.S. operations and a clutch of upbeat quarterly earnings reports lifted sentiment in the absence of a fiscal coronavirus relief deal. down 0.34% (Compiled by Shivani Kumaresan in Bengaluru) ((Shivani.Kumaresan@thomsonreuters.com ; +1 646 223 8780)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The top three S&P 500 .PG.INX percentage gainers: ** Varian Medical Systems Inc , up 23% ** Kansas City So , up 4% ** Microsoft Corp , up 2.9% The top three S&P 500 .PL.INX percentage losers: ** Loews Corp , down 6.1% ** Carnival Corp , down 3.6% ** Royal Caribbean Cruises Ltd , down 3.2% The top three NYSE .PG.N percentage gainers: ** ADT Inc , up 55.2% ** Varian Medical Systems Inc , up 23% ** Jernigan Capital Inc , up 22% The top three NYSE .PL.N percentage losers: ** Companhia Energetica de Minas Gerais , down 7.9% ** Resideo Technologies Inc , down 6.5% ** Loews Corp , down 6.1% The top three Nasdaq .PG.O percentage gainers: ** Datasea Inc , up 180.4% ** Highway Holdings Ltd , up 56.7% ** Marathon Patent Group Inc , up 63% The top three Nasdaq .PL.O percentage losers: ** Tiziana Life Sciences PLC , down 15.2% ** Mid-Con Energy Partners LP , down 11.5% ** Sonnet Biotherapeutics Holdings Inc , down 10.3% ** AbbVie Inc ABBV.N: up 0.5% BUZZ-Street View: AbbVie in good stead to tackle Humira competition ** Varian Medical Systems Inc VAR.N: up 23.0% BUZZ-Jumps on Siemens Healthineers' $16.4 bln buyout deal ** Pinterest Inc PINS.N: up 1.5% BUZZ-Up as brokerage raises rating on growth prospects ** Chevron Corp CVX.N: up 0.9% BUZZ-Street View: Chevron has strong balance sheet despite challenging quarter ** Expedia Group Inc EXPE.O: up 0.3% BUZZ-Up after Susquehanna hikes PT on recovery hopes ** Marathon Petroleum Corp MPC.N: up 2.1% BUZZ-Rises on $21 bln Speedway sale to 7-Eleven owner ** ADT Inc ADT.N: up 55.1% BUZZ-surges on $450 mln Google investment in home security partnership ** Charter Communications Inc CHTR.O: up 0.8% BUZZ-Street View: Charter Communications waltzes into Q3 after impressive results ** Merck & Co Inc MRK.N: up 2.5% BUZZ-Street View: Merck's late launch of COVID-19 vaccines may be advantageous ** VistaGen Therapeutics Inc VTGN.O: down 17.1% BUZZ-Plunges on discounted share sale offer ** Co-Diagnostics Inc CODX.O: up 7.7% BUZZ-Co-Diagnostics tech to be used in FDA-authorized COVID-19 test, shares up ** Eli Lilly & Co LLY.N: up 1.6% BUZZ-Up on starting late-stage trial of COVID-19 drug in nursing homes ** McKesson Corp MCK.N: up 3.6% BUZZ-Rises on higher 2021 forecast, profit beat ** BioCryst Pharmaceuticals Inc BCRX.O: up 9.3% BUZZ-Rises on 'Fast Track' tag for potential blood disorder treatment ** Ontonomy Inc OTIC.O: up 1.1% BUZZ-Rises on deal to develop hearing loss treatment compound ** Keurig Dr Pepper Inc KDP.N: down 2.0% BUZZ-Down as Goldman shops large block ** Spirit AeroSystems Holdings Inc SPR.N: down 3.9% BUZZ-Falls as co cuts production of 737 MAX jet parts ** Tyme Technologies Inc TYME.O: up 20.2% BUZZ-Surges as cancer treatment gets 'orphan drug' status ** Jernigan Capital Inc JCAP.N: up 22.9% BUZZ-To be acquired by NexPoint; shares rise The 11 major S&P 500 sectors: Communication Services Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh Wall Street's main indexes opened higher on Monday as Microsoft's pursuit of TikTok's U.S. operations and a clutch of upbeat quarterly earnings reports lifted sentiment in the absence of a fiscal coronavirus relief deal. down 0.34% (Compiled by Shivani Kumaresan in Bengaluru) ((Shivani.Kumaresan@thomsonreuters.com ; +1 646 223 8780)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The top three S&P 500 .PG.INX percentage gainers: ** Varian Medical Systems Inc , up 23% ** Kansas City So , up 4% ** Microsoft Corp , up 2.9% The top three S&P 500 .PL.INX percentage losers: ** Loews Corp , down 6.1% ** Carnival Corp , down 3.6% ** Royal Caribbean Cruises Ltd , down 3.2% The top three NYSE .PG.N percentage gainers: ** ADT Inc , up 55.2% ** Varian Medical Systems Inc , up 23% ** Jernigan Capital Inc , up 22% The top three NYSE .PL.N percentage losers: ** Companhia Energetica de Minas Gerais , down 7.9% ** Resideo Technologies Inc , down 6.5% ** Loews Corp , down 6.1% The top three Nasdaq .PG.O percentage gainers: ** Datasea Inc , up 180.4% ** Highway Holdings Ltd , up 56.7% ** Marathon Patent Group Inc , up 63% The top three Nasdaq .PL.O percentage losers: ** Tiziana Life Sciences PLC , down 15.2% ** Mid-Con Energy Partners LP , down 11.5% ** Sonnet Biotherapeutics Holdings Inc , down 10.3% ** AbbVie Inc ABBV.N: up 0.5% BUZZ-Street View: AbbVie in good stead to tackle Humira competition ** Varian Medical Systems Inc VAR.N: up 23.0% BUZZ-Jumps on Siemens Healthineers' $16.4 bln buyout deal ** Pinterest Inc PINS.N: up 1.5% BUZZ-Up as brokerage raises rating on growth prospects ** Chevron Corp CVX.N: up 0.9% BUZZ-Street View: Chevron has strong balance sheet despite challenging quarter ** Expedia Group Inc EXPE.O: up 0.3% BUZZ-Up after Susquehanna hikes PT on recovery hopes ** Marathon Petroleum Corp MPC.N: up 2.1% BUZZ-Rises on $21 bln Speedway sale to 7-Eleven owner ** ADT Inc ADT.N: up 55.1% BUZZ-surges on $450 mln Google investment in home security partnership ** Charter Communications Inc CHTR.O: up 0.8% BUZZ-Street View: Charter Communications waltzes into Q3 after impressive results ** Merck & Co Inc MRK.N: up 2.5% BUZZ-Street View: Merck's late launch of COVID-19 vaccines may be advantageous ** VistaGen Therapeutics Inc VTGN.O: down 17.1% BUZZ-Plunges on discounted share sale offer ** Co-Diagnostics Inc CODX.O: up 7.7% BUZZ-Co-Diagnostics tech to be used in FDA-authorized COVID-19 test, shares up ** Eli Lilly & Co LLY.N: up 1.6% BUZZ-Up on starting late-stage trial of COVID-19 drug in nursing homes ** McKesson Corp MCK.N: up 3.6% BUZZ-Rises on higher 2021 forecast, profit beat ** BioCryst Pharmaceuticals Inc BCRX.O: up 9.3% BUZZ-Rises on 'Fast Track' tag for potential blood disorder treatment ** Ontonomy Inc OTIC.O: up 1.1% BUZZ-Rises on deal to develop hearing loss treatment compound ** Keurig Dr Pepper Inc KDP.N: down 2.0% BUZZ-Down as Goldman shops large block ** Spirit AeroSystems Holdings Inc SPR.N: down 3.9% BUZZ-Falls as co cuts production of 737 MAX jet parts ** Tyme Technologies Inc TYME.O: up 20.2% BUZZ-Surges as cancer treatment gets 'orphan drug' status ** Jernigan Capital Inc JCAP.N: up 22.9% BUZZ-To be acquired by NexPoint; shares rise The 11 major S&P 500 sectors: Communication Services ET, the Dow Jones Industrial Average .DJI was up 0.50% at 26,559.83. up 0.31% Consumer Discretionary | The top three S&P 500 .PG.INX percentage gainers: ** Varian Medical Systems Inc , up 23% ** Kansas City So , up 4% ** Microsoft Corp , up 2.9% The top three S&P 500 .PL.INX percentage losers: ** Loews Corp , down 6.1% ** Carnival Corp , down 3.6% ** Royal Caribbean Cruises Ltd , down 3.2% The top three NYSE .PG.N percentage gainers: ** ADT Inc , up 55.2% ** Varian Medical Systems Inc , up 23% ** Jernigan Capital Inc , up 22% The top three NYSE .PL.N percentage losers: ** Companhia Energetica de Minas Gerais , down 7.9% ** Resideo Technologies Inc , down 6.5% ** Loews Corp , down 6.1% The top three Nasdaq .PG.O percentage gainers: ** Datasea Inc , up 180.4% ** Highway Holdings Ltd , up 56.7% ** Marathon Patent Group Inc , up 63% The top three Nasdaq .PL.O percentage losers: ** Tiziana Life Sciences PLC , down 15.2% ** Mid-Con Energy Partners LP , down 11.5% ** Sonnet Biotherapeutics Holdings Inc , down 10.3% ** AbbVie Inc ABBV.N: up 0.5% BUZZ-Street View: AbbVie in good stead to tackle Humira competition ** Varian Medical Systems Inc VAR.N: up 23.0% BUZZ-Jumps on Siemens Healthineers' $16.4 bln buyout deal ** Pinterest Inc PINS.N: up 1.5% BUZZ-Up as brokerage raises rating on growth prospects ** Chevron Corp CVX.N: up 0.9% BUZZ-Street View: Chevron has strong balance sheet despite challenging quarter ** Expedia Group Inc EXPE.O: up 0.3% BUZZ-Up after Susquehanna hikes PT on recovery hopes ** Marathon Petroleum Corp MPC.N: up 2.1% BUZZ-Rises on $21 bln Speedway sale to 7-Eleven owner ** ADT Inc ADT.N: up 55.1% BUZZ-surges on $450 mln Google investment in home security partnership ** Charter Communications Inc CHTR.O: up 0.8% BUZZ-Street View: Charter Communications waltzes into Q3 after impressive results ** Merck & Co Inc MRK.N: up 2.5% BUZZ-Street View: Merck's late launch of COVID-19 vaccines may be advantageous ** VistaGen Therapeutics Inc VTGN.O: down 17.1% BUZZ-Plunges on discounted share sale offer ** Co-Diagnostics Inc CODX.O: up 7.7% BUZZ-Co-Diagnostics tech to be used in FDA-authorized COVID-19 test, shares up ** Eli Lilly & Co LLY.N: up 1.6% BUZZ-Up on starting late-stage trial of COVID-19 drug in nursing homes ** McKesson Corp MCK.N: up 3.6% BUZZ-Rises on higher 2021 forecast, profit beat ** BioCryst Pharmaceuticals Inc BCRX.O: up 9.3% BUZZ-Rises on 'Fast Track' tag for potential blood disorder treatment ** Ontonomy Inc OTIC.O: up 1.1% BUZZ-Rises on deal to develop hearing loss treatment compound ** Keurig Dr Pepper Inc KDP.N: down 2.0% BUZZ-Down as Goldman shops large block ** Spirit AeroSystems Holdings Inc SPR.N: down 3.9% BUZZ-Falls as co cuts production of 737 MAX jet parts ** Tyme Technologies Inc TYME.O: up 20.2% BUZZ-Surges as cancer treatment gets 'orphan drug' status ** Jernigan Capital Inc JCAP.N: up 22.9% BUZZ-To be acquired by NexPoint; shares rise The 11 major S&P 500 sectors: Communication Services Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh Wall Street's main indexes opened higher on Monday as Microsoft's pursuit of TikTok's U.S. operations and a clutch of upbeat quarterly earnings reports lifted sentiment in the absence of a fiscal coronavirus relief deal. ET, the Dow Jones Industrial Average .DJI was up 0.50% at 26,559.83. |
24441.0 | 2020-08-03 00:00:00 UTC | BUZZ-U.S. STOCKS ON THE MOVE-ADT Inc, Marathon Petroleum, Eli Lilly, VistaGen Therapeutics | ABBV | https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-adt-inc-marathon-petroleum-eli-lilly-vistagen-therapeutics | nan | nan | Eikon search string for individual stock moves: STXBZ
The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi
The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh
Wall Street's main indexes were set to open higher on Monday as Microsoft's pursuit of TikTok's U.S. operations and a clutch of upbeat quarterly earnings reports lifted sentiment in the absence of a fiscal coronavirus relief deal. .N
At 08:30 a.m. ET, Dow e-minis 1YMc1 were up 0.51% at 26,454. S&P 500 e-minis ESc1 were up 0.62% at 3,283.75, while Nasdaq 100 e-minis NQc1 were up 0.91% at 10,990. The top three NYSE percentage gainers premarket .PRPG.NQ: ** ADT Inc , up 73.6% ** Borr Drillng Ltd , up 30.9% ** Forum Energy Technologies Inc , up 29.7% The top three NYSE percentage losers premarket .PRPL.NQ: ** LMP Capital & Income Fund , down 21.6% ** Mogu Inc , down 14.1% ** Cango Inc , down 12.8% The top three Nasdaq percentage gainers premarket .PRPG.O: ** Highway Holdings Ltd , up 87.1% ** Immunic Inc , up 40.9% ** Marathon Patent Group Inc , up 36.9% The top three Nasdaq percentage losers premarket .PRPL.O: ** Betterware De Mexico SA BWMX.O, down 21.9% ** Inspired Entertainment Inc INSE.O, down 16.7% ** AnPac Bio-Medical Science Co , down 16.3% ** AbbVie Inc ABBV.N: up 0.6% premarket BUZZ-Street View: AbbVie in good stead to tackle Humira competition ** Varian Medical Systems Inc VAR.N: up 22.4% premarket BUZZ-Jumps on Siemens Healthineers' $16.4 bln buyout deal ** Pinterest Inc PINS.N: up 2.8% premarket BUZZ-Up as brokerage raises rating on growth prospects ** Colgate-Palmolive CO CL.N: down 0.1% premarket BUZZ-Street View: Colgate-Palmolive's H2 growth could slow down in emerging markets ** Chevron Corp CVX.N: up 0.1% premarket BUZZ-Street View: Chevron has strong balance sheet despite challenging quarter ** Expedia Group Inc EXPE.O: up 1.5% premarket BUZZ-Up after Susquehanna hikes PT on recovery hopes ** Marathon Petroleum Corp MPC.N: up 9.1% premarket BUZZ-Rises on $21 bln Speedway sale to 7-Eleven owner ** ADT Inc ADT.N: up 73.6% premarket BUZZ-Surges on $450 mln Google investment in home security partnership ** Charter Communications Inc CHTR.O: up 0.3% premarket BUZZ-Street View: Charter Communications waltzes into Q3 after impressive results ** Merck & Co Inc MRK.N: up 1.5% premarket BUZZ-Street View: Merck's late launch of COVID-19 vaccines may be advantageous ** VistaGen Therapeutics Inc VTGN.O: down 15.1% premarket BUZZ-Plunges on discounted share sale offer ** Co-Diagnostics Inc CODX.O: up 12.1% premarket BUZZ-Co-Diagnostics tech to be used in FDA-authorized COVID-19 test, shares up ** Eli Lilly & Co LLY.N: up 2.6% premarket BUZZ-Up on starting late-stage trial of COVID-19 drug in nursing homes ** Exxon Mobil Corp XOM.N: up 0.3% premarket BUZZ-Street View: Exxon Mobil's reduced capex improves near-term cash burn ** McKesson Corp MCK.N: up 4.2% premarket BUZZ-Rises on higher 2021 forecast, profit beat ** BioCryst Pharmaceuticals Inc BCRX.O: up 10.6% premarket BUZZ-Rises on 'Fast Track' tag for potential blood disorder treatment
(Compiled by Shivani Kumaresan in Bengaluru)
((Shivani.Kumaresan@thomsonreuters.com ; +1 646 223 8780;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The top three NYSE percentage gainers premarket .PRPG.NQ: ** ADT Inc , up 73.6% ** Borr Drillng Ltd , up 30.9% ** Forum Energy Technologies Inc , up 29.7% The top three NYSE percentage losers premarket .PRPL.NQ: ** LMP Capital & Income Fund , down 21.6% ** Mogu Inc , down 14.1% ** Cango Inc , down 12.8% The top three Nasdaq percentage gainers premarket .PRPG.O: ** Highway Holdings Ltd , up 87.1% ** Immunic Inc , up 40.9% ** Marathon Patent Group Inc , up 36.9% The top three Nasdaq percentage losers premarket .PRPL.O: ** Betterware De Mexico SA BWMX.O, down 21.9% ** Inspired Entertainment Inc INSE.O, down 16.7% ** AnPac Bio-Medical Science Co , down 16.3% ** AbbVie Inc ABBV.N: up 0.6% premarket BUZZ-Street View: AbbVie in good stead to tackle Humira competition ** Varian Medical Systems Inc VAR.N: up 22.4% premarket BUZZ-Jumps on Siemens Healthineers' $16.4 bln buyout deal ** Pinterest Inc PINS.N: up 2.8% premarket BUZZ-Up as brokerage raises rating on growth prospects ** Colgate-Palmolive CO CL.N: down 0.1% premarket BUZZ-Street View: Colgate-Palmolive's H2 growth could slow down in emerging markets ** Chevron Corp CVX.N: up 0.1% premarket BUZZ-Street View: Chevron has strong balance sheet despite challenging quarter ** Expedia Group Inc EXPE.O: up 1.5% premarket BUZZ-Up after Susquehanna hikes PT on recovery hopes ** Marathon Petroleum Corp MPC.N: up 9.1% premarket BUZZ-Rises on $21 bln Speedway sale to 7-Eleven owner ** ADT Inc ADT.N: up 73.6% premarket BUZZ-Surges on $450 mln Google investment in home security partnership ** Charter Communications Inc CHTR.O: up 0.3% premarket BUZZ-Street View: Charter Communications waltzes into Q3 after impressive results ** Merck & Co Inc MRK.N: up 1.5% premarket BUZZ-Street View: Merck's late launch of COVID-19 vaccines may be advantageous ** VistaGen Therapeutics Inc VTGN.O: down 15.1% premarket BUZZ-Plunges on discounted share sale offer ** Co-Diagnostics Inc CODX.O: up 12.1% premarket BUZZ-Co-Diagnostics tech to be used in FDA-authorized COVID-19 test, shares up ** Eli Lilly & Co LLY.N: up 2.6% premarket BUZZ-Up on starting late-stage trial of COVID-19 drug in nursing homes ** Exxon Mobil Corp XOM.N: up 0.3% premarket BUZZ-Street View: Exxon Mobil's reduced capex improves near-term cash burn ** McKesson Corp MCK.N: up 4.2% premarket BUZZ-Rises on higher 2021 forecast, profit beat ** BioCryst Pharmaceuticals Inc BCRX.O: up 10.6% premarket BUZZ-Rises on 'Fast Track' tag for potential blood disorder treatment (Compiled by Shivani Kumaresan in Bengaluru) ((Shivani.Kumaresan@thomsonreuters.com ; +1 646 223 8780;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh Wall Street's main indexes were set to open higher on Monday as Microsoft's pursuit of TikTok's U.S. operations and a clutch of upbeat quarterly earnings reports lifted sentiment in the absence of a fiscal coronavirus relief deal. ET, Dow e-minis 1YMc1 were up 0.51% at 26,454. | The top three NYSE percentage gainers premarket .PRPG.NQ: ** ADT Inc , up 73.6% ** Borr Drillng Ltd , up 30.9% ** Forum Energy Technologies Inc , up 29.7% The top three NYSE percentage losers premarket .PRPL.NQ: ** LMP Capital & Income Fund , down 21.6% ** Mogu Inc , down 14.1% ** Cango Inc , down 12.8% The top three Nasdaq percentage gainers premarket .PRPG.O: ** Highway Holdings Ltd , up 87.1% ** Immunic Inc , up 40.9% ** Marathon Patent Group Inc , up 36.9% The top three Nasdaq percentage losers premarket .PRPL.O: ** Betterware De Mexico SA BWMX.O, down 21.9% ** Inspired Entertainment Inc INSE.O, down 16.7% ** AnPac Bio-Medical Science Co , down 16.3% ** AbbVie Inc ABBV.N: up 0.6% premarket BUZZ-Street View: AbbVie in good stead to tackle Humira competition ** Varian Medical Systems Inc VAR.N: up 22.4% premarket BUZZ-Jumps on Siemens Healthineers' $16.4 bln buyout deal ** Pinterest Inc PINS.N: up 2.8% premarket BUZZ-Up as brokerage raises rating on growth prospects ** Colgate-Palmolive CO CL.N: down 0.1% premarket BUZZ-Street View: Colgate-Palmolive's H2 growth could slow down in emerging markets ** Chevron Corp CVX.N: up 0.1% premarket BUZZ-Street View: Chevron has strong balance sheet despite challenging quarter ** Expedia Group Inc EXPE.O: up 1.5% premarket BUZZ-Up after Susquehanna hikes PT on recovery hopes ** Marathon Petroleum Corp MPC.N: up 9.1% premarket BUZZ-Rises on $21 bln Speedway sale to 7-Eleven owner ** ADT Inc ADT.N: up 73.6% premarket BUZZ-Surges on $450 mln Google investment in home security partnership ** Charter Communications Inc CHTR.O: up 0.3% premarket BUZZ-Street View: Charter Communications waltzes into Q3 after impressive results ** Merck & Co Inc MRK.N: up 1.5% premarket BUZZ-Street View: Merck's late launch of COVID-19 vaccines may be advantageous ** VistaGen Therapeutics Inc VTGN.O: down 15.1% premarket BUZZ-Plunges on discounted share sale offer ** Co-Diagnostics Inc CODX.O: up 12.1% premarket BUZZ-Co-Diagnostics tech to be used in FDA-authorized COVID-19 test, shares up ** Eli Lilly & Co LLY.N: up 2.6% premarket BUZZ-Up on starting late-stage trial of COVID-19 drug in nursing homes ** Exxon Mobil Corp XOM.N: up 0.3% premarket BUZZ-Street View: Exxon Mobil's reduced capex improves near-term cash burn ** McKesson Corp MCK.N: up 4.2% premarket BUZZ-Rises on higher 2021 forecast, profit beat ** BioCryst Pharmaceuticals Inc BCRX.O: up 10.6% premarket BUZZ-Rises on 'Fast Track' tag for potential blood disorder treatment (Compiled by Shivani Kumaresan in Bengaluru) ((Shivani.Kumaresan@thomsonreuters.com ; +1 646 223 8780;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh Wall Street's main indexes were set to open higher on Monday as Microsoft's pursuit of TikTok's U.S. operations and a clutch of upbeat quarterly earnings reports lifted sentiment in the absence of a fiscal coronavirus relief deal. S&P 500 e-minis ESc1 were up 0.62% at 3,283.75, while Nasdaq 100 e-minis NQc1 were up 0.91% at 10,990. | The top three NYSE percentage gainers premarket .PRPG.NQ: ** ADT Inc , up 73.6% ** Borr Drillng Ltd , up 30.9% ** Forum Energy Technologies Inc , up 29.7% The top three NYSE percentage losers premarket .PRPL.NQ: ** LMP Capital & Income Fund , down 21.6% ** Mogu Inc , down 14.1% ** Cango Inc , down 12.8% The top three Nasdaq percentage gainers premarket .PRPG.O: ** Highway Holdings Ltd , up 87.1% ** Immunic Inc , up 40.9% ** Marathon Patent Group Inc , up 36.9% The top three Nasdaq percentage losers premarket .PRPL.O: ** Betterware De Mexico SA BWMX.O, down 21.9% ** Inspired Entertainment Inc INSE.O, down 16.7% ** AnPac Bio-Medical Science Co , down 16.3% ** AbbVie Inc ABBV.N: up 0.6% premarket BUZZ-Street View: AbbVie in good stead to tackle Humira competition ** Varian Medical Systems Inc VAR.N: up 22.4% premarket BUZZ-Jumps on Siemens Healthineers' $16.4 bln buyout deal ** Pinterest Inc PINS.N: up 2.8% premarket BUZZ-Up as brokerage raises rating on growth prospects ** Colgate-Palmolive CO CL.N: down 0.1% premarket BUZZ-Street View: Colgate-Palmolive's H2 growth could slow down in emerging markets ** Chevron Corp CVX.N: up 0.1% premarket BUZZ-Street View: Chevron has strong balance sheet despite challenging quarter ** Expedia Group Inc EXPE.O: up 1.5% premarket BUZZ-Up after Susquehanna hikes PT on recovery hopes ** Marathon Petroleum Corp MPC.N: up 9.1% premarket BUZZ-Rises on $21 bln Speedway sale to 7-Eleven owner ** ADT Inc ADT.N: up 73.6% premarket BUZZ-Surges on $450 mln Google investment in home security partnership ** Charter Communications Inc CHTR.O: up 0.3% premarket BUZZ-Street View: Charter Communications waltzes into Q3 after impressive results ** Merck & Co Inc MRK.N: up 1.5% premarket BUZZ-Street View: Merck's late launch of COVID-19 vaccines may be advantageous ** VistaGen Therapeutics Inc VTGN.O: down 15.1% premarket BUZZ-Plunges on discounted share sale offer ** Co-Diagnostics Inc CODX.O: up 12.1% premarket BUZZ-Co-Diagnostics tech to be used in FDA-authorized COVID-19 test, shares up ** Eli Lilly & Co LLY.N: up 2.6% premarket BUZZ-Up on starting late-stage trial of COVID-19 drug in nursing homes ** Exxon Mobil Corp XOM.N: up 0.3% premarket BUZZ-Street View: Exxon Mobil's reduced capex improves near-term cash burn ** McKesson Corp MCK.N: up 4.2% premarket BUZZ-Rises on higher 2021 forecast, profit beat ** BioCryst Pharmaceuticals Inc BCRX.O: up 10.6% premarket BUZZ-Rises on 'Fast Track' tag for potential blood disorder treatment (Compiled by Shivani Kumaresan in Bengaluru) ((Shivani.Kumaresan@thomsonreuters.com ; +1 646 223 8780;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh Wall Street's main indexes were set to open higher on Monday as Microsoft's pursuit of TikTok's U.S. operations and a clutch of upbeat quarterly earnings reports lifted sentiment in the absence of a fiscal coronavirus relief deal. S&P 500 e-minis ESc1 were up 0.62% at 3,283.75, while Nasdaq 100 e-minis NQc1 were up 0.91% at 10,990. | The top three NYSE percentage gainers premarket .PRPG.NQ: ** ADT Inc , up 73.6% ** Borr Drillng Ltd , up 30.9% ** Forum Energy Technologies Inc , up 29.7% The top three NYSE percentage losers premarket .PRPL.NQ: ** LMP Capital & Income Fund , down 21.6% ** Mogu Inc , down 14.1% ** Cango Inc , down 12.8% The top three Nasdaq percentage gainers premarket .PRPG.O: ** Highway Holdings Ltd , up 87.1% ** Immunic Inc , up 40.9% ** Marathon Patent Group Inc , up 36.9% The top three Nasdaq percentage losers premarket .PRPL.O: ** Betterware De Mexico SA BWMX.O, down 21.9% ** Inspired Entertainment Inc INSE.O, down 16.7% ** AnPac Bio-Medical Science Co , down 16.3% ** AbbVie Inc ABBV.N: up 0.6% premarket BUZZ-Street View: AbbVie in good stead to tackle Humira competition ** Varian Medical Systems Inc VAR.N: up 22.4% premarket BUZZ-Jumps on Siemens Healthineers' $16.4 bln buyout deal ** Pinterest Inc PINS.N: up 2.8% premarket BUZZ-Up as brokerage raises rating on growth prospects ** Colgate-Palmolive CO CL.N: down 0.1% premarket BUZZ-Street View: Colgate-Palmolive's H2 growth could slow down in emerging markets ** Chevron Corp CVX.N: up 0.1% premarket BUZZ-Street View: Chevron has strong balance sheet despite challenging quarter ** Expedia Group Inc EXPE.O: up 1.5% premarket BUZZ-Up after Susquehanna hikes PT on recovery hopes ** Marathon Petroleum Corp MPC.N: up 9.1% premarket BUZZ-Rises on $21 bln Speedway sale to 7-Eleven owner ** ADT Inc ADT.N: up 73.6% premarket BUZZ-Surges on $450 mln Google investment in home security partnership ** Charter Communications Inc CHTR.O: up 0.3% premarket BUZZ-Street View: Charter Communications waltzes into Q3 after impressive results ** Merck & Co Inc MRK.N: up 1.5% premarket BUZZ-Street View: Merck's late launch of COVID-19 vaccines may be advantageous ** VistaGen Therapeutics Inc VTGN.O: down 15.1% premarket BUZZ-Plunges on discounted share sale offer ** Co-Diagnostics Inc CODX.O: up 12.1% premarket BUZZ-Co-Diagnostics tech to be used in FDA-authorized COVID-19 test, shares up ** Eli Lilly & Co LLY.N: up 2.6% premarket BUZZ-Up on starting late-stage trial of COVID-19 drug in nursing homes ** Exxon Mobil Corp XOM.N: up 0.3% premarket BUZZ-Street View: Exxon Mobil's reduced capex improves near-term cash burn ** McKesson Corp MCK.N: up 4.2% premarket BUZZ-Rises on higher 2021 forecast, profit beat ** BioCryst Pharmaceuticals Inc BCRX.O: up 10.6% premarket BUZZ-Rises on 'Fast Track' tag for potential blood disorder treatment (Compiled by Shivani Kumaresan in Bengaluru) ((Shivani.Kumaresan@thomsonreuters.com ; +1 646 223 8780;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh Wall Street's main indexes were set to open higher on Monday as Microsoft's pursuit of TikTok's U.S. operations and a clutch of upbeat quarterly earnings reports lifted sentiment in the absence of a fiscal coronavirus relief deal. ET, Dow e-minis 1YMc1 were up 0.51% at 26,454. |
24442.0 | 2020-08-03 00:00:00 UTC | Rival drugmakers launch joint trial of medicines for COVID-19 | ABBV | https://www.nasdaq.com/articles/rival-drugmakers-launch-joint-trial-of-medicines-for-covid-19-2020-08-03 | nan | nan | By Deena Beasley
Aug 3 (Reuters) - Rival drugmakers AbbVie Inc ABBV.N, Amgen Inc AMGN.O and Takeda Pharmaceuticals Inc 4502.T on Monday said they have begun treating patients in a trial to quickly show whether a drug from each company can be repurposed and used against COVID-19, the disease caused by the novel coronavirus.
The COVID-19 pandemic is an "all hands on deck moment," David Reese, Amgen's research and development chief told Reuters. "We wanted a trial to be able to quickly sift through multiple agents and prioritize."
The study is a collaboration among pharmaceutical industry members of the recently-formed COVID Research & Development Alliance, Quantum Leap Healthcare Collaborative, a partnership of medical researchers and investors, and the Food and Drug Administration.
The first segment will test whether Amgen's psoriasis drug Otezla, Takeda's anti-inflammatory Firazyr and AbbVie's cenicriviroc, which has been tried in patients with HIV, will help with the overactive, and potentially damaging, immune response that sometimes happens in patients with severe COVID-19.
The study's "adaptive platform" means several treatment candidates can be tested at the same time, with the most promising moving forward and the least promising dropping out, Quantum Leap co-founder Dr. Laura Esserman told Reuters.
"We could have some results in as early as six weeks," she said, adding that additional drugs will soon be added to the roster.
Company officials said Otezla may be able to suppress inflammation from an overactive immune response; Firazyr may help limit fluid in the lungs; and cenicriviroc, which blocks activity of certain immune system cells, could reduce the severity of acute respiratory distress caused by the virus.
The drugs are being dosed in combination with Gilead Sciences Inc's GILD.O antiviral drug remdesivir and generic steroid dexamethasone, both of which have been shown in rigorous trials to help COVID-19 patients and are now considered to be standard care, Dr. Esserman said. A comparison group of patients will be given remdesivir and dexamethasone alone.
Hospitals have tried other anti-inflammatory drugs in COVID-19 patients, including Regeneron's REGN.O Kevzara and Roche Holding's ROG.S Actemra, but trials of both arthritis drugs failed to show effectiveness. Roche is continuing to test Actemra in combination with remdesivir.
The National Institute of Allergy and Infectious Diseases' ongoing adaptive COVID-19 trial is studying remdesivir in combination with Olumiant, an arthritis drug sold by Eli Lilly & Co LLY.N. Those results are expected next month.
Since the outbreak began seven months ago, so far killing more than 675,000 people worldwide, hundreds of clinical trials have been launched around the world to test whether existing drugs or experimental compounds could be effective treatments.
"There are a huge number of trials that for all the best intentions have been stood up around the world, but many are smaller - what we would call underpowered - and will not provide definitive answers," Amgen's Reese said.
(Reporting By Deena Beasley; Editing by Aurora Ellis)
((deena.beasley@thomsonreuters.com; 213 955 6746; Reuters Messaging: deena.beasley.thomsonreuters.com@reuters.net))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | By Deena Beasley Aug 3 (Reuters) - Rival drugmakers AbbVie Inc ABBV.N, Amgen Inc AMGN.O and Takeda Pharmaceuticals Inc 4502.T on Monday said they have begun treating patients in a trial to quickly show whether a drug from each company can be repurposed and used against COVID-19, the disease caused by the novel coronavirus. The first segment will test whether Amgen's psoriasis drug Otezla, Takeda's anti-inflammatory Firazyr and AbbVie's cenicriviroc, which has been tried in patients with HIV, will help with the overactive, and potentially damaging, immune response that sometimes happens in patients with severe COVID-19. The National Institute of Allergy and Infectious Diseases' ongoing adaptive COVID-19 trial is studying remdesivir in combination with Olumiant, an arthritis drug sold by Eli Lilly & Co LLY.N. | The first segment will test whether Amgen's psoriasis drug Otezla, Takeda's anti-inflammatory Firazyr and AbbVie's cenicriviroc, which has been tried in patients with HIV, will help with the overactive, and potentially damaging, immune response that sometimes happens in patients with severe COVID-19. By Deena Beasley Aug 3 (Reuters) - Rival drugmakers AbbVie Inc ABBV.N, Amgen Inc AMGN.O and Takeda Pharmaceuticals Inc 4502.T on Monday said they have begun treating patients in a trial to quickly show whether a drug from each company can be repurposed and used against COVID-19, the disease caused by the novel coronavirus. The COVID-19 pandemic is an "all hands on deck moment," David Reese, Amgen's research and development chief told Reuters. | By Deena Beasley Aug 3 (Reuters) - Rival drugmakers AbbVie Inc ABBV.N, Amgen Inc AMGN.O and Takeda Pharmaceuticals Inc 4502.T on Monday said they have begun treating patients in a trial to quickly show whether a drug from each company can be repurposed and used against COVID-19, the disease caused by the novel coronavirus. The first segment will test whether Amgen's psoriasis drug Otezla, Takeda's anti-inflammatory Firazyr and AbbVie's cenicriviroc, which has been tried in patients with HIV, will help with the overactive, and potentially damaging, immune response that sometimes happens in patients with severe COVID-19. The drugs are being dosed in combination with Gilead Sciences Inc's GILD.O antiviral drug remdesivir and generic steroid dexamethasone, both of which have been shown in rigorous trials to help COVID-19 patients and are now considered to be standard care, Dr. Esserman said. | The first segment will test whether Amgen's psoriasis drug Otezla, Takeda's anti-inflammatory Firazyr and AbbVie's cenicriviroc, which has been tried in patients with HIV, will help with the overactive, and potentially damaging, immune response that sometimes happens in patients with severe COVID-19. By Deena Beasley Aug 3 (Reuters) - Rival drugmakers AbbVie Inc ABBV.N, Amgen Inc AMGN.O and Takeda Pharmaceuticals Inc 4502.T on Monday said they have begun treating patients in a trial to quickly show whether a drug from each company can be repurposed and used against COVID-19, the disease caused by the novel coronavirus. Roche is continuing to test Actemra in combination with remdesivir. |
24443.0 | 2020-08-03 00:00:00 UTC | BUZZ-U.S. STOCKS ON THE MOVE-Varian Medical, Pinterest, Chevron, AbbVie | ABBV | https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-varian-medical-pinterest-chevron-abbvie-2020-08-03 | nan | nan | Eikon search string for individual stock moves: STXBZ
The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi
The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh
Futures linked to the S&P 500 and the Dow indexes were muted on Monday with lawmakers at an impasse about a coronavirus relief deal, while investors remained cautious after Fitch revised its U.S. outlook to negative, citing eroding credit strength. .N
At 7:00 a.m. ET, Dow e-minis 1YMc1 were up 0.36% at 26,414. S&P 500 e-minis ESc1 were up 0.50% at 3,279.75, while Nasdaq 100 e-minis NQc1 were up 0.90% at 10,988.5. The top three NYSE percentage gainers premarket .PRPG.NQ: ** ADT Inc , up 62.4% ** Borr Drillng Ltd , up 32.1% ** Forum Energy Technologies Inc , up 23.9% The top three NYSE percentage losers premarket .PRPL.NQ: ** Cango Inc , down 12.8% ** Marine Products Corp , down 10.4% ** Mogu Inc , down 10.8% The top three Nasdaq percentage gainers premarket .PRPG.O: ** Highway Holdings Ltd , up 143.3% ** Immunic Inc , up 39.8% ** Marathon Patent Group Inc , up 34.0% The top three Nasdaq percentage losers premarket .PRPL.O: ** Inspired Entertainment Inc , down 16.7% ** Vistagen Therapeutics Inc , down 16.1% ** Navios Maritime Containers Lp , down 10.4% ** AbbVie Inc ABBV.N: up 0.1% premarket BUZZ-Street View: AbbVie in good stead to tackle Humira competition ** Varian Medical Systems Inc VAR.N: up 22.3% premarket BUZZ-Jumps on Siemens Healthineers' $16.4 bln buyout deal ** Pinterest Inc PINS.N: up 2.7% premarket BUZZ-Up as brokerage raises rating on growth prospects ** Chevron Corp CVX.N: up 0.1% premarket BUZZ-Street View: Chevron has strong balance sheet despite challenging quarter
(Compiled by Shivani Kumaresan in Bengaluru)
((Shivani.Kumaresan@thomsonreuters.com ; +1 646 223 8780;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The top three NYSE percentage gainers premarket .PRPG.NQ: ** ADT Inc , up 62.4% ** Borr Drillng Ltd , up 32.1% ** Forum Energy Technologies Inc , up 23.9% The top three NYSE percentage losers premarket .PRPL.NQ: ** Cango Inc , down 12.8% ** Marine Products Corp , down 10.4% ** Mogu Inc , down 10.8% The top three Nasdaq percentage gainers premarket .PRPG.O: ** Highway Holdings Ltd , up 143.3% ** Immunic Inc , up 39.8% ** Marathon Patent Group Inc , up 34.0% The top three Nasdaq percentage losers premarket .PRPL.O: ** Inspired Entertainment Inc , down 16.7% ** Vistagen Therapeutics Inc , down 16.1% ** Navios Maritime Containers Lp , down 10.4% ** AbbVie Inc ABBV.N: up 0.1% premarket BUZZ-Street View: AbbVie in good stead to tackle Humira competition ** Varian Medical Systems Inc VAR.N: up 22.3% premarket BUZZ-Jumps on Siemens Healthineers' $16.4 bln buyout deal ** Pinterest Inc PINS.N: up 2.7% premarket BUZZ-Up as brokerage raises rating on growth prospects ** Chevron Corp CVX.N: up 0.1% premarket BUZZ-Street View: Chevron has strong balance sheet despite challenging quarter (Compiled by Shivani Kumaresan in Bengaluru) ((Shivani.Kumaresan@thomsonreuters.com ; +1 646 223 8780;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh Futures linked to the S&P 500 and the Dow indexes were muted on Monday with lawmakers at an impasse about a coronavirus relief deal, while investors remained cautious after Fitch revised its U.S. outlook to negative, citing eroding credit strength. ET, Dow e-minis 1YMc1 were up 0.36% at 26,414. | The top three NYSE percentage gainers premarket .PRPG.NQ: ** ADT Inc , up 62.4% ** Borr Drillng Ltd , up 32.1% ** Forum Energy Technologies Inc , up 23.9% The top three NYSE percentage losers premarket .PRPL.NQ: ** Cango Inc , down 12.8% ** Marine Products Corp , down 10.4% ** Mogu Inc , down 10.8% The top three Nasdaq percentage gainers premarket .PRPG.O: ** Highway Holdings Ltd , up 143.3% ** Immunic Inc , up 39.8% ** Marathon Patent Group Inc , up 34.0% The top three Nasdaq percentage losers premarket .PRPL.O: ** Inspired Entertainment Inc , down 16.7% ** Vistagen Therapeutics Inc , down 16.1% ** Navios Maritime Containers Lp , down 10.4% ** AbbVie Inc ABBV.N: up 0.1% premarket BUZZ-Street View: AbbVie in good stead to tackle Humira competition ** Varian Medical Systems Inc VAR.N: up 22.3% premarket BUZZ-Jumps on Siemens Healthineers' $16.4 bln buyout deal ** Pinterest Inc PINS.N: up 2.7% premarket BUZZ-Up as brokerage raises rating on growth prospects ** Chevron Corp CVX.N: up 0.1% premarket BUZZ-Street View: Chevron has strong balance sheet despite challenging quarter (Compiled by Shivani Kumaresan in Bengaluru) ((Shivani.Kumaresan@thomsonreuters.com ; +1 646 223 8780;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh Futures linked to the S&P 500 and the Dow indexes were muted on Monday with lawmakers at an impasse about a coronavirus relief deal, while investors remained cautious after Fitch revised its U.S. outlook to negative, citing eroding credit strength. ET, Dow e-minis 1YMc1 were up 0.36% at 26,414. | The top three NYSE percentage gainers premarket .PRPG.NQ: ** ADT Inc , up 62.4% ** Borr Drillng Ltd , up 32.1% ** Forum Energy Technologies Inc , up 23.9% The top three NYSE percentage losers premarket .PRPL.NQ: ** Cango Inc , down 12.8% ** Marine Products Corp , down 10.4% ** Mogu Inc , down 10.8% The top three Nasdaq percentage gainers premarket .PRPG.O: ** Highway Holdings Ltd , up 143.3% ** Immunic Inc , up 39.8% ** Marathon Patent Group Inc , up 34.0% The top three Nasdaq percentage losers premarket .PRPL.O: ** Inspired Entertainment Inc , down 16.7% ** Vistagen Therapeutics Inc , down 16.1% ** Navios Maritime Containers Lp , down 10.4% ** AbbVie Inc ABBV.N: up 0.1% premarket BUZZ-Street View: AbbVie in good stead to tackle Humira competition ** Varian Medical Systems Inc VAR.N: up 22.3% premarket BUZZ-Jumps on Siemens Healthineers' $16.4 bln buyout deal ** Pinterest Inc PINS.N: up 2.7% premarket BUZZ-Up as brokerage raises rating on growth prospects ** Chevron Corp CVX.N: up 0.1% premarket BUZZ-Street View: Chevron has strong balance sheet despite challenging quarter (Compiled by Shivani Kumaresan in Bengaluru) ((Shivani.Kumaresan@thomsonreuters.com ; +1 646 223 8780;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh Futures linked to the S&P 500 and the Dow indexes were muted on Monday with lawmakers at an impasse about a coronavirus relief deal, while investors remained cautious after Fitch revised its U.S. outlook to negative, citing eroding credit strength. S&P 500 e-minis ESc1 were up 0.50% at 3,279.75, while Nasdaq 100 e-minis NQc1 were up 0.90% at 10,988.5. | The top three NYSE percentage gainers premarket .PRPG.NQ: ** ADT Inc , up 62.4% ** Borr Drillng Ltd , up 32.1% ** Forum Energy Technologies Inc , up 23.9% The top three NYSE percentage losers premarket .PRPL.NQ: ** Cango Inc , down 12.8% ** Marine Products Corp , down 10.4% ** Mogu Inc , down 10.8% The top three Nasdaq percentage gainers premarket .PRPG.O: ** Highway Holdings Ltd , up 143.3% ** Immunic Inc , up 39.8% ** Marathon Patent Group Inc , up 34.0% The top three Nasdaq percentage losers premarket .PRPL.O: ** Inspired Entertainment Inc , down 16.7% ** Vistagen Therapeutics Inc , down 16.1% ** Navios Maritime Containers Lp , down 10.4% ** AbbVie Inc ABBV.N: up 0.1% premarket BUZZ-Street View: AbbVie in good stead to tackle Humira competition ** Varian Medical Systems Inc VAR.N: up 22.3% premarket BUZZ-Jumps on Siemens Healthineers' $16.4 bln buyout deal ** Pinterest Inc PINS.N: up 2.7% premarket BUZZ-Up as brokerage raises rating on growth prospects ** Chevron Corp CVX.N: up 0.1% premarket BUZZ-Street View: Chevron has strong balance sheet despite challenging quarter (Compiled by Shivani Kumaresan in Bengaluru) ((Shivani.Kumaresan@thomsonreuters.com ; +1 646 223 8780;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh Futures linked to the S&P 500 and the Dow indexes were muted on Monday with lawmakers at an impasse about a coronavirus relief deal, while investors remained cautious after Fitch revised its U.S. outlook to negative, citing eroding credit strength. ET, Dow e-minis 1YMc1 were up 0.36% at 26,414. |
24444.0 | 2020-07-31 00:00:00 UTC | Drugmaker AbbVie profit beats as Humira helps offset COVID-19 hit | ABBV | https://www.nasdaq.com/articles/drugmaker-abbvie-profit-beats-as-humira-helps-offset-covid-19-hit-2020-07-31 | nan | nan | Adds CEO comment, shares
July 31 (Reuters) - Drugmaker AbbVie Inc ABBV.N on Friday reported a better-than-expected adjusted quarterly profit as sales of its blockbuster drug, Humira, more than offset weak demand for newly acquired aesthetic portfolio.
Share of the company were up 2.5% before the bell.
The company has long relied on its flagship arthritis drug, Humira, and bought Botox maker Allergan for $63 billion in May to reduce its dependence on the treatment ahead of its U.S. patent expiration in 2023.
"The adverse impact from COVID-19 on legacy AbbVie was less than expected... and new patient starts have stabilized and started to recover," AbbVie Chief Executive Officer Richard Gonzalez said in a statement.
AbbVie said U.S. sales of Humira rose 4.8% to $3.97 billion, while international sales fell about 20% due to competition from cheaper versions.
Combined sales beat analysts' estimates of $4.62 billion.
The company had cautioned in May of a potential hit during the pandemic to sales from Botox and other aesthetic products, as people avoided non-emergency procedures due to shelter-in-place restrictions imposed to control the pandemic.
Total Botox cosmetic comparable sales plunged 43.1% to $226 million and therapeutic sales fell 22.3% to $297 in the second quarter ended June 30, on a comparable basis.
Like several other drugmakers, AbbVie is also looking to develop a therapy for COVID-19 and collaborating with three organizations, including the Netherlands' Utrecht University, to develop an antibody that targets the spike protein of the virus.
AbbVie forecast a combined company 2020 adjusted earnings estimate, which includes the results of Allergan from May 8 through Dec. 31, of $10.35 to $10.45 per share, representing annualized net accretion from the Allergan deal of 11%.
Excluding items, AbbVie reported a profit of $2.34 per share, beating estimates of $2.19 per share, according to Refinitiv IBES data.
(Reporting By Manojna Maddipatla and Mrinalika Roy in Bengaluru; Editing by Shinjini Ganguli)
((manojna.kalyani@thomsonreuters.com; +91 8061822700;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Adds CEO comment, shares July 31 (Reuters) - Drugmaker AbbVie Inc ABBV.N on Friday reported a better-than-expected adjusted quarterly profit as sales of its blockbuster drug, Humira, more than offset weak demand for newly acquired aesthetic portfolio. "The adverse impact from COVID-19 on legacy AbbVie was less than expected... and new patient starts have stabilized and started to recover," AbbVie Chief Executive Officer Richard Gonzalez said in a statement. AbbVie said U.S. sales of Humira rose 4.8% to $3.97 billion, while international sales fell about 20% due to competition from cheaper versions. | Adds CEO comment, shares July 31 (Reuters) - Drugmaker AbbVie Inc ABBV.N on Friday reported a better-than-expected adjusted quarterly profit as sales of its blockbuster drug, Humira, more than offset weak demand for newly acquired aesthetic portfolio. Excluding items, AbbVie reported a profit of $2.34 per share, beating estimates of $2.19 per share, according to Refinitiv IBES data. "The adverse impact from COVID-19 on legacy AbbVie was less than expected... and new patient starts have stabilized and started to recover," AbbVie Chief Executive Officer Richard Gonzalez said in a statement. | Adds CEO comment, shares July 31 (Reuters) - Drugmaker AbbVie Inc ABBV.N on Friday reported a better-than-expected adjusted quarterly profit as sales of its blockbuster drug, Humira, more than offset weak demand for newly acquired aesthetic portfolio. AbbVie said U.S. sales of Humira rose 4.8% to $3.97 billion, while international sales fell about 20% due to competition from cheaper versions. AbbVie forecast a combined company 2020 adjusted earnings estimate, which includes the results of Allergan from May 8 through Dec. 31, of $10.35 to $10.45 per share, representing annualized net accretion from the Allergan deal of 11%. | AbbVie said U.S. sales of Humira rose 4.8% to $3.97 billion, while international sales fell about 20% due to competition from cheaper versions. AbbVie forecast a combined company 2020 adjusted earnings estimate, which includes the results of Allergan from May 8 through Dec. 31, of $10.35 to $10.45 per share, representing annualized net accretion from the Allergan deal of 11%. Excluding items, AbbVie reported a profit of $2.34 per share, beating estimates of $2.19 per share, according to Refinitiv IBES data. |
24445.0 | 2020-07-31 00:00:00 UTC | Noteworthy Friday Option Activity: IBM, ABBV, F | ABBV | https://www.nasdaq.com/articles/noteworthy-friday-option-activity%3A-ibm-abbv-f-2020-07-31 | nan | nan | Looking at options trading activity among components of the S&P 500 index, there is noteworthy activity today in International Business Machines Corp (Symbol: IBM), where a total volume of 22,995 contracts has been traded thus far today, a contract volume which is representative of approximately 2.3 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 44.1% of IBM's average daily trading volume over the past month, of 5.2 million shares. Especially high volume was seen for the $122 strike put option expiring July 31, 2020, with 4,768 contracts trading so far today, representing approximately 476,800 underlying shares of IBM. Below is a chart showing IBM's trailing twelve month trading history, with the $122 strike highlighted in orange:
AbbVie Inc (Symbol: ABBV) options are showing a volume of 26,481 contracts thus far today. That number of contracts represents approximately 2.6 million underlying shares, working out to a sizeable 44% of ABBV's average daily trading volume over the past month, of 6.0 million shares. Especially high volume was seen for the $100 strike call option expiring September 18, 2020, with 2,760 contracts trading so far today, representing approximately 276,000 underlying shares of ABBV. Below is a chart showing ABBV's trailing twelve month trading history, with the $100 strike highlighted in orange:
And Ford Motor Co. (Symbol: F) saw options trading volume of 313,567 contracts, representing approximately 31.4 million underlying shares or approximately 42.9% of F's average daily trading volume over the past month, of 73.2 million shares. Particularly high volume was seen for the $6 strike put option expiring August 21, 2020, with 81,901 contracts trading so far today, representing approximately 8.2 million underlying shares of F. Below is a chart showing F's trailing twelve month trading history, with the $6 strike highlighted in orange:
For the various different available expirations for IBM options, ABBV options, or F options, visit StockOptionsChannel.com.
Today's Most Active Call & Put Options of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Especially high volume was seen for the $100 strike call option expiring September 18, 2020, with 2,760 contracts trading so far today, representing approximately 276,000 underlying shares of ABBV. Below is a chart showing IBM's trailing twelve month trading history, with the $122 strike highlighted in orange: AbbVie Inc (Symbol: ABBV) options are showing a volume of 26,481 contracts thus far today. That number of contracts represents approximately 2.6 million underlying shares, working out to a sizeable 44% of ABBV's average daily trading volume over the past month, of 6.0 million shares. | Below is a chart showing IBM's trailing twelve month trading history, with the $122 strike highlighted in orange: AbbVie Inc (Symbol: ABBV) options are showing a volume of 26,481 contracts thus far today. Below is a chart showing ABBV's trailing twelve month trading history, with the $100 strike highlighted in orange: And Ford Motor Co. (Symbol: F) saw options trading volume of 313,567 contracts, representing approximately 31.4 million underlying shares or approximately 42.9% of F's average daily trading volume over the past month, of 73.2 million shares. That number of contracts represents approximately 2.6 million underlying shares, working out to a sizeable 44% of ABBV's average daily trading volume over the past month, of 6.0 million shares. | Below is a chart showing ABBV's trailing twelve month trading history, with the $100 strike highlighted in orange: And Ford Motor Co. (Symbol: F) saw options trading volume of 313,567 contracts, representing approximately 31.4 million underlying shares or approximately 42.9% of F's average daily trading volume over the past month, of 73.2 million shares. Particularly high volume was seen for the $6 strike put option expiring August 21, 2020, with 81,901 contracts trading so far today, representing approximately 8.2 million underlying shares of F. Below is a chart showing F's trailing twelve month trading history, with the $6 strike highlighted in orange: For the various different available expirations for IBM options, ABBV options, or F options, visit StockOptionsChannel.com. Below is a chart showing IBM's trailing twelve month trading history, with the $122 strike highlighted in orange: AbbVie Inc (Symbol: ABBV) options are showing a volume of 26,481 contracts thus far today. | Below is a chart showing ABBV's trailing twelve month trading history, with the $100 strike highlighted in orange: And Ford Motor Co. (Symbol: F) saw options trading volume of 313,567 contracts, representing approximately 31.4 million underlying shares or approximately 42.9% of F's average daily trading volume over the past month, of 73.2 million shares. Particularly high volume was seen for the $6 strike put option expiring August 21, 2020, with 81,901 contracts trading so far today, representing approximately 8.2 million underlying shares of F. Below is a chart showing F's trailing twelve month trading history, with the $6 strike highlighted in orange: For the various different available expirations for IBM options, ABBV options, or F options, visit StockOptionsChannel.com. Below is a chart showing IBM's trailing twelve month trading history, with the $122 strike highlighted in orange: AbbVie Inc (Symbol: ABBV) options are showing a volume of 26,481 contracts thus far today. |
24446.0 | 2020-07-31 00:00:00 UTC | Validea Peter Lynch Strategy Daily Upgrade Report - 7/31/2020 | ABBV | https://www.nasdaq.com/articles/validea-peter-lynch-strategy-daily-upgrade-report-7-31-2020-2020-07-31 | nan | nan | The following are today's upgrades for Validea's P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relative to earnings growth that also possess strong balance sheets.
ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Peter Lynch changed from 72% to 74% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions. It offers products in various categories, including HUMIRA (adalimumab), Oncology products, Virology Products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products, which include Duopa and Duodopa (carbidopa and levodopa), Anesthesia products and ZINBRYTA (daclizumab).
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: FAIL
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
Detailed Analysis of ABBVIE INC
Full Guru Analysis for ABBV
Full Factor Report for ABBV
NORTHEAST BANK (NBN) is a small-cap value stock in the Regional Banks industry. The rating according to our strategy based on Peter Lynch changed from 83% to 93% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Northeast Bank is a bank holding company. The Company's banking subsidiary is Northeast Bank (the Bank). The Company provides a range of banking services to individual and corporate customers throughout south-central and western Maine and conducts loan purchasing and origination activities nationwide through its subsidiary. The Company conducts its loan-related activities through three primary channels: the Community Banking Division, the Loan Acquisition and Servicing Group (LASG), and the Small Business Administration (SBA) Division. It offers various loans, such as commercial and industrial loans, consumer loans, multi-family and other commercial real estate loans, and residential loans. It originates residential mortgage loans secured by one- to four-family properties throughout Maine, southern New Hampshire, and Massachusetts. Its deposit products consist of demand deposit, negotiable order of withdrawal (NOW), money market, savings and certificate of deposit accounts.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: NEUTRAL
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: NEUTRAL
EQUITY/ASSETS RATIO: PASS
RETURN ON ASSETS: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
Detailed Analysis of NORTHEAST BANK
Full Guru Analysis for NBN
Full Factor Report for NBN
More details on Validea's Peter Lynch strategy
Peter Lynch Stock Ideas
About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Lynch's common sense approach and quick wit made him one of the most quoted investors on Wall Street. ("Go for a business that any idiot can run -- because sooner or later, any idiot probably is going to run it," is one of his many pearls of wisdom.) Lynch's bestseller One Up on Wall Street is something of a "stocks for the everyman/everywoman", breaking his approach down into easy-to-understand concepts.
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. Detailed Analysis of ABBVIE INC Full Guru Analysis for ABBV Full Factor Report for ABBV NORTHEAST BANK (NBN) is a small-cap value stock in the Regional Banks industry. | Detailed Analysis of ABBVIE INC Full Guru Analysis for ABBV Full Factor Report for ABBV NORTHEAST BANK (NBN) is a small-cap value stock in the Regional Banks industry. ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. | Detailed Analysis of ABBVIE INC Full Guru Analysis for ABBV Full Factor Report for ABBV NORTHEAST BANK (NBN) is a small-cap value stock in the Regional Banks industry. ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. | ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. Detailed Analysis of ABBVIE INC Full Guru Analysis for ABBV Full Factor Report for ABBV NORTHEAST BANK (NBN) is a small-cap value stock in the Regional Banks industry. |
24447.0 | 2020-07-31 00:00:00 UTC | After Hours Most Active for Jul 31, 2020 : CTL, RUN, AGNC, IAA, MSFT, FE, REXR, HPE, ABBV, QQQ, HBAN, NWL | ABBV | https://www.nasdaq.com/articles/after-hours-most-active-for-jul-31-2020-%3A-ctl-run-agnc-iaa-msft-fe-rexr-hpe-abbv-qqq-hban | nan | nan | The NASDAQ 100 After Hours Indicator is up 2.51 to 10,908.39. The total After hours volume is currently 91,891,734 shares traded.
The following are the most active stocks for the after hours session:
CenturyLink, Inc. (CTL) is +0.04 at $9.69, with 5,843,336 shares traded.CTL is scheduled to provide an earnings report on 8/5/2020, for the fiscal quarter ending Jun2020. The consensus earnings per share forecast is 0.32 per share, which represents a 34 percent increase over the EPS one Year Ago
Sunrun Inc. (RUN) is +0.01 at $36.70, with 5,152,009 shares traded. As reported by Zacks, the current mean recommendation for RUN is in the "buy range".
AGNC Investment Corp. (AGNC) is +0.03 at $13.63, with 5,103,189 shares traded. As reported by Zacks, the current mean recommendation for AGNC is in the "buy range".
IAA, Inc. (IAA) is unchanged at $43.35, with 4,394,930 shares traded.IAA is scheduled to provide an earnings report on 8/4/2020, for the fiscal quarter ending Jun2020. The consensus earnings per share forecast is 0.15 per share, which represents a 44 percent increase over the EPS one Year Ago
Microsoft Corporation (MSFT) is -0.01 at $205.00, with 3,570,351 shares traded. Over the last four weeks they have had 9 up revisions for the earnings forecast, for the fiscal quarter ending Sep 2020. The consensus EPS forecast is $1.53. As reported by Zacks, the current mean recommendation for MSFT is in the "buy range".
FirstEnergy Corp. (FE) is unchanged at $29.00, with 3,493,487 shares traded. FE's current last sale is 70.73% of the target price of $41.
Rexford Industrial Realty, Inc. (REXR) is unchanged at $46.93, with 3,490,977 shares traded. REXR's current last sale is 104.29% of the target price of $45.
Hewlett Packard Enterprise Company (HPE) is unchanged at $9.87, with 3,484,405 shares traded. HPE's current last sale is 89.73% of the target price of $11.
AbbVie Inc. (ABBV) is unchanged at $94.91, with 3,457,871 shares traded. PR Newswire Reports: AbbVie Reports Second-Quarter 2020 Financial Results
Invesco QQQ Trust, Series 1 (QQQ) is -0.07 at $265.72, with 3,456,471 shares traded. This represents a 61.11% increase from its 52 Week Low.
Huntington Bancshares Incorporated (HBAN) is -0.02 at $9.25, with 3,176,708 shares traded. Over the last four weeks they have had 6 up revisions for the earnings forecast, for the fiscal quarter ending Sep 2020. The consensus EPS forecast is $0.2. HBAN's current last sale is 92.5% of the target price of $10.
Newell Brands Inc. (NWL) is -0.01 at $16.39, with 2,857,683 shares traded. Business Wire Reports: Newell Brands Announces Second Quarter 2020 Results
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie Inc. (ABBV) is unchanged at $94.91, with 3,457,871 shares traded. PR Newswire Reports: AbbVie Reports Second-Quarter 2020 Financial Results CenturyLink, Inc. (CTL) is +0.04 at $9.69, with 5,843,336 shares traded.CTL is scheduled to provide an earnings report on 8/5/2020, for the fiscal quarter ending Jun2020. | AbbVie Inc. (ABBV) is unchanged at $94.91, with 3,457,871 shares traded. PR Newswire Reports: AbbVie Reports Second-Quarter 2020 Financial Results The consensus earnings per share forecast is 0.32 per share, which represents a 34 percent increase over the EPS one Year Ago | AbbVie Inc. (ABBV) is unchanged at $94.91, with 3,457,871 shares traded. PR Newswire Reports: AbbVie Reports Second-Quarter 2020 Financial Results The consensus earnings per share forecast is 0.32 per share, which represents a 34 percent increase over the EPS one Year Ago | AbbVie Inc. (ABBV) is unchanged at $94.91, with 3,457,871 shares traded. PR Newswire Reports: AbbVie Reports Second-Quarter 2020 Financial Results Over the last four weeks they have had 9 up revisions for the earnings forecast, for the fiscal quarter ending Sep 2020. |
24448.0 | 2020-07-31 00:00:00 UTC | 5 Key Things You'll Want to Know About AbbVie's Q2 Update | ABBV | https://www.nasdaq.com/articles/5-key-things-youll-want-to-know-about-abbvies-q2-update-2020-07-31 | nan | nan | AbbVie (NYSE: ABBV) announced its second-quarter results before the market opened on Friday. This quarterly update was significantly different than any other in the big drugmaker's history. That's because Q2 was the first time for AbbVie to report quarterly results after the closing of its acquisition of Allergan on May 8, 2020.
How did AbbVie fare in its first quarterly results with Allergan under its wing? There was good news and bad news. Here are five key things you'll want to know about AbbVie's Q2 update.
Image source: Getty Images.
1. Allergan acquisition hurt instead of helped
AbbVie reported total revenue of $10.425 billion in Q2, up 26.3% year over year. It makes sense that the company's revenue would increase significantly with the inclusion of the sales for Allergan's products. However, the Allergan acquisition actually hurt AbbVie more than it helped in the second quarter.
On an operational basis (calculated by assuming the Allergan acquisition occurred on Jan. 1, 2019), AbbVie's total revenue declined 5.3%. And the slide resulted mainly from lower sales of Allergan's products.
Sales for Allergan's vaunted Botox cosmetic franchise plunged 43.1% year over year to $226 million. It wasn't a much better story for Botox therapeutics, with sales sinking 22.3% to $297 million. Sales for eye-care drug Restasis fell 19.5% to $138 million. One of the few bright spots for Allergan was antipsychotic drug Vraylar, with sales jumping 70.4% to $192 million.
The COVID-19 pandemic was the culprit behind the dismal overall performance of Allergan's lineup. Unfortunately for AbbVie, the timing of the close of the acquisition wasn't great.
2. Humira is no longer a growth driver
Humira stood out as a key growth driver for AbbVie since the company was spun off from Abbott Labs in 2013. But the blockbuster immunology drug is now no longer a growth driver at all.
AbbVie reported sales of Humira totaled $4.84 billion in the second quarter, down 0.7% year over year. International sales of the drug fell 19.9% year over year to $863 million. The sharp decline resulted from biosimilar competition. Although U.S. sales for Humira rose 4.8% to $3.97 billion, the increase wasn't enough to offset the international sales drop.
It's possible, though, that the second quarter could be an anomaly. The COVID-19 pandemic could have temporarily affected sales of Humira in the U.S. However, the Q2 results underscored that the luster for AbbVie's onetime superstar is dimming.
3. Cancer drugs and new immunology drugs shined
Now for some good news: AbbVie's cancer drugs and new immunology drugs performed very well in the second quarter.
Sales for blood cancer drug Imbruvica in Q2 jumped 17.2% year over year to $1.29 billion. This included nearly $1.06 billion in U.S. sales plus $233 million in international profit sharing. (Johnson & Johnson markets Imbruvica outside of the U.S.) Sales for Venclexta soared 79.2% to $303 million.
And while Humira's best days are in the past, the future is looking even brighter for AbbVie's new immunology drugs. Sales for Skyrizi totaled $330 million in Q2. Rinvoq raked in sales of $149 million. Both drugs received U.S. Food and Drug Administration approvals for their first indications last year.
4. AbbVie beat Wall Street estimates anyway
There's even more good news. Even though AbbVie's revenue fell year over year on an operational basis, the company still beat Wall Street estimates. The consensus analysts' estimate projected Q2 revenue of $10.08 billion. As previously mentioned, AbbVie's actual reported revenue totaled $10.425 billion.
AbbVie also topped analysts' bottom-line estimates. The drugmaker reported adjusted earnings per share (EPS) of $2.34 in Q2. The average analysts' estimate was for adjusted earnings of $2.19 per share.
5. What to expect with the rest of the year
AbbVie previously projected that its diluted EPS based on generally accepted accounting principles (GAAP) for full-year 2020 would be between $7.60 and $7.70. This was stand-alone guidance without including the Allergan acquisition. Now, though, the company expects full-year GAAP EPS will be between $4.12 and $4.22 -- including Allergan.
The outlook looks better on a non-GAAP adjusted basis, though. AbbVie previously provided stand-alone full-year guidance of adjusted EPS between $9.61 and $9.71. It now anticipates adjusted EPS will be between $10.35 and $10.45 with Allergan included.
The COVID-19 pandemic will almost certainly continue to be the main wild card impacting the big pharma stock. AbbVie's pipeline progress could be a positive factor, though. The company plans to file for regulatory approvals of Rinvoq in treating atopic dermatitis later this year. It also will soon file for approvals for migraine candidate atogepant.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of June 2, 2020
Keith Speights owns shares of AbbVie. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | On an operational basis (calculated by assuming the Allergan acquisition occurred on Jan. 1, 2019), AbbVie's total revenue declined 5.3%. What to expect with the rest of the year AbbVie previously projected that its diluted EPS based on generally accepted accounting principles (GAAP) for full-year 2020 would be between $7.60 and $7.70. AbbVie (NYSE: ABBV) announced its second-quarter results before the market opened on Friday. | Allergan acquisition hurt instead of helped AbbVie reported total revenue of $10.425 billion in Q2, up 26.3% year over year. Cancer drugs and new immunology drugs shined Now for some good news: AbbVie's cancer drugs and new immunology drugs performed very well in the second quarter. Even though AbbVie's revenue fell year over year on an operational basis, the company still beat Wall Street estimates. | Allergan acquisition hurt instead of helped AbbVie reported total revenue of $10.425 billion in Q2, up 26.3% year over year. AbbVie reported sales of Humira totaled $4.84 billion in the second quarter, down 0.7% year over year. Cancer drugs and new immunology drugs shined Now for some good news: AbbVie's cancer drugs and new immunology drugs performed very well in the second quarter. | That's because Q2 was the first time for AbbVie to report quarterly results after the closing of its acquisition of Allergan on May 8, 2020. How did AbbVie fare in its first quarterly results with Allergan under its wing? AbbVie reported sales of Humira totaled $4.84 billion in the second quarter, down 0.7% year over year. |
24449.0 | 2020-07-31 00:00:00 UTC | AbbVie Q2 adjusted earnings Beat Estimates | ABBV | https://www.nasdaq.com/articles/abbvie-q2-adjusted-earnings-beat-estimates-2020-07-31 | nan | nan | (RTTNews) - Below are the earnings highlights for AbbVie (ABBV):
-Earnings: -$738 million in Q2 vs. $741 million in the same period last year. -EPS: -$0.46 in Q2 vs. $0.49 in the same period last year. -Excluding items, AbbVie reported adjusted earnings of $3.90 billion or $2.34 per share for the period. -Analysts projected $2.19 per share -Revenue: $10.43 billion in Q2 vs. $8.26 billion in the same period last year.
-Guidance: Full year EPS guidance: $10.35 to $10.45
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - Below are the earnings highlights for AbbVie (ABBV): -Earnings: -$738 million in Q2 vs. $741 million in the same period last year. -Excluding items, AbbVie reported adjusted earnings of $3.90 billion or $2.34 per share for the period. -Guidance: Full year EPS guidance: $10.35 to $10.45 The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - Below are the earnings highlights for AbbVie (ABBV): -Earnings: -$738 million in Q2 vs. $741 million in the same period last year. -Excluding items, AbbVie reported adjusted earnings of $3.90 billion or $2.34 per share for the period. -Analysts projected $2.19 per share -Revenue: $10.43 billion in Q2 vs. $8.26 billion in the same period last year. | (RTTNews) - Below are the earnings highlights for AbbVie (ABBV): -Earnings: -$738 million in Q2 vs. $741 million in the same period last year. -Excluding items, AbbVie reported adjusted earnings of $3.90 billion or $2.34 per share for the period. -Analysts projected $2.19 per share -Revenue: $10.43 billion in Q2 vs. $8.26 billion in the same period last year. | (RTTNews) - Below are the earnings highlights for AbbVie (ABBV): -Earnings: -$738 million in Q2 vs. $741 million in the same period last year. -Excluding items, AbbVie reported adjusted earnings of $3.90 billion or $2.34 per share for the period. -Guidance: Full year EPS guidance: $10.35 to $10.45 The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. |
24450.0 | 2020-07-31 00:00:00 UTC | AbbVie reports loss as COVID-19 hits Botox sales | ABBV | https://www.nasdaq.com/articles/abbvie-reports-loss-as-covid-19-hits-botox-sales-2020-07-31 | nan | nan | July 31 (Reuters) - Drugmaker AbbVie Inc ABBV.N reported a loss in the second quarter on Friday, as comparable sales from wrinkle treatment Botox, acquired as part of its $63 billion Allergan Plc AGN.N deal, slumped due to the impact of the COVID-19 pandemic.
The company had cautioned earlier against a potential hit to sales from Botox and other aesthetic products during the pandemic, as people avoided non-emergency procedures due to shelter-in-place restrictions imposed to control the virus.
The drugmaker bought Allergan in May for a hefty sum, acquiring its medical aesthetics business including Botox, hoping the segments would emerge as new growth drivers before AbbVie's arthritis drug, Humira, loses U.S. patent in 2023.
Total Botox cosmetic comparable sales plunged 43.1% to $226 million and therapeutic sales fell 22.3% to $297 in the second quarter ended June 30, on a comparable basis.
International sales of Humira fell about 20% due to competition from cheaper versions.
Like several other drugmakers, AbbVie is also looking to develop a therapy for COVID-19 and collaborating with three organizations, including the Netherlands' Utrecht University, to develop an antibody that targets the spike protein of the virus.
AbbVie forecast a combined company 2020 adjusted profit estimate, which includes the results of Allergan from May 8 through Dec. 31, of $10.35 to $10.45 per share, representing annualized net accretion from the Allergan deal of 11%.
Second-quarter net loss attributable to shareholders was $738 million, or 46 cents per share, compared with a profit of $741 million, or 49 cents per share, a year earlier.
Revenue rose about 26.3% to $10.43 billion.
(Reporting By Manojna Maddipatla and Mrinalika Roy in Bengaluru; Editing by Shinjini Ganguli)
((manojna.kalyani@thomsonreuters.com; +91 8061822700;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | July 31 (Reuters) - Drugmaker AbbVie Inc ABBV.N reported a loss in the second quarter on Friday, as comparable sales from wrinkle treatment Botox, acquired as part of its $63 billion Allergan Plc AGN.N deal, slumped due to the impact of the COVID-19 pandemic. The drugmaker bought Allergan in May for a hefty sum, acquiring its medical aesthetics business including Botox, hoping the segments would emerge as new growth drivers before AbbVie's arthritis drug, Humira, loses U.S. patent in 2023. Like several other drugmakers, AbbVie is also looking to develop a therapy for COVID-19 and collaborating with three organizations, including the Netherlands' Utrecht University, to develop an antibody that targets the spike protein of the virus. | July 31 (Reuters) - Drugmaker AbbVie Inc ABBV.N reported a loss in the second quarter on Friday, as comparable sales from wrinkle treatment Botox, acquired as part of its $63 billion Allergan Plc AGN.N deal, slumped due to the impact of the COVID-19 pandemic. The drugmaker bought Allergan in May for a hefty sum, acquiring its medical aesthetics business including Botox, hoping the segments would emerge as new growth drivers before AbbVie's arthritis drug, Humira, loses U.S. patent in 2023. Like several other drugmakers, AbbVie is also looking to develop a therapy for COVID-19 and collaborating with three organizations, including the Netherlands' Utrecht University, to develop an antibody that targets the spike protein of the virus. | July 31 (Reuters) - Drugmaker AbbVie Inc ABBV.N reported a loss in the second quarter on Friday, as comparable sales from wrinkle treatment Botox, acquired as part of its $63 billion Allergan Plc AGN.N deal, slumped due to the impact of the COVID-19 pandemic. The drugmaker bought Allergan in May for a hefty sum, acquiring its medical aesthetics business including Botox, hoping the segments would emerge as new growth drivers before AbbVie's arthritis drug, Humira, loses U.S. patent in 2023. Like several other drugmakers, AbbVie is also looking to develop a therapy for COVID-19 and collaborating with three organizations, including the Netherlands' Utrecht University, to develop an antibody that targets the spike protein of the virus. | The drugmaker bought Allergan in May for a hefty sum, acquiring its medical aesthetics business including Botox, hoping the segments would emerge as new growth drivers before AbbVie's arthritis drug, Humira, loses U.S. patent in 2023. July 31 (Reuters) - Drugmaker AbbVie Inc ABBV.N reported a loss in the second quarter on Friday, as comparable sales from wrinkle treatment Botox, acquired as part of its $63 billion Allergan Plc AGN.N deal, slumped due to the impact of the COVID-19 pandemic. Like several other drugmakers, AbbVie is also looking to develop a therapy for COVID-19 and collaborating with three organizations, including the Netherlands' Utrecht University, to develop an antibody that targets the spike protein of the virus. |
24451.0 | 2020-07-31 00:00:00 UTC | BUZZ-U.S. STOCKS ON THE MOVE-AbbVie, Xilinx, Pinterest, Expedia Group | ABBV | https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-abbvie-xilinx-pinterest-expedia-group-2020-07-31 | nan | nan | * Eikon search string for individual stock moves: [STXBZ]
* The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi
* The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh Wall Street's main indexes jumped at the open on Friday, with Apple and Facebook hitting a record high as stunning quarterly reports from some of the biggest U.S. tech firms helped keep nagging pandemic nerves at bay. [.N]
At 9:30 a.m. ET, the Dow Jones Industrial Average was up 0.12% at 26,345.45. The S&P 500 was up 0.27% at 3,254.96 and the Nasdaq Composite was up 0.79% at 10,671.51. The top three S&P 500 percentage gainers: ** Facebook Inc , up 7.6% ** Johnson Controls International PLC , up 5.5% ** Apple Inc , up 5.2% The top three S&P 500 percentage losers: ** Expedia Group Inc , down 6% ** Host Hotels & Resorts Inc , down 4.8% ** Alphabet Inc , down 4.4% The top three NYSE percentage gainers: ** Pinterest Inc , up 27.6% ** Select Medical Holdings Corp , up 18.2% ** Griffon Corp , up 16.8% The top three NYSE percentage losers: ** Eastman Kodak Co , down 19.2% ** Pros Holdings Inc , down 17.3% ** Spartan Energy Acquisition Corp , down 12.5% The top three Nasdaq percentage gainers: ** Sonnet Biotherapeutics Holdings Inc , up 119.6% ** Electrocore Inc , up 65.6% ** Applied Dna Sciences Inc , up 32% The top three Nasdaq percentage losers: ** Precipio Inc , down 38.1% ** Taoping Inc , down 36.9% ** Liminal Biosciences Inc , down 31.6% ** Chevron Corp : down 3.5% RPT-BUZZ-PREVIEW: Chevron shares slip ahead of results on Friday ** Amazon.com Inc : up 4.5% ** Facebook Inc : up 7.6% BUZZ-Big tech quartet rises as quarterly results smash expectations during pandemic ** Apple Inc : up 5.2% BUZZ-Street View: Apple's showstopper results set stage for 5G cycle ** Gilead Sciences Inc : down 2.4% BUZZ-Street View: Gilead's remdesivir not enough to change long term story ** Amazon.com Inc : up 4.5% BUZZ-Street View: Amazon's pandemic-driven growth rate here to stay ** Under Armour Inc : up 0.8% BUZZ-Jumps as e-commerce strength drives sales beat ** Merck & Co Inc : up 2.8% BUZZ-Rises as strong cancer drug demand powers Q2 profit beat ** United Parcel Service Inc : up 1.1% BUZZ-Street View: United Parcel Service heading in right direction ** Goodyear Tire & Rubber Co : up 1.9% BUZZ-Rises as results beat on recovering demand ** AbbVie Inc : up 1.1% BUZZ-Gains as Q2 profit beats on arthritis drug strength ** Xilinx Inc : down 3.5% BUZZ-Drops on Q1 revenue slump ** Pinterest Inc : up 27.8% BUZZ-Soars on strong quarterly revenue, recovering ad demand ** Expedia Group Inc : down 6% BUZZ-Falls as quarterly gross bookings plunge 90% ** Shake Shack Inc : down 6.8% BUZZ-Drops as urban exposure drags
The 11 major S&P 500 sectors: Communication Services up 0.11% Consumer Discretionary up 1.67% Consumer Staples
down 0.20% Energy
down 1.03% Financial
down 0.26% Health
down 0.24% Industrial
down 0.20% Information Technology up 0.69% Materials
up 0.25% Real Estate
down 0.34% Utilities
up 0.31% (Compiled by Shivani Kumaresan in Bengaluru) ((Shivani.Kumaresan@thomsonreuters.com ; +1 646 223 8780)) Keywords: MARKETS USA STOCKS/PULSE
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The top three S&P 500 percentage gainers: ** Facebook Inc , up 7.6% ** Johnson Controls International PLC , up 5.5% ** Apple Inc , up 5.2% The top three S&P 500 percentage losers: ** Expedia Group Inc , down 6% ** Host Hotels & Resorts Inc , down 4.8% ** Alphabet Inc , down 4.4% The top three NYSE percentage gainers: ** Pinterest Inc , up 27.6% ** Select Medical Holdings Corp , up 18.2% ** Griffon Corp , up 16.8% The top three NYSE percentage losers: ** Eastman Kodak Co , down 19.2% ** Pros Holdings Inc , down 17.3% ** Spartan Energy Acquisition Corp , down 12.5% The top three Nasdaq percentage gainers: ** Sonnet Biotherapeutics Holdings Inc , up 119.6% ** Electrocore Inc , up 65.6% ** Applied Dna Sciences Inc , up 32% The top three Nasdaq percentage losers: ** Precipio Inc , down 38.1% ** Taoping Inc , down 36.9% ** Liminal Biosciences Inc , down 31.6% ** Chevron Corp : down 3.5% RPT-BUZZ-PREVIEW: Chevron shares slip ahead of results on Friday ** Amazon.com Inc : up 4.5% ** Facebook Inc : up 7.6% BUZZ-Big tech quartet rises as quarterly results smash expectations during pandemic ** Apple Inc : up 5.2% BUZZ-Street View: Apple's showstopper results set stage for 5G cycle ** Gilead Sciences Inc : down 2.4% BUZZ-Street View: Gilead's remdesivir not enough to change long term story ** Amazon.com Inc : up 4.5% BUZZ-Street View: Amazon's pandemic-driven growth rate here to stay ** Under Armour Inc : up 0.8% BUZZ-Jumps as e-commerce strength drives sales beat ** Merck & Co Inc : up 2.8% BUZZ-Rises as strong cancer drug demand powers Q2 profit beat ** United Parcel Service Inc : up 1.1% BUZZ-Street View: United Parcel Service heading in right direction ** Goodyear Tire & Rubber Co : up 1.9% BUZZ-Rises as results beat on recovering demand ** AbbVie Inc : up 1.1% BUZZ-Gains as Q2 profit beats on arthritis drug strength ** Xilinx Inc : down 3.5% BUZZ-Drops on Q1 revenue slump ** Pinterest Inc : up 27.8% BUZZ-Soars on strong quarterly revenue, recovering ad demand ** Expedia Group Inc : down 6% BUZZ-Falls as quarterly gross bookings plunge 90% ** Shake Shack Inc : down 6.8% BUZZ-Drops as urban exposure drags The 11 major S&P 500 sectors: Communication Services up 0.11% Consumer Discretionary up 1.67% Consumer Staples down 0.20% Energy down 1.03% Financial down 0.26% Health down 0.24% Industrial down 0.20% Information Technology up 0.69% Materials up 0.25% Real Estate down 0.34% Utilities up 0.31% (Compiled by Shivani Kumaresan in Bengaluru) ((Shivani.Kumaresan@thomsonreuters.com ; +1 646 223 8780)) Keywords: MARKETS USA STOCKS/PULSE The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. * Eikon search string for individual stock moves: [STXBZ] * The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi * The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh Wall Street's main indexes jumped at the open on Friday, with Apple and Facebook hitting a record high as stunning quarterly reports from some of the biggest U.S. tech firms helped keep nagging pandemic nerves at bay. ET, the Dow Jones Industrial Average was up 0.12% at 26,345.45. | The top three S&P 500 percentage gainers: ** Facebook Inc , up 7.6% ** Johnson Controls International PLC , up 5.5% ** Apple Inc , up 5.2% The top three S&P 500 percentage losers: ** Expedia Group Inc , down 6% ** Host Hotels & Resorts Inc , down 4.8% ** Alphabet Inc , down 4.4% The top three NYSE percentage gainers: ** Pinterest Inc , up 27.6% ** Select Medical Holdings Corp , up 18.2% ** Griffon Corp , up 16.8% The top three NYSE percentage losers: ** Eastman Kodak Co , down 19.2% ** Pros Holdings Inc , down 17.3% ** Spartan Energy Acquisition Corp , down 12.5% The top three Nasdaq percentage gainers: ** Sonnet Biotherapeutics Holdings Inc , up 119.6% ** Electrocore Inc , up 65.6% ** Applied Dna Sciences Inc , up 32% The top three Nasdaq percentage losers: ** Precipio Inc , down 38.1% ** Taoping Inc , down 36.9% ** Liminal Biosciences Inc , down 31.6% ** Chevron Corp : down 3.5% RPT-BUZZ-PREVIEW: Chevron shares slip ahead of results on Friday ** Amazon.com Inc : up 4.5% ** Facebook Inc : up 7.6% BUZZ-Big tech quartet rises as quarterly results smash expectations during pandemic ** Apple Inc : up 5.2% BUZZ-Street View: Apple's showstopper results set stage for 5G cycle ** Gilead Sciences Inc : down 2.4% BUZZ-Street View: Gilead's remdesivir not enough to change long term story ** Amazon.com Inc : up 4.5% BUZZ-Street View: Amazon's pandemic-driven growth rate here to stay ** Under Armour Inc : up 0.8% BUZZ-Jumps as e-commerce strength drives sales beat ** Merck & Co Inc : up 2.8% BUZZ-Rises as strong cancer drug demand powers Q2 profit beat ** United Parcel Service Inc : up 1.1% BUZZ-Street View: United Parcel Service heading in right direction ** Goodyear Tire & Rubber Co : up 1.9% BUZZ-Rises as results beat on recovering demand ** AbbVie Inc : up 1.1% BUZZ-Gains as Q2 profit beats on arthritis drug strength ** Xilinx Inc : down 3.5% BUZZ-Drops on Q1 revenue slump ** Pinterest Inc : up 27.8% BUZZ-Soars on strong quarterly revenue, recovering ad demand ** Expedia Group Inc : down 6% BUZZ-Falls as quarterly gross bookings plunge 90% ** Shake Shack Inc : down 6.8% BUZZ-Drops as urban exposure drags The 11 major S&P 500 sectors: Communication Services up 0.11% Consumer Discretionary up 1.67% Consumer Staples down 0.20% Energy down 1.03% Financial down 0.26% Health down 0.24% Industrial down 0.20% Information Technology up 0.69% Materials up 0.25% Real Estate down 0.34% Utilities up 0.31% (Compiled by Shivani Kumaresan in Bengaluru) ((Shivani.Kumaresan@thomsonreuters.com ; +1 646 223 8780)) Keywords: MARKETS USA STOCKS/PULSE The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. * Eikon search string for individual stock moves: [STXBZ] * The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi * The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh Wall Street's main indexes jumped at the open on Friday, with Apple and Facebook hitting a record high as stunning quarterly reports from some of the biggest U.S. tech firms helped keep nagging pandemic nerves at bay. [.N] At 9:30 a.m. | The top three S&P 500 percentage gainers: ** Facebook Inc , up 7.6% ** Johnson Controls International PLC , up 5.5% ** Apple Inc , up 5.2% The top three S&P 500 percentage losers: ** Expedia Group Inc , down 6% ** Host Hotels & Resorts Inc , down 4.8% ** Alphabet Inc , down 4.4% The top three NYSE percentage gainers: ** Pinterest Inc , up 27.6% ** Select Medical Holdings Corp , up 18.2% ** Griffon Corp , up 16.8% The top three NYSE percentage losers: ** Eastman Kodak Co , down 19.2% ** Pros Holdings Inc , down 17.3% ** Spartan Energy Acquisition Corp , down 12.5% The top three Nasdaq percentage gainers: ** Sonnet Biotherapeutics Holdings Inc , up 119.6% ** Electrocore Inc , up 65.6% ** Applied Dna Sciences Inc , up 32% The top three Nasdaq percentage losers: ** Precipio Inc , down 38.1% ** Taoping Inc , down 36.9% ** Liminal Biosciences Inc , down 31.6% ** Chevron Corp : down 3.5% RPT-BUZZ-PREVIEW: Chevron shares slip ahead of results on Friday ** Amazon.com Inc : up 4.5% ** Facebook Inc : up 7.6% BUZZ-Big tech quartet rises as quarterly results smash expectations during pandemic ** Apple Inc : up 5.2% BUZZ-Street View: Apple's showstopper results set stage for 5G cycle ** Gilead Sciences Inc : down 2.4% BUZZ-Street View: Gilead's remdesivir not enough to change long term story ** Amazon.com Inc : up 4.5% BUZZ-Street View: Amazon's pandemic-driven growth rate here to stay ** Under Armour Inc : up 0.8% BUZZ-Jumps as e-commerce strength drives sales beat ** Merck & Co Inc : up 2.8% BUZZ-Rises as strong cancer drug demand powers Q2 profit beat ** United Parcel Service Inc : up 1.1% BUZZ-Street View: United Parcel Service heading in right direction ** Goodyear Tire & Rubber Co : up 1.9% BUZZ-Rises as results beat on recovering demand ** AbbVie Inc : up 1.1% BUZZ-Gains as Q2 profit beats on arthritis drug strength ** Xilinx Inc : down 3.5% BUZZ-Drops on Q1 revenue slump ** Pinterest Inc : up 27.8% BUZZ-Soars on strong quarterly revenue, recovering ad demand ** Expedia Group Inc : down 6% BUZZ-Falls as quarterly gross bookings plunge 90% ** Shake Shack Inc : down 6.8% BUZZ-Drops as urban exposure drags The 11 major S&P 500 sectors: Communication Services up 0.11% Consumer Discretionary up 1.67% Consumer Staples down 0.20% Energy down 1.03% Financial down 0.26% Health down 0.24% Industrial down 0.20% Information Technology up 0.69% Materials up 0.25% Real Estate down 0.34% Utilities up 0.31% (Compiled by Shivani Kumaresan in Bengaluru) ((Shivani.Kumaresan@thomsonreuters.com ; +1 646 223 8780)) Keywords: MARKETS USA STOCKS/PULSE The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. * Eikon search string for individual stock moves: [STXBZ] * The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi * The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh Wall Street's main indexes jumped at the open on Friday, with Apple and Facebook hitting a record high as stunning quarterly reports from some of the biggest U.S. tech firms helped keep nagging pandemic nerves at bay. ET, the Dow Jones Industrial Average was up 0.12% at 26,345.45. | The top three S&P 500 percentage gainers: ** Facebook Inc , up 7.6% ** Johnson Controls International PLC , up 5.5% ** Apple Inc , up 5.2% The top three S&P 500 percentage losers: ** Expedia Group Inc , down 6% ** Host Hotels & Resorts Inc , down 4.8% ** Alphabet Inc , down 4.4% The top three NYSE percentage gainers: ** Pinterest Inc , up 27.6% ** Select Medical Holdings Corp , up 18.2% ** Griffon Corp , up 16.8% The top three NYSE percentage losers: ** Eastman Kodak Co , down 19.2% ** Pros Holdings Inc , down 17.3% ** Spartan Energy Acquisition Corp , down 12.5% The top three Nasdaq percentage gainers: ** Sonnet Biotherapeutics Holdings Inc , up 119.6% ** Electrocore Inc , up 65.6% ** Applied Dna Sciences Inc , up 32% The top three Nasdaq percentage losers: ** Precipio Inc , down 38.1% ** Taoping Inc , down 36.9% ** Liminal Biosciences Inc , down 31.6% ** Chevron Corp : down 3.5% RPT-BUZZ-PREVIEW: Chevron shares slip ahead of results on Friday ** Amazon.com Inc : up 4.5% ** Facebook Inc : up 7.6% BUZZ-Big tech quartet rises as quarterly results smash expectations during pandemic ** Apple Inc : up 5.2% BUZZ-Street View: Apple's showstopper results set stage for 5G cycle ** Gilead Sciences Inc : down 2.4% BUZZ-Street View: Gilead's remdesivir not enough to change long term story ** Amazon.com Inc : up 4.5% BUZZ-Street View: Amazon's pandemic-driven growth rate here to stay ** Under Armour Inc : up 0.8% BUZZ-Jumps as e-commerce strength drives sales beat ** Merck & Co Inc : up 2.8% BUZZ-Rises as strong cancer drug demand powers Q2 profit beat ** United Parcel Service Inc : up 1.1% BUZZ-Street View: United Parcel Service heading in right direction ** Goodyear Tire & Rubber Co : up 1.9% BUZZ-Rises as results beat on recovering demand ** AbbVie Inc : up 1.1% BUZZ-Gains as Q2 profit beats on arthritis drug strength ** Xilinx Inc : down 3.5% BUZZ-Drops on Q1 revenue slump ** Pinterest Inc : up 27.8% BUZZ-Soars on strong quarterly revenue, recovering ad demand ** Expedia Group Inc : down 6% BUZZ-Falls as quarterly gross bookings plunge 90% ** Shake Shack Inc : down 6.8% BUZZ-Drops as urban exposure drags The 11 major S&P 500 sectors: Communication Services up 0.11% Consumer Discretionary up 1.67% Consumer Staples down 0.20% Energy down 1.03% Financial down 0.26% Health down 0.24% Industrial down 0.20% Information Technology up 0.69% Materials up 0.25% Real Estate down 0.34% Utilities up 0.31% (Compiled by Shivani Kumaresan in Bengaluru) ((Shivani.Kumaresan@thomsonreuters.com ; +1 646 223 8780)) Keywords: MARKETS USA STOCKS/PULSE The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. * Eikon search string for individual stock moves: [STXBZ] * The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi * The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh Wall Street's main indexes jumped at the open on Friday, with Apple and Facebook hitting a record high as stunning quarterly reports from some of the biggest U.S. tech firms helped keep nagging pandemic nerves at bay. ET, the Dow Jones Industrial Average was up 0.12% at 26,345.45. |
24452.0 | 2020-07-31 00:00:00 UTC | AbbVie (ABBV) Q2 2020 Earnings Call Transcript | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-q2-2020-earnings-call-transcript-2020-08-01 | nan | nan | Image source: The Motley Fool.
AbbVie (NYSE: ABBV)
Q2 2020 Earnings Call
Jul 31, 2020, 9:00 a.m. ET
Contents:
Prepared Remarks
Questions and Answers
Call Participants
Prepared Remarks:
Operator
Good morning, and thank you for standing by. Welcome to the AbbVie second-quarter 2020earnings conference call [Operator instructions] I would now like to introduce Ms. Liz Shea, vice president of investor relations.
Liz Shea -- Vice President of Investor Relations
Good morning and thanks for joining us. Also on the call with me today are: Rick Gonzalez, chairman of the board and chief executive officer; Michael Severino, vice chairman and president; and Rob Michael, executive vice president and chief financial officer. Joining us for the Q&A portion of the call is Laura Schumacher, vice chairman, external affairs, chief legal officer and corporate secretary. Before we get started, I remind you that some statements we make today may be considered forward-looking statements for purposes of the Private Securities Litigation Reform Act 1995.
AbbVie cautions that these forward-looking statements are subject to risks and uncertainties including the impact of the COVID-19 pandemic on AbbVie's operations, results and financial results that may cause actual results to differ materially from those indicated in the forward-looking statements. Additional information about these risks and uncertainties is included in our 2019 annual report on Form 10-K and in our other SEC filings. AbbVie undertakes no obligation to update these forward-looking statements except as required by law. On today's conference call, as in the past, non-GAAP financial measures will be used to help investors understand AbbVie's ongoing business performance.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of June 2, 2020
These non-GAAP financial measures are reconciled with comparable GAAP financial measures in our earnings release and regulatory filings from today which can be found on our website. Please note that the second-quarter financial results and guidance provided on today's call for sales, EPS and line items of the P&L reflect a full period of legacy AbbVie operations and a partial year of contribution from the Allergan portfolio since the transaction closed in early May of this year. In addition, we have provided a quarterly comparable historical trend analysis for key product revenues of the newly combined company as a supplemental table in our earnings release this quarter. This table supports the comparison of sales growth on a comparable operational basis including full quarter, current year and historical results for Allergan on a pro forma basis.
Comparable operational percent changes are presented at a constant -- at constant currency rate. For this comparison of underlying performance, all historically reported Allergan revenues have been recast informed to conform to AbbVie's revenue recognition accounting policies and exclude the recent divestitures of Zenpep and Viokace. Following our prepared remarks, we'll take your questions. So with that, I will now turn the call over to Rick.
Rick Gonzalez -- Chairman of the Board and Chief Executive Officer
Thank you Liz. Good morning everyone, and thank you for joining us. Today, I'll discuss our second-quarter performance and highlights. And for the first time, I'll provide our 2020 outlook for the newly combined company.
Mike will then discuss recent advancements across R&D programs. And Rob will review the quarter and our updated guidance in more detail. Following our remarks, we'll take your questions. I'd like to start off by recognizing all of our employees including those joining AbbVie from Allergan, for all of their hard work and dedication during this pandemic.
The AbbVie team has been working diligently and carefully within our facilities and remotely to ensure that our business continues to operate properly and our patients continue to receive their medicines. Before I speak to the strong financial performance this quarter, I'd like to characterize the state of the recovery of the business from the COVID crisis. Let me start with the legacy AbbVie side of the business which has demonstrated robust performance leading into the pandemic and has remained resilient. The impact on continuing patients for Humira and new patients for Rinvoq, Skyrizi and Venclexta were not as pronounced as we had previously anticipated.
While patient flow has not recovered in most therapeutic segments, we're encouraged by the level of stabilization and the recent positive demand trends. Overall, the legacy AbbVie business continues to perform very well with stand-alone revenue growth in the second quarter of approximately eight and a half percent on an operational basis excluding the negative impact from COVID. On the legacy Allergan side of the business, we saw significant COVID-related impacts on Botox Therapeutic and our aesthetics business in the second quarter. Both businesses are seeing a rapid recovery and are now performing near pre-COVID levels.
Other key brands, such as Vraylar and Ubrelvy, were impacted in a manner similar to the AbbVie-based business. And we're pleased with the recent trends and progress. Overall, COVID had a substantial impact on second quarter reported revenues with an estimated net unfavorable impact of more than $900 million. However, by the end of June, the total business had recovered to more than 90% of pre-COVID levels.
So I'm pleased with the resilience and the rapid recovery across our portfolio. And I'm confident in the continued strong underlying demand and performance of the combined new company. Despite the impact from COVID, we delivered a strong second-quarter performance. Adjusted earnings per share of $2.34 were well above our expectations.
The $0.21 beat included $0.11 of net accretion from Allergan as well as $0.10 of favorable performance versus the midpoint of our stand-alone guidance. Total revenues were $10.4 billion including approximately $8.4 billion of legacy AbbVie sales, significantly above our expectations for the stand-alone portfolio, with continued robust performance in both hem/onc and immunology despite the impact from COVID. Hem/onc revenues of approximately $1.6 billion were up strong double digits again this quarter. Imbruvica sales grew approximately 17% on an operational basis reflecting continued strong performance in CLL, where we remain the clear market leader.
Venclexta sales were up more than 80% on an operational basis with strong growth in CLL and AML. During the quarter, we also announced a strategic collaboration with Genmab to further build our oncology portfolio with a CD3xCD20 bispecific antibody. It has the potential to be a best-in-class therapy across B-cell malignancies. Our leading immunology business delivered revenues of more than $5.3 billion reflecting growth of more than eight and a half percent on an operational basis.
U.S. Humira revenue growth remained strong, up 5% with continued demand from the large installed patient base partially offset by the impact of COVID-19. International Humira biosimilar dynamics in the quarter were better than our expectations. Skyrizi continues to perform well and has maintained its leading in-play psoriasis patient share which includes both new and switching patients at more than 30%.
As expected, we saw modest delays to new patient starts during the quarter as a result of the COVID-19 dynamics. However, recent prescription trends and increasing enrollment in our ambassador program, two leading indicators, demonstrate a strong growth trajectory and support our full-year guidance of $1.4 billion. We're also seeing very encouraging trends for Rinvoq, where rheumatology office visits are approaching pre-COVID levels. Rinvoq revenues were up more than 70% on a sequential basis and currently reflect 15% in-play RA patient share which is now nearly at parity to Humira, the market leader in, in-play share and above all other agents in the segment.
We're also making excellent progress with our immunology pipeline which Mike will discuss further momentarily. As I noted during the quarter, we successfully completed the acquisition of Allergan, creating a stronger and a more diverse AbbVie. The transaction significantly expands and diversifies AbbVie's revenue base and complements our existing leadership positions in immunology and hematological oncology with additional growth franchises in aesthetics and neuroscience. We have growth opportunities in neuroscience with Botox Therapeutics, Vraylar and Ubrelvy.
And we have the leading global aesthetics business with flagship brands including Botox Cosmetics and Juvederm. I'll start with neuroscience which had sales of roughly $735 million to AbbVie in the second quarter. Vraylar continues to demonstrate rapid growth and is well on its way to surpassing $1 billion in annual revenues. Underlying demand has remained resilient despite the COVID-19 pandemic with strong double-digit growth again this quarter.
We see significant room for continued expansion within Vraylar's existing indications, bipolar disorder and schizophrenia. Major depressive disorder or MDD, represents another potential large indication with two Phase 3 trials well under way. Also within neuroscience, we now have a portfolio of migraine therapies that have the potential to support long-term growth in a highly attractive and underserved market. Our migraine portfolio is anchored with Botox Therapeutic which had revenues of roughly $300 million to AbbVie in the second quarter.
Despite multiple new competitive entrants, Botox Therapeutic has largely retained its total treated patient base, a testament to its efficacy, safety and brand recognition. Like many physician-administered products, Botox Therapeutics saw a significant impact from COVID-19 in the second quarter with global sales down approximately 20% on a comparable operational basis. However, we're pleased by the recent data trends which demonstrate a fast recovery and performance is now close to pre-COVID levels. The launch of Ubrelvy, the first-to-market in leading oral CGRP for acute migraine is off to an excellent start.
Feedback from physicians has been very positive, given Ubrelvy's efficacy, safety and convenient dosing profile relative to current standards of care. Commercial access for Ubrelvy is now at 70% which along with increased consumer promotion, will further support the product's launch trajectory. We're also developing atogepant for the prevention of episodic and chronic migraine. We recently disclosed positive top-line results from a Phase 3 study in episodic migraine which will support regulatory submission early next year.
As a fourth pillar of growth, we now have the world's leading global aesthetics franchise which generated sales of roughly $480 million to AbbVie in second quarter. As anticipated, we saw a decline in year over year comparable operational growth with aesthetics healthcare providers closed during the initial phase of COVID. It's now been roughly two months since most major geographies have begun to reopen. And we're pleased with the strong recovery trends we're seeing.
As of the end of June, the vast majority of our aesthetics accounts have reopened in the U.S. and we're seeing considerable pent-up demand. Current U.S. aesthetic revenues have recovered and are approaching 95% of pre-COVID levels.
Outside the U.S., we're also seeing steady recovery trends in China and Western Europe. Current international aesthetics revenues have recovered to approximately 90% of pre-COVID levels. Overall, we're very pleased with the momentum we're seeing on our aesthetics franchise. More broadly, we see aesthetics as a durable cash pay business with an opportunity for significant market growth as well as continued new innovation driving long-term performance.
While strategically important, the acquisition of Allergan will also drive strong financial benefits. Integration has been relatively seamless, and we're impressed by the caliber of talent that we've welcomed into AbbVie. We remain on track with our synergy target of more than $2 billion in expense rationalization by the third year from transaction closing which Rob will discuss further in his prepared remarks here momentarily. When you take these synergies into consideration, along with the continued P&L leverage from our expected sales growth, we expect further operating margin expansion over the next couple of years.
While the COVID crisis remains a fluid situation, our business continues to remain resilient and demonstrate strong underlying growth. Although we continue to carefully watch COVID-related events in the U.S., we're pleased with our recent business trends and the progress we're making toward recovery. And we expect performance will continue to ramp to normalized levels over the course of the second half of 2020. With these current assumptions and based on our recent outperformance of our base business, today, we're issuing full-year 2020 adjusted earnings per share guidance for our new combined company of $10.35 to $10.45 reflecting growth of 16.3% at the midpoint.
This guidance assumes $0.70 of net accretion from the Allergan transaction in 2020 which represents 11% accretion on an annualized basis, ahead of our initial projections for the transaction, despite the COVID impact that I outlined earlier. Overall, we continue to see good momentum across our total portfolio and across our pipeline. We reported a very strong second-quarter performance and remain encouraged by the recent recovery trends which are faster than we expected. We continue to expect the COVID pandemic will have a transient impact on our business with further recovery continuing through the second half of 2020.
With the closing of the Allergan transaction, AbbVie is well positioned for enhanced long-term growth potential, a growing dividend, rapid debt repayment and strong investment in innovation across our therapeutic categories. With that, I'll turn the call over to Mike. Mike?
Michael Severino -- Vice Chairman and President
Thank you Rick. We had a very productive quarter with continued progress across all stages of our pipeline. Additionally, with the recent closing of the Allergan acquisition, we added promising pipeline assets in the areas of aesthetics and neuroscience. We look forward to sharing updates as those programs progress through development.
In immunology, we continue to advance our programs for Rinvoq and Skyrizi in several new disease areas. This year, we intend to submit regulatory applications for three additional indications for Rinvoq. In June, we submitted applications for Rinvoq in psoriatic arthritis. We expect to file applications for atopic dermatitis and ankylosing spondylitis later this year.
We also recently reported top-line results from our three registrational trials for Rinvoq in atopic dermatitis. Two of these Phase 3 studies, Measure Up 1 and Measure Up 2, evaluated Rinvoq as a monotherapy for the treatment of adolescent and adult subjects with moderate to severe atopic dermatitis for candidates for systemic therapy. In the Measure Up 1 and Measure Up 2 studies, both doses of Rinvoq met all primary and secondary endpoints, demonstrating significant improvement in skin clearance and itch compared to placebo. In Measure Up 1, roughly 70% of patients receiving the 15-milligram dose and 80% of patients on the 30-milligram dose achieved a 75% or greater improvement in skin lesions by week 16.
We saw a similar rates of skin clearance in the Measure Up 2 study with roughly 60% of patients receiving the low dose and 73% of patients on the high dose, achieving a 75% or greater improvement by week 16. We also saw very rapid responses in these studies with clinically meaningful reductions in itch observed as early as one day after the first dose in patients receiving 30 milligrams and two days after the first dose in patients receiving 15 milligrams in both studies. We also saw very strong results in our third registrational trial, the AD Up study which evaluated Rinvoq in combination with topical corticosteroids. Similar to the results from the two Measure Up trials, Rinvoq met all primary and secondary endpoints in the AD Up study with patients who received Rinvoq showing significant improvements in skin clearance and reduction in itch compared to patients receiving placebo plus topical steroids following 16 weeks of treatment.
Treatment with Rinvoq also led to a significant increase in the number of steroid-free days. And more patients receiving Rinvoq were able to stop topical corticosteroids altogether. We're very encouraged by both the level of efficacy and the safety profile we've seen across all three Phase 3 atopic dermatitis studies. And we remain very confident that Rinvoq has the potential to provide a strong benefit-risk profile in moderate to severe atopic dermatitis.
In addition to these three registrational studies, we are also evaluating Rinvoq in a head-to-head Phase 3 trial against dupilumab and expect to see data from this study later this year. In the area of inflammatory bowel disease, our Phase 3 program for Rinvoq in ulcerative colitis is progressing ahead of schedule. And we now expect to see top-line data from the first Phase 3 induction study later this year. We also recently reported top-line results from a proof-of-concept study, evaluating our novel TNF steroid conjugate, ABBV-3373 in RA.
In this study, our goal is to drive a greater reduction in disease activity beyond the levels that can be achieved with Humira or other high-efficacy agents, such as Rinvoq. To achieve adequate statistical power, we used preplanned historical Humira data in combination with in-trial data when comparing ABBV-3373 to Humira. The study used two analyses for the primary endpoint which evaluated improvement from baseline in DAS28 score. The first analysis used a propensity matching strategy to compare 3373 with historical Humira data.
This analysis showed a greater change in DAS28 from baseline to week 12 for 3373 compared to the prespecified Humira data. The second analysis used the Bayesian approach to compare 3373 to a combined in-trial and historical Humira data set. And this analysis predicted with a 90% probability that 3373 was associated with a greater improvement in DAS28. Based on these encouraging results, we plan to advance the TNF steroid conjugate program in RA with a Phase 2b dose-ranging study expected to begin in the first half of 2021.
We also plan to begin clinical studies next year in other immune-mediated diseases. Also in the area of immunology, we're making good progress advancing the programs for Skyrizi in new disease areas. We expect to see data from Phase 3 studies in psoriatic arthritis later this year and in Crohn's disease at the end of this year or early next year with regulatory submissions for both indications expected in 2021. In oncology, we continue to advance our hem/onc strategy with several important data readouts and study starts occurring this year.
We've established a leading hem/onc portfolio with Imbruvica and Venclexta in areas such as CLL and AML. And we will continue to generate data to demonstrate the utility of both drugs across a wide range of patient populations and cancer types. At the recent EHA Congress, detailed results from the Phase 3 VIALE-A study were reported which showed the treatment with a combination of Venclexta plus azacitidine resulted in a 34% reduction in the risk of death compared to azacitidine plus placebo in AML patients, who are ineligible for intensive chemotherapy. The median overall survival for patients in the Venclexta arm was 14.7 months versus 9.6 months in the placebo arm.
Patients in the Venclexta arm also showed more than double the rate of composite complete remission compared to those treated with azacitidine alone. This filing is currently being reviewed by the FDA under the real-time oncology review program in Project Orbis. To date, the AML program has focused on Venclexta's use as a frontline treatment in transplant-ineligible patients. This year, we are expanding the program into other patient segments with the goal of establishing Venclexta as a gold standard across the AML patient spectrum.
Earlier this year, we initiated two Phase 3 studies evaluating Venclexta as a maintenance therapy in AML. One trial in fit patients with AML who have received stem cell transplant but remain at high-risk for relapse. And a second trial in patients with AML who are in first remission after receiving conventional induction and consolidation chemotherapies. In addition, building upon the survival advantage observed in the transplant-ineligible population, we are planning to initiate a new randomized study later this year testing Venclexta in combination with intensive chemotherapy in patients who are eligible for more intensive induction regimens.
Our comprehensive development program will position Venclexta as a foundation for combination therapies in AML across all patient segments. We also recently announced a broad oncology collaboration with Genmab to jointly develop and commercialize three next-generation bispecific antibody products and establish a discovery collaboration to create additional differentiated antibody-based therapeutics for cancer. The lead asset in this partnership, epcoritamab, a CD3xCD20 bispecific antibody, has demonstrated a strong efficacy profile, favorable safety and a more convenient dosing regimen in early phase trials. We believe epcoritamab has the potential to become a best-in-class therapy across a number of B-cell malignancies including diffuse large B-cell lymphoma and follicular lymphoma.
And we are rapidly advancing it to Phase 3 trials. And lastly, a few updates from other areas of our pipeline. We previously presented positive progression-free survival data from two Phase 3 studies for veliparib in frontline ovarian cancer and BRCA breast cancer. Based on developments in the field and additional discussions with the FDA, we will not be submitting regulatory applications without mature overall survival data.
We will continue to follow patients in the ongoing trials as overall survival data mature. In eye care, we recently announced receipt of a complete response letter from the FDA for the abicipar BLA. The CRL indicated that the rate of intraocular inflammation observed in the Phase 3 program resulted in an unfavorable benefit-risk ratio. We are currently reviewing the abicipar program to determine next steps and will provide updates as they become available.
In women's health, in the quarter, we received FDA approval of Oriahnn as the first nonsurgical oral treatment for the management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women. This new nonsurgical treatment represents an important therapeutic option for women suffering from uterine fibroids. And in neuroscience, we recently reported top-line results from a Phase 3 study evaluating atogepant for the prevention of episodic migraine. In this study, all three doses of atogepant met the primary endpoint, evaluating the change from baseline in mean monthly migraine days across the 12-week treatment period.
The two higher doses, 30 milligrams and 60 milligrams, also met all secondary endpoints while the 10-milligram dose met four out of six of the secondaries. Allergan had previously reported positive results from one registration-enabling study. And following this second positive study, we plan to submit our regulatory applications in episodic migraine prevention in the first quarter of 2021. In summary, we've seen tremendous progress across all stages of our pipeline in the first half of the year, and we remain on track for further advancements in the remainder of 2020.
With that, I'll turn the call over to Rob for additional comments on our second-quarter performance and financial outlook. Rob?
Rob Michael -- Executive Vice President and Chief Financial Officer
Thank you Mike. Starting with second-quarter results. We delivered top and bottom-line performance ahead of expectations. We reported adjusted earnings per share of $2.34, above our guidance midpoint by $0.21.
This includes $0.10 of stronger performance from legacy AbbVie and $0.11 of accretion from Allergan. Total net revenues were $10.4 billion including $2 billion in sales contribution from the Allergan portfolio. Legacy AbbVie was approximately $300 million ahead of our stand-alone sales guidance driven by Rinvoq, Skyrizi and Humira. COVID-related inventory stocking for the first quarter largely reversed as expected.
U.S. Humira sales were approximately $4 billion, ahead of expectations due to the lower impact from COVID on continuing patient prescriptions. Wholesaler inventory levels remained below half a month in the quarter. International Humira sales were $863 million, down 17.4% operationally reflecting biosimilar competition across Europe and other international markets and ahead of our expectations.
Skyrizi global sales were $330 million with continued strong U.S. in-play market share. We also continue to see robust demand for Rinvoq with sales of $149 million in the quarter and a rapid increase in U.S. in-play market share.
Hematologic oncology global sales were nearly $1.6 billion, up 25.8% on an operational basis, with continued strong performance of both Imbruvica and Venclexta. Imbruvica global net revenues were approximately $1.3 billion, up 17.2% driven by continued strong performance in CLL. Venclexta revenues were $303 million with strong demand across all approved indications. Global Mavyret sales were $376 million, down 51.4% on an operational basis as treated patient volumes have declined during the COVID pandemic.
Allergan Aesthetics contributed sales of $481 million in the quarter. Botox Cosmetic with sales of $226 million and Juvederm with sales of $113 million are both seeing a faster-than-expected recovery from the COVID pandemic. Neuroscience global revenues were $734 million. These results were led by Botox Therapeutic, Vraylar and Ubrelvy with combined sales of more than $500 million.
We also saw a significant contribution from our eye care business which had global sales of $417 million. Turning now to the P&L profile for the second quarter. Adjusted gross margin was 82.8% of sales, adjusted R&D investment was 12.8% of sales and adjusted SG&A expense was 22.9% of sales. The adjusted operating margin ratio was 47% of sales including a negative impact of 70 basis points due to the reversal of COVID-related inventory stocking from the first quarter.
Adjusted net interest expense was $484 million and the adjusted tax rate was 11.4%. Today, we are issuing combined company guidance for the first time. As Rick previously discussed, we are closely monitoring the impact of the COVID pandemic and have factored the latest trends into our updated forecast. We now expect full-year adjusted earnings per share between $10.35 and $10.45 including $0.70 of accretion from the Allergan transaction which represents an annualized contribution of 11%.
Excluded from this guidance is $6.23 of known intangible amortization and specified items. This guidance now contemplates full-year revenue of approximately $45.5 billion. At current rates, we now expect foreign exchange to have a 30-basis-point unfavorable impact on full-year reported sales growth. Included in this revenue guidance are the following updated full-year assumptions.
We now expect U.S. Humira sales growth of approximately 8%. We now expect international Humira sales of approximately $3.5 billion. For Rinvoq, we now expect global revenues of approximately $600 million.
For global HCV, we now expect sales of approximately $2.1 billion as treatments remain below pre-COVID levels. For aesthetics, we expect global sales of approximately $2.4 billion including approximately $1 billion from Botox Cosmetic and approximately $650 million from Juvederm. For neuroscience, we expect global sales of approximately $3.5 billion including approximately $1.4 billion from Botox Therapeutic and approximately $950 million from Vraylar. For eye care, we expect global revenues of approximately $2.1 billion including approximately $700 million from RESTASIS which assumes no generic competition in 2020.
And for women's health, we expect global revenues of approximately $700 million. All other full-year product guidance assumptions remain unchanged. Moving to the P&L. We now forecast adjusted gross margin just above 82% of sales, adjusted R&D investment to be approximately $5.8 billion, adjusted SG&A expense to be approximately $9.9 billion and adjusted operating margin of approximately 48% of sales.
This P&L guidance includes approximately $600 million in expense synergies for the partial year in 2020. We remain on track to deliver greater than $2 billion in expense synergies by 2022. We now expect adjusted net interest expense of approximately $2 billion which includes the cost of financing the Allergan transaction. We now model a non-GAAP tax rate of just above 11% for the newly combined company.
Finally, we now expect our full-year average share count to approach 1.7 billion shares including the equity issue to finance the Allergan acquisition. As we look ahead to the third quarter, we anticipate adjusted revenue of approximately $12.8 billion. At current rates, we expect foreign exchange to have a modest unfavorable impact on reported sales growth. We are forecasting an adjusted operating margin ratio of just above 48% of sales.
We model a non-GAAP tax rate of 11.6% and we expect the average share count to approach 1.8 billion shares. We expect adjusted earnings per share between $2.73 and $2.77 excluding approximately $1.59 of known intangible amortization and specified items. AbbVie remains well positioned to execute on our capital allocation priorities including rapidly paying down debt, supporting a strong and growing dividend and pursuing additional innovative mid- to late-stage pipeline assets. We generated $6.9 billion of operating cash flow in the first half of the year.
And our cash balance at the end of June was $6 billion. We are on track to pay down $15 billion to $18 billion of combined company debt by the end of 2021, of which nearly $7 billion has already been repaid. We expect to achieve a net debt-to-EBITDA ratio of 2.5 times by the end of 2021 with further deleveraging through 2023. In closing, AbbVie's performance and financial condition remain strong.
We are very pleased with the momentum of the business heading into the second half of 2020. With that, I'll turn the call back over to Liz.
Liz Shea -- Vice President of Investor Relations
Thanks Rob. We will now open the call for questions. Operator, first question, please.
Questions & Answers:
Operator
[Operator instructions] Our first question today is from Randall Stanicky from RBC Capital Markets.
Randall Stanicky -- RBC Capital Markets -- Analyst
I just have two. One for Rick and one for Rob. Rick, a bigger-picture question, a huge part of the AbbVie story is...
Liz Shea -- Vice President of Investor Relations
Randall, Randall, sorry to interrupt. We can't hear you very well. Is there any way you can turn up your mic or speak up?
Randall Stanicky -- RBC Capital Markets -- Analyst
Great. Is that better?
Liz Shea -- Vice President of Investor Relations
Slightly. Yes.
Rick Gonzalez -- Chairman of the Board and Chief Executive Officer
It's OK.
Randall Stanicky -- RBC Capital Markets -- Analyst
Great. Rick, I wanted to ask, a big part of the AbbVie story is growth on the other side of Humira in 2023. There's still some trepidation with -- from investors in getting comfortable with the step-down. What would you say to those investors to get people comfortable that there's a growth story on the other side of Humira? And what do you need to do specifically between now and then strategically to position the business for that?
Rick Gonzalez -- Chairman of the Board and Chief Executive Officer
OK. Randall, did you have a second question or is that...
Randall Stanicky -- RBC Capital Markets -- Analyst
Yeah. The second question, I'll ask it upfront for Rob. Just if you could help us understand the steady state, the run rate for R&D. I think you said $5.8 billion for this year that will go higher on an annualized basis.
But you're also pulling $1 billion of R&D synergies out of that as well.
Rick Gonzalez -- Chairman of the Board and Chief Executive Officer
OK. I'll cover your first question, Randall, and then Rob can jump in and talk through the R&D funding question that you had. So look, I think it's a great question. It is one that obviously the vast majority of investors are interested in.
We have described I think to investors the rationale of why we were excited about doing the Allergan transaction. It obviously gives us a tremendous amount of ability to be able to manage our way through the loss of exclusivity in the U.S. of Humira. It provides us with two more major growth franchises for the company to help drive growth.
And it allows us to continue to invest aggressively, both in internal R&D as well as external. And so I think it provides the framework to allow us to continue to perform as we have performed over the last number of years. I mean, clearly, we have -- we certainly have a track record of showing that we can grow this business and we can build on this business. We've demonstrated that since 2013, when we spun out.
So what makes me excited and what makes me comfortable that I can ultimately grow the business through the LOE? I think it starts with, look, we have six major growth assets in our business today if you step back and you look at them, six medicines that have tremendous opportunity to be able to grow: Skyrizi, Rinvoq, Imbruvica, Venclexta, Vraylar, Ubrelvy. We'll probably have atogepant here in the not-too-distant future. So we'll have a seventh asset, all in markets that have a significant opportunity to be able to grow. When I look at our R&D productivity, both in the indication expansion area as well as new assets, and I'll talk about that here in a second, I'm very comfortable with our ability to be able to continue to drive the pipeline.
When you look at the projections that we made for Rinvoq and Skyrizi as an example, when we made those projections a year or two ago, those peak projections for 2025, we based those projections on the fact that those assets had to achieve roughly high single-digit market share positions. As we mentioned, right now, if you look at Skyrizi, it's achieving in-play share of 30%. Rinvoq has really stood up and rapidly started to capture share. It's at 15% and growing at a very aggressive clip.
I would predict that it will quickly become the in-play market leader above Humira here in the not-too-distant future. But they're already significantly above what those estimates were. The longer you stay at in-play shares that look like that, obviously the greater you're going to exceed that. If you get to 20% instead of high single digits, obviously the revenue will be approximately two times what we had originally projected.
So that gives me a high level of comfort. When I look at Venclexta, as an example, there's still a significant opportunity to grow there. If we get an indication expansion, both broadening AML as well as the T1114 in multiple myeloma, those are two significant opportunities that we'll continue to be able to drive growth. Imbruvica still has significant opportunity to be able to drive growth.
When I look at Vraylar, as an example, that's a very interesting asset, has a great profile in that market, the drug does. It's obviously growing significantly. I mean it's been growing now at the rate of about 80% to 90% year over year. There's still plenty of room to grow in bipolar and schizophrenia.
And if one of those two Phase 3 studies plays out effectively, MDD will be a very large additional indication which will allow us to be able to drive significant growth there. And then there's the migraine franchise. I think migraine is something that's underappreciated. If you look at the penetration right now of oral agents in the acute area, it's running about 12% to 14% of total scripts.
So obviously, there's a significant opportunity to be able to continue to expand that market. We think we have the asset to be able to do that. And obviously, we think we have the promotional ability to do it. So I think we have the tools right now to be able to drive significant growth through the LOE.
On the other side of the LOE obviously our pipeline will continue to play out with the additional indications. You're starting to see assets like our TNF steroid. Of all, I think the Genmab collaboration is an important collaboration to continue to build out. Our hem/onc can potentially sell two more platforms.
And so there's a lot of exciting opportunities. So I feel very confident in, one, how the business is running now despite all of the disruption associated with COVID. But I look at the part of the business that we control directly, I feel very good about how the business is running. And so I believe we will navigate our way through it.
And I think as we get a little closer, investors will gain an even greater appreciation of that.
Rob Michael -- Executive Vice President and Chief Financial Officer
So Randall, this is Rob. On your question on R&D, so if you think through the partial year synergies, the $600 million, about $400 million of that comes from R&D. And by 2022, about 50% of the greater than $2 billion in synergies will come from R&D. So while I would expect the expenses to annualize obviously with the partial year close, we'll also see those synergies ramp up.
So the best way to think about it is a steady-state R&D level in the $6 billion range.
Randall Stanicky -- RBC Capital Markets -- Analyst
Great. Thanks.
Liz Shea -- Vice President of Investor Relations
Thanks Randall. Operator, next question please.
Operator
And our next question is from Navin Jacob from UBS.
Navin Jacob -- UBS -- Analyst
Hi. Thanks for taking the question. Just wanted to expand on some of the opportunities that Rick had just mentioned.
Liz Shea -- Vice President of Investor Relations
Again, Navin, can you speak up a little bit? Our...
Rick Gonzalez -- Chairman of the Board and Chief Executive Officer
Well, let's see if we can turn our end up.
Navin Jacob -- UBS -- Analyst
Sure. So is this OK? Can you hear me OK?
Rick Gonzalez -- Chairman of the Board and Chief Executive Officer
That's better.
Liz Shea -- Vice President of Investor Relations
Better. Thank you.
Navin Jacob -- UBS -- Analyst
OK. I will yell. So with regard to...
Rick Gonzalez -- Chairman of the Board and Chief Executive Officer
We can hear you now. We turned our end up. So you don't need to yell.
Navin Jacob -- UBS -- Analyst
All right. Fair enough. With regards to the Venclexta opportunity in multiple myeloma, the Canova trial, wondering if you could give us an update there and how large could that potential opportunity be. Obviously, relapsed/refractory multiple myeloma is pretty competitive.
So just wondering what sort of -- how we should be thinking about that, where that excitement is coming from. And then if you could remind us also about your subcutaneous version -- pump version of Duopa that's supposed to read out in the first half of 2021. How should we be thinking about that opportunity? Could that be a blockbuster opportunity?
Michael Severino -- Vice Chairman and President
This is Mike. I'll take those. With respect to Venclexta, we see very real potential in the T1114 multiple myeloma population. If we look across our trials, early phase trials and then some set analyses of later phase trials, where we have data from T1114, we see very consistent responses.
We see high response rates and we see long progression-free survival in the T1114 population. And that makes sense because that T1114 population has a transformed cell that has a B-cell-like phenotype and it's BCL-2 high. So it would be expected to be uniquely sensitive to Venclexta and to BCL-2 inhibition. So we have the Phase 3 study well under way now.
It's an event-driven trial. But we would hope to have data in the near future in '21. And that study is designed to confirm those earlier observations. In terms of how large an opportunity it can be, the T1114 population is about 20% of multiple myeloma.
And multiple myeloma is a big indication. So 20% of that is a lot. Now as you mentioned, it's becoming a competitive space. But one of the advantages of having a biomarker-driven therapy is that we can identify and physicians can identify in practice what patients are likely to respond to Venclexta.
So we'll know what a Venclexta patient looks like. And we think that will be a real opportunity and a real advantage. So we're very optimistic about that aspect of the program, and we think it represents an important additional role for Venclexta. With respect to 951, that is a program that's designed to deliver Duopa-like efficacy through a subcutaneous insulin pump-like device.
And so to do that, we had to develop two novel prodrugs. These are NMEs that are rapidly converted to the active agents in circulation. And they allow delivery of levodopa and carbidopa ultimately through this insulin pump-like device that you just can't do with the parent compounds because of their physical properties and chemical limitations and local tolerability limitations. So it really does represent a real breakthrough.
What we know about the efficacy of Duopa is that it is very, very strong. It really is transformational. But it takes a lot to get that efficacy. Patients have to have a gastric tube placed to then thread it down into the small bowel.
They have to maintain that. So this is a much more patient-accessible, patient-friendly, if you will, way to deliver the same sort of efficacy. And so we think that has a potential to really expand the number of patients who would be willing to consider a therapy such as 951. And it's a big market.
If you look at Duopa, despite all the limitations, it's doing about $0.5 billion in sales. If you look at deep brain stimulation, there's also considerable use. In aggregate, this market today is well over $1 billion, probably $1.5 billion. And not all patients who would qualify by their patient profile are willing to undergo these therapies.
So we think that 951 can be a very real opportunity and can be quite substantial.
Liz Shea -- Vice President of Investor Relations
Thanks Navin. Operator, next question please.
Operator
Thank you. And our next question is from Chris Schott from JP Morgan.
Chris Schott -- J.P. Morgan -- Analyst
Great. Thank you so much for the questions. So just two for me. The first, can you just elaborate a little bit more about how you're thinking about the size of the opportunity for Rinvoq in atopic derm now that we have the Phase 3? I guess just a little bit more just how you see this fitting into the treatment paradigm.
And then my second question was on the 2020 guidance. If I back out the $0.70 of Allergan accretion, it seems like the base AbbVie numbers are unchanged despite what looked like very, very strong results in the first half of the year. So just help me understand a little bit the dynamics that are happening with that kind of underlying AbbVie set of assumptions.
Michael Severino -- Vice Chairman and President
This is Mike. I'll take the first one and then I'll hand it over to Rick for the second one. With respect to atopic dermatitis, we're very pleased with the results that we demonstrated across the Phase 3 trials. They actually exceeded our expectations based on the Phase 2b results.
And those IIb results were very strong and had earned us a breakthrough therapy designation. And we're pleased not only with the efficacy but also with the safety profile. We've said for quite some time that one needs to look at the safety of a drug in the intended population. Because things like background therapies, risk factors in the population can have a substantial influence on what that profile looks like, not only for the active agent but for the comparator or for placebo.
And if you look at the profile in the AD studies, it looks very favorable to our eye. And these were substantial studies and a substantial program overall. This wasn't a quick study to get an indication expansion. We ran a Phase 3 program for atopic dermatitis that could stand-alone for an additional submission.
So we think that very strong data package will be a real advantage when we bring this indication to market. If you look at the size of the market overall, I think it's been underappreciated for years. Now that's changing now. There are a large number of patients who would be eligible for systemic therapy.
Obviously, dupilumab is off to a good start over the past several years in that indication. But if you look at their efficacy, only about half of patients achieve an adequate response, if you consider that adequate response in EASI-75. And so in our study, we drove very good numbers there, higher than that roughly 50%, albeit there through cross-trial comparisons. So we think that there is a real opportunity for a high-efficacy agent in this space.
And so it really can play on both ends of the spectrum. Patients who don't achieve an adequate response with earlier therapies, this is an obvious choice. But with the efficacy and the safety profile that we've observed, we see no reason why it wouldn't be used upfront as well. And of course, we'll have head-to-head data against dupilumab later on this year, as we said in our prepared remarks.
Rob Michael -- Executive Vice President and Chief Financial Officer
So Chris, this is Rob. I'll take your question on guidance. So if you take that $0.70 of accretion and you back off the midpoint of $10.40, it gives you a stand-alone of $9.70 EPS which is $0.04 higher than our previous guidance. And it's really driven by the sales changes that we've made today.
So for U.S. Humira, we took that up 1% which equals about $150 million because we're seeing less impact of COVID on continuing patients. Humira OUS, we've taken up $100 million. We're seeing less erosion than we initially had planned.
On Rinvoq, that's up $100 million as well, really driven by the rapid in-play share that we're seeing. And that's partially offset by Mavyret as we've seen the market really decline during COVID. But net-net, revenue is up about $150 million, EPS, up $0.04 versus our previous guidance for stand-alone AbbVie.
Rick Gonzalez -- Chairman of the Board and Chief Executive Officer
And the only thing I'd add on that is obviously we were more favorable on base AbbVie in the quarter than the $0.04. But there's still uncertainty as it relates to COVID. And so we're keeping some coverage there to see how things play out in the third quarter.
Liz Shea -- Vice President of Investor Relations
Thanks Chris. Operator, next question please.
Operator
Thank you. And our next question is from Steve Scala from Cowen.
Steve Scala -- Cowen and Company -- Analyst
Thank you. First, congratulations on delivering ahead of expectations in the midst of a major integration, new launches and a global pandemic. It's really impressive. Rick, you stated that the impact of the pandemic was less than expected.
That certainly hasn't been the case at other companies. You also said that you're seeing recovery in the aesthetics portfolio which sounds as though it snapped back faster than the legacy AbbVie. So I'm just curious, to what do you attribute these dynamics? And do you expect the second half of the year to look more like the first half or more like May and June relative to patient volumes, clinic traffic and so forth? And then secondly, you stated that you expect margin improvement over the next few years. Could you provide some parameters around that expectation? Thank you.
Rick Gonzalez -- Chairman of the Board and Chief Executive Officer
OK. So this is Rick. I'll take the first one. Your observation is correct.
So I think the way to think about it is that both in the second quarter, many of the assets didn't drop as far as we expected. That was part of the favorability. I'd say that was particularly the case in a number of areas in the legacy AbbVie portfolio associated with the business. On the aesthetics, it is pretty much the way you're describing it.
What we saw happening in the aesthetics business and to a very similar extent to Botox Therapeutic is that we saw a rapid drop in the case of aesthetics as those practices virtually closed. I'd say almost all, if not all of the practices had closed. So aesthetic revenues dropped significantly for a period of time in that mid-April time frame. As we started to see geographies remove the shelter-in-place orders around the U.S., we saw the aesthetics practices quickly put in place safety measures to be able to allow patients to come back into their offices.
And I'd say the vast majority of those practices ramped back up and went back into doing procedures fairly quickly. As we approached that mid-May time frame, we actually saw -- let's take Botox as an example. And Botox would be the leading indicator because it's the procedure -- Botox Cosmetic, it is the procedure that people would go to first. It ramped back up, went well over 100% of pre-COVID levels to around 120%, 125%.
And then it -- and that was obviously pent-up demand that was coming back into the channel, so patients returned quickly. And then as that pent-up demand started to burn off as we got through June, you started to see it drop back down. And now it's settled in sort of in the mid-90s right now. We think it will reach -- it will stabilize back up over the course of third quarter, back close to pre-COVID levels and then start growing again.
And so I can tell you, I'm extremely pleased with how both aesthetics and Botox Therapeutics had returned. I think it's a testament of those brands and those patients. As far as the assumptions we made in the second half obviously we're assuming the second half performs a lot better than the first half. We're not assuming any kind of a broad-based shelter in-place activity.
And we'll continue to see more and more patients come back into physicians' offices. On the AbbVie side of the business, we are monitoring those patients by individual practice. It's appropriate for our particular businesses. And I'd say, for the most part, they are returning close to pre-COVID levels.
They do vary a little bit by specialty. As an example, rheum and GI have come back faster than medical derm has. But medical derm has returned as well, to some extent, and we're continuing to see it return. Oncology practices in certain conditions, we've seen -- we saw some tailing off of CLL treatment in the second quarter.
That's now returning back to normalized levels. So I think the second half will obviously be much better than the first half. And I think we should return to normalized levels as we proceed through the second half of the year. Rob, anything you want to add on that?
Rob Michael -- Executive Vice President and Chief Financial Officer
I can answer the question on margin. Steve, this is Rob. On operating margin, I think when you think about we have a partial year of synergies and a top line that's been pressured by COVID, we have a 48% operating margin profile. As you think about '21 and '22, we're going to obviously run -- we're going to ramp those synergies as well as we'll see top-line growth and where you'd see the P&L leverage that we've demonstrated in past year.
So I would expect to see our operating margin expand in '21 and '22. With 2023, with the U.S. Humira event obviously, we would see operating margin pulled back. But I would expect it to be in the 45% range which still puts us top tier in the industry.
Steve Scala -- Cowen and Company -- Analyst
Thank you.
Liz Shea -- Vice President of Investor Relations
Thanks Steve. Operator, next question please.
Operator
Thank you. Our next question is from Geoffrey Porges from Leerink.
Geoffrey Porges -- SVB Leerink -- Analyst
Thank you and congratulations. Very helpful to get the guidance. Could you talk a little bit about atogepant? Particularly, what's the size of the addressable opportunity for the full portfolio of oral migraine medicines? And perhaps how much of an issue is the constipation data that you've seen? And then Rick, look, there's a massive economic disruption going on. And I'd be interested in your commentary about how consumers and payers are reacting to that disruption and how that's factored into your guidance.
Are we seeing switches from IV to oral, from generic to brand? How is that playing out in your experience and observation? Thanks.
Rick Gonzalez -- Chairman of the Board and Chief Executive Officer
All right. Great. So maybe we'll have Mike talk a little bit about the profile of the drug. And what I'd say is I think we probably want to come back at a later date once we've had a little better opportunity to analyze the chronic migraine market.
And it's going to depend, to a great extent, on the profile of the drug, obviously. But it's a very large market, a very significant market. And -- but Mike, maybe if you want to talk a little bit about constipation and then I'll come back and talk about the payer dynamics.
Michael Severino -- Vice Chairman and President
Sure. I'll talk about atogepant. We're very pleased with the data we've seen. And of course, this fits into an important part of our migraine portfolio with Ubrelvy for acute migraine, now with atogepant with two data readouts in episodic migraine and an ongoing program in chronic migraine.
And of course, there's Botox Therapeutic in chronic migraine, so it really rounds out our portfolio. The efficacy that we saw was very strong. As we said in our prepared remarks, we hit the primary and all secondaries across the two upper doses and the primary and four out of six secondaries for the lowest dose studied. So that is an efficacy profile that I think exceeded our expectations going into the study.
With respect to the safety, our view of the safety profile looks very favorable. The constipation that was observed in the overwhelming majority of cases was mild or moderate. It didn't limit treatment. So patients stayed on treatment.
They could be managed easily with interventions like stool softeners or fiber supplementation. So we don't see it as something that is limiting, particularly in light of the very strong efficacy that we have demonstrated. And the only other point I'd add is that we have a good understanding of it and it's on target. So it comes with the efficacy, you get a very strong efficacy and you have this manageable tolerability profile that I described.
Rick Gonzalez -- Chairman of the Board and Chief Executive Officer
Geoff, on the -- on your second question, you probably recall back on our first-quarter guidance, when we outlined that we had built in to our forecast for the remainder of the year some impact for some channels shifting that we thought could occur due to the high unemployment. And essentially, we haven't seen much of that at all. In fact, I would tell you, we haven't seen any of it to any material effect right now. And one of the things that we do to watch that carefully is our PAP program.
We've been advertising extensively to consumers to make sure that they know if they lost their insurance or they lost their jobs and they don't have insurance coverage and they can't afford their AbbVie medicines to come to us. We have a very extensive patient assistance program. And we're not seeing any significant increase in those requests. It could be because of the furloughs.
We're not 100% sure yet. And potentially, we could see some increase as we go further here, depending upon what happens with stimulus programs going forward. We have still maintained some level of coverage in our forecast that we're providing now. So we believe we have sufficient coverage to deal with it, and we'll just have to see how it sorts itself out.
Liz Shea -- Vice President of Investor Relations
Thanks Geoffrey. Operator, next question please.
Operator
Thank you. Our next question is from Vamil Divan from Mizuho.
Vamil Divan -- Mizuho Securities -- Analyst
Hi. Great. Thank you so much for taking my question. Maybe just to continue on the migraine question.
You mentioned Ubrelvy and the potential there. Can you maybe just talk a little bit about the net pricing that you're thinking about in that space? I guess maybe relative to the injectable antibodies that are helpful for prevention already, there's only the two players, it sounds like, here between you and Biohaven -- or on the injectable side. So just trying to get a sense how you see this sort of pricing dynamic play out. We're getting a lot of questions on that front.
And then maybe for Rick, I'm just curious around some of the executive orders we've seen on the drug pricing side for the administration. I don't know if I may have missed your comments earlier, but just curious if you have any sort of additional thoughts about what you heard from some of your peers on this issue this week on their calls. But every company obviously has a different product mix and maybe some different perspectives. So curious what your views are especially as it relates to the rebate rule order.
Thanks so much.
Rick Gonzalez -- Chairman of the Board and Chief Executive Officer
Right. OK. I'll cover both of those questions. So on migraine, I mean obviously we don't publicly talk about our net price.
We have fairly significant managed care coverage on the asset already. I think it's about 70%. And obviously, it had to be priced in a way that was appropriate to be able to get that level of coverage. This is a market where market expansion is important.
As I said, I think if you look at the penetration right now of acute migraine products, against the -- or at least the oral CGRPs against the total migraine acute market, it's about 12% penetrated right now. So there's a significant opportunity to be able to grow that market. And it gives you some idea of the magnitude of this market. So you certainly want it to be in a position where it can have access to be able to allow patients to be able to use the products.
These products certainly have demonstrated that they have strong demand from patients to be able to provide them appropriate levels of relief. And so I would just tell you that that's an important aspect of the overall strategy here is to be able to grow this market over the long term. On the executive orders, as you have probably seen, they're pretty high level at this point and they provide some high-level direction. So I think until we see them sort of start to sort out, I think it's a little difficult to give you a lot of specificity around what they look like.
Now I will say, if I look at them in the backdrop of AbbVie's business, I would say I don't think they will have a significant impact on our business. If you look at Part B, as an example, we have a very small Part B business. I think it's around 2% to 3%. 3% I guess is the right number now.
So it's a very insignificant part. If you look at the importation bill or executive order, it's very similar to what's already been given out to the states. And it excludes biologics which obviously is an important part of our business. If you look at the third one, it's insulin and EpiPen.
We're not in that business. And then the rebate rule. Certainly, as we look at rebates, we're absolutely supportive of patients being able to get the benefit of the discount associated with the rebate or discount. As we've said many times before, for us, whether it's a rebate or a discount is not very material to us.
What I would say is, when I look at that executive order, it does say that you have to be able to implement it without increasing premiums. And everything I know about how rebates are redistributed, I would say that I think that that will be difficult to do. So I don't know how that will ultimately play out, so -- I mean at a high-level look at what we think about them right now. But I think right now, I wouldn't anticipate that they have a significant risk associated with AbbVie.
Liz Shea -- Vice President of Investor Relations
Thanks Vamil. Operator, next question please.
Operator
Thank you. And our next question is from David Risinger from Morgan Stanley.
David Risinger -- Morgan Stanley -- Analyst
Great. Thanks so much and congrats on all of the encouraging updates. So first, Rick, could you please discuss maybe in a little bit more detail the most significant revenue synergy opportunities you see as a result of the combination with Allergan? I know that the combined company can do more with certain franchises. But if you could put some finer points on that that would be very helpful.
Then second, with respect to next year's readouts, AbbVie has a very large pipeline of Phase 2 candidates with proof-of-concept readouts in 2021. But could you point us to the ones that have the biggest commercial potential? So if there is validation in 2021, what are the biggest product opportunities that we should be paying attention to? And then one little tidbit. The Ubrelvy number was $22 million in the quarter. That was strong.
How much stocking was in there? Thank you.
Rick Gonzalez -- Chairman of the Board and Chief Executive Officer
OK. So I'll cover the first one and then I'll have Mike cover the second and Rob can cover the third. So if I look at the business overall, I said that the integration has gone very seamlessly. And I think that's a tribute to all the planning that we did.
We had some extra time to be able to do it and I think that benefited us. And so I think the two organizations have come together in a way that's been quite good. Now I would say I think the places where we have an opportunity to be able to provide some synergy and benefit, certainly, when you look at our therapeutic businesses, when you look at our -- many of the tactical kinds of execution techniques that we use in the marketplace, I think many of those are applicable to the Allergan therapeutic portfolio. Certainly, when you look at managed care, that's an area that we have demonstrated that we're quite skilled at being able to effectively manage our way through that.
And then the third area I'd say is if I look at aesthetics, aesthetics is a very attractive market. It has a significant opportunity to be able to grow that market which I mean by bringing in more people into the market more quickly. You can do that several different ways. Obviously, some of it is driven by promotional activity.
I'd say Allergan is very skilled from a social media standpoint. And I think that's an area that's probably been underfunded. Historically, it's an area that we have a high level of interest in funding to a greater extent. And we obviously have the financial wherewithal to be able to do that.
The second thing is being able to bring more new innovation more rapidly into that market. And I think that's an area that we'll also be able to provide a benefit both in the way we operate R&D and the ability to be able to rapidly innovate. I think that will be a benefit to the overall business. And I think we have an opportunity to be able to accelerate the growth of that business in a meaningful way over time.
And it's a market I like a lot I think both based on demographics, the cash pay aspects of it and how it responds to appropriate innovation in that market. So that's an area that I think, over time, you can expect us to continue to make sure that we're doing what we know how to do to be able to ultimately grow that market over the long term. Those would be some of the things I'd tell you at a high level. Mike?
Michael Severino -- Vice Chairman and President
I'll take the second question. So we do, as you point out, have a number of data readouts from Phase 2 studies or other proof-of-concept studies in 2021 and also in the following years, in 2022 and beyond. And a number of these are very large opportunities. I'd point to our oncology programs.
We have a number of immuno-oncology programs that would be large opportunities if they hit. Our GARP program I think is a very good example of that. Our bispecifics I think are a very good example of that. We just brought in, through the Genmab collaboration, epcoritamab which is a large opportunity.
Obviously, that's post proof of concept. But there are two additional molecules there that are just a little bit earlier in development that could be large opportunities. We have bispecifics in BCMA, more than one program that could be very large opportunities if they were, in fact, best-in-class. And we think they have the potential to be best-in-class.
The last thing I would point to in oncology is our novel, so targeted ADC technology with ABBV-155 being in the lead in non-small cell lung cancer. That is a BCL-XL warhead targeted by a B7-H3 antibody. If that were to hit, and we'd see those data next year, that would be a large opportunity. Obviously, in immunology, we're advancing our TNF steroid program.
But I think those are data that we've already reported out. And then the last thing that I would mention is in our neuroscience portfolio. Obviously, Alzheimer's disease, if those programs were to hit, they would be a very large opportunity, given the enormous unmet medical need. Now obviously, in Alzheimer's disease, it's higher risk, higher reward.
But if we got favorable data, it would be a very, very meaningful opportunity.
Rob Michael -- Executive Vice President and Chief Financial Officer
And David, this is Rob. On Ubrelvy. If you look at just the full quarter revenue of $27 million, it really follows the prescription growth on a sequential basis. So there's really a negligible stocking impact.
And we'd expect to see continued sequential growth for that product.
Liz Shea -- Vice President of Investor Relations
Thanks David. Operator, next question please.
Operator
Thank you. Our next question is from Chris Raymond from Piper Sandler.
Chris Raymond -- Piper Sandler -- Analyst
Thanks. Just back to atogepant in sort of a competitive setup. So Rick, I heard your comments on how this is underappreciated. We've done some checks to see if it indicated that that's the case.
And I know this -- it's not approved yet. So pardon, if you don't mind, the commercial question here. But there's been some chatter out there, especially from some Biohaven boys that placebo-adjusted migraine days maybe don't matter as much as absolute days. And so just maybe, you're in the field with Ubrelvy, from a rep-to-doc dialogue perspective, what do you guys see as the most important attribute, especially as you'll be positioning this in the prevention setting versus subcus and the other oral therapies -- or the other oral therapy that happens to be a dissolving tablet?
Michael Severino -- Vice Chairman and President
Well, this is Mike. I'll take the first part of that and then Rick may want to add. With respect to efficacy, the most important attribute is the placebo-adjusted migraine days. If one were solely to look at the total days, one could conclude that placebo is, in fact, a good therapy for these patients because we see reductions.
And so you have to account for that. And there are differences from study-to-study based on design, population enrolled and what that placebo difference is. So it absolutely has to be taken into account. And when you look at our placebo-adjusted results, they're very strong.
They range between 1.2 and 1.7 days which in this disease area is a very meaningful response rate. And it's higher than what has been reported with other oral agents, obviously with the caveat of a cross-trial comparison. So we think that on the most important efficacy parameter, we performed very, very well. And of course, we've hit all the secondaries across two of those three doses, as I've described.
And as we get the data out into the public domain, you'll get more color on that.
Rick Gonzalez -- Chairman of the Board and Chief Executive Officer
Yeah. I would just reiterate what Mike says. I mean physicians are well skilled in understanding what placebo rates are. And I just don't even think it's appropriate not to represent a product's efficacy without looking at the placebo rate.
So I mean I think that will be the way doctors look at it. And I think that is the way the products will be marketed. And certainly, if I had a lower rate, I may have an interest in that. But at the end of the day, I think that is the appropriate way to look at it.
Chris Raymond -- Piper Sandler -- Analyst
Great. Thank you.
Liz Shea -- Vice President of Investor Relations
Thanks Chris. Operator, next question please.
Operator
Thank you. Our next question is from Tim Anderson from Wolfe Research.
Tim Anderson -- Wolfe Research -- Analyst
Hi. Thank you. A few pipeline questions, please. On the TNF steroid conjugate, some KOLs have a mixed view of that approach.
For those that are skeptical, what's the most common reason that you hear? Second question on Vraylar, what are your odds of regulatory success in depression? Even just qualitatively, is this a high-risk, medium-risk or low-risk endeavor? And then can you clarify why your Genmab CD3xCD20 would be best-in-class?
Michael Severino -- Vice Chairman and President
OK. I'll take those questions. With respect to the TNF steroid conjugate, what I would say is, it's important to keep in mind that this is an early phase trial and this was intended to be a proof-of-concept trial. One can't do a fully powered head-to-head against an active competitor like Humira in Phase 1 or Phase 2 because that typically requires or always requires essentially a large Phase 3 study.
Head-to-head studies are often among the largest studies in a Phase 3 program. So what we were looking for was evidence to support the profile that I described which is that we had a high probability of success in those trials downstream. If folks have a mixed view, then what we hear is they'd like to see those later data. And what I would say is we're well on the path to generating them.
We're pleased with the results that we've seen, and we think it's a very promising platform, and we're going to be advancing into larger-scale trials and people will get the data that they're looking for. With respect to Vraylar in the adjunctive treatment of major depressive disorder, I think the question was how would I characterize the risk there? There already is one positive study in hand. And so of the two studies that are under way, we would need one additional study to read out positive to support the indication. I think that historically, this has been a challenging indication.
But I think the -- both the rationale and the data from earlier studies in the Vraylar program are strong. So I would probably put it in the moderate probability range. We didn't build it into our model. Our success with Vraylar was not dependent on it.
But we think it represents a very attractive upside opportunity if, in fact, it hits. And with respect to why Genmab CD3xCD20 has the potential to be best-in-class? I would point to two things. One is the efficacy data reported from the early phase trials, particularly in DLBCL which is a very difficult-to-treat tumor type, puts it at the higher end of efficacy. And the safety profile has been very favorable in terms of what's been observed to date, both with respect to cytokine release syndrome and the lack of occurrence in the early phase trials of higher-grade CRS and also with respect to the neurological symptoms that can accompany this class of therapy.
So it seems to have threaded that sweet spot between achieving very strong efficacy with a good safety profile. It also has subcu administration with its existing formulation. Others are working toward that. But Genmab already has the data in hand.
And the dosing schedule fits very well into the regimens that will be used in the diseases that we'd study, particularly DLBCL and follicular lymphoma. So we see aggregate of that that we think gives it a very, very strong profile.
Tim Anderson -- Wolfe Research -- Analyst
Thank you.
Liz Shea -- Vice President of Investor Relations
Thanks Tim. Operator, we have time for one final question, please.
Operator
Thank you. Our final question today is from Terence Flynn from Goldman Sachs.
Terence Flynn -- Goldman Sachs -- Analyst
Great. Thanks for taking the question and congrats on the Allergan integration. You mentioned in your comments that Rinvoq uptakes accelerating here, was just wondering if you could provide a little bit more color on that. Is that being driven by COVID and maybe teleprescribing having an advantage over some of the injectables? And if so, do you see that as being a durable change here as we come out of the pandemic? And then the second one I had was just on Venclexta.
I noticed you're running some trials for solid tumors. Maybe just remind us of the rationale here behind that approach. And how optimistic are you there as you move into later stages? Thank you.
Rick Gonzalez -- Chairman of the Board and Chief Executive Officer
OK. Thanks. I'll take the first question. Mike can cover the second one.
So Rinvoq clearly has started to ramp in a fairly significant way. I think it's associated with two things. One is any time you see a pro -- it's about eight months into its launch, you typically start to see that inflection point on successful products. As you go out and you present the data to physicians and start to educate physicians and they start to get some use, you tend to see that inflection point start to happen around six months.
So I think it's the natural inflection point that we would have expected if the product was being successfully accepted into the marketplace the way we hoped as a high-efficacy agent. I think there is some benefit that we're seeing during the COVID crisis that it is an oral, so it's a little easier to prescribe than an injectable might be. So we're probably getting some collateral benefit associated with that. But I don't think that's the fundamental benefit that we're seeing.
Mike?
Michael Severino -- Vice Chairman and President
Right. So I'll take the question with respect to Venclexta in solid tumors. I think there's two different lines of evidence. In breast cancer, there are -- there is an investigator-sponsored study that showed promise in breast cancer.
And so there's a follow-up study there to confirm that. And if that were confirmed, it would be obviously a substantial opportunity, given the unmet need there. And then there are other solid tumors, such as both small cell lung cancer and non-small cell lung cancer, where there's preclinical rationale that warrants exploration. And so I would characterize the solid tumor program as higher risk but high reward, worthy of exploration.
The solid tumor program in Venclexta has not been baked into our thinking and isn't necessary for any of the success that we have talked about with the molecule. But if something were to hit there, represents very nice upside. And I think there's enough rationale to warrant the exploration.
Liz Shea -- Vice President of Investor Relations
OK. Thank you. So that concludes today's conference call. If you'd like to listen to a replay of the call, please visit our website at investors.abbvie.com.
Thanks again for joining us.
Operator
[Operator signoff]
Duration: 83 minutes
Call participants:
Liz Shea -- Vice President of Investor Relations
Rick Gonzalez -- Chairman of the Board and Chief Executive Officer
Michael Severino -- Vice Chairman and President
Rob Michael -- Executive Vice President and Chief Financial Officer
Randall Stanicky -- RBC Capital Markets -- Analyst
Navin Jacob -- UBS -- Analyst
Chris Schott -- J.P. Morgan -- Analyst
Steve Scala -- Cowen and Company -- Analyst
Geoffrey Porges -- SVB Leerink -- Analyst
Vamil Divan -- Mizuho Securities -- Analyst
David Risinger -- Morgan Stanley -- Analyst
Chris Raymond -- Piper Sandler -- Analyst
Tim Anderson -- Wolfe Research -- Analyst
Terence Flynn -- Goldman Sachs -- Analyst
More ABBV analysis
All earnings call transcripts
This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability.
Motley Fool Transcribing has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | With the closing of the Allergan transaction, AbbVie is well positioned for enhanced long-term growth potential, a growing dividend, rapid debt repayment and strong investment in innovation across our therapeutic categories. AbbVie remains well positioned to execute on our capital allocation priorities including rapidly paying down debt, supporting a strong and growing dividend and pursuing additional innovative mid- to late-stage pipeline assets. AbbVie (NYSE: ABBV) Q2 2020 Earnings Call Jul 31, 2020, 9:00 a.m. | Operator [Operator signoff] Duration: 83 minutes Call participants: Liz Shea -- Vice President of Investor Relations Rick Gonzalez -- Chairman of the Board and Chief Executive Officer Michael Severino -- Vice Chairman and President Rob Michael -- Executive Vice President and Chief Financial Officer Randall Stanicky -- RBC Capital Markets -- Analyst Navin Jacob -- UBS -- Analyst Chris Schott -- J.P. Morgan -- Analyst Steve Scala -- Cowen and Company -- Analyst Geoffrey Porges -- SVB Leerink -- Analyst Vamil Divan -- Mizuho Securities -- Analyst David Risinger -- Morgan Stanley -- Analyst Chris Raymond -- Piper Sandler -- Analyst Tim Anderson -- Wolfe Research -- Analyst Terence Flynn -- Goldman Sachs -- Analyst More ABBV analysis All earnings call transcripts This article is a transcript of this conference call produced for The Motley Fool. AbbVie (NYSE: ABBV) Q2 2020 Earnings Call Jul 31, 2020, 9:00 a.m. Welcome to the AbbVie second-quarter 2020earnings conference call [Operator instructions] I would now like to introduce Ms. Liz Shea, vice president of investor relations. | Total revenues were $10.4 billion including approximately $8.4 billion of legacy AbbVie sales, significantly above our expectations for the stand-alone portfolio, with continued robust performance in both hem/onc and immunology despite the impact from COVID. Operator [Operator signoff] Duration: 83 minutes Call participants: Liz Shea -- Vice President of Investor Relations Rick Gonzalez -- Chairman of the Board and Chief Executive Officer Michael Severino -- Vice Chairman and President Rob Michael -- Executive Vice President and Chief Financial Officer Randall Stanicky -- RBC Capital Markets -- Analyst Navin Jacob -- UBS -- Analyst Chris Schott -- J.P. Morgan -- Analyst Steve Scala -- Cowen and Company -- Analyst Geoffrey Porges -- SVB Leerink -- Analyst Vamil Divan -- Mizuho Securities -- Analyst David Risinger -- Morgan Stanley -- Analyst Chris Raymond -- Piper Sandler -- Analyst Tim Anderson -- Wolfe Research -- Analyst Terence Flynn -- Goldman Sachs -- Analyst More ABBV analysis All earnings call transcripts This article is a transcript of this conference call produced for The Motley Fool. AbbVie (NYSE: ABBV) Q2 2020 Earnings Call Jul 31, 2020, 9:00 a.m. | Operator [Operator signoff] Duration: 83 minutes Call participants: Liz Shea -- Vice President of Investor Relations Rick Gonzalez -- Chairman of the Board and Chief Executive Officer Michael Severino -- Vice Chairman and President Rob Michael -- Executive Vice President and Chief Financial Officer Randall Stanicky -- RBC Capital Markets -- Analyst Navin Jacob -- UBS -- Analyst Chris Schott -- J.P. Morgan -- Analyst Steve Scala -- Cowen and Company -- Analyst Geoffrey Porges -- SVB Leerink -- Analyst Vamil Divan -- Mizuho Securities -- Analyst David Risinger -- Morgan Stanley -- Analyst Chris Raymond -- Piper Sandler -- Analyst Tim Anderson -- Wolfe Research -- Analyst Terence Flynn -- Goldman Sachs -- Analyst More ABBV analysis All earnings call transcripts This article is a transcript of this conference call produced for The Motley Fool. AbbVie (NYSE: ABBV) Q2 2020 Earnings Call Jul 31, 2020, 9:00 a.m. Welcome to the AbbVie second-quarter 2020earnings conference call [Operator instructions] I would now like to introduce Ms. Liz Shea, vice president of investor relations. |
24453.0 | 2020-07-30 00:00:00 UTC | Pre-Market Earnings Report for July 31, 2020 : MRK, XOM, CVX, ABBV, CHTR, CAT, D, CL, ITW, AON, LHX, IDXX | ABBV | https://www.nasdaq.com/articles/pre-market-earnings-report-for-july-31-2020-%3A-mrk-xom-cvx-abbv-chtr-cat-d-cl-itw-aon-lhx | nan | nan | The following companies are expected to report earnings prior to market open on 07/31/2020. Visit our Earnings Calendar for a full list of expected earnings releases.
Merck & Company, Inc. (MRK) is reporting for the quarter ending June 30, 2020. The large cap pharmaceutical company's consensus earnings per share forecast from the 4 analysts that follow the stock is $1.14. This value represents a 12.31% decrease compared to the same quarter last year. In the past year MRK has beat the expectations every quarter. The highest one was in the 1st calendar quarter where they beat the consensus by 7.91%. Zacks Investment Research reports that the 2020 Price to Earnings ratio for MRK is 14.92 vs. an industry ratio of 16.40.
Exxon Mobil Corporation (XOM) is reporting for the quarter ending June 30, 2020. The oil company's consensus earnings per share forecast from the 8 analysts that follow the stock is $-0.63. This value represents a 186.30% decrease compared to the same quarter last year. XOM missed the consensus earnings per share in the 4th calendar quarter of 2019 by -6.82%. Zacks Investment Research reports that the 2020 Price to Earnings ratio for XOM is -115.87 vs. an industry ratio of 1.30.
Chevron Corporation (CVX) is reporting for the quarter ending June 30, 2020. The oil company's consensus earnings per share forecast from the 7 analysts that follow the stock is $-0.93. This value represents a 140.97% decrease compared to the same quarter last year. In the past year CVX has beat the expectations every quarter. The highest one was in the 1st calendar quarter where they beat the consensus by 101.56%. Zacks Investment Research reports that the 2020 Price to Earnings ratio for CVX is 112.59 vs. an industry ratio of 1.30, implying that they will have a higher earnings growth than their competitors in the same industry.
AbbVie Inc. (ABBV) is reporting for the quarter ending June 30, 2020. The large cap pharmaceutical company's consensus earnings per share forecast from the 5 analysts that follow the stock is $2.24. This value represents a 0.88% decrease compared to the same quarter last year. In the past year ABBV has beat the expectations every quarter. The highest one was in the 1st calendar quarter where they beat the consensus by 6.61%. Zacks Investment Research reports that the 2020 Price to Earnings ratio for ABBV is 9.28 vs. an industry ratio of 16.40.
Charter Communications, Inc. (CHTR) is reporting for the quarter ending June 30, 2020. The cable tv company's consensus earnings per share forecast from the 14 analysts that follow the stock is $2.53. This value represents a 82.01% increase compared to the same quarter last year. The "days to cover" for this stock exceeds 11 days. Zacks Investment Research reports that the 2020 Price to Earnings ratio for CHTR is 50.39 vs. an industry ratio of 23.30, implying that they will have a higher earnings growth than their competitors in the same industry.
Caterpillar, Inc. (CAT) is reporting for the quarter ending June 30, 2020. The machinery company's consensus earnings per share forecast from the 9 analysts that follow the stock is $0.66. This value represents a 76.68% decrease compared to the same quarter last year. Zacks Investment Research reports that the 2020 Price to Earnings ratio for CAT is 27.08 vs. an industry ratio of 23.10, implying that they will have a higher earnings growth than their competitors in the same industry.
Dominion Energy, Inc. (D) is reporting for the quarter ending June 30, 2020. The electric power utilities company's consensus earnings per share forecast from the 5 analysts that follow the stock is $0.77. This value represents a no change for the same quarter last year. D missed the consensus earnings per share in the 1st calendar quarter of 2020 by -0.91%. Zacks Investment Research reports that the 2020 Price to Earnings ratio for D is 22.66 vs. an industry ratio of 18.20, implying that they will have a higher earnings growth than their competitors in the same industry.
Colgate-Palmolive Company (CL) is reporting for the quarter ending June 30, 2020. The cleaning company's consensus earnings per share forecast from the 7 analysts that follow the stock is $0.71. This value represents a 1.39% decrease compared to the same quarter last year. CL missed the consensus earnings per share in the 2nd calendar quarter of 2019 by -1.37%. Zacks Investment Research reports that the 2020 Price to Earnings ratio for CL is 26.28 vs. an industry ratio of 26.00, implying that they will have a higher earnings growth than their competitors in the same industry.
Illinois Tool Works Inc. (ITW) is reporting for the quarter ending June 30, 2020. The machinery company's consensus earnings per share forecast from the 8 analysts that follow the stock is $0.72. This value represents a 64.00% decrease compared to the same quarter last year. In the past year ITW has beat the expectations every quarter. The highest one was in the 1st calendar quarter where they beat the consensus by 3.51%. Zacks Investment Research reports that the 2020 Price to Earnings ratio for ITW is 35.58 vs. an industry ratio of 68.30.
Aon plc (AON) is reporting for the quarter ending June 30, 2020. The insurance brokers company's consensus earnings per share forecast from the 7 analysts that follow the stock is $1.92. This value represents a 2.67% increase compared to the same quarter last year. Zacks Investment Research reports that the 2020 Price to Earnings ratio for AON is 21.09 vs. an industry ratio of 25.40.
L3Harris Technologies, Inc. (LHX) is reporting for the quarter ending June 30, 2020. The aerospace and defense company's consensus earnings per share forecast from the 7 analysts that follow the stock is $2.62. This value represents a 7.38% increase compared to the same quarter last year. In the past year LHX has beat the expectations every quarter. The highest one was in the 1st calendar quarter where they beat the consensus by 7.28%. Zacks Investment Research reports that the 2020 Price to Earnings ratio for LHX is 15.34 vs. an industry ratio of 8.10, implying that they will have a higher earnings growth than their competitors in the same industry.
IDEXX Laboratories, Inc. (IDXX) is reporting for the quarter ending June 30, 2020. The medical instruments company's consensus earnings per share forecast from the 4 analysts that follow the stock is $1.19. This value represents a 16.78% decrease compared to the same quarter last year. In the past year IDXX has beat the expectations every quarter. The highest one was in the 1st calendar quarter where they beat the consensus by 4.88%. Zacks Investment Research reports that the 2020 Price to Earnings ratio for IDXX is 73.68 vs. an industry ratio of -26.10, implying that they will have a higher earnings growth than their competitors in the same industry.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie Inc. (ABBV) is reporting for the quarter ending June 30, 2020. In the past year ABBV has beat the expectations every quarter. Zacks Investment Research reports that the 2020 Price to Earnings ratio for ABBV is 9.28 vs. an industry ratio of 16.40. | AbbVie Inc. (ABBV) is reporting for the quarter ending June 30, 2020. In the past year ABBV has beat the expectations every quarter. Zacks Investment Research reports that the 2020 Price to Earnings ratio for ABBV is 9.28 vs. an industry ratio of 16.40. | AbbVie Inc. (ABBV) is reporting for the quarter ending June 30, 2020. In the past year ABBV has beat the expectations every quarter. Zacks Investment Research reports that the 2020 Price to Earnings ratio for ABBV is 9.28 vs. an industry ratio of 16.40. | In the past year ABBV has beat the expectations every quarter. AbbVie Inc. (ABBV) is reporting for the quarter ending June 30, 2020. Zacks Investment Research reports that the 2020 Price to Earnings ratio for ABBV is 9.28 vs. an industry ratio of 16.40. |
24454.0 | 2020-07-29 00:00:00 UTC | Why Alector Is Tumbling 28.7% Today | ABBV | https://www.nasdaq.com/articles/why-alector-is-tumbling-28.7-today-2020-07-29 | nan | nan | What happened
Shares in Alector (NASDAQ: ALEC) are tumbling 28.7% at 12:30 p.m. EDT on Wednesday over concerns COVID-19 could negatively impact patient enrollment and monitoring in clinical-stage trials of AL001.
So what
The biotech company's AL001 is being evaluated for use in frontotemporal dementia patients with a progranulin gene (PGRN) mutation.
IMAGE SOURCE: GETTY IMAGES.
On Tuesday, management unveiled preliminary, early-stage data suggesting AL001 is generally safe and well tolerated but that "due to the COVID-19 pandemic, several clinical sites for the phase 2 study were temporarily closed or conducted reduced or remote patient assessments during the evaluation period. As a result, some participants missed a dose of AL001 or missed clinical assessments during the treatment period."
Worry that enrollment in AL001's trials could be slower than expected and missed doses and follow-up visits could create obstacles to analyzing trial results appear to be outweighing otherwise encouraging data.
Specifically, no treatment-related serious adverse events were observed in participants in its phase 1b trial or within the 10 patients initially dosed in its phase 2 study. Additionally, all the participants in its phase 2 study so far have seen a return of plasma progranulin levels to normal range, hinting at AL001's efficacy.
Alector plans on enrolling 40 people in its phase 2 study, and a phase 3 study was initiated in July.
Now what
Frontotemporal dementia is a devastating disease without any treatments approved by the Food and Drug Administration. Of the 170,000 people in the U.S. and European Union with this disease, roughly 15,000 have a mutation that could conceivably be addressed by AL001.
Alector is moving forward with its development timeline for AL001, but investors are right to be a bit cautious. There's a high failure rate in neurodegenerative disease trials, and the impact of COVID-19 on AL001's trials creates uncertainty.
Nevertheless, Alector had $548 million in cash on its balance sheet as of March 31, and it has multiple intriguing drugs in development, including AL002, an Alzheimer's disease drug licensed to AbbVie that's expected to enter phase 2 trials this year. Therefore, this could be an interesting company to keep tabs on.
10 stocks we like better than Alector
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now… and Alector wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of June 2, 2020
Todd Campbell has no position in any of the stocks mentioned. His clients may have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Nevertheless, Alector had $548 million in cash on its balance sheet as of March 31, and it has multiple intriguing drugs in development, including AL002, an Alzheimer's disease drug licensed to AbbVie that's expected to enter phase 2 trials this year. What happened Shares in Alector (NASDAQ: ALEC) are tumbling 28.7% at 12:30 p.m. EDT on Wednesday over concerns COVID-19 could negatively impact patient enrollment and monitoring in clinical-stage trials of AL001. On Tuesday, management unveiled preliminary, early-stage data suggesting AL001 is generally safe and well tolerated but that "due to the COVID-19 pandemic, several clinical sites for the phase 2 study were temporarily closed or conducted reduced or remote patient assessments during the evaluation period. | Nevertheless, Alector had $548 million in cash on its balance sheet as of March 31, and it has multiple intriguing drugs in development, including AL002, an Alzheimer's disease drug licensed to AbbVie that's expected to enter phase 2 trials this year. As a result, some participants missed a dose of AL001 or missed clinical assessments during the treatment period." Specifically, no treatment-related serious adverse events were observed in participants in its phase 1b trial or within the 10 patients initially dosed in its phase 2 study. | Nevertheless, Alector had $548 million in cash on its balance sheet as of March 31, and it has multiple intriguing drugs in development, including AL002, an Alzheimer's disease drug licensed to AbbVie that's expected to enter phase 2 trials this year. Specifically, no treatment-related serious adverse events were observed in participants in its phase 1b trial or within the 10 patients initially dosed in its phase 2 study. See the 10 stocks *Stock Advisor returns as of June 2, 2020 Todd Campbell has no position in any of the stocks mentioned. | Nevertheless, Alector had $548 million in cash on its balance sheet as of March 31, and it has multiple intriguing drugs in development, including AL002, an Alzheimer's disease drug licensed to AbbVie that's expected to enter phase 2 trials this year. Alector plans on enrolling 40 people in its phase 2 study, and a phase 3 study was initiated in July. See the 10 stocks *Stock Advisor returns as of June 2, 2020 Todd Campbell has no position in any of the stocks mentioned. |
24455.0 | 2020-07-29 00:00:00 UTC | AbbVie Announces Positive Late-stage Data For Atogepant In Migraine Prevention | ABBV | https://www.nasdaq.com/articles/abbvie-announces-positive-late-stage-data-for-atogepant-in-migraine-prevention-2020-07-29 | nan | nan | (RTTNews) - AbbVie (ABBV) said that the Phase 3 ADVANCE trial evaluating the investigational medicine atogepant, an orally administered calcitonin gene-related peptide receptor antagonist or gepant met its primary endpoint of statistically significantly greater reduction in mean monthly migraine days, compared to placebo, for all doses across the 12-week treatment period.
The trial also demonstrated statistically significant improvements in all six secondary endpoints in the 30 mg and 60 mg once-daily treatment arms.
The company said it plans to move forward with regulatory submissions in the United States and other countries, based on the data from the trial and previous Phase 2/3 trial.
The company noted that the results support its commitment to providing multiple treatment options, including BOTOX (onabotulinumtoxinA) for the prevention of chronic migraine and UBRELVY (ubrogepant), to treat migraine.
Migraine is a complex, chronic disease with episodic attacks that are often incapacitating and characterized by headache pain as well as neurologic and autonomic symptoms.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - AbbVie (ABBV) said that the Phase 3 ADVANCE trial evaluating the investigational medicine atogepant, an orally administered calcitonin gene-related peptide receptor antagonist or gepant met its primary endpoint of statistically significantly greater reduction in mean monthly migraine days, compared to placebo, for all doses across the 12-week treatment period. The company noted that the results support its commitment to providing multiple treatment options, including BOTOX (onabotulinumtoxinA) for the prevention of chronic migraine and UBRELVY (ubrogepant), to treat migraine. Migraine is a complex, chronic disease with episodic attacks that are often incapacitating and characterized by headache pain as well as neurologic and autonomic symptoms. | (RTTNews) - AbbVie (ABBV) said that the Phase 3 ADVANCE trial evaluating the investigational medicine atogepant, an orally administered calcitonin gene-related peptide receptor antagonist or gepant met its primary endpoint of statistically significantly greater reduction in mean monthly migraine days, compared to placebo, for all doses across the 12-week treatment period. The trial also demonstrated statistically significant improvements in all six secondary endpoints in the 30 mg and 60 mg once-daily treatment arms. The company noted that the results support its commitment to providing multiple treatment options, including BOTOX (onabotulinumtoxinA) for the prevention of chronic migraine and UBRELVY (ubrogepant), to treat migraine. | (RTTNews) - AbbVie (ABBV) said that the Phase 3 ADVANCE trial evaluating the investigational medicine atogepant, an orally administered calcitonin gene-related peptide receptor antagonist or gepant met its primary endpoint of statistically significantly greater reduction in mean monthly migraine days, compared to placebo, for all doses across the 12-week treatment period. The company noted that the results support its commitment to providing multiple treatment options, including BOTOX (onabotulinumtoxinA) for the prevention of chronic migraine and UBRELVY (ubrogepant), to treat migraine. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - AbbVie (ABBV) said that the Phase 3 ADVANCE trial evaluating the investigational medicine atogepant, an orally administered calcitonin gene-related peptide receptor antagonist or gepant met its primary endpoint of statistically significantly greater reduction in mean monthly migraine days, compared to placebo, for all doses across the 12-week treatment period. The trial also demonstrated statistically significant improvements in all six secondary endpoints in the 30 mg and 60 mg once-daily treatment arms. The company said it plans to move forward with regulatory submissions in the United States and other countries, based on the data from the trial and previous Phase 2/3 trial. |
24456.0 | 2020-07-26 00:00:00 UTC | 3 Coronavirus Stocks With the Highest Dividend Yields | ABBV | https://www.nasdaq.com/articles/3-coronavirus-stocks-with-the-highest-dividend-yields-2020-07-26 | nan | nan | Great growth prospects might be the first thing that comes to mind when you think about coronavirus stocks. And several companies with COVID-19 programs certainly do have strong growth opportunities.
On the other hand, it's likely that dividends wouldn't be the first thought on most investors' minds when the topic of coronavirus stocks arises. But there actually are quite a few companies focused on developing COVID-19 tests, therapies, and vaccines that offer attractive dividends. Here are three coronavirus stocks with the highest dividend yields.
Image source: Getty Images.
1. Takeda Pharmaceutical
Takeda Pharmaceutical (NYSE: TAK) ranks at the top of the list of high-yielding coronavirus stocks with a dividend yield of 4.83%. However, the Japanese drugmaker's dividend track record isn't as impressive. Takeda's dividend has fallen more than 20% over the last 10 years.
The company's efforts to fight COVID-19 don't get as much attention as some of its rivals. Takeda is collaborating with other companies to develop a hyperimmune globulin (H-IG) candidate targeting COVID-19. H-IGs are plasma-derived therapies that have demonstrated efficacy in treating other severe viral infections.
Takeda's lineup includes several drugs that should continue to drive growth. These include inflammatory bowel disease drug Entyvio and antidepressant Trintellix. The company also anticipates a significant expansion in China with prospects of more than 15 drug approvals over the next five years.
Some investors might be concerned that Takeda's debt could impact the company's ability to keep its dividend at current levels. However, Takeda is quickly paying down its debt. Chief Financial Officer Costa Saroukos stated in the company's quarterly conference call in May that Takeda has "great confidence in our ability to maintain the dividend at this level."
2. AbbVie
AbbVie (NYSE: ABBV) runs neck-and-neck with Takeda. The big drugmaker's dividend currently yields 4.81%. In addition, AbbVie is a Dividend Aristocrat with 47 consecutive years of dividend increases.
The company's HIV drug Kaletra flopped in a clinical study targeting COVID-19 earlier this year. However, AbbVie is evaluating Imbruvica in a phase 2 study to see if its cancer drug can reduce severe immune responses known as cytokine storms in COVID-19 patients. It also teamed up with Harbour BioMed, Utrecht University, and Erasmus Medical Center to develop an antibody therapy candidate to prevent and treat COVID-19.
AbbVie might not be able to deliver exceptional earnings growth over the next few years to go along with its attractive dividend. The company's top-selling drug, Humira, faces competition from biosimilars in the U.S. beginning in 2023.
Still, though, AbbVie shouldn't have any problems keeping the dividends flowing. Its lineup includes several other drugs for which sales are growing briskly, notably including blood cancer drugs Imbruvica and Venclexta and new autoimmune-disease drugs Rinvoq and Skyrizi. AbbVie's recent acquisition of Allergan will also reduce its dependence on Humira.
3. GlaxoSmithKline
GlaxoSmithKline (NYSE: GSK) comes in third place after AbbVie. The London-based pharmaceutical company offers a dividend that currently yields 4.59%.
Two of the 24 or counting COVID-19 vaccine candidates in clinical testing have direct connections with GSK. Clover Pharmaceuticals and Medicago each have candidates in phase 1 clinical trials that use GSK's adjuvant technology. GSK also partnered with Sanofi to develop a COVID-19 vaccine candidate that's expected to begin clinical testing this year.
GSK faces several headwinds. Sales for older products, particularly respiratory drug Advair, continue to weigh on the company's growth. HIV drugs Tivicay and Triumeq are also losing market share. The company expects its earnings to decline year over year in 2020. Analysts project low single-digit-percentage earnings growth over the next five years.
The good news is that GSK's dividend doesn't appear to be in jeopardy. The company has several products for which sales are soaring, including respiratory drug Trelegy Ellipta, HIV drugs Juluca and Dovato, and shingles vaccine Shingrix. Momentum for these and some of GSK's other products should generate sufficient cash flow to keep the dividend yield relatively high.
10 stocks we like better than GlaxoSmithKline
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and GlaxoSmithKline wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of June 2, 2020
Keith Speights owns shares of AbbVie. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | However, AbbVie is evaluating Imbruvica in a phase 2 study to see if its cancer drug can reduce severe immune responses known as cytokine storms in COVID-19 patients. AbbVie AbbVie (NYSE: ABBV) runs neck-and-neck with Takeda. In addition, AbbVie is a Dividend Aristocrat with 47 consecutive years of dividend increases. | AbbVie AbbVie (NYSE: ABBV) runs neck-and-neck with Takeda. In addition, AbbVie is a Dividend Aristocrat with 47 consecutive years of dividend increases. However, AbbVie is evaluating Imbruvica in a phase 2 study to see if its cancer drug can reduce severe immune responses known as cytokine storms in COVID-19 patients. | In addition, AbbVie is a Dividend Aristocrat with 47 consecutive years of dividend increases. AbbVie AbbVie (NYSE: ABBV) runs neck-and-neck with Takeda. However, AbbVie is evaluating Imbruvica in a phase 2 study to see if its cancer drug can reduce severe immune responses known as cytokine storms in COVID-19 patients. | AbbVie AbbVie (NYSE: ABBV) runs neck-and-neck with Takeda. In addition, AbbVie is a Dividend Aristocrat with 47 consecutive years of dividend increases. However, AbbVie is evaluating Imbruvica in a phase 2 study to see if its cancer drug can reduce severe immune responses known as cytokine storms in COVID-19 patients. |
24457.0 | 2020-07-25 00:00:00 UTC | 2 Market-Beating Dividend Stocks With Above-Average Payouts | ABBV | https://www.nasdaq.com/articles/2-market-beating-dividend-stocks-with-above-average-payouts-2020-07-25 | nan | nan | It's been a volatile year in the markets, and the S&P 500's returns are flat year to date. While that's good news for investors who were fearing the worst (a prolonged market crash) in March, 2020's still been a lousy year for many stocks. But two stocks have been the exception to the norm, outperforming the markets and also paying dividends of 3% or more. Here are two gems to consider adding to your portfolio right now:
1. AbbVie
AbbVie (NYSE: ABBV) is an even stronger, more versatile healthcare stock to hold in your portfolio now that it's completed its $63 billion acquisition of Botox maker Allergan. AbbVie made the announcement on May 8 that the deal was final, calling it a "turning point" that will allow the now stronger biopharmaceutical company to not only become more diversified with a wider range of products, but also to have the "financial strength" to continue innovating and investing in new products.
Image source: Getty Images.
One of the newest drugs in AbbVie's portfolio as a result of the acquisition is migraine treatment Ubrelvy, which the Food and Drug Administration approved late last year. AbbVie will release its second-quarter results on July 31, the first report since closing the deal with Allergan.
When the Illinois-based company released its first-quarter results on May 1, its net sales of $8.6 billion were up over 10% year over year. The company's arthritis drug, Humira, drove a lot of that growth with its sales up 5.8% from the prior-year period. It also got a boost from Skyrizi, which treats plaque psoriasis. The drug added $300 million in revenue in Q1; in the same period a year ago, it wasn't yet contributing anything to AbbVie's top line.
The company's net earnings of more than $3 billion were also strong, up 23% from the prior-year period. AbbVie's been doing well of late, and the addition of Allergan into the mix should only make it a better buy over the long run.
Year to date, the stock's up around 11% and it currently pays a quarterly dividend of $1.18, which yields 4.8% annually -- well above the S&P 500 average of 2%. The stock's also a Dividend Aristocrat, having increased its dividend payments for more than 25 years in a row, which includes when it was still a part of Abbott Labs.
2. General Mills
General Mills (NYSE: GIS) is another top stock that's doing well this year. Up over 21%, it's been soundly beating both the S&P 500 and AbbVie. The packaged foods company has been prospering amid the COVID-19 pandemic as consumers are stocking up on essentials to make meals at home.
On July 1, the Minnesota-based company released its full-year results for fiscal 2020. While net sales for the full year rose by just 5%, in the fourth quarter they were up a staggering 21% from the prior-year period, which the company says is due to the pandemic and "a significant increase in at-home food demand."
Operating profit during the quarter rose by 16%, which was in line with the 17% increase General Mills generated for the full year. In the previous year, however, the company's operating profit grew by just 4%.
General Mills pays a quarterly dividend of $0.49, which today yields just a shade over 3% per year. The last time the company increased its payouts was in 2017.
Which stock is the better buy today?
It may be tempting to look at General Mills' stock, see a high performer, and want to climb aboard the bandwagon.
However, investors need to remember that 2020 is turning into an odd year, driven by the COVID-19 pandemic. Once the pandemic's over, people will likely return to their old routines, including eating out and making fewer meals at home. Consistent double-digit sales growth just isn't a realistic expectation investors should have for General Mills. The last year the company produced that kind of revenue growth was in fiscal 2012, when sales were up 12% from the previous year.
AbbVie, with its incorporation of Allergan, looks to be in a better position to generate more sustainable sales growth in future years now that it has a more diversified portfolio of drugs to work with. And with a higher dividend yield, it gives investors the best mix of possible sales growth and recurring income.
10 stocks we like better than General Mills
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and General Mills wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of June 2, 2020
David Jagielski has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The drug added $300 million in revenue in Q1; in the same period a year ago, it wasn't yet contributing anything to AbbVie's top line. AbbVie, with its incorporation of Allergan, looks to be in a better position to generate more sustainable sales growth in future years now that it has a more diversified portfolio of drugs to work with. AbbVie AbbVie (NYSE: ABBV) is an even stronger, more versatile healthcare stock to hold in your portfolio now that it's completed its $63 billion acquisition of Botox maker Allergan. | AbbVie AbbVie (NYSE: ABBV) is an even stronger, more versatile healthcare stock to hold in your portfolio now that it's completed its $63 billion acquisition of Botox maker Allergan. AbbVie made the announcement on May 8 that the deal was final, calling it a "turning point" that will allow the now stronger biopharmaceutical company to not only become more diversified with a wider range of products, but also to have the "financial strength" to continue innovating and investing in new products. One of the newest drugs in AbbVie's portfolio as a result of the acquisition is migraine treatment Ubrelvy, which the Food and Drug Administration approved late last year. | AbbVie AbbVie (NYSE: ABBV) is an even stronger, more versatile healthcare stock to hold in your portfolio now that it's completed its $63 billion acquisition of Botox maker Allergan. AbbVie made the announcement on May 8 that the deal was final, calling it a "turning point" that will allow the now stronger biopharmaceutical company to not only become more diversified with a wider range of products, but also to have the "financial strength" to continue innovating and investing in new products. One of the newest drugs in AbbVie's portfolio as a result of the acquisition is migraine treatment Ubrelvy, which the Food and Drug Administration approved late last year. | AbbVie, with its incorporation of Allergan, looks to be in a better position to generate more sustainable sales growth in future years now that it has a more diversified portfolio of drugs to work with. AbbVie AbbVie (NYSE: ABBV) is an even stronger, more versatile healthcare stock to hold in your portfolio now that it's completed its $63 billion acquisition of Botox maker Allergan. AbbVie made the announcement on May 8 that the deal was final, calling it a "turning point" that will allow the now stronger biopharmaceutical company to not only become more diversified with a wider range of products, but also to have the "financial strength" to continue innovating and investing in new products. |
24458.0 | 2020-07-24 00:00:00 UTC | ESGV, FB, ABBV, COST: ETF Inflow Alert | ABBV | https://www.nasdaq.com/articles/esgv-fb-abbv-cost%3A-etf-inflow-alert-2020-07-24 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard ESG U.S. Stock ETF (Symbol: ESGV) where we have detected an approximate $109.1 million dollar inflow -- that's a 7.1% increase week over week in outstanding units (from 25,950,000 to 27,800,000). Among the largest underlying components of ESGV, in trading today Facebook Inc (Symbol: FB) is off about 1.2%, AbbVie Inc (Symbol: ABBV) is down about 0.9%, and Costco Wholesale Corp (Symbol: COST) is lower by about 0.1%. For a complete list of holdings, visit the ESGV Holdings page » The chart below shows the one year price performance of ESGV, versus its 200 day moving average:
Looking at the chart above, ESGV's low point in its 52 week range is $38.85 per share, with $60.172 as the 52 week high point — that compares with a last trade of $58.60. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ».
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of ESGV, in trading today Facebook Inc (Symbol: FB) is off about 1.2%, AbbVie Inc (Symbol: ABBV) is down about 0.9%, and Costco Wholesale Corp (Symbol: COST) is lower by about 0.1%. For a complete list of holdings, visit the ESGV Holdings page » The chart below shows the one year price performance of ESGV, versus its 200 day moving average: Looking at the chart above, ESGV's low point in its 52 week range is $38.85 per share, with $60.172 as the 52 week high point — that compares with a last trade of $58.60. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of ESGV, in trading today Facebook Inc (Symbol: FB) is off about 1.2%, AbbVie Inc (Symbol: ABBV) is down about 0.9%, and Costco Wholesale Corp (Symbol: COST) is lower by about 0.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard ESG U.S. Stock ETF (Symbol: ESGV) where we have detected an approximate $109.1 million dollar inflow -- that's a 7.1% increase week over week in outstanding units (from 25,950,000 to 27,800,000). For a complete list of holdings, visit the ESGV Holdings page » The chart below shows the one year price performance of ESGV, versus its 200 day moving average: Looking at the chart above, ESGV's low point in its 52 week range is $38.85 per share, with $60.172 as the 52 week high point — that compares with a last trade of $58.60. | Among the largest underlying components of ESGV, in trading today Facebook Inc (Symbol: FB) is off about 1.2%, AbbVie Inc (Symbol: ABBV) is down about 0.9%, and Costco Wholesale Corp (Symbol: COST) is lower by about 0.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard ESG U.S. Stock ETF (Symbol: ESGV) where we have detected an approximate $109.1 million dollar inflow -- that's a 7.1% increase week over week in outstanding units (from 25,950,000 to 27,800,000). For a complete list of holdings, visit the ESGV Holdings page » The chart below shows the one year price performance of ESGV, versus its 200 day moving average: Looking at the chart above, ESGV's low point in its 52 week range is $38.85 per share, with $60.172 as the 52 week high point — that compares with a last trade of $58.60. | Among the largest underlying components of ESGV, in trading today Facebook Inc (Symbol: FB) is off about 1.2%, AbbVie Inc (Symbol: ABBV) is down about 0.9%, and Costco Wholesale Corp (Symbol: COST) is lower by about 0.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard ESG U.S. Stock ETF (Symbol: ESGV) where we have detected an approximate $109.1 million dollar inflow -- that's a 7.1% increase week over week in outstanding units (from 25,950,000 to 27,800,000). For a complete list of holdings, visit the ESGV Holdings page » The chart below shows the one year price performance of ESGV, versus its 200 day moving average: Looking at the chart above, ESGV's low point in its 52 week range is $38.85 per share, with $60.172 as the 52 week high point — that compares with a last trade of $58.60. |
24459.0 | 2020-07-24 00:00:00 UTC | 5 High-Yield Drug Stocks That Are Undervalued With Great Upside | ABBV | https://www.nasdaq.com/articles/5-high-yield-drug-stocks-that-are-undervalued-with-great-upside-2020-07-24 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
These five high yield drug stocks pay dividends with attractive yields, and also are undervalued. And as a result, these stocks offer good upside potential to investors. As a group, they are cheap. Yet, they have solid earnings that cover their dividends, plus good growth prospects.
I wanted to find these high-yield drug stocks since there is a lot of news out there about pharmaceutical companies that are trying to find a vaccine. I figured some of these larger drug companies can be both innovative and also have a diversified level of income.
This helps the pharmaceutical company satisfy the return objectives of its existing investors. However, they also offer enough growth prospects to provide upside potential for new investors.
For example, the average upside of this group of drug stocks is over 38%. Yet, the average dividend yield is 4.1% and the average price-to-earnings ratio (P/E) is just 12.5 times. This is for earnings estimated for fiscal year 2021, and it is very cheap.
10 Cybersecurity Stocks We Need Now More Than Ever
That said, the five high yield drug stocks are:
AbbVie (NYSE:ABBV)
GlaxoSmithKline (NYSE:GSK)
Novartis (NYSE:NVS)
Pfizer (NYSE:PFE)
Sanofi (NASDAQ:SNY)
So, with all of that in mind, let’s dive in.
High-Yield Drug Stocks: AbbVie (ABBV)
Click to Enlarge
Source: Mark R. Hake, CFA
Market Value: $170 billion
Forward P/E: 8.3x
Dividend Yield: 4.8%
Target Price Upside: 87%
AbbVie stock is a large $170 billion market capitalization drug stock that is both cheap and has a very attractive dividend yield. In addition, its growth prospects are high. In fact, it recently closed on the $63 billion acquisition of Allergan.
Allergan is well known for its Botox and other beauty products. In turn, the deal will help AbbVie diversify its earnings and “buys time” before its arthritis drug Humira goes off-patent in 2023.
Overall, that is why AbbVie is so cheap. It accounted for over 54% of the company’s sales as of first quarter of FY2020. The market assumes that generic drugs will eventually overtake that revenue stream for AbbVie, but things are not as bad as that.
With Allergan, Humira will account for only 38.4% of sales. And given that other drugs in AbbVie’s portfolio are likely growing faster than Humira, that portion will continue to fall.
Moreover, ABBV stock has a history of paying consistent quarterly dividends that tend to rise each year. You can see this in the chart here.
Click to Enlarge
Source: Mark R. Hake, CFA
Based on my analysis of the stock, it is worth at least 81% more than today’s price.
For example, the company’s historical yield over the last four years is 4.22%. Given today’s yield of 4.8%, that implies AbbVie stock is worth almost 15% more than today.
Also, based on its historical P/E ratio, the stock is worth over double today’s price. And lastly, based on a comparison with its peers, the stock should have an 80% higher price. Averaging these three methods, AbbVie stock is worth $182.30, or 87% more than today.
Therefore, ABBV stock is one of the top drug stocks available.
GlaxoSmithKline (GSK)
Click to Enlarge
Source: Mark R. Hake, CFA
Market Value: $100 billion
Forward P/E: 13.8x
Dividend Yield: 4.5%
Target Price Upside: 24%
GlaxoSmithKline is the world’s largest vaccine maker, and the UK-headquartered company is relying on proven methods of making a vaccine. In fact, Reuters says it prefers the “slow and steady approach of focusing on an established technology that has the best chance of reaching the widest possible demographic.”
They recognize that the world will need billions of doses, and therefore are not worried if they are first to market with a vaccine. Many other vaccine makers will not have the capacity to match what GlaxoSmithKline can do quickly. And once its vaccine is ready — which, only started its trials in June — it can make large amounts.A
Additionally, GlaxoSmithKline believes its vaccine will have better efficacy and last longer. This may mean it can work better with the elderly.
As Barron’s points out, the company has a huge pipeline of drugs, including options for cancer and HIV prevention. GlaxoSmithKline also plans on spinning off its consumer health division, which makes Advil and Panadol.
Moreover, GSK stock has a history of paying consistent quarterly dividends that tend to have a higher year-end dividend each year. You can see this is true in the chart here.
Click to Enlarge
Source: Mark R. Hake, CFA
So, based on my analysis of the stock, it is worth at least 24% more than today’s price.
For example, the company’s historical price-to-earnings over the last four years is 25 times. Given today’s P/E ratio of 14 times this year and 13.8 times next year, that implies GSK stock is worth almost 84% more than today.
And lastly, based on a comparison with its peers, the stock should be much higher. Averaging three valuations methods, GSK stock is worth $51.51, or 24% more than today.
7 Semiconductor Stocks Ready for Big Growth
Collectively, GSK stock is another one to keep your eye on.
Novartis (NVS)
Click to Enlarge
Source: Mark R. Hake, CFA
Market Value: $194 billion
Forward P/E: 14.1x
Dividend Yield: 3.6%
Target Price Upside: 17%
Novartis, a Swiss company, owns Sandoz, a well-known drug company. Sandoz plans on giving away 15 of its generic drugs that treat symptoms of COVID-19 to developing countries. In June, it agreed to $729 million in fines with the U.S. government to settle charges it paid kickbacks to doctors and patients.
Moreover, Novartis will start a Covid-19 clinical trial of their cancer drug, Jakafi, which was developed by Incyte Corp.(NASDAQ:INCY). In turn, Novartis sells the drug outside the U.S. Barron’s recently described the use of this cancer drug for a Covid-19 trial, and how Jakafi could help patients suffering severe immune overreactions caused by Covid-19.
Novartis and Incyte have a Phase 3 trial, comparing those who use it with Covid-19 and those with Covid-19 who don’t. The drug could eliminate hospital intensive care and mechanical breathing assistance. In fact, this drug is one of many in the category of existing drugs that could potentially act as a treatment for Covid-19.
Investors should also consider its attractive 3.6% dividend yield. NVS stock has consistently paid annual dividends that reflect its profitability,and you can see this in the chart.
Click to Enlarge
Source: Mark R. Hake, CFA
Therefore, based on my analysis, it is worth at least 17% more than today’s price.
For example, its historical price-to-earnings over the last four years is 21 times. And given today’s P/E ratio of 14 times this year, NVS stock is worth almost 46% more than today.
Finally, based on a comparison with its peers, the stock should be much higher. Averaging three valuations methods, NVS stock is worth $100.62, or 17% more than today — making NVS stock another great drug stock.
Pfizer (PFE)
Click to Enlarge
Source: Mark R. Hake, CFA
Market Value: $204 billion
Forward P/E: 11.8x
Dividend Yield: 4.1%
Target Price Upside: 34%
Pfizer recently indicated that its Covid-19 vaccine trials will be rolled out very quickly. On that note, Barron’s reported that analysts believe the aggressive timeline was “laudable, but seems challenging.” One analyst believes that the positive vaccine data and the trial timeline will act as a “catalyst” for PFE stock.
Moreover, Pfizer is working in collaboration with a German company, BioNtech (NASDAQ:BNTX), on this vaccine. And according to Barron’s, all 24 patients who received lower doses of the vaccine developed levels of neutralizing antibodies after 28 days. These levels were about two times higher than those found in patients who have recovered from the coronavirus.
On July 13, the FDA gave the companies’ vaccine trial a “fast track” status. The two vaccines, BNT162b1 and BNT162b2, could get “priority review” leading to approval within six months. By comparison, Moderna (NASDAQ:MRNA) which uses similar technology, according to Reuters, got this fast track status in May.
Nevertheless, this could why PFE stock has been rising. There are also valuation-related reasons to buy the stock.
PFE stock has a history of paying consistent quarterly dividends that tend to rise each year. You can see this in the chart here.
Click to Enlarge
Source: Mark R. Hake, CFA
Based on my analysis of the stock, it is worth at least 34% more than today’s price.
For example, its historical yield over the last four years is 3.77%. And given today’s yield of 4.1%, PFE stock is worth almost 10% more than today.
4 Underappreciated Tech Stocks to Buy Now Before They Rise
Averaging three valuation methods PFE stock is worth $49.15, or 34% more than today.
Sanofi (SNY)
Click to Enlarge
Source: Mark R. Hake, CFA
Market Value: $134 billion
Forward P/E: 14.4x
Dividend Yield: 3.2%
Target Price Upside: 29%
Sanofi is also in the Covid-19 vaccine race as well. In late June, Sanofi partnered with another company, Translate Bio (NASDAQ:TBIO). The companies have worked together before, and use a messenger RNA technology like Moderna and Pfizer/BioNTech for their Covid-19 vaccine drug. In turn, this technology induces antibodies for a specific protein related to the novel coronavirus.
Also, Sanofi’s Pasteur division is going to spend $1.9 billion to get a vaccine by mid-2021, with trials are expected to start in Q4. Therefore, Sanofi offers both capital and a huge vaccine manufacturing capability to Translate Bio.
Moreover, SNY stock has a history of paying consistent annual dividends that reflect its profitability each year. You can see this in the given chart.
Click to Enlarge
Source: Mark R. Hake, CFA
So, based on my analysis of the stock, it is worth at least 29% more than today’s price.
For example, its historical price-to-earnings over the last four years is 40 times. Given today’s P/E ratio of 35 times this year and 14.4 times next year, SNY stock is worth almost 43% more than today.
Lastly, based on a comparison with its peers, SNY stock should be 6 to 7% higher. Averaging three valuations methods, SNY stock is worth $68.80, or 29% more than today. And with all of that in mind, PFE is one of the best drug stocks on the market.
Summary: High Yield Drug Stocks
These high yield drug stocks are admirable in that most of them are developing Covid-19 vaccines. In addition, they also have attractive dividends with attractive upside potential.
Source: Mark R. Hake, CFA
Overall, these are not day trades or momentum stocks. On the other hand, though, they are solidly profitable and can afford their high-yield dividends. They are likely to reach their target upside.
Moreover, this chart sows that the average dividend yield is 4.1% for this group of stocks. They also boast a low average P/E at 12.5 times, and offer a potential upside of almost 38%. That is a very respectable ROI for most investors.
Therefore, for these reasons, these five high-yielding drug stocks could be great options for investors.
Mark Hake runs the Total Yield Value Guide which you can review here. The Guide focuses on high total yield value stocks. Subscribers receive a two-week free trial.As of this writing, Mark does not hold a position in any of the aforementioned securities.
The post 5 High-Yield Drug Stocks That Are Undervalued With Great Upside appeared first on InvestorPlace.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | 10 Cybersecurity Stocks We Need Now More Than Ever That said, the five high yield drug stocks are: AbbVie (NYSE:ABBV) GlaxoSmithKline (NYSE:GSK) Novartis (NYSE:NVS) Pfizer (NYSE:PFE) Sanofi (NASDAQ:SNY) So, with all of that in mind, let’s dive in. High-Yield Drug Stocks: AbbVie (ABBV) Click to Enlarge Source: Mark R. Hake, CFA Market Value: $170 billion Forward P/E: 8.3x Dividend Yield: 4.8% Target Price Upside: 87% AbbVie stock is a large $170 billion market capitalization drug stock that is both cheap and has a very attractive dividend yield. | 10 Cybersecurity Stocks We Need Now More Than Ever That said, the five high yield drug stocks are: AbbVie (NYSE:ABBV) GlaxoSmithKline (NYSE:GSK) Novartis (NYSE:NVS) Pfizer (NYSE:PFE) Sanofi (NASDAQ:SNY) So, with all of that in mind, let’s dive in. Click to Enlarge Source: Mark R. Hake, CFA Market Value: $170 billion Forward P/E: 8.3x Dividend Yield: 4.8% Target Price Upside: 87% AbbVie stock is a large $170 billion market capitalization drug stock that is both cheap and has a very attractive dividend yield. High-Yield Drug Stocks: AbbVie (ABBV) | Click to Enlarge Source: Mark R. Hake, CFA Market Value: $170 billion Forward P/E: 8.3x Dividend Yield: 4.8% Target Price Upside: 87% AbbVie stock is a large $170 billion market capitalization drug stock that is both cheap and has a very attractive dividend yield. 10 Cybersecurity Stocks We Need Now More Than Ever That said, the five high yield drug stocks are: AbbVie (NYSE:ABBV) GlaxoSmithKline (NYSE:GSK) Novartis (NYSE:NVS) Pfizer (NYSE:PFE) Sanofi (NASDAQ:SNY) So, with all of that in mind, let’s dive in. High-Yield Drug Stocks: AbbVie (ABBV) | Click to Enlarge Source: Mark R. Hake, CFA Market Value: $170 billion Forward P/E: 8.3x Dividend Yield: 4.8% Target Price Upside: 87% AbbVie stock is a large $170 billion market capitalization drug stock that is both cheap and has a very attractive dividend yield. 10 Cybersecurity Stocks We Need Now More Than Ever That said, the five high yield drug stocks are: AbbVie (NYSE:ABBV) GlaxoSmithKline (NYSE:GSK) Novartis (NYSE:NVS) Pfizer (NYSE:PFE) Sanofi (NASDAQ:SNY) So, with all of that in mind, let’s dive in. High-Yield Drug Stocks: AbbVie (ABBV) |
24460.0 | 2020-07-23 00:00:00 UTC | The 8 Most Reliable Blue-Chip Stocks In the Market Today | ABBV | https://www.nasdaq.com/articles/the-8-most-reliable-blue-chip-stocks-in-the-market-today-2020-07-23 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Buying blue-chip stocks usually comes with the idea that you’re not really going to be wringing all the best out of growth in the markets.
You get big, diversified companies that are built for stability rather than speed.
But nothing can be further from the truth.
First, there is now a shift from growth to value stocks going on with institutional investors. And they represent a vast majority of the trading happening day to day.
These kinds of rotations into one sector and out of another are massive. And this one presents a great opportunity for smart investors to buy big, quality stocks that will now get a significant tailwind from this new sector rotation.
Second, many of these blue-chip stocks are already on fire because they represent the best in their industries and during the pandemic they have continued to be market leaders. Others are part of significant trends that have been in place and will continue to grow.
These 7 Robinhood Stocks Have the Legs for Future Gains
The eight most reliable blue-chip stocks in the market today won’t be surprises, but they are important stocks to own.
Amazon (NASDAQ:AMZN)
Apple (NASDAQ:AAPL)
Microsoft (NASDAQ:MSFT)
Dollar General (NYSE:DG)
AbbVie (NYSE:ABBV)
Walmart (NYSE:WMT)
Visa (NYSE:V)
Procter & Gamble (NYSE:PG)
Here’s a look at what makes each a dependable investment today.
Blue-Chip Stocks to Buy: Amazon (AMZN)
AMZN) logistics center in Szczecin, Poland." width="300" height="169">
Source: Mike Mareen / Shutterstock.com
Unless you have been living under a rock for the past decade, you have a good idea what a massive force this company has been, not only for retail, but also in the cloud computing space.
Remember, that even today, its Amazon Web Services (AWS) division makes up a lion’s share of the company’s overall operating profits and it continues to outpace the growth of the overall company.
Combine that with the massive revenue the retail and advertising sectors add and you have massive, cash-rich juggernaut.
And during the pandemic lockdowns, AMZN demand grew significantly. AMZN stock is up 63% year to date for good reason. And that momentum hasn’t slowed.
Apple (AAPL)
AAPL) iPhone SE with a wooden table in the background" width="300" height="169">
Source: George Dolgikh / Shutterstock.com
This beacon of consumer electronics companies has finally become a media contender. By that, I mean Apple TV.
The challenge with creating a “walled garden” of equipment and software (i.e., Apple products support Apple devices) is that when you want to break out into the broader world of non-Apple consumers, it can be tough slogging.
But the pandemic certainly helped Apple pull this off. And a good amount of new programming that has critics talking about its quality content has helped as well.
Add to that the recent ruling in Ireland that Apple doesn’t owe $14 billion in taxes will be a boost to its bottom line.
10 Cybersecurity Stocks We Need Now More Than Ever
The stock is up 33% year to date and 90% in the past 12 months, pretty good for company with a $1.7 trillion market cap. And AAPL stock still has a 2.7% dividend.
Microsoft (MSFT)
MSFT) logo above the entrance." width="300" height="169">
Source: NYCStock / Shutterstock.com
It’s hard to believe that in the era of disruptive technology companies, which always includes Microsoft, it has been an industry leader since 1975 when it inked its first contract with Big Blue, aka, IBM (NYSE:IBM).
At the time, IBM was master of all it surveyed. Times have certainly changed, but they have continued to change for the better for MSFT stock.
Its software got it to the party, but since then it has added hardware that is now competitive with the best hardware makers around, including on the gaming front.
And its transition to a recurring model has really been a gamechanger, especially in the current uncertain climate.
MSFT stock is up 30% year to date and delivers a nearly 1% dividend.
Dollar General (DG)
Source: Jonathan Weiss / Shutterstock.com
This chain of retail stores has been around since 1939. It has an excess of 16,000 stores in more than 45 states.
If you haven’t seen or visited a Dollar General it’s likely because you live in the big city. These stores are built to service more rural communities outside the big city centers.
That gives them very little competition since even the big box retailers can’t touch every small community, but have to find strategic locations where they can draw on a number of small communities. This also makes it one of the most enduring blue-chip stocks to watch today.
Dollar General stores are in those towns. So, consumers may drive 45 minutes to a big box store on the weekend to do grocery shopping, but to grab a light bulb or some snacks or laundry detergent, the Dollar General is around the corner.
And the pandemic has boosted DG’s operations significantly. Not only are the stores convenient, but they’re small, so you don’t spend all day exposed. Plus, the prices are low, which helps if you’re one of the tens of millions who have lost your job.
7 Semiconductor Stocks Ready for Big Growth
DG stock is up 22% year to date and has a 0.8% dividend.
AbbVie (ABBV)
ABBV) website and logo on mobile phone" width="300" height="169">
Source: Piotr Swat / Shutterstock.com
No, ABBV doesn’t have a leading candidate for a Covid-19 vaccine.
It has one better. It has the top-selling drug of all time. Humira.
And that isn’t the only arrow in its quiver. But in just the past 3 years, Humira brought in nearly $20 billion — a year. That isn’t a blockbuster, that’s a city buster.
Usually, a blockbuster is a drug that can do $1 billion or more a year. AbbVie has four of them, with others close behind, making it one of the premier biopharmaceutical names among all the blue-chip stocks to consider.
It has a huge pipeline of approved drugs on the market, as well as more drugs in the pipeline. That is what’s key when looking at pharmaceutical companies.
ABBV stock is only up 12% year to date, while the dumb money chases a Covid-19 vaccine. And it’s trading at a modest price-to-earnings ratio of 17x.
Walmart (WMT)
Source: Jonathan Weiss / Shutterstock.com
Walmart is the biggest retailer in the world when it comes to brick-and-mortar stores. Although, if you include online shopping, Amazon is the champ.
But Walmart is doing everything it can to cover that ground as well. This month it’s planning to launch its full attack on Amazon Prime, with Walmart Plus. This service is expected to offer free same-day shipping of groceries and products, early access to sales, discounts to gas at Walmart gas stations and (for some) free 2-hour delivery access.
All that for an annual fee of $98. Prime costs about $20 more a year.
This is going to be a very interesting holiday season as the two U.S. retail titans vie for primacy.
These 7 Robinhood Stocks Have the Legs for Future Gains
WMT stock is up 11% year to date and has a 1.6% dividend.
Visa (V)
Source: Kikinunchi / Shutterstock.com
This payments services firm has been around since 1958, and is really the reason credit and debit cards exist today. That history has helped ensure its placement among the top blue-chip stocks to buy today.
Initially credit cards were issued by banks and vendors that partnered with the issuing banks. Visa was a group of California banks that got together to issue a card that could be used across the state.
And then the concept grew into a national organization.
But that isn’t why V stock remains a major player today. The innovation that was at the core of its birth has remained and that innovation today means Visa is one of the leading companies in the digital banking revolution.
Remember, Visa is not a bank. It allows consumers to buy on credit and then holds that transaction for the banks until the consumer pays. It makes money off the consumer transaction as well as a fee from the bank for assuming some of that risk.
The play here is it’s dominance in one of the biggest financial trends that’s occurring right now: the digitization of banking.
V stock is up 3% year to date and offers a 0.6% dividend.
Procter & Gamble (PG)
Source: rblfmr / Shutterstock.com
If you’re a company that has been around since Houston, Texas was founded, U.S. troops were still fighting the Second Seminole War in Florida, the Panic of 1837 happened, and Martin van Buren took over the presidency from Andrew Jackson, you’re one of a very select few.
And staying in business for 183 years makes you the kind of business that has products that are necessary and demanded in good times and bad.
What’s more, through those good and bad times, you continued to deliver both growth and safe, reliable dividends for your investors. That’s Procter & Gamble.
If you’re looking for a rock-solid, long-term growth stock, PG stock should be on the top of that list. Its collection of consumer staples, like Pampers, Charmin, Bounty, Oral B, Braun, Gillette, Tide and many others, are a testament to its dominance in the U.S. (and global) marketplace.
Its consolidation of brands that has been going on in recent years, has only strengthened its position.
The stock has had less attention in recent months as sexier stocks have prevailed. But that doesn’t mean it has lost any of its long-term potential or value.
7 Stocks for Beginners
PG stock is about break even year to date and has a 2.5% dividend.
As of this writing, Gregg Early didn’t hold a position in any of the aforementioned securities.
The post The 8 Most Reliable Blue-Chip Stocks In the Market Today appeared first on InvestorPlace.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Amazon (NASDAQ:AMZN) Apple (NASDAQ:AAPL) Microsoft (NASDAQ:MSFT) Dollar General (NYSE:DG) AbbVie (NYSE:ABBV) Walmart (NYSE:WMT) Visa (NYSE:V) Procter & Gamble (NYSE:PG) Here’s a look at what makes each a dependable investment today. AbbVie (ABBV) ABBV) website and logo on mobile phone" width="300" height="169"> Source: Piotr Swat / Shutterstock.com No, ABBV doesn’t have a leading candidate for a Covid-19 vaccine. AbbVie has four of them, with others close behind, making it one of the premier biopharmaceutical names among all the blue-chip stocks to consider. | Amazon (NASDAQ:AMZN) Apple (NASDAQ:AAPL) Microsoft (NASDAQ:MSFT) Dollar General (NYSE:DG) AbbVie (NYSE:ABBV) Walmart (NYSE:WMT) Visa (NYSE:V) Procter & Gamble (NYSE:PG) Here’s a look at what makes each a dependable investment today. AbbVie (ABBV) ABBV) website and logo on mobile phone" width="300" height="169"> Source: Piotr Swat / Shutterstock.com No, ABBV doesn’t have a leading candidate for a Covid-19 vaccine. AbbVie has four of them, with others close behind, making it one of the premier biopharmaceutical names among all the blue-chip stocks to consider. | Amazon (NASDAQ:AMZN) Apple (NASDAQ:AAPL) Microsoft (NASDAQ:MSFT) Dollar General (NYSE:DG) AbbVie (NYSE:ABBV) Walmart (NYSE:WMT) Visa (NYSE:V) Procter & Gamble (NYSE:PG) Here’s a look at what makes each a dependable investment today. AbbVie (ABBV) ABBV) website and logo on mobile phone" width="300" height="169"> Source: Piotr Swat / Shutterstock.com No, ABBV doesn’t have a leading candidate for a Covid-19 vaccine. AbbVie has four of them, with others close behind, making it one of the premier biopharmaceutical names among all the blue-chip stocks to consider. | Amazon (NASDAQ:AMZN) Apple (NASDAQ:AAPL) Microsoft (NASDAQ:MSFT) Dollar General (NYSE:DG) AbbVie (NYSE:ABBV) Walmart (NYSE:WMT) Visa (NYSE:V) Procter & Gamble (NYSE:PG) Here’s a look at what makes each a dependable investment today. AbbVie (ABBV) ABBV) website and logo on mobile phone" width="300" height="169"> Source: Piotr Swat / Shutterstock.com No, ABBV doesn’t have a leading candidate for a Covid-19 vaccine. AbbVie has four of them, with others close behind, making it one of the premier biopharmaceutical names among all the blue-chip stocks to consider. |
24461.0 | 2020-07-23 00:00:00 UTC | BUZZ-U.S. STOCKS ON THE MOVE-Microsoft Corp, Tesla Inc | ABBV | https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-microsoft-corp-tesla-inc-2020-07-23 | nan | nan | Eikon search string for individual stock moves: STXBZ
The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi
The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh
S&P 500 and Dow futures hovered near five-month highs on Thursday, as signs that a new coronavirus relief package was at hand lifted sentiment ahead of weekly unemployment data. .N
At 07:00 a.m. ET, Dow e-minis 1YMc1 were up 0.37% at 26,984. S&P 500 e-minis ESc1 were up 0.38% at 3,277.75, while Nasdaq 100 e-minis NQc1 were up 0.85% at 10,895.75. The top three NYSE percentage gainers premarket .PRPG.NQ: ** Bluegreen Vacations Corp , up 12.8% ** Helix Enery Solutions Group , up 12.6% ** Meritage Homes Corp MTH.N, up 9.5% The top three NYSE percentage losers premarket .PRPL.NQ: ** Jumia Technologies AG , down 8.3% ** Pacific Coast Oil Trust , down 6.4% ** Relx PLC , down 5.4% The top three Nasdaq percentage gainers premarket .PRPG.O: ** Entera Bio Ltd , up 83.2% ** Liquid Media Group Ltd , up 49.4% ** US Energy Corp , up 47.6% The top three Nasdaq percentage losers premarket .PRPL.O: ** Ascena Retail Group Inc , down 31.6% ** Kingold Jewelry Inc , down 13% ** Lonestar Resources US Inc , down 10.6% ** Tesla Inc TSLA.O: up 5.1% premarket BUZZ-Street View: Tesla's underwhelming Q2 a far cry from its stock performance ** Microsoft Corp MSFT.O: down 2.1% premarket BUZZ-Street View: Azure woes cloud Microsoft's Q4; better positioned than rivals ** Kinder Morgan Inc KMI.N: down 1.4% premarket BUZZ-Street View: Kinder Morgan Q2 lacks clarity in uncertain macro environment
(Compiled by Shivani Kumaresan in Bengaluru; Editing by Rashmi Aich)
((Shivani.Kumaresan@thomsonreuters.com ; +1 646 223 8780;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh S&P 500 and Dow futures hovered near five-month highs on Thursday, as signs that a new coronavirus relief package was at hand lifted sentiment ahead of weekly unemployment data. ET, Dow e-minis 1YMc1 were up 0.37% at 26,984. The top three NYSE percentage gainers premarket .PRPG.NQ: ** Bluegreen Vacations Corp , up 12.8% ** Helix Enery Solutions Group , up 12.6% ** Meritage Homes Corp MTH.N, up 9.5% The top three NYSE percentage losers premarket .PRPL.NQ: ** Jumia Technologies AG , down 8.3% ** Pacific Coast Oil Trust , down 6.4% ** Relx PLC , down 5.4% The top three Nasdaq percentage gainers premarket .PRPG.O: ** Entera Bio Ltd , up 83.2% ** Liquid Media Group Ltd , up 49.4% ** US Energy Corp , up 47.6% The top three Nasdaq percentage losers premarket .PRPL.O: ** Ascena Retail Group Inc , down 31.6% ** Kingold Jewelry Inc , down 13% ** Lonestar Resources US Inc , down 10.6% ** Tesla Inc TSLA.O: up 5.1% premarket BUZZ-Street View: Tesla's underwhelming Q2 a far cry from its stock performance ** Microsoft Corp MSFT.O: down 2.1% premarket BUZZ-Street View: Azure woes cloud Microsoft's Q4; better positioned than rivals ** Kinder Morgan Inc KMI.N: down 1.4% premarket BUZZ-Street View: Kinder Morgan Q2 lacks clarity in uncertain macro environment (Compiled by Shivani Kumaresan in Bengaluru; Editing by Rashmi Aich) ((Shivani.Kumaresan@thomsonreuters.com ; +1 646 223 8780;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh S&P 500 and Dow futures hovered near five-month highs on Thursday, as signs that a new coronavirus relief package was at hand lifted sentiment ahead of weekly unemployment data. ET, Dow e-minis 1YMc1 were up 0.37% at 26,984. The top three NYSE percentage gainers premarket .PRPG.NQ: ** Bluegreen Vacations Corp , up 12.8% ** Helix Enery Solutions Group , up 12.6% ** Meritage Homes Corp MTH.N, up 9.5% The top three NYSE percentage losers premarket .PRPL.NQ: ** Jumia Technologies AG , down 8.3% ** Pacific Coast Oil Trust , down 6.4% ** Relx PLC , down 5.4% The top three Nasdaq percentage gainers premarket .PRPG.O: ** Entera Bio Ltd , up 83.2% ** Liquid Media Group Ltd , up 49.4% ** US Energy Corp , up 47.6% The top three Nasdaq percentage losers premarket .PRPL.O: ** Ascena Retail Group Inc , down 31.6% ** Kingold Jewelry Inc , down 13% ** Lonestar Resources US Inc , down 10.6% ** Tesla Inc TSLA.O: up 5.1% premarket BUZZ-Street View: Tesla's underwhelming Q2 a far cry from its stock performance ** Microsoft Corp MSFT.O: down 2.1% premarket BUZZ-Street View: Azure woes cloud Microsoft's Q4; better positioned than rivals ** Kinder Morgan Inc KMI.N: down 1.4% premarket BUZZ-Street View: Kinder Morgan Q2 lacks clarity in uncertain macro environment (Compiled by Shivani Kumaresan in Bengaluru; Editing by Rashmi Aich) ((Shivani.Kumaresan@thomsonreuters.com ; +1 646 223 8780;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh S&P 500 and Dow futures hovered near five-month highs on Thursday, as signs that a new coronavirus relief package was at hand lifted sentiment ahead of weekly unemployment data. S&P 500 e-minis ESc1 were up 0.38% at 3,277.75, while Nasdaq 100 e-minis NQc1 were up 0.85% at 10,895.75. The top three NYSE percentage gainers premarket .PRPG.NQ: ** Bluegreen Vacations Corp , up 12.8% ** Helix Enery Solutions Group , up 12.6% ** Meritage Homes Corp MTH.N, up 9.5% The top three NYSE percentage losers premarket .PRPL.NQ: ** Jumia Technologies AG , down 8.3% ** Pacific Coast Oil Trust , down 6.4% ** Relx PLC , down 5.4% The top three Nasdaq percentage gainers premarket .PRPG.O: ** Entera Bio Ltd , up 83.2% ** Liquid Media Group Ltd , up 49.4% ** US Energy Corp , up 47.6% The top three Nasdaq percentage losers premarket .PRPL.O: ** Ascena Retail Group Inc , down 31.6% ** Kingold Jewelry Inc , down 13% ** Lonestar Resources US Inc , down 10.6% ** Tesla Inc TSLA.O: up 5.1% premarket BUZZ-Street View: Tesla's underwhelming Q2 a far cry from its stock performance ** Microsoft Corp MSFT.O: down 2.1% premarket BUZZ-Street View: Azure woes cloud Microsoft's Q4; better positioned than rivals ** Kinder Morgan Inc KMI.N: down 1.4% premarket BUZZ-Street View: Kinder Morgan Q2 lacks clarity in uncertain macro environment (Compiled by Shivani Kumaresan in Bengaluru; Editing by Rashmi Aich) ((Shivani.Kumaresan@thomsonreuters.com ; +1 646 223 8780;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh S&P 500 and Dow futures hovered near five-month highs on Thursday, as signs that a new coronavirus relief package was at hand lifted sentiment ahead of weekly unemployment data. ET, Dow e-minis 1YMc1 were up 0.37% at 26,984. S&P 500 e-minis ESc1 were up 0.38% at 3,277.75, while Nasdaq 100 e-minis NQc1 were up 0.85% at 10,895.75. |
24462.0 | 2020-07-22 00:00:00 UTC | Is AbbVie a Great Dividend Stock? | ABBV | https://www.nasdaq.com/articles/is-abbvie-a-great-dividend-stock-2020-07-22 | nan | nan | Many investors consider dividend stocks an important part of any well-rounded portfolio. And while there is no shortage of such stocks on the market, they aren't all created equal. After all, most companies aren't legally obligated to reward shareholders by way of dividends, and given that we are currently in a recession, many have already slashed or suspended their dividend payments. Fortunately, there are still some dividend stocks worth buying, and AbbVie (NYSE: ABBV) is one of them. Here's why the pharma giant is a great dividend stock.
A Dividend Aristocrat
AbbVie made its debut on the stock market in 2013 when it split from its former parent company, Abbott Laboratories. When we include the time AbbVie spent as a division of Abbott, the company has raised its dividends for 47 consecutive years, making the drugmaker a Dividend Aristocrat. This select group refers to companies in the S&P 500 that have raised their dividend payouts for at least 25 consecutive years.
Image source: Getty Images.
In other words, AbbVie, like other companies in this elite class, is unlikely to suspend its dividends anytime soon, at least if history is any guide. Also, AbbVie currently offers a dividend yield of 4.6%, compared with about 2% for the S&P 500, and the company sports a cash payout ratio of 48.3%. This reasonable payout ratio gives the company plenty of room to sustain dividend increases.
AbbVie can still deliver strong financial results
Even though AbbVie boasts a stellar dividend history, a high dividend yield, and a reasonable payout ratio, it is critical to ensure that the company can continue growing its revenue and earnings at a good clip before adding it to your dividend portfolio. And while detractors may point to declining sales of Humira, the company's biggest cash cow, sales of this blockbuster drug are still growing in the U.S., which is helping it recoup some of its losses in international markets.
During the first quarter, the rheumatoid arthritis treatment generated $3.7 billion in revenue domestically, a 13.7% year-over-year increase. Furthermore, the pharma giant has a robust lineup (beyond Humira) that will allow it to continue generating solid financial results. For instance, there's Venclexta and Imbruvica, two cancer drugs whose combined worldwide sales of $1.5 billion during the first quarter increased by about 32% year over year. Overall, the company reported a revenue figure of $8.6 billion during the quarter, a 10.1% increase compared to the prior-year quarter.
AbbVie's earnings per share came in at $2.02, compared with the $1.65 recorded during the first quarter of the previous fiscal year. And let's not forget about AbbVie's acquisition of Allergan, a transaction that closed in May. AbbVie successfully decreased its top-line exposure to Humira thanks to this deal. In particular, the company got its hands on Allergan's Botox, which generates well over a billion dollars in revenue per year.
The key takeaway
It is worth noting that AbbVie's acquisition of Allergan significantly increased its debt level. At the end of the first quarter, the company had more than $80 billion in long-term liabilities. However, AbbVie's CEO, Richard Gonzalez, had this to stay during the company's first-quarter earnings conference call: "We remain confident that the AbbVie/Allergan combination will generate significant cash flows, which will support our strong and growing dividend and rapid debt repayment, and we remain highly committed to both of those priorities." That's why AbbVie's debt load shouldn't be a deal-breaker for investors, in my view.
Overall, AbbVie fits all the criteria of a great dividend stock: A high yield, a low payout ratio, and the ability to raise its dividend payouts along with its revenue and profits. Income-seeking investors can't go wrong with this pharma stock.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now… and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of June 2, 2020
Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | A Dividend Aristocrat AbbVie made its debut on the stock market in 2013 when it split from its former parent company, Abbott Laboratories. The key takeaway It is worth noting that AbbVie's acquisition of Allergan significantly increased its debt level. However, AbbVie's CEO, Richard Gonzalez, had this to stay during the company's first-quarter earnings conference call: "We remain confident that the AbbVie/Allergan combination will generate significant cash flows, which will support our strong and growing dividend and rapid debt repayment, and we remain highly committed to both of those priorities." | AbbVie can still deliver strong financial results Even though AbbVie boasts a stellar dividend history, a high dividend yield, and a reasonable payout ratio, it is critical to ensure that the company can continue growing its revenue and earnings at a good clip before adding it to your dividend portfolio. The key takeaway It is worth noting that AbbVie's acquisition of Allergan significantly increased its debt level. Overall, AbbVie fits all the criteria of a great dividend stock: A high yield, a low payout ratio, and the ability to raise its dividend payouts along with its revenue and profits. | When we include the time AbbVie spent as a division of Abbott, the company has raised its dividends for 47 consecutive years, making the drugmaker a Dividend Aristocrat. AbbVie can still deliver strong financial results Even though AbbVie boasts a stellar dividend history, a high dividend yield, and a reasonable payout ratio, it is critical to ensure that the company can continue growing its revenue and earnings at a good clip before adding it to your dividend portfolio. Overall, AbbVie fits all the criteria of a great dividend stock: A high yield, a low payout ratio, and the ability to raise its dividend payouts along with its revenue and profits. | AbbVie can still deliver strong financial results Even though AbbVie boasts a stellar dividend history, a high dividend yield, and a reasonable payout ratio, it is critical to ensure that the company can continue growing its revenue and earnings at a good clip before adding it to your dividend portfolio. * David and Tom just revealed what they believe are the ten best stocks for investors to buy right now… and AbbVie wasn't one of them! Fortunately, there are still some dividend stocks worth buying, and AbbVie (NYSE: ABBV) is one of them. |
24463.0 | 2020-07-22 00:00:00 UTC | Validea John Neff Strategy Daily Upgrade Report - 7/22/2020 | ABBV | https://www.nasdaq.com/articles/validea-john-neff-strategy-daily-upgrade-report-7-22-2020-2020-07-22 | nan | nan | The following are today's upgrades for Validea's Low PE Investor model based on the published strategy of John Neff. This strategy looks for firms with persistent earnings growth that trade at a discount relative to their earnings growth and dividend yield.
UNITEDHEALTH GROUP INC (UNH) is a large-cap growth stock in the Insurance (Accident & Health) industry. The rating according to our strategy based on John Neff changed from 62% to 81% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: UnitedHealth Group Incorporated is a health and well-being company. The Company operates through four segments: UnitedHealthcare, OptumHealth, OptumInsight and OptumRx. It conducts its operations through two business platforms: health benefits operating under UnitedHealthcare and health services operating under Optum. UnitedHealthcare provides healthcare benefits to an array of customers and markets, and includes UnitedHealthcare Employer & Individual, UnitedHealthcare Medicare & Retirement, UnitedHealthcare Community & State, and UnitedHealthcare Global businesses. Optum is a health services business serving the healthcare marketplace, including payers, care providers, employers, governments, life sciences companies and consumers, through its OptumHealth, OptumInsight and OptumRx businesses. OptumInsight provides services, technology and healthcare solutions to participants in the healthcare industry. OptumRx provides retail network contracting, purchasing and clinical solutions.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
EPS GROWTH: FAIL
FUTURE EPS GROWTH: PASS
SALES GROWTH: PASS
TOTAL RETURN/PE: PASS
FREE CASH FLOW: PASS
EPS PERSISTENCE: PASS
Detailed Analysis of UNITEDHEALTH GROUP INC
Full Guru Analysis for UNH
Full Factor Report for UNH
ZIONS BANCORPORATION NA (ZION) is a mid-cap value stock in the Regional Banks industry. The rating according to our strategy based on John Neff changed from 60% to 79% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Zions Bancorporation, National Association is a financial holding company. The Company conducts its banking operations through separately managed and branded segments, including Zions Bank, Amegy Bank, California Bank & Trust, National Bank of Arizona, Nevada State Bank (NSB), Vectra Bank Colorado, The Commerce Bank of Washington (TCBW) and Other. It focuses on providing community banking services through its business lines, including small and medium-sized business and corporate banking; commercial and residential development, construction and term lending; retail banking; treasury cash management and related products and services; residential mortgage servicing and lending; trust and wealth management; limited capital markets activities, including municipal finance advisory and underwriting, and investment activities. It provides a range of banking and related services, primarily in Arizona, California, Colorado, Idaho, Nevada, New Mexico, Oregon, Texas, Utah, Washington and Wyoming.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
EPS GROWTH: PASS
FUTURE EPS GROWTH: FAIL
SALES GROWTH: PASS
TOTAL RETURN/PE: PASS
FREE CASH FLOW: PASS
EPS PERSISTENCE: FAIL
Detailed Analysis of ZIONS BANCORPORATION NA
Full Guru Analysis for ZION
Full Factor Report for ZION
GUARANTY BANCSHARES, INC. (GNTY) is a small-cap value stock in the Regional Banks industry. The rating according to our strategy based on John Neff changed from 62% to 79% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Guaranty Bancshares, Inc. is the holding company for Guaranty Bank & Trust (Guaranty). Guaranty offers various solutions, such as personal banking, business banking, mortgage and wealth management. Its personal banking solutions include checking accounts, which include compare accounts, green checking, student checking, choice checking, guaranty interest checking, order checks and debit cards; savings accounts, which include regular savings, premier money market, certificate of deposit, individual retirement account (IRA) options and health savings account, and online banking, which includes money desktop and e-statements. Guaranty offers various loans, including line of credit, small business administration loans and real estate loans. Guaranty also offers mobile banking solutions, mortgage warehouse lending solutions and treasury management solutions. It has approximately 30 bank locations in over 20 Texas communities.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
EPS GROWTH: PASS
FUTURE EPS GROWTH: FAIL
SALES GROWTH: PASS
TOTAL RETURN/PE: PASS
FREE CASH FLOW: PASS
EPS PERSISTENCE: FAIL
Detailed Analysis of GUARANTY BANCSHARES, INC.
Full Guru Analysis for GNTY
Full Factor Report for GNTY
ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on John Neff changed from 60% to 79% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions. It offers products in various categories, including HUMIRA (adalimumab), Oncology products, Virology Products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products, which include Duopa and Duodopa (carbidopa and levodopa), Anesthesia products and ZINBRYTA (daclizumab).
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
EPS GROWTH: FAIL
FUTURE EPS GROWTH: PASS
SALES GROWTH: PASS
TOTAL RETURN/PE: PASS
FREE CASH FLOW: PASS
EPS PERSISTENCE: FAIL
Detailed Analysis of ABBVIE INC
Full Guru Analysis for ABBV
Full Factor Report for ABBV
LIFE STORAGE INC (LSI) is a mid-cap growth stock in the Misc. Transportation industry. The rating according to our strategy based on John Neff changed from 60% to 79% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Life Storage, Inc., formerly Sovran Self Storage, Inc., is a self-administered and self-managed real estate company. The Company acquires, owns and manages self-storage properties. The Company owns its assets and conducts its operations through Life Storage LP (the Operating Partnership) and subsidiaries of the Operating Partnership. The Company operates over 775 storage facilities in 28 states under the names Life Storage and Uncle Bob's Self Storage. The Company's properties are located in various states of the United States, such as Alabama, Arizona, Colorado, California, Florida, Georgia, Maine, Kentucky, Nevada, New Jersey, Ohio, North Carolina, South Carolina, Texas, Utah and Virginia.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
EPS GROWTH: PASS
FUTURE EPS GROWTH: FAIL
SALES GROWTH: PASS
TOTAL RETURN/PE: PASS
FREE CASH FLOW: PASS
EPS PERSISTENCE: FAIL
Detailed Analysis of LIFE STORAGE INC
Full Guru Analysis for LSI
Full Factor Report for LSI
COSAN LTD (USA) (CZZ) is a mid-cap growth stock in the Oil & Gas Operations industry. The rating according to our strategy based on John Neff changed from 62% to 81% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Cosan Limited (Cosan) is a holding company. The Company's segments include Raizen Energia, Raizen Combustiveis, COMGAS, Cosan Logistica, Lubricants and Other business. The Company's other business include other investments, in addition to the corporate activities. The Company offers Logistics services, including transportation, port loading and storage of sugar, leasing or lending of locomotives, wagons and other railway equipment, through its subsidiaries Rumo Logistica Operadora Multimodal S.A. (Rumo), logistic segment (Logistic). The Company is also engaged in production and distribution of lubricants, through its indirect subsidiaries Cosan Lubrificantes e Especialidades S.A. (Moove) and Comma Oil & Chemicals Ltd. (Comma), under the Mobil licensed trademark in Brazil, Bolivia, Uruguay and Paraguay, in addition to the European and Asian market using the Comma brand and corporate activities (Lubricants).
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
EPS GROWTH: FAIL
FUTURE EPS GROWTH: PASS
SALES GROWTH: PASS
TOTAL RETURN/PE: PASS
FREE CASH FLOW: PASS
EPS PERSISTENCE: PASS
Detailed Analysis of COSAN LTD (USA)
Full Guru Analysis for CZZ
Full Factor Report for CZZ
More details on Validea's John Neff strategy
About John Neff: While known as the manager with whom many top managers entrusted their own money, Neff was far from the smooth-talking, high-profile Wall Streeter you might expect. He was mild-mannered and low-key, and the same might be said of the Windsor Fund that he managed for more than three decades. In fact, Neff himself described the fund as "relatively prosaic, dull, [and] conservative." There was nothing dull about his results, however. From 1964 to 1995, Neff guided Windsor to a 13.7 percent average annual return, easily outpacing the S&P 500's 10.6 percent return during that time. That 3.1 percentage point difference is huge over time -- a $10,000 investment in Windsor (with dividends reinvested) at the start of Neff's tenure would have ended up as more than $564,000 by the time he retired, more than twice what the same investment in the S&P would have yielded (about $233,000). Considering the length of his tenure, that track record may be the best ever for a manager of such a large fund.
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Detailed Analysis of GUARANTY BANCSHARES, INC. Full Guru Analysis for GNTY Full Factor Report for GNTY ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. Detailed Analysis of ABBVIE INC Full Guru Analysis for ABBV Full Factor Report for ABBV LIFE STORAGE INC (LSI) is a mid-cap growth stock in the Misc. | Detailed Analysis of GUARANTY BANCSHARES, INC. Full Guru Analysis for GNTY Full Factor Report for GNTY ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. Detailed Analysis of ABBVIE INC Full Guru Analysis for ABBV Full Factor Report for ABBV LIFE STORAGE INC (LSI) is a mid-cap growth stock in the Misc. | Detailed Analysis of GUARANTY BANCSHARES, INC. Full Guru Analysis for GNTY Full Factor Report for GNTY ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. Detailed Analysis of ABBVIE INC Full Guru Analysis for ABBV Full Factor Report for ABBV LIFE STORAGE INC (LSI) is a mid-cap growth stock in the Misc. | Detailed Analysis of GUARANTY BANCSHARES, INC. Full Guru Analysis for GNTY Full Factor Report for GNTY ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. Detailed Analysis of ABBVIE INC Full Guru Analysis for ABBV Full Factor Report for ABBV LIFE STORAGE INC (LSI) is a mid-cap growth stock in the Misc. |
24464.0 | 2020-07-21 00:00:00 UTC | Gilead Sciences Invests $300 Million in an Immuno-Oncology Startup | ABBV | https://www.nasdaq.com/articles/gilead-sciences-invests-%24300-million-in-an-immuno-oncology-startup-2020-07-21 | nan | nan | Gilead Sciences (NASDAQ: GILD) announced Tuesday it's paying $300 million for a 49.9% ownership stake in Tizona Therapeutics and an option to acquire the company outright later for up to $1.25 billion in fees and potential milestone payments.
The deal provides the privately owned company with financing to support the development of TTX-080, a potential first-in-class immunotherapy targeting HLA-G, an immune checkpoint molecule expressed in multiple tumor types. A phase 1 study of HLA-G as monotherapy and in combination with existing treatments is set to begin enrolling patients this quarter.
IMAGE SOURCE: GETTY IMAGES.
If successful, TTX-080 could offer an alternative treatment for patients who don't respond to checkpoint inhibitors targeting the immune checkpoint PD-1, including the blockbuster drugs Opdivo and Keytruda. TTX-080 may enhance the efficacy of PD-1 inhibitors, suggesting there's also a potential pathway to improving the standard of care in eligible solid tumor cancer patients.
The biotech giant will be able to exercise its option to acquire the remaining equity of Tizona Therapeutics "following the completion of Phase 1b studies for TTX-080, or earlier."
Management expects this deal to close in the third quarter, after Tizona has spun-out its other drug in development, TTX-030, as a separate company. An anti-CD39 antibody, TTX-030 is being developed in partnership with AbbVie (NYSE: ABBV).
10 stocks we like better than Gilead Sciences
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Gilead Sciences wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of June 2, 2020
Todd Campbell owns shares of Gilead Sciences. His clients may have positions in the companies mentioned. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | An anti-CD39 antibody, TTX-030 is being developed in partnership with AbbVie (NYSE: ABBV). Gilead Sciences (NASDAQ: GILD) announced Tuesday it's paying $300 million for a 49.9% ownership stake in Tizona Therapeutics and an option to acquire the company outright later for up to $1.25 billion in fees and potential milestone payments. The deal provides the privately owned company with financing to support the development of TTX-080, a potential first-in-class immunotherapy targeting HLA-G, an immune checkpoint molecule expressed in multiple tumor types. | An anti-CD39 antibody, TTX-030 is being developed in partnership with AbbVie (NYSE: ABBV). The deal provides the privately owned company with financing to support the development of TTX-080, a potential first-in-class immunotherapy targeting HLA-G, an immune checkpoint molecule expressed in multiple tumor types. If successful, TTX-080 could offer an alternative treatment for patients who don't respond to checkpoint inhibitors targeting the immune checkpoint PD-1, including the blockbuster drugs Opdivo and Keytruda. | An anti-CD39 antibody, TTX-030 is being developed in partnership with AbbVie (NYSE: ABBV). Gilead Sciences (NASDAQ: GILD) announced Tuesday it's paying $300 million for a 49.9% ownership stake in Tizona Therapeutics and an option to acquire the company outright later for up to $1.25 billion in fees and potential milestone payments. The deal provides the privately owned company with financing to support the development of TTX-080, a potential first-in-class immunotherapy targeting HLA-G, an immune checkpoint molecule expressed in multiple tumor types. | An anti-CD39 antibody, TTX-030 is being developed in partnership with AbbVie (NYSE: ABBV). The deal provides the privately owned company with financing to support the development of TTX-080, a potential first-in-class immunotherapy targeting HLA-G, an immune checkpoint molecule expressed in multiple tumor types. The biotech giant will be able to exercise its option to acquire the remaining equity of Tizona Therapeutics "following the completion of Phase 1b studies for TTX-080, or earlier." |
24465.0 | 2020-07-21 00:00:00 UTC | Gilead To Acquire 49.9% Equity Interest In Tizona - Quick Facts | ABBV | https://www.nasdaq.com/articles/gilead-to-acquire-49.9-equity-interest-in-tizona-quick-facts-2020-07-21 | nan | nan | (RTTNews) - Gilead Sciences, Inc. (GILD) said the company will invest $300 million to acquire a 49.9 percent equity interest in Tizona Therapeutics, Inc., a privately held company developing cancer immunotherapies. The U.S. FDA has approved Tizona's Investigational New Drug application for TTX-080. Tizona plans to begin a Phase 1 clinical trial evaluating TTX-080 both as a monotherapy and in combination with other agents in patients with advanced cancers.
Gilead will have an exclusive option to purchase the remaining equity of Tizona exercisable following the completion of Phase 1b studies for TTX-080, or earlier if Gilead chooses. Tizona equity holders will be eligible to receive up to $1.25 billion in an option exercise fee and potential future milestone payments.
Tizona will spin off TTX-030, the company's investigational anti-CD39 antibody partnered with AbbVie, into a separate entity prior to closing of the deal.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Tizona will spin off TTX-030, the company's investigational anti-CD39 antibody partnered with AbbVie, into a separate entity prior to closing of the deal. Tizona plans to begin a Phase 1 clinical trial evaluating TTX-080 both as a monotherapy and in combination with other agents in patients with advanced cancers. Tizona equity holders will be eligible to receive up to $1.25 billion in an option exercise fee and potential future milestone payments. | Tizona will spin off TTX-030, the company's investigational anti-CD39 antibody partnered with AbbVie, into a separate entity prior to closing of the deal. The U.S. FDA has approved Tizona's Investigational New Drug application for TTX-080. Gilead will have an exclusive option to purchase the remaining equity of Tizona exercisable following the completion of Phase 1b studies for TTX-080, or earlier if Gilead chooses. | Tizona will spin off TTX-030, the company's investigational anti-CD39 antibody partnered with AbbVie, into a separate entity prior to closing of the deal. (RTTNews) - Gilead Sciences, Inc. (GILD) said the company will invest $300 million to acquire a 49.9 percent equity interest in Tizona Therapeutics, Inc., a privately held company developing cancer immunotherapies. Gilead will have an exclusive option to purchase the remaining equity of Tizona exercisable following the completion of Phase 1b studies for TTX-080, or earlier if Gilead chooses. | Tizona will spin off TTX-030, the company's investigational anti-CD39 antibody partnered with AbbVie, into a separate entity prior to closing of the deal. (RTTNews) - Gilead Sciences, Inc. (GILD) said the company will invest $300 million to acquire a 49.9 percent equity interest in Tizona Therapeutics, Inc., a privately held company developing cancer immunotherapies. The U.S. FDA has approved Tizona's Investigational New Drug application for TTX-080. |
24466.0 | 2020-07-21 00:00:00 UTC | 2 High-Yield Dividend Stocks I'd Buy Right Now | ABBV | https://www.nasdaq.com/articles/2-high-yield-dividend-stocks-id-buy-right-now-2020-07-21 | nan | nan | When evaluating dividend-paying stocks, it's important to consider the company's overall business prospects and the dividend growth record. It's a lot more fun watching share price increases while accumulating growing dividend payouts than falling for unsustainably high dividend yields and watching your investment drop.
That's why I like rock-solid companies like AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) for investors looking for dividends. Both companies have great businesses well positioned for the future, and it is highly unlikely either will have problems paying its dividends. Let's look at each business more closely.
Reasons to be in AbbVie: valuation and dividend yield
There's a lot to like about pharmaceutical firm AbbVie's 4.8% dividend. The company has had 48 consecutive years of dividend increases and a three-year dividend growth rate of 22.6%.
AbbVie's stock price has been held back due to future uncertainty about losing exclusivity on its blockbuster immunology drug Humira in 2023. But that eventuality is being outweighed by good news on several fronts, as the company is filling its pipeline with promising new treatments.
On June 10, AbbVie announced a collaboration deal with Danish company Genmab. The companies will collaborate on three anticancer antibodies that will ultimately allow the delivery of a therapeutic toxin directly to cancer cells while sparing normal, healthy cells. AbbVie is paying $750 million up front and up to $3.15 billion later, if the development programs succeed.
AbbVie acquired fellow drugmaker Allergan in a deal that closed in May, which bolstered AbbVie's offerings with lucrative treatments such as Botox. While Botox is well known as a cosmetic procedure drug, it is also useful in treating a variety of medical conditions.
On July 9, Allergan announced that the U.S. Food and Drug Administration (FDA) had approved a supplemental Biologics License Application (sBLA) that supports expanded use of Botox for the treatment of spasticity in pediatric patients, including those with lower limb spasticity caused by cerebral palsy.
Image source: Getty Images.
Other, newer drugs in AbbVie's arsenal that Wall Street is optimistic about include Skyrizi and Rinvoq. Analysts expect Skyrizi, which treats psoriasis and other autoimmune disorders, to grow annual sales from about $1 billion to $4.4 billion by 2025. Rinvoq, which treats arthritis and eczema, is expected to grow from a few hundred million a year now to $3.7 billion in 2025.
AbbVie has built a substantial oncology franchise with Imbruvica and Venclexta, which generated combined revenues of nearly $5.5 billion in 2019. Strong double-digit growth is expected in 2020.
AbbVie's price-to-earnings ratio is 17, well below the industry average P/E of 34, and its price/earnings-to-growth ratio is 0.66, indicating that AbbVie shares are undervalued.
Besides the company's growing dividend, strong demand trends for Humira in the United States, an impressive portfolio of new drugs, and continued strong sales performance of Imbruvica and Venclexta are some solid reasons to own the stock.
Johnson & Johnson: Great dividend growth rolls into the future
In April, Johnson & Johnson increased its dividend for the 58th consecutive year, this time by 6.3%. Its dividend now stands at 2.7% and will probably continue to increase yearly based on the company's business outlook.
On July 17, Johnson & Johnson posted second-quarter results, widely expected to be the most brutal of 2020. The company ended up beating estimates for both earnings and sales and raised its adjusted earnings and sales outlook for 2020.
The COVID-19 health crisis affected Johnson & Johnson's business segments in varied ways. The pharmaceutical unit saw sales increases in oncology drugs and psoriasis treatments, but the slowdown in patient visits to doctors hurt sales of some physician-administered drugs. In the consumer health segment, skin care and beauty sales suffered due to social distancing, while over-the-counter medicines and oral care increased. The medical devices unit was hit the hardest due to the stoppage of elective surgical procedures, but the decline wasn't as severe as expected, and the company now expects a lower-than-previously forecast decline for the second half of the year.
Johnson & Johnson sees the financial outlook improving for the rest of 2020 due to better-than-expected performance in medical devices as global economies recover. Management revised their forecast for the negative sales effects of delayed procedures in the medical devices unit, lowering it to $3.8 billion-$5.3 billion from the $4 billion-$7 billion expected earlier. Management also sees continued strength in the pharma segment and higher growth in the consumer health unit.
Finally, the company is a player in developing a coronavirus vaccine. In fact, the U.S. government has given $456 million to Johnson & Johnson for that purpose, while the company has invested another $500 million in the project. If successful, a vaccine would be a significant growth driver for the company.
Johnson & Johnson is the kind of dividend-paying investment likely destined to reward investors royally over the coming years. The stock price is up only 2.4% this year, and I think it has plenty of room to run.
{%sfr%}
10 stocks we like better than Johnson & Johnson
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Johnson & Johnson wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of June 2, 2020
Anne Burdakin owns shares of AbbVie and Johnson & Johnson. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie's stock price has been held back due to future uncertainty about losing exclusivity on its blockbuster immunology drug Humira in 2023. That's why I like rock-solid companies like AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) for investors looking for dividends. Reasons to be in AbbVie: valuation and dividend yield There's a lot to like about pharmaceutical firm AbbVie's 4.8% dividend. | That's why I like rock-solid companies like AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) for investors looking for dividends. Reasons to be in AbbVie: valuation and dividend yield There's a lot to like about pharmaceutical firm AbbVie's 4.8% dividend. AbbVie's stock price has been held back due to future uncertainty about losing exclusivity on its blockbuster immunology drug Humira in 2023. | That's why I like rock-solid companies like AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) for investors looking for dividends. See the 10 stocks *Stock Advisor returns as of June 2, 2020 Anne Burdakin owns shares of AbbVie and Johnson & Johnson. Reasons to be in AbbVie: valuation and dividend yield There's a lot to like about pharmaceutical firm AbbVie's 4.8% dividend. | See the 10 stocks *Stock Advisor returns as of June 2, 2020 Anne Burdakin owns shares of AbbVie and Johnson & Johnson. That's why I like rock-solid companies like AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) for investors looking for dividends. Reasons to be in AbbVie: valuation and dividend yield There's a lot to like about pharmaceutical firm AbbVie's 4.8% dividend. |
24467.0 | 2020-07-21 00:00:00 UTC | 2 Best Gene-Editing Stocks to Buy in July | ABBV | https://www.nasdaq.com/articles/2-best-gene-editing-stocks-to-buy-in-july-2020-07-21 | nan | nan | Gene-editing stocks are favorites for biotech industry speculators thanks to their air of high-tech mystique and their potential to make blockbuster therapies. According to Market Research Future, the global genome editing market will expand at a compound annual growth rate of 18.3% over the next three years. Many investors may be willing to accept higher levels of risk to take advantage of that growth.
While there are a handful of promising gene-editing stocks, only a couple are worth buying today.
Image source: Getty Images.
CRISPR Therapeutics
Unlike many biotech companies, CRISPR Therapeutics (NASDAQ: CRSP) is profitable despite the fact that its most advanced pipeline projects are only in the clinical stage. As a result of its numerous drug development collaborations with Vertex (NASDAQ: VRTX), it has the additional distinction of posting trailing-12-month levered free cash flow in excess of $54 million, making it a slightly safer long-term pick for investors than myriad other money-burning clinical-stage biotech companies.
Aside from its substantial collaboration income, CRISPR is a favorable stock for long-term growth because its therapy pipeline is packed with compelling projects. It has three chimeric antigen receptor T-cell therapies in development for oncology applications and four in vivo therapies designed to edit patients' genes directly to cure hereditary diseases. It's thus no surprise that giants like Bayer (OTC: BAYRY) are interested in working on early-stage programs with CRISPR.
Indeed, in the past 12 months, the company earned revenue of $289 million and spent nearly $200 million of it on research and development (R&D). This impressively large proportion indicates a highly innovative company. In late June, it announced that it was issuing new common stock with the goal of raising $450 million. Its stock surged shortly thereafter.
Given the scale of the R&D expenditures and recent financing, it's probable that CRISPR is highly comfortable with raising additional funding specifically to tackle pressing research issues. This dilutive habit may dissuade a few experienced biotech investors, but it's important to note that the stock has grown 548% in the past five years despite four rounds of new stock offerings. In the same period, CRISPR has also advanced five of its pipeline projects to the clinical stage, initiated five new preclinical programs, forged four new paid development collaborations, and entered into two development-for-licensing agreements.
SPY data by YCharts
Editas Medicine
Editas Medicine (NASDAQ: EDIT) is significantly smaller than CRISPR Therapeutics, with a market cap of $2 billion compared with CRISPR's $6.3 billion. While its $24.2 million in trailing-12-month revenue from collaborations don't make it profitable, its year-over-year quarterly revenue growth is 177%, suggesting that it may eventually be profitable without any approved products on the market. In the meantime, Editas is content to issue new stock, which it has done for the past four years, and it's grown its stock price by 80% over the past five.
Editas spent more than $115 million on R&D in the last 12 months, accounting for more than half of its total operating expenses. Like CRISPR, Editas has a roster of large collaborators including Abbvie (NYSE: ABBV) and Bristol Myers Squibb (NYSE: BMY). Growing revenues from these collaborations is one of the company's talents, with Abbvie retaining the option to license up to five new eye health programs and Bristol Myers Squibb paying $100 million up front for its immuno-oncology drug discovery contract.
Editas' pipeline has nine therapies in preclinical development and one early-stage clinical project: EDIT-101, an in vivo gene-editing therapy for Leber congenital amaurosis. There are only several thousand patients in the U.S. and Europe with this condition, which causes childhood blindness. The clinical trial for EDIT-101 will be the very first in vivo gene therapy using the much-hyped CRISPR/Cas9 gene-editing system. If the company can demonstrate that in vivo gene editing is safe and effective, it will have a tremendously powerful position in the market, and many collaborators are sure to initiate new revenue-generating agreements with the company.
Advancing in vivo gene therapies such as EDIT-101 is the company's priority. The phase 1 trial is scheduled to begin before the end of the year. While the pandemic has caused a few delays, look for the company to announce the start of dosing for EDIT-101 in the fall, and be prepared for its price to skyrocket if it reports favorable preliminary results.
10 stocks we like better than Editas Medicine
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Editas Medicine wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of June 2, 2020
Alex Carchidi has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Bristol Myers Squibb, CRISPR Therapeutics, and Editas Medicine. The Motley Fool recommends Vertex Pharmaceuticals. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Growing revenues from these collaborations is one of the company's talents, with Abbvie retaining the option to license up to five new eye health programs and Bristol Myers Squibb paying $100 million up front for its immuno-oncology drug discovery contract. Like CRISPR, Editas has a roster of large collaborators including Abbvie (NYSE: ABBV) and Bristol Myers Squibb (NYSE: BMY). As a result of its numerous drug development collaborations with Vertex (NASDAQ: VRTX), it has the additional distinction of posting trailing-12-month levered free cash flow in excess of $54 million, making it a slightly safer long-term pick for investors than myriad other money-burning clinical-stage biotech companies. | Like CRISPR, Editas has a roster of large collaborators including Abbvie (NYSE: ABBV) and Bristol Myers Squibb (NYSE: BMY). Growing revenues from these collaborations is one of the company's talents, with Abbvie retaining the option to license up to five new eye health programs and Bristol Myers Squibb paying $100 million up front for its immuno-oncology drug discovery contract. SPY data by YCharts Editas Medicine Editas Medicine (NASDAQ: EDIT) is significantly smaller than CRISPR Therapeutics, with a market cap of $2 billion compared with CRISPR's $6.3 billion. | Like CRISPR, Editas has a roster of large collaborators including Abbvie (NYSE: ABBV) and Bristol Myers Squibb (NYSE: BMY). Growing revenues from these collaborations is one of the company's talents, with Abbvie retaining the option to license up to five new eye health programs and Bristol Myers Squibb paying $100 million up front for its immuno-oncology drug discovery contract. SPY data by YCharts Editas Medicine Editas Medicine (NASDAQ: EDIT) is significantly smaller than CRISPR Therapeutics, with a market cap of $2 billion compared with CRISPR's $6.3 billion. | Like CRISPR, Editas has a roster of large collaborators including Abbvie (NYSE: ABBV) and Bristol Myers Squibb (NYSE: BMY). Growing revenues from these collaborations is one of the company's talents, with Abbvie retaining the option to license up to five new eye health programs and Bristol Myers Squibb paying $100 million up front for its immuno-oncology drug discovery contract. Indeed, in the past 12 months, the company earned revenue of $289 million and spent nearly $200 million of it on research and development (R&D). |
24468.0 | 2020-07-19 00:00:00 UTC | 3 Fantastic Dividend Stocks to Buy When the Market Crashes Again | ABBV | https://www.nasdaq.com/articles/3-fantastic-dividend-stocks-to-buy-when-the-market-crashes-again-2020-07-19 | nan | nan | Yes, the stock market will crash again. That's a 100% certainty. What isn't so certain is when it will happen. But you can bet on another market crash coming down the road, perhaps even this year.
If you do take that bet, though, make sure you hold some cash to the side. Major market downturns create excellent buying opportunities. You can especially scoop up shares of dividend stocks at lower prices and lock in higher yields. Here are three fantastic dividend stocks to buy when the market crashes again.
Image source: Getty Images.
Brookfield Infrastructure
You have a couple of alternatives with Brookfield Infrastructure. Brookfield Infrastructure Partners (NYSE: BIP) is a limited partnership (LP) that offers a juicy dividend yield of close to 4.5%. Earlier this year, the company gave investors a gift by creating a new entity, Brookfield Infrastructure Corporation (NYSE: BIPC). They're economically equivalent and pay the same dividend. But because of its share price, Brookfield Infrastructure Corporation's dividend yield stands at close to 4.1%.
What's the difference between the two (aside from the small difference in dividend yields)? They have different tax implications. Also, some retirement accounts and indexes don't allow LPs. Otherwise, the same reasons for buying apply to both stocks. And there are plenty of reasons to invest in either Brookfield Infrastructure entity in addition to the attractive dividend yield.
Brookfield Infrastructure is remarkably diversified. It owns infrastructure assets across multiple sectors -- data, energy, transport, and utilities. These assets are also diversified geographically across four regions, with no region generating more than 30% of total cash flow. This diversification makes the company resilient to macroeconomic headwinds.
Don't think Brookfield Infrastructure is just a boring low-growth stock, though. The company continually reevaluates its assets, selling lower-performing ones and reinvesting in more promising ones. Whenever the market plunges again, an investment in either of the Brookfield Infrastructure stocks will give you solid long-term growth prospects plus a strong dividend, which should add up to market-beating total returns.
Brookfield Renewable Partners
Brookfield Renewable Partners (NYSE: BEP) is a sibling of Brookfield Infrastructure. The companies are managed by the same partner, Brookfield Asset Managers. Brookfield Renewable is also a limited partnership. And it pays a strong dividend that currently yields close to 4.1%.
As its name hints, Brookfield Renewable focuses on renewable energy. It owns hydroelectric, solar, and wind power-generation facilities plus energy storage facilities. Roughly 75% of the company's funds from operations (FFO) has been made from generating hydroelectric power in the past. But Brookfield Renewable is beefing up its solar and wind assets through an acquisition of TerraForm.
Fossil-fuel energy is going the way of the dinosaurs (which, by the way, didn't produce fossil fuels -- they come from dead plants). That's not happening only because of environmental concerns. Renewable energy sources such as solar and wind are already more cost-effective than natural gas and other fossil fuels.
Brookfield Renewable thinks that it can deliver average annual returns of at least 12% and up to 15%. If you get a chance to buy the stock at a discount during a market crash, your returns would likely be even higher.
AbbVie
At last, we have a great dividend stock to buy in the next market crash that isn't named Brookfield. AbbVie (NYSE: ABBV) offers a dividend yield of 4.7% -- the highest of the group. It's also a Dividend Aristocrat with 47 consecutive years of dividend increases under its belt.
I'll admit that AbbVie might seem like somewhat riskier than the Brookfield companies. The company relies heavily on immunology drug Humira. Within the next three years, Humira's sales will begin to fall significantly as biosimilar rivals enter the U.S. market.
However, AbbVie seems to have a pretty good plan to cope with the anticipated sales decline for Humira. The company has built up an impressive roster with fast-rising stars including blood cancer drugs Imbruvica and Venclexta and new immunology drugs Rinvoq and Skyrizi.
In addition, AbbVie's recent acquisition of Allergan gives it additional cash flow that makes it less dependent on Humira. Allergan's blockbuster Botox franchise is its crown jewel. AbbVie also picked up new products with great potential, including antipsychotic drug Vraylar. The pharma stock isn't likely to deliver tremendous growth over the next few years, but it's one that income-seeking investors might want to snag when the next market downturn comes.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of June 2, 2020
Keith Speights owns shares of AbbVie, Brookfield Infrastructure, Brookfield Infrastructure Partners, and Brookfield Renewable Partners L.P. The Motley Fool owns shares of and recommends Brookfield Asset Management. The Motley Fool recommends Brookfield Infrastructure and Brookfield Infrastructure Partners. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie At last, we have a great dividend stock to buy in the next market crash that isn't named Brookfield. AbbVie (NYSE: ABBV) offers a dividend yield of 4.7% -- the highest of the group. I'll admit that AbbVie might seem like somewhat riskier than the Brookfield companies. | See the 10 stocks *Stock Advisor returns as of June 2, 2020 Keith Speights owns shares of AbbVie, Brookfield Infrastructure, Brookfield Infrastructure Partners, and Brookfield Renewable Partners L.P. AbbVie At last, we have a great dividend stock to buy in the next market crash that isn't named Brookfield. AbbVie (NYSE: ABBV) offers a dividend yield of 4.7% -- the highest of the group. | AbbVie At last, we have a great dividend stock to buy in the next market crash that isn't named Brookfield. See the 10 stocks *Stock Advisor returns as of June 2, 2020 Keith Speights owns shares of AbbVie, Brookfield Infrastructure, Brookfield Infrastructure Partners, and Brookfield Renewable Partners L.P. AbbVie (NYSE: ABBV) offers a dividend yield of 4.7% -- the highest of the group. | AbbVie At last, we have a great dividend stock to buy in the next market crash that isn't named Brookfield. See the 10 stocks *Stock Advisor returns as of June 2, 2020 Keith Speights owns shares of AbbVie, Brookfield Infrastructure, Brookfield Infrastructure Partners, and Brookfield Renewable Partners L.P. AbbVie (NYSE: ABBV) offers a dividend yield of 4.7% -- the highest of the group. |
24469.0 | 2020-07-17 00:00:00 UTC | South Korea approves human trials of Celltrion's COVID-19 antibody drug | ABBV | https://www.nasdaq.com/articles/south-korea-approves-human-trials-of-celltrions-covid-19-antibody-drug-2020-07-17 | nan | nan | By Sangmi Cha
SEOUL, July 17 (Reuters) - South Korea on Friday approved an early stage clinical trial of Celltrion Inc's 068270.KS experimental COVID-19 treatment drug, making it the country's first such antibody drug to be tested on humans.
Drugmakers worldwide are scrambling to develop vaccines and treatments for the flu-like illness caused by the novel coronavirus that has infected nearly 14 million people and killed more than 580,000 globally.
Celltrion's antibody treatment is directed against the surface of the virus and designed to block it from locking on to human cells.
The company plans to enrol 32 healthy volunteers in collaboration with a local hospital for Phase I study of the drug, which demonstrated an up to 100-fold reduction in viral load in animal tests.
Celltrion said overseas human trials of its treatment will begin soon across Europe, including the UK, which will be followed by global second and third trials in patients with mild and moderate symptoms.
It anticipates primary results from these studies by the end of this year and aims to commercialize the drug by early 2021, it said.
"Our human trials are conducted globally, so we will be able to export for sure, but will offer it to patients abroad only after securing domestic supplies for South Korea," Kee Woo-sung, its chief executive officer, told Reuters.
Its antibody treatment was developed after it was identified from a blood sample taken from one of the first South Korean patients who recovered from COVID-19 in February.
He said drugmakers should make prices for their COVID-19 treatments affordable to help end the pandemic, adding prices of its drug will be cheaper than that of Gilead Sciences Inc's GILD.O antiviral drug remdesivir.
In June, Gilead priced its COVID-19 treatment remdesivir at $2,340 per patient for developed nations.
Other companies developing potential COVID-19 treatments include Eli Lilly and Co LLY.N, Regeneron Pharmaceuticals Inc REGN.O and AbbVie ABBV.N.
(Reporting by Sangmi Cha; Editing by Miyoung Kim and Kim Coghill)
((Sangmi.Cha@thomsonreuters.com; +82 2 3704 5646; Reuters Messaging: sangmi.cha.thomsonreuters.com@reuters.net))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Other companies developing potential COVID-19 treatments include Eli Lilly and Co LLY.N, Regeneron Pharmaceuticals Inc REGN.O and AbbVie ABBV.N. Drugmakers worldwide are scrambling to develop vaccines and treatments for the flu-like illness caused by the novel coronavirus that has infected nearly 14 million people and killed more than 580,000 globally. The company plans to enrol 32 healthy volunteers in collaboration with a local hospital for Phase I study of the drug, which demonstrated an up to 100-fold reduction in viral load in animal tests. | Other companies developing potential COVID-19 treatments include Eli Lilly and Co LLY.N, Regeneron Pharmaceuticals Inc REGN.O and AbbVie ABBV.N. By Sangmi Cha SEOUL, July 17 (Reuters) - South Korea on Friday approved an early stage clinical trial of Celltrion Inc's 068270.KS experimental COVID-19 treatment drug, making it the country's first such antibody drug to be tested on humans. In June, Gilead priced its COVID-19 treatment remdesivir at $2,340 per patient for developed nations. | Other companies developing potential COVID-19 treatments include Eli Lilly and Co LLY.N, Regeneron Pharmaceuticals Inc REGN.O and AbbVie ABBV.N. By Sangmi Cha SEOUL, July 17 (Reuters) - South Korea on Friday approved an early stage clinical trial of Celltrion Inc's 068270.KS experimental COVID-19 treatment drug, making it the country's first such antibody drug to be tested on humans. Celltrion said overseas human trials of its treatment will begin soon across Europe, including the UK, which will be followed by global second and third trials in patients with mild and moderate symptoms. | Other companies developing potential COVID-19 treatments include Eli Lilly and Co LLY.N, Regeneron Pharmaceuticals Inc REGN.O and AbbVie ABBV.N. By Sangmi Cha SEOUL, July 17 (Reuters) - South Korea on Friday approved an early stage clinical trial of Celltrion Inc's 068270.KS experimental COVID-19 treatment drug, making it the country's first such antibody drug to be tested on humans. Drugmakers worldwide are scrambling to develop vaccines and treatments for the flu-like illness caused by the novel coronavirus that has infected nearly 14 million people and killed more than 580,000 globally. |
24470.0 | 2020-07-17 00:00:00 UTC | These 3 Stocks Are Still Ridiculously Cheap Right Now | ABBV | https://www.nasdaq.com/articles/these-3-stocks-are-still-ridiculously-cheap-right-now-2020-07-17 | nan | nan | In some ways, the stock market crash earlier this year seems like a distant memory. After all, we just experienced one of the best quarterly stock market performances in decades in the Q2. Now, you're likely to hear people talk about how steep the market's valuation is.
But not every stock is priced at a premium. In fact, some remain relative bargains despite the tremendous broad market recovery of recent months. Here are three stocks that are still ridiculously cheap right now (listed in alphabetical order).
Image source: Getty Images.
1. AbbVie
AbbVie (NYSE: ABBV) shares are up more than 20% in the last three months. But the big pharma stock trades at only a little over 10 times expected earnings.
There's one obvious reason why AbbVie sports such a cheap valuation. It already faces biosimilar competition in Europe for Humira -- by far its top-selling drug -- and will have to adjust to it in the U.S. in 2023. Investors are worried that the company could be in trouble when the gravy train from the popular immunosuppressive starts to dry up.
Keep in mind, though, that Humira's sales won't evaporate overnight. The drug's international sales declined significantly after biosimilars hit the market, but still topped $1 billion in the first quarter of 2020. More importantly, AbbVie has other arrows in its quiver that will help offset future sales declines for Humira, notable among them new immunology drugs Rinvoq and Skyrizi, and cancer drugs Imbruvica and Venclexta.
AbbVie won't have to deliver impressive earnings growth to provide an attractive total return. That's because the company offers an outstanding dividend with a current yield of close to 4.8%. Investors should also like its track record of dividend hikes: The company has boosted its payout in each of the last 47 years.
2. Bristol Myers Squibb
Bristol Myers Squibb (NYSE: BMY) is trading at a forward price-to-earnings ratio of 9.4. And it's price/earnings-to-growth (PEG) ratio of 0.95 makes the stock look even more attractively valued.
The drugmaker's lineup is loaded with blockbusters. Sales continue to soar for blood thinner Eliquis, arthritis drug Orencia, and cancer drug Sprycel. Cancer immunotherapy Opdivo is likely to pick up momentum with new approved indications. Bristol Myers Squibb also has added three big winners thanks to its acquisition of Celgene -- blood cancer drugs Revlimid and Pomalyst and solid tumor drug Abraxane.
But the company's newer drugs and late-stage pipeline candidates are what really make Bristol Myers Squibb a stock to watch. Blood disorder drug Reblozyl and multiple sclerosis drug Zeposia could easily become blockbusters in the not-too-distant future. It hopes to win regulatory approvals for CAR-T cell therapies ide-cel and liso-cel -- both could generate peak annual sales of $2 billion or more.
Wall Street analysts think that Bristol Myers Squibb will grow its earnings by an average of nearly 22% annually over the next five years. Add to that mix the company's dividend, which currently yields more than 3%, and this cheap pharma stock could provide impressive total returns to investors.
3. Pfizer
You might have noticed a pattern: The first two cheap stocks discussed here are pharmaceutical companies. So is the third. Pfizer (NYSE: PFE), too, is a drugmaker with an inexpensive valuation. Its shares currently trade at less than 12.5 times expected earnings.
It might seem to be a less-than-ideal pick at first glance, though. Pfizer faces rapidly declining sales for nerve pain drug Lyrica. In addition, it reported disappointing results last month from a late-stage study of Ibrance as adjuvant therapy in treating early-stage breast cancer. Ibrance's market prospects now appear to be much lower because of this clinical setback.
However, Pfizer won't be weighed down by Lyrica for much longer. The company plans to spin off its Upjohn unit (which markets Lyrica and other older drugs) and merge it with Mylan. Pfizer's pipeline also includes several candidates that could be big winners, including the COVID-19 vaccine candidate that it's developing with German biotech BioNTech.
Income investors have loved Pfizer for a long time. That shouldn't change after the Upjohn-Mylan deal wraps up. Its dividend yield won't be much lower than its current yield of 4.3%. If its pipeline delivers on its promise, the future for Pfizer will look much brighter than its recent past.
10 stocks we like better than Pfizer
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Pfizer wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of June 2, 2020
Keith Speights owns shares of AbbVie, Bristol Myers Squibb, and Pfizer. The Motley Fool owns shares of and recommends Bristol Myers Squibb. The Motley Fool recommends Mylan. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie AbbVie (NYSE: ABBV) shares are up more than 20% in the last three months. There's one obvious reason why AbbVie sports such a cheap valuation. More importantly, AbbVie has other arrows in its quiver that will help offset future sales declines for Humira, notable among them new immunology drugs Rinvoq and Skyrizi, and cancer drugs Imbruvica and Venclexta. | AbbVie won't have to deliver impressive earnings growth to provide an attractive total return. AbbVie AbbVie (NYSE: ABBV) shares are up more than 20% in the last three months. There's one obvious reason why AbbVie sports such a cheap valuation. | See the 10 stocks *Stock Advisor returns as of June 2, 2020 Keith Speights owns shares of AbbVie, Bristol Myers Squibb, and Pfizer. AbbVie AbbVie (NYSE: ABBV) shares are up more than 20% in the last three months. There's one obvious reason why AbbVie sports such a cheap valuation. | See the 10 stocks *Stock Advisor returns as of June 2, 2020 Keith Speights owns shares of AbbVie, Bristol Myers Squibb, and Pfizer. AbbVie AbbVie (NYSE: ABBV) shares are up more than 20% in the last three months. There's one obvious reason why AbbVie sports such a cheap valuation. |
24471.0 | 2020-07-16 00:00:00 UTC | iShares Russell Top 200 Growth ETF Experiences Big Inflow | ABBV | https://www.nasdaq.com/articles/ishares-russell-top-200-growth-etf-experiences-big-inflow-2020-07-16 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell Top 200 Growth ETF (Symbol: IWY) where we have detected an approximate $106.7 million dollar inflow -- that's a 4.0% increase week over week in outstanding units (from 24,050,000 to 25,000,000). Among the largest underlying components of IWY, in trading today Facebook Inc (Symbol: FB) is off about 1.1%, AbbVie Inc (Symbol: ABBV) is down about 1.4%, and ServiceNow Inc (Symbol: NOW) is lower by about 3%. For a complete list of holdings, visit the IWY Holdings page » The chart below shows the one year price performance of IWY, versus its 200 day moving average:
Looking at the chart above, IWY's low point in its 52 week range is $71.8649 per share, with $115.34 as the 52 week high point — that compares with a last trade of $110.92. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ».
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of IWY, in trading today Facebook Inc (Symbol: FB) is off about 1.1%, AbbVie Inc (Symbol: ABBV) is down about 1.4%, and ServiceNow Inc (Symbol: NOW) is lower by about 3%. For a complete list of holdings, visit the IWY Holdings page » The chart below shows the one year price performance of IWY, versus its 200 day moving average: Looking at the chart above, IWY's low point in its 52 week range is $71.8649 per share, with $115.34 as the 52 week high point — that compares with a last trade of $110.92. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of IWY, in trading today Facebook Inc (Symbol: FB) is off about 1.1%, AbbVie Inc (Symbol: ABBV) is down about 1.4%, and ServiceNow Inc (Symbol: NOW) is lower by about 3%. For a complete list of holdings, visit the IWY Holdings page » The chart below shows the one year price performance of IWY, versus its 200 day moving average: Looking at the chart above, IWY's low point in its 52 week range is $71.8649 per share, with $115.34 as the 52 week high point — that compares with a last trade of $110.92. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ». | Among the largest underlying components of IWY, in trading today Facebook Inc (Symbol: FB) is off about 1.1%, AbbVie Inc (Symbol: ABBV) is down about 1.4%, and ServiceNow Inc (Symbol: NOW) is lower by about 3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell Top 200 Growth ETF (Symbol: IWY) where we have detected an approximate $106.7 million dollar inflow -- that's a 4.0% increase week over week in outstanding units (from 24,050,000 to 25,000,000). For a complete list of holdings, visit the IWY Holdings page » The chart below shows the one year price performance of IWY, versus its 200 day moving average: Looking at the chart above, IWY's low point in its 52 week range is $71.8649 per share, with $115.34 as the 52 week high point — that compares with a last trade of $110.92. | Among the largest underlying components of IWY, in trading today Facebook Inc (Symbol: FB) is off about 1.1%, AbbVie Inc (Symbol: ABBV) is down about 1.4%, and ServiceNow Inc (Symbol: NOW) is lower by about 3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell Top 200 Growth ETF (Symbol: IWY) where we have detected an approximate $106.7 million dollar inflow -- that's a 4.0% increase week over week in outstanding units (from 24,050,000 to 25,000,000). For a complete list of holdings, visit the IWY Holdings page » The chart below shows the one year price performance of IWY, versus its 200 day moving average: Looking at the chart above, IWY's low point in its 52 week range is $71.8649 per share, with $115.34 as the 52 week high point — that compares with a last trade of $110.92. |
24472.0 | 2020-07-14 00:00:00 UTC | The 7 Best Pharmaceutical Stocks That Go Beyond the Covid-19 Chase | ABBV | https://www.nasdaq.com/articles/the-7-best-pharmaceutical-stocks-that-go-beyond-the-covid-19-chase-2020-07-14 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
It’s easy to miss the forest for the trees in markets like this. Especially when it comes to pharmaceutical stocks.
What I mean is that, in some sectors, there are great stocks that get overlooked because a few of them are working on event-driven issues, while others are creating long-term solutions to major trends.
This is especially true in the pharmaceutical and biotech spaces right now. Maybe it’s because the Kentucky Derby was postponed, but people are betting on pharmas discovering a vaccine to Covid-19 like it’s the only horse race out there.
The fact is, there’s a whole racing season and betting on one horse in one race isn’t successful investing. And neither is betting on pharmaceutical stocks for one medicine.
That’s where my grading system comes in.
My algorithmic system of analysis has led to several market breakthroughs — from Adobe (NASDAQ:ABDE) and Qualcomm (NASDAQ:QCOM) to Nike (NYSE:NKE) and Home Depot (NYSE:HD) — allowing me to become a multibillionaire by the time I was in my 30s. Now, I’m looking to build even more profits through my Master Key investments.
Overall, there are plenty of massively successful drugs. However, they’re blockbusters because they can be used for a variety ailments. Or, the top companies have a strong pipeline of drugs that address issues that are important to a large number of people.
10 Micro-Cap Stocks to Buy Today for Value and Growth
The seven best pharmaceutical stocks beyond the Covid-19 chase are great firms that will score big wins for many years to come. They are:
United Therapeutics (NASDAQ:UTHR)
Novo Nordisk (NYSE:NVO)
Dr Reddy’s Laboratories (NYSE:RDY)
AbbVie (NYSE:ABBV)
Eli Lilly & Co (NYSE:LLY)
Zoetis (NYSE:ZTS)
Horizon Therapeutics (NASDAQ:HZNP)
Let’s look at what makes each worth your consideration.
The Best Pharmaceutical Stocks: United Therapeutics (UTHR)
Source: Shutterstock
Established in 1996 near the National Institutes of Health in the DC metro area, this biotech has an extensive library of drugs and devices to treat pulmonary hypertension (PH).
It has one device in the market currently, Remunity, a subcutaneous pump that allows patients with PH to stay mobile and active. It is also waiting for Food and Drug Administration clearance for another device, Trevyent.
This is a relatively rare disease, but doctors in the West are seeing cases grow in women by 2.5% annually.
UTHR also has a robust program for growing organs — lungs, kidneys, heart — and has a number of drugs in trials for PH-related diseases as well as brain cancer.
Many of these devices and drugs will have other uses for patients that have challenges from related pulmonary challenges.
UTHR stock is up 53% in the past 12 months but still trades at a price-to-earnings ratio under 10.
Novo Nordisk (NVO)
Source: joreks / Shutterstock.com
More than 30 years ago, NVO became the world’s leading insulin producer. Given how quickly diabetes has grown since then, it’s no surprise that NVO is now one of the leading pharmas in the treatment of Type 1 and Type 2 diabetes.
With a market cap of $154 billion, this Denmark-based drug company is a force to be reckoned with. And its influence in the industry remains significant.
It also focuses on obesity, as well as biopharmaceuticals for hormone replacement therapy, growth hormone therapy and hemophilia. These aren’t sexy spaces, but they are enormous and NVO is a well-established player.
You could say it’s more like Ted Williams than Babe Ruth. It’s not looking for home runs as much as it is solid, reliable base hits. And that is always good to have in your portfolio. In fact, you can find some of those through my Master Key investing model.
5 Value Stocks to Buy That Also Pay Dividends
The stock is up 38% in the past year, yields 1.3% and is trading at a P/E that is about average for the S&P 500.
Dr Reddy’s Laboratories (RDY)
Source: AjayTvm / Shutterstock.com
In 1984, Dr. Kallam Anji Reddy launched his generic pharmaceutical company with the goal of providing medicines that all Indians could afford.
Today, his generic-drugs-driving company is providing the world with affordable medicine.
Bear in mind, it’s not a major powerhouse, with only an $8 billion market cap, but it is a global player. And that market cap is based off real revenue, not hopeful drug trials.
Given its Asian roots, it doesn’t get a lot of play in the U.S., but that can be an advantage, since it keeps away a lot of the dumb money that FOMO investors pass around in markets like the one we’re in.
RDY has a portfolio of generics, over-the-counter medicines as well as its own oncology and inflammation drugs and has built a strong global business.
The stock is up 36% in the past 12 months and has a dividend that’s slightly better than a long-term CD.
AbbVie (ABBV)
Source: Piotr Swat / Shutterstock.com
More than half of Abbvie’s revenue every year comes from its blockbuster drug Humira. It has made nearly $20 billion annually in the past 2 years. It also has Imbruvica, which made $4 billion last year and Mavyret that made nearly $3 billion.
The point is this company is a well-established pharma powerhouse. But it’s also one of the best pharmaceutical stocks to consider today.
Its $172 billion market cap puts it in the top echelon of big pharma firms.
The crazy thing is, after running up 40% in the past 12 months, it still yields 4.8% and it’s trading at a P/E far below market averages.
The One-Stop Shop for Tech Startup Wealth
Sometimes, even in crazy markets like this one, you can find some real values in big, sturdy companies that have significant growth potential. That said, growth — like these pharmaceutical plays, is where I really shine. And you can truly see that through my Master Key investing model.
Eli Lilly & Co (LLY)
Source: Jonathan Weiss / Shutterstock.com
The history of LLY goes back to 1876. It was the drug company that first made and distributed the Jonas Salk’s polio vaccine. It was a pioneer in developing insulin medications, and remains a key insulin drug maker.
It also has a long list of widely prescribed psychological medications like Prozac, Cymbalta and Zyprexa.
LLY has staid a market leader by maintaining a number of strong portfolios in broad treatment areas. It has winners, but it’s the cumulative power of its portfolio that’s most important.
In 2019, Trulicity was its biggest drug at $4 billion in sales, followed by Humalog, which had sales near $3 billion. Overall revenue in 2019 was around $22 billion, so its top two drugs only made up 33% of its revenue base.
LLY stock is up 53% in the past 12 months and still has a 1.8% dividend. It’s getting pricey but its growth is still far outpacing its valuation, which makes it one of the stand out pharmaceutical stocks today.
Zoetis (ZTS)
Source: JHVEPhoto / Shutterstock.com
With all the talk about potential vaccines and cures for Covid-19, many people have forgotten about the virus that was running rampant as late as last fall.
It wasn’t human, but it was decimating the population of pigs around the world, especially in China. It’s called the African Swine Flu (ASF) and it halved the pork production in China in a matter of months.
China is largest consumer of pork, so that’s a very big deal. It had huge impacts on the economy. And large U.S. producers were under stress because some of the largest are now Chinese subsidiaries.
ZTS in an animal health firm. And it was already developing a vaccine for ASF just as the epidemic — ASF that is — began to break.
It’s also getting notoriety now because more people understand the link between animal viruses and people. And a company like ZTS is on the front lines and can be very helpful in helping both animals and humans. Their technology is at the forefront of animal healthcare, and you can find similar companies that hold the secret to unlocking massive gains in high-growth industries here.
7 Software Stocks Surging Forward
ZTS stock is up 20% in the past year and has a $65 billion market cap, so it’s a major player in its sector.
Horizon Therapeutics (HZNP)
Source: Shutterstock
This Ireland-based firm has a handful of drugs that are in the market. It specializes in the rare disease and rheumatoid markets, with drugs ranging from treating gout to fibrotic thyroid eye disease.
The stock has taken off this year because two if its recent releases look like they could be blockbusters — Krystexxa and Tepezza. The former is a new treatment for gout. The latter is the only FDA-approved Thyroid Eye Disease treatment.
While it has a number of treatments for osteo and rheumatoid arthritis as well, there’s a lot of competition for these medicines. But the coast is clear for Krystexxa and Tepezza.
HZNP is up 143% in the past 12 months, and 84% since its Q1 numbers came out 3 months ago.
With an $11 billion market cap, it’s also a tempting target for larger drug companies looking to add to their portfolios in these areas. All of these aspects combine to make it one of the best pharmaceutical stocks to consider now.
Find Your ‘Master Key’ to Investing
Businesses like Intel (NASDAQ:INTC), Amazon (NASDAQ:AMZN) and Netflix (NASDAQ:NFLX) are obviously monsters when it comes to Wall Street. However, at InvestorPlace, they’re what our network of financial insiders refer to as “Master Key” investments.
What is a Master Key investment?
Well, in a literal sense, a master key is a single key that can be used to unlock any door in a building — even though each door has its own individual key. In turn, whoever holds this master key has the power to unlock any door.
And that’s exactly the kind of investment opportunity we look for.
These Master Key investments are by far the best and most lucrative you can make. But, that’s only if you get in on them early.
That said, click here to see how I found these stocks and unlock the door to a more profitable portfolio.
Louis Navellier had an unconventional start, as a grad student who accidentally built a market-beating stock system — with returns rivaling even Warren Buffett. In his latest feat, Louis discovered the “Master Key” to profiting from the biggest tech revolution of this (or any) generation. Louis Navellier may hold some of the aforementioned securities in one or more of his newsletters.
The post The 7 Best Pharmaceutical Stocks That Go Beyond the Covid-19 Chase appeared first on InvestorPlace.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | They are: United Therapeutics (NASDAQ:UTHR) Novo Nordisk (NYSE:NVO) Dr Reddy’s Laboratories (NYSE:RDY) AbbVie (NYSE:ABBV) Eli Lilly & Co (NYSE:LLY) Zoetis (NYSE:ZTS) Horizon Therapeutics (NASDAQ:HZNP) Let’s look at what makes each worth your consideration. AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com More than half of Abbvie’s revenue every year comes from its blockbuster drug Humira. The Best Pharmaceutical Stocks: United Therapeutics (UTHR) Source: Shutterstock Established in 1996 near the National Institutes of Health in the DC metro area, this biotech has an extensive library of drugs and devices to treat pulmonary hypertension (PH). | They are: United Therapeutics (NASDAQ:UTHR) Novo Nordisk (NYSE:NVO) Dr Reddy’s Laboratories (NYSE:RDY) AbbVie (NYSE:ABBV) Eli Lilly & Co (NYSE:LLY) Zoetis (NYSE:ZTS) Horizon Therapeutics (NASDAQ:HZNP) Let’s look at what makes each worth your consideration. AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com More than half of Abbvie’s revenue every year comes from its blockbuster drug Humira. The Best Pharmaceutical Stocks: United Therapeutics (UTHR) Source: Shutterstock Established in 1996 near the National Institutes of Health in the DC metro area, this biotech has an extensive library of drugs and devices to treat pulmonary hypertension (PH). | They are: United Therapeutics (NASDAQ:UTHR) Novo Nordisk (NYSE:NVO) Dr Reddy’s Laboratories (NYSE:RDY) AbbVie (NYSE:ABBV) Eli Lilly & Co (NYSE:LLY) Zoetis (NYSE:ZTS) Horizon Therapeutics (NASDAQ:HZNP) Let’s look at what makes each worth your consideration. AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com More than half of Abbvie’s revenue every year comes from its blockbuster drug Humira. 10 Micro-Cap Stocks to Buy Today for Value and Growth The seven best pharmaceutical stocks beyond the Covid-19 chase are great firms that will score big wins for many years to come. | They are: United Therapeutics (NASDAQ:UTHR) Novo Nordisk (NYSE:NVO) Dr Reddy’s Laboratories (NYSE:RDY) AbbVie (NYSE:ABBV) Eli Lilly & Co (NYSE:LLY) Zoetis (NYSE:ZTS) Horizon Therapeutics (NASDAQ:HZNP) Let’s look at what makes each worth your consideration. AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com More than half of Abbvie’s revenue every year comes from its blockbuster drug Humira. Especially when it comes to pharmaceutical stocks. |
24473.0 | 2020-07-14 00:00:00 UTC | Bill Gross predicts value outperforms growth, based on rates correlation | ABBV | https://www.nasdaq.com/articles/bill-gross-predicts-value-outperforms-growth-based-on-rates-correlation-2020-07-14 | nan | nan | By Kate Duguid
NEW YORK, July 14 (Reuters) - Billionaire investor Bill Gross is predicting that value stocks like IBM IBM.N and Altria Group MO.N are likely to fare better than growth stocks like Apple AAPL.O or Amazon.com AMZN.O in the near term, due to a correlation with real interest rates.
U.S. real yields - which adjust for inflation - have been declining in response to the Federal Reserve's aggressive monetary actions over the past few months to limit the economic fallout of the coronavirus pandemic. The yield on the 10-year Treasury Inflation-Protected Security (TIPS) US10YTIP=RR has been trading with a negative yield since late March and is now minus 0.803%, near an all-time-low.
Gross, who co-founded Pacific Investment Management Company, then spent four years at Janus Henderson before leaving in 2019 to manage his own money, said that the reason that the "Fab 5 stocks" and growth stocks in general had done "so fabulously well" centers on falling real interest rates that "are still reaching historic lows." Gross is referring to a clutch of high-performing stocks: Amazon, Facebook FB.O, Apple, Netflix NFLX.O and Google's parent Alphabet GOOGL.O, according to his spokesperson.
The yields of TIPS are highly correlated with growth stocks, but have far less of an effect on the prices of traditional value stocks, he wrote.
The future price disparity of Microsoft MSFT.O, Apple and Amazon "is subject to an ongoing decline in real rates, which to my mind, have seen their best days," Gross said. "Value stocks, versus growth stocks, should be an investor's preference in the near-term future," he writes.
Gross said that as well as IBM and Altria, he likes stocks such as midstream company Enterprise Products Partners EPD.N and pharmaceutical giant AbbVie ABBV.N.
"Happiness is a healthy body, sinking a few 10-foot putts, and investing in value, versus the 'Fab 5'," wrote Gross, who also said he was COVID-19 free.
(Reporting by Kate Duguid; Additional reporting by Gertrude Chavez-Dreyfuss; Editing by Megan Davies and Christopher Cushing)
((kate.duguid@thomsonreuters.com; +646-223-6118; Reuters Messaging: kate.duguid@thomsonreuters.com@thomsonreuters.net))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Gross said that as well as IBM and Altria, he likes stocks such as midstream company Enterprise Products Partners EPD.N and pharmaceutical giant AbbVie ABBV.N. U.S. real yields - which adjust for inflation - have been declining in response to the Federal Reserve's aggressive monetary actions over the past few months to limit the economic fallout of the coronavirus pandemic. The future price disparity of Microsoft MSFT.O, Apple and Amazon "is subject to an ongoing decline in real rates, which to my mind, have seen their best days," Gross said. | Gross said that as well as IBM and Altria, he likes stocks such as midstream company Enterprise Products Partners EPD.N and pharmaceutical giant AbbVie ABBV.N. By Kate Duguid NEW YORK, July 14 (Reuters) - Billionaire investor Bill Gross is predicting that value stocks like IBM IBM.N and Altria Group MO.N are likely to fare better than growth stocks like Apple AAPL.O or Amazon.com AMZN.O in the near term, due to a correlation with real interest rates. Gross, who co-founded Pacific Investment Management Company, then spent four years at Janus Henderson before leaving in 2019 to manage his own money, said that the reason that the "Fab 5 stocks" and growth stocks in general had done "so fabulously well" centers on falling real interest rates that "are still reaching historic lows." | Gross said that as well as IBM and Altria, he likes stocks such as midstream company Enterprise Products Partners EPD.N and pharmaceutical giant AbbVie ABBV.N. By Kate Duguid NEW YORK, July 14 (Reuters) - Billionaire investor Bill Gross is predicting that value stocks like IBM IBM.N and Altria Group MO.N are likely to fare better than growth stocks like Apple AAPL.O or Amazon.com AMZN.O in the near term, due to a correlation with real interest rates. Gross, who co-founded Pacific Investment Management Company, then spent four years at Janus Henderson before leaving in 2019 to manage his own money, said that the reason that the "Fab 5 stocks" and growth stocks in general had done "so fabulously well" centers on falling real interest rates that "are still reaching historic lows." | Gross said that as well as IBM and Altria, he likes stocks such as midstream company Enterprise Products Partners EPD.N and pharmaceutical giant AbbVie ABBV.N. By Kate Duguid NEW YORK, July 14 (Reuters) - Billionaire investor Bill Gross is predicting that value stocks like IBM IBM.N and Altria Group MO.N are likely to fare better than growth stocks like Apple AAPL.O or Amazon.com AMZN.O in the near term, due to a correlation with real interest rates. U.S. real yields - which adjust for inflation - have been declining in response to the Federal Reserve's aggressive monetary actions over the past few months to limit the economic fallout of the coronavirus pandemic. |
24474.0 | 2020-07-13 00:00:00 UTC | Notable Monday Option Activity: GPI, ISRG, ABBV | ABBV | https://www.nasdaq.com/articles/notable-monday-option-activity%3A-gpi-isrg-abbv-2020-07-13 | nan | nan | Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Group 1 Automotive, Inc. (Symbol: GPI), where a total volume of 3,292 contracts has been traded thus far today, a contract volume which is representative of approximately 329,200 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 115.1% of GPI's average daily trading volume over the past month, of 286,075 shares. Especially high volume was seen for the $70 strike call option expiring August 21, 2020, with 1,002 contracts trading so far today, representing approximately 100,200 underlying shares of GPI. Below is a chart showing GPI's trailing twelve month trading history, with the $70 strike highlighted in orange:
Intuitive Surgical Inc (Symbol: ISRG) options are showing a volume of 5,780 contracts thus far today. That number of contracts represents approximately 578,000 underlying shares, working out to a sizeable 101.5% of ISRG's average daily trading volume over the past month, of 569,250 shares. Particularly high volume was seen for the $600 strike call option expiring July 17, 2020, with 1,036 contracts trading so far today, representing approximately 103,600 underlying shares of ISRG. Below is a chart showing ISRG's trailing twelve month trading history, with the $600 strike highlighted in orange:
And AbbVie Inc (Symbol: ABBV) options are showing a volume of 62,802 contracts thus far today. That number of contracts represents approximately 6.3 million underlying shares, working out to a sizeable 85.9% of ABBV's average daily trading volume over the past month, of 7.3 million shares. Particularly high volume was seen for the $65 strike call option expiring January 15, 2021, with 9,802 contracts trading so far today, representing approximately 980,200 underlying shares of ABBV. Below is a chart showing ABBV's trailing twelve month trading history, with the $65 strike highlighted in orange:
For the various different available expirations for GPI options, ISRG options, or ABBV options, visit StockOptionsChannel.com.
Today's Most Active Call & Put Options of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Particularly high volume was seen for the $65 strike call option expiring January 15, 2021, with 9,802 contracts trading so far today, representing approximately 980,200 underlying shares of ABBV. Below is a chart showing ISRG's trailing twelve month trading history, with the $600 strike highlighted in orange: And AbbVie Inc (Symbol: ABBV) options are showing a volume of 62,802 contracts thus far today. That number of contracts represents approximately 6.3 million underlying shares, working out to a sizeable 85.9% of ABBV's average daily trading volume over the past month, of 7.3 million shares. | Below is a chart showing ISRG's trailing twelve month trading history, with the $600 strike highlighted in orange: And AbbVie Inc (Symbol: ABBV) options are showing a volume of 62,802 contracts thus far today. That number of contracts represents approximately 6.3 million underlying shares, working out to a sizeable 85.9% of ABBV's average daily trading volume over the past month, of 7.3 million shares. Particularly high volume was seen for the $65 strike call option expiring January 15, 2021, with 9,802 contracts trading so far today, representing approximately 980,200 underlying shares of ABBV. | Below is a chart showing ISRG's trailing twelve month trading history, with the $600 strike highlighted in orange: And AbbVie Inc (Symbol: ABBV) options are showing a volume of 62,802 contracts thus far today. That number of contracts represents approximately 6.3 million underlying shares, working out to a sizeable 85.9% of ABBV's average daily trading volume over the past month, of 7.3 million shares. Particularly high volume was seen for the $65 strike call option expiring January 15, 2021, with 9,802 contracts trading so far today, representing approximately 980,200 underlying shares of ABBV. | Particularly high volume was seen for the $65 strike call option expiring January 15, 2021, with 9,802 contracts trading so far today, representing approximately 980,200 underlying shares of ABBV. Below is a chart showing ABBV's trailing twelve month trading history, with the $65 strike highlighted in orange: For the various different available expirations for GPI options, ISRG options, or ABBV options, visit StockOptionsChannel.com. Below is a chart showing ISRG's trailing twelve month trading history, with the $600 strike highlighted in orange: And AbbVie Inc (Symbol: ABBV) options are showing a volume of 62,802 contracts thus far today. |
24475.0 | 2020-07-10 00:00:00 UTC | Ex-Dividend Reminder: AbbVie, American Financial Group and Pennymac Mortgage Investment Trust | ABBV | https://www.nasdaq.com/articles/ex-dividend-reminder%3A-abbvie-american-financial-group-and-pennymac-mortgage-investment | nan | nan | Looking at the universe of stocks we cover at Dividend Channel, on 7/14/20, AbbVie Inc (Symbol: ABBV), American Financial Group Inc (Symbol: AFG), and Pennymac Mortgage Investment Trust (Symbol: PMT) will all trade ex-dividend for their respective upcoming dividends. AbbVie Inc will pay its quarterly dividend of $1.18 on 8/14/20, American Financial Group Inc will pay its quarterly dividend of $0.45 on 7/27/20, and Pennymac Mortgage Investment Trust will pay its quarterly dividend of $0.40 on 7/30/20. As a percentage of ABBV's recent stock price of $97.61, this dividend works out to approximately 1.21%, so look for shares of AbbVie Inc to trade 1.21% lower — all else being equal — when ABBV shares open for trading on 7/14/20. Similarly, investors should look for AFG to open 0.78% lower in price and for PMT to open 2.35% lower, all else being equal.
Below are dividend history charts for ABBV, AFG, and PMT, showing historical dividends prior to the most recent ones declared.
AbbVie Inc (Symbol: ABBV):
American Financial Group Inc (Symbol: AFG):
Pennymac Mortgage Investment Trust (Symbol: PMT):
In general, dividends are not always predictable, following the ups and downs of company profits over time. Therefore, a good first due diligence step in forming an expectation of annual yield going forward, is looking at the history above, for a sense of stability over time. This can help in judging whether the most recent dividends from these companies are likely to continue. If they do continue, the current estimated yields on annualized basis would be 4.84% for AbbVie Inc, 3.10% for American Financial Group Inc, and 9.40% for Pennymac Mortgage Investment Trust.
In Friday trading, AbbVie Inc shares are currently off about 0.3%, American Financial Group Inc shares are up about 2%, and Pennymac Mortgage Investment Trust shares are off about 0.3% on the day.
Click here to learn which 25 S.A.F.E. dividend stocks should be on your radar screen »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | As a percentage of ABBV's recent stock price of $97.61, this dividend works out to approximately 1.21%, so look for shares of AbbVie Inc to trade 1.21% lower — all else being equal — when ABBV shares open for trading on 7/14/20. If they do continue, the current estimated yields on annualized basis would be 4.84% for AbbVie Inc, 3.10% for American Financial Group Inc, and 9.40% for Pennymac Mortgage Investment Trust. Looking at the universe of stocks we cover at Dividend Channel, on 7/14/20, AbbVie Inc (Symbol: ABBV), American Financial Group Inc (Symbol: AFG), and Pennymac Mortgage Investment Trust (Symbol: PMT) will all trade ex-dividend for their respective upcoming dividends. | Looking at the universe of stocks we cover at Dividend Channel, on 7/14/20, AbbVie Inc (Symbol: ABBV), American Financial Group Inc (Symbol: AFG), and Pennymac Mortgage Investment Trust (Symbol: PMT) will all trade ex-dividend for their respective upcoming dividends. AbbVie Inc will pay its quarterly dividend of $1.18 on 8/14/20, American Financial Group Inc will pay its quarterly dividend of $0.45 on 7/27/20, and Pennymac Mortgage Investment Trust will pay its quarterly dividend of $0.40 on 7/30/20. AbbVie Inc (Symbol: ABBV): American Financial Group Inc (Symbol: AFG): Pennymac Mortgage Investment Trust (Symbol: PMT): In general, dividends are not always predictable, following the ups and downs of company profits over time. | Looking at the universe of stocks we cover at Dividend Channel, on 7/14/20, AbbVie Inc (Symbol: ABBV), American Financial Group Inc (Symbol: AFG), and Pennymac Mortgage Investment Trust (Symbol: PMT) will all trade ex-dividend for their respective upcoming dividends. AbbVie Inc will pay its quarterly dividend of $1.18 on 8/14/20, American Financial Group Inc will pay its quarterly dividend of $0.45 on 7/27/20, and Pennymac Mortgage Investment Trust will pay its quarterly dividend of $0.40 on 7/30/20. AbbVie Inc (Symbol: ABBV): American Financial Group Inc (Symbol: AFG): Pennymac Mortgage Investment Trust (Symbol: PMT): In general, dividends are not always predictable, following the ups and downs of company profits over time. | Looking at the universe of stocks we cover at Dividend Channel, on 7/14/20, AbbVie Inc (Symbol: ABBV), American Financial Group Inc (Symbol: AFG), and Pennymac Mortgage Investment Trust (Symbol: PMT) will all trade ex-dividend for their respective upcoming dividends. As a percentage of ABBV's recent stock price of $97.61, this dividend works out to approximately 1.21%, so look for shares of AbbVie Inc to trade 1.21% lower — all else being equal — when ABBV shares open for trading on 7/14/20. If they do continue, the current estimated yields on annualized basis would be 4.84% for AbbVie Inc, 3.10% for American Financial Group Inc, and 9.40% for Pennymac Mortgage Investment Trust. |
24476.0 | 2020-07-10 00:00:00 UTC | Botox, Keytruda Get FDA Approval For New Uses, BVXV Abuzz, First Droopy Eyelid Treatment Is Here | ABBV | https://www.nasdaq.com/articles/botox-keytruda-get-fda-approval-for-new-uses-bvxv-abuzz-first-droopy-eyelid-treatment-is | nan | nan | (RTTNews) - Today's Daily Dose brings you news about Altimmune's AdCOVID vaccine, the growing list of approved indications for AbbVie's Botox, an update on Aldeyra's Dry Eye disease drug candidate Reproxalap and FDA approval of Merck's Keytruda for yet another indication.
Read on…
1. FDA Approves Expanded Use of AbbVie's Botox
The FDA has approved the expanded use of BOTOX for the treatment of spasticity in pediatric patients 2 years of age and older, including those with lower limb spasticity caused by cerebral palsy.
Last October, BOTOX received the FDA nod in the indication of lower limb spasticity in pediatric patients, excluding those with cerebral palsy.
BOTOX, developed by Allergan, an AbbVie (ABBV) company, received its first FDA approval in 1989 for two rare eye muscle disorders - blepharospasm and strabismus in adults. Since then, it has received approval for a number of therapeutic indications, including Chronic Migraine, overactive bladder, leakage of urine (incontinence) due to overactive bladder caused by a neurologic condition, cervical dystonia, spasticity, and severe underarm sweating (axillary hyperhidrosis).
In 2019, BOTOX recorded annual sales of $3.79 billion - with therapeutic indications accounting for $2.13 billion and cosmetic sales registering $1.66 billion.
ABBV closed Thursday's trading at $97.94, down 1.35%.
2. Aldeyra To Initiate New Trials For Dry Eye Disease Drug Candidate
Shares of Aldeyra Therapeutics Inc. (ALDX) jumped more than 19 percent on Thursday as the Company continues to make progress with its Dry Eye disease drug candidate Reproxalap.
Aldeyra said that it intends to initiate two clinical trials to assess the activity of Reproxalap in reducing tear levels of RASP (reactive aldehyde species). The FDA has confirmed the use of RASP as an objective sign for the treatment of dry eye disease.
Top-line results from the first of the RASP trials are expected by the end of 2020, pending potential disruptions due to the COVID-19 pandemic. In addition, a safety trial in dry eye disease patients is expected to be initiated in the fourth quarter of 2020.
The Company expects to seek FDA approval of Reproxalap for dry eye disease in late 2021.
ALDX closed Thursday's trading at $5.20, up 19.27%.
3. Altimmune Gains Altitude
Altimmune Inc. (ALT) has teamed up with DynPort Vaccine Co. to coordinate U.S. Government funding efforts for AdCOVID.
DynPort Vaccine Co. develops vaccines and therapeutics for US Government customers.
AdCOVID, Altimmune's single-dose intranasal COVID-19 vaccine candidate, is under preclinical studies at the University of Alabama at Birmingham. The Company expects to begin the manufacturing of AdCOVID during this quarter, followed by a phase I clinical trial during the next quarter.
Shares of Altimmune have been rallying ever since its foray into COVID-19 drug and vaccine development space in February. The stock touched a new 52-week high of $24.65 in intraday trading on Thursday, before closing at $20.22, up 18.73%.
Related Reading
Altimmune's (ALT) Astounding Journey From $1 To $20 In Just Few Months
4. BiondVax Hits All-time High
Shares of BiondVax Pharmaceuticals Ltd. (BVXV) closed at an all-time high of $38.99, up 21.09% from the previous day's close.
BiondVax is an Israel-based biopharmaceutical company developing a universal flu vaccine. The Company's universal flu vaccine candidate, called M-001, is under a phase III trial across 83 sites and seven countries. The results from this phase III trial are expected by end of 2020.
BVXV has traded in a range of $5.20 to $41.64 in the last 1 year. The stock touched a high of $41.64 in intraday trading on Thursday, before closing at $38.99, up 21.09%.
5. Merck's Keytruda Scores Another Approval
Merck's (MRK) supplemental Biologics License Application for KEYTRUDA as monotherapy for second-line treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma has been granted priority review by the FDA - with a decision date set for October 30, 2020.
Classical Hodgkin lymphoma accounts for more than nine in 10 cases of Hodgkin lymphoma, which impacts approximately 7,400 patients a year in the U.S., according to the Company.
KEYTRUDA received accelerated approval in 2017 for treatment of adult and pediatric patients with Classical Hodgkin Lymphoma refractory to treatment, or who have relapsed after three or more prior lines of therapy.
Keytruda, one of Merck's blockbuster drugs, is approved for the treatment of Melanoma, Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Head, and Neck Squamous Cell Cancer, Primary Mediastinal Large B-Cell Lymphoma, Urothelial Carcinoma, Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer, Gastric Cancer, Esophageal Cancer, Cervical Cancer, Renal Cell Carcinoma and Merkel Cell Carcinoma, among others.
The drug notched up sales of $3.3 billion in the first quarter of 2020, up 45% over the year-ago quarter.
MRK closed Thursday's trading at $76.69, down 1.58%.
6. Osmotica's Droopy Eyelid Treatment Gets FDA Approval
The FDA has approved Osmotica Pharmaceuticals plc's (OSMT) eye drop Upneeq for the treatment of acquired blepharoptosis.
Acquired blepharoptosis, also known as ptosis, is a unilateral or bilateral drooping of the upper eyelid that usually occurs from a partial or complete dysfunction of the muscles that elevate the upper eyelid.
Upneeq, formerly known as RVL-1201, is a novel, once-daily ophthalmic formulation of oxymetazoline, a direct-acting a-adrenergic receptor agonist, which when administered to the eye is believed to selectively target Müller's muscle and elevate the upper eyelid.
Upneeq, which becomes the first and only FDA-approved pharmacologic treatment for acquired blepharoptosis, is expected to become commercially available next month to a selected group of ophthalmologists and optometrists.
OSMT closed Thursday's trading at $7.00, up 10.06%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | BOTOX, developed by Allergan, an AbbVie (ABBV) company, received its first FDA approval in 1989 for two rare eye muscle disorders - blepharospasm and strabismus in adults. (RTTNews) - Today's Daily Dose brings you news about Altimmune's AdCOVID vaccine, the growing list of approved indications for AbbVie's Botox, an update on Aldeyra's Dry Eye disease drug candidate Reproxalap and FDA approval of Merck's Keytruda for yet another indication. FDA Approves Expanded Use of AbbVie's Botox The FDA has approved the expanded use of BOTOX for the treatment of spasticity in pediatric patients 2 years of age and older, including those with lower limb spasticity caused by cerebral palsy. | (RTTNews) - Today's Daily Dose brings you news about Altimmune's AdCOVID vaccine, the growing list of approved indications for AbbVie's Botox, an update on Aldeyra's Dry Eye disease drug candidate Reproxalap and FDA approval of Merck's Keytruda for yet another indication. FDA Approves Expanded Use of AbbVie's Botox The FDA has approved the expanded use of BOTOX for the treatment of spasticity in pediatric patients 2 years of age and older, including those with lower limb spasticity caused by cerebral palsy. BOTOX, developed by Allergan, an AbbVie (ABBV) company, received its first FDA approval in 1989 for two rare eye muscle disorders - blepharospasm and strabismus in adults. | (RTTNews) - Today's Daily Dose brings you news about Altimmune's AdCOVID vaccine, the growing list of approved indications for AbbVie's Botox, an update on Aldeyra's Dry Eye disease drug candidate Reproxalap and FDA approval of Merck's Keytruda for yet another indication. FDA Approves Expanded Use of AbbVie's Botox The FDA has approved the expanded use of BOTOX for the treatment of spasticity in pediatric patients 2 years of age and older, including those with lower limb spasticity caused by cerebral palsy. BOTOX, developed by Allergan, an AbbVie (ABBV) company, received its first FDA approval in 1989 for two rare eye muscle disorders - blepharospasm and strabismus in adults. | (RTTNews) - Today's Daily Dose brings you news about Altimmune's AdCOVID vaccine, the growing list of approved indications for AbbVie's Botox, an update on Aldeyra's Dry Eye disease drug candidate Reproxalap and FDA approval of Merck's Keytruda for yet another indication. FDA Approves Expanded Use of AbbVie's Botox The FDA has approved the expanded use of BOTOX for the treatment of spasticity in pediatric patients 2 years of age and older, including those with lower limb spasticity caused by cerebral palsy. BOTOX, developed by Allergan, an AbbVie (ABBV) company, received its first FDA approval in 1989 for two rare eye muscle disorders - blepharospasm and strabismus in adults. |
24477.0 | 2020-07-09 00:00:00 UTC | 3 Top Biotech Stocks to Watch in July | ABBV | https://www.nasdaq.com/articles/3-top-biotech-stocks-to-watch-in-july-2020-07-09 | nan | nan | Between erratic market conditions, risk-fraught clinical trials, and unpredictable drug development pipelines, biotech investors know that with some stocks, discretion is the better part of valor. Nonetheless, July is a critical month for several leading biotech companies, and there's a lot that investors need to know if they want to make a prudent decision about whether to invest.
Moderna's growth streak may face trouble ahead
As one of the first biotech companies to move into clinical trials with a COVID-19 vaccine candidate, Moderna (NASDAQ: MRNA) has had a rollercoaster of a year, with its stock growing in the triple digits from March to May. But Moderna's shares stumbled immediately after the company announced at the end of June that its highly anticipated COVID-19 vaccine phase 3 clinical trials had been delayed for an unknown period. The delay is related to Moderna's dosing protocol, but it's unclear if it means that the company's phase 2 results were worse than expected.
Image Source: Getty Images.
The company's COVID-19 vaccine is far from its only pipeline project, and Moderna has a small handful of phase 2 programs that it will move forward in the fall whether or not its vaccine development efforts are successful. If Moderna's COVID-19 trial proceeds and reports favorable results, even with the recent troubling delay, its 47.7% year-over-year quarterly revenue decline will be easy for investors to ignore.
Either way, with more than $1.2 billion in cash on hand and less than $152 million in debt, Moderna has plenty of runway to get its pipeline projects off the ground. This means that more conservative investors might consider waiting for news about Moderna's other ongoing projects before proceeding.
Sangamo inches closer to the market with its gene therapy for hemophilia
Gene therapy company Sangamo Therapeutics (NASDAQ: SGMO) recently initiated a reorganization of its research and development (R&D) business units into two separate wings, with one wing dedicated to preclinical research and the other to clinical development. Despite the market's mildly negative reception, this is good news because it means the company is anticipating a need for more robust development resources in the future. The change will help the company prepare to move forward with clinical trial operations and develop manufacturing protocols for its cellular and gene therapies.
Sangamo is worth watching because its first major pipeline project is just months way from potentially getting regulatory approval. At present, Sangamo is highly unprofitable, but it nets $107.4 million in trailing-12-month revenue from its phase 3 clinical trial collaborations with Pfizer for its hemophilia A gene therapy, as well as two phase 2 collaborations with Sanofi.
The ultimate buy signal for Sangamo will be when its phase 3 gene therapy trial for hemophilia concludes and the company receives regulatory approval to sell it on the market, but there will likely be good news in the interim. Follow Sangamo's press releases regarding its hemophilia gene therapy closely, as positive results will lend validity to the two other gene therapy programs in Sangamo's pipeline, thereby prompting stock growth.
MRNA data by YCharts
Editas' high-stakes phase 1 gene therapy trial may wow investors
Editas (NASDAQ: EDIT) is a closely followed biotech thanks to its heavy utilization of popular gene editing technologies like CRISPR. While the company's stock price has grown substantially during its short history, investors may soon see it truly take off.
Editas' EDIT-101 gene therapy for Leber congenital amaurosis recently advanced into phase 1 clinical trials, in which the first patients were dosed with the therapy. While results from this initial dosing have not yet been published, there's a good chance that Editas will report on early progress by the end of the summer. If the early patient-dosing studies indicate that Editas's therapy is broadly safe in the short term, its stock price will get a powerful boost.
Editas has no products approved for sale, but it has posted year-over-year quarterly revenue growth of 176.6% thanks to its numerous preclinical development collaborations with companies like Abbvie. These collaborations will ensure that Editas can keep the lights on while it pushes its novel gene therapies through risky clinical trials.
10 stocks we like better than Sangamo Therapeutics
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Sangamo Therapeutics wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of June 2, 2020
Alex Carchidi has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Editas Medicine. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Editas has no products approved for sale, but it has posted year-over-year quarterly revenue growth of 176.6% thanks to its numerous preclinical development collaborations with companies like Abbvie. Between erratic market conditions, risk-fraught clinical trials, and unpredictable drug development pipelines, biotech investors know that with some stocks, discretion is the better part of valor. But Moderna's shares stumbled immediately after the company announced at the end of June that its highly anticipated COVID-19 vaccine phase 3 clinical trials had been delayed for an unknown period. | Editas has no products approved for sale, but it has posted year-over-year quarterly revenue growth of 176.6% thanks to its numerous preclinical development collaborations with companies like Abbvie. If Moderna's COVID-19 trial proceeds and reports favorable results, even with the recent troubling delay, its 47.7% year-over-year quarterly revenue decline will be easy for investors to ignore. Sangamo inches closer to the market with its gene therapy for hemophilia Gene therapy company Sangamo Therapeutics (NASDAQ: SGMO) recently initiated a reorganization of its research and development (R&D) business units into two separate wings, with one wing dedicated to preclinical research and the other to clinical development. | Editas has no products approved for sale, but it has posted year-over-year quarterly revenue growth of 176.6% thanks to its numerous preclinical development collaborations with companies like Abbvie. Sangamo inches closer to the market with its gene therapy for hemophilia Gene therapy company Sangamo Therapeutics (NASDAQ: SGMO) recently initiated a reorganization of its research and development (R&D) business units into two separate wings, with one wing dedicated to preclinical research and the other to clinical development. Follow Sangamo's press releases regarding its hemophilia gene therapy closely, as positive results will lend validity to the two other gene therapy programs in Sangamo's pipeline, thereby prompting stock growth. | Editas has no products approved for sale, but it has posted year-over-year quarterly revenue growth of 176.6% thanks to its numerous preclinical development collaborations with companies like Abbvie. The delay is related to Moderna's dosing protocol, but it's unclear if it means that the company's phase 2 results were worse than expected. The ultimate buy signal for Sangamo will be when its phase 3 gene therapy trial for hemophilia concludes and the company receives regulatory approval to sell it on the market, but there will likely be good news in the interim. |
24478.0 | 2020-07-09 00:00:00 UTC | AbbVie : FDA Oks Expanded BOTOX Label For Treatment Of Pediatric Patients With Spasticity | ABBV | https://www.nasdaq.com/articles/abbvie-%3A-fda-oks-expanded-botox-label-for-treatment-of-pediatric-patients-with-spasticity | nan | nan | (RTTNews) - Allergan, an AbbVie (ABBV) company, said that the U.S. Food and Drug Administration approved a supplemental Biologics License Application or sBLA that supports expanded use of BOTOX for the treatment of spasticity in pediatric patients 2 years of age and older, including those with lower limb spasticity caused by cerebral palsy.
The label expansion is based on Allergan and another manufacturer selectively waiving orphan exclusivity marketing rights each company held for the use of their respective neurotoxins in the treatment of pediatric patients with spasticity caused by cerebral palsy.
BOTOX was first approved in June 2019 for the treatment of pediatric patients with upper limb spasticity and in October 2019 for the treatment of pediatric patients with lower limb spasticity, excluding spasticity caused by cerebral palsy.
BOTOX has not been shown to improve upper extremity functional abilities, or range of motion at a joint affected by a fixed contracture.
Spasticity is a debilitating neurological condition involving muscle stiffness that can result in tight muscles in the upper and lower limbs. The severity can range from mild to severe, often interfering with normal muscular movement and function. This can result in delayed or impaired motor development, as well as difficulty with posture and positioning.
Common causes of spasticity in children include cerebral palsy, traumatic brain injury, multiple sclerosis, spinal cord injury, and stroke.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - Allergan, an AbbVie (ABBV) company, said that the U.S. Food and Drug Administration approved a supplemental Biologics License Application or sBLA that supports expanded use of BOTOX for the treatment of spasticity in pediatric patients 2 years of age and older, including those with lower limb spasticity caused by cerebral palsy. The label expansion is based on Allergan and another manufacturer selectively waiving orphan exclusivity marketing rights each company held for the use of their respective neurotoxins in the treatment of pediatric patients with spasticity caused by cerebral palsy. BOTOX has not been shown to improve upper extremity functional abilities, or range of motion at a joint affected by a fixed contracture. | (RTTNews) - Allergan, an AbbVie (ABBV) company, said that the U.S. Food and Drug Administration approved a supplemental Biologics License Application or sBLA that supports expanded use of BOTOX for the treatment of spasticity in pediatric patients 2 years of age and older, including those with lower limb spasticity caused by cerebral palsy. The label expansion is based on Allergan and another manufacturer selectively waiving orphan exclusivity marketing rights each company held for the use of their respective neurotoxins in the treatment of pediatric patients with spasticity caused by cerebral palsy. BOTOX was first approved in June 2019 for the treatment of pediatric patients with upper limb spasticity and in October 2019 for the treatment of pediatric patients with lower limb spasticity, excluding spasticity caused by cerebral palsy. | (RTTNews) - Allergan, an AbbVie (ABBV) company, said that the U.S. Food and Drug Administration approved a supplemental Biologics License Application or sBLA that supports expanded use of BOTOX for the treatment of spasticity in pediatric patients 2 years of age and older, including those with lower limb spasticity caused by cerebral palsy. BOTOX was first approved in June 2019 for the treatment of pediatric patients with upper limb spasticity and in October 2019 for the treatment of pediatric patients with lower limb spasticity, excluding spasticity caused by cerebral palsy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - Allergan, an AbbVie (ABBV) company, said that the U.S. Food and Drug Administration approved a supplemental Biologics License Application or sBLA that supports expanded use of BOTOX for the treatment of spasticity in pediatric patients 2 years of age and older, including those with lower limb spasticity caused by cerebral palsy. BOTOX was first approved in June 2019 for the treatment of pediatric patients with upper limb spasticity and in October 2019 for the treatment of pediatric patients with lower limb spasticity, excluding spasticity caused by cerebral palsy. BOTOX has not been shown to improve upper extremity functional abilities, or range of motion at a joint affected by a fixed contracture. |
24479.0 | 2020-07-08 00:00:00 UTC | AbbVie Remains One of the Safest Pharma Investments You Can Make | ABBV | https://www.nasdaq.com/articles/abbvie-remains-one-of-the-safest-pharma-investments-you-can-make-2020-07-08 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
When it comes to biotechnology market investing, sometimes it’s best just to de-risk your portfolio by sticking with well-known firms like AbbVie (NYSE:ABBV). There’s no perfectly safe investment, but among pharmaceutical plays, AbbVie stock involves less risk than many others in the sector.
Source: Piotr Swat / Shutterstock.com
For one thing, it’s a well-known and highly respected company. Plus, there’s no shortage of trading volume when it comes to ABBV stock. With 10 million shares of the stock traded on a typical day, you shouldn’t have any problems getting in and out of your position.
Perhaps most importantly, AbbVie has a pipeline of medical solutions that should keep the revenues flowing in. And after an acquisition that could transform the pharmaceutical industry as we know it, the upward trajectory of ABBV stock may just be unstoppable.
AbbVie Stock at a Glance
An argument could be made, based on the price action alone, that ABBV is a great novel coronavirus stock. The rebound from the March low of $62.55 has been smooth and practically uninterrupted. That’s the kind of price movement that inspires confidence and can help take ABBV far beyond $100.
The next objective for the bulls could be to take out the previous high mark from 2018. In particular, they’ll want to keep their eye on $125 as that will have psychological significance. Breaking above that number with heavy volume will deal a major blow to the bears and short sellers.
8 Social Media Stocks to Buy or Sell
That, however, is a longer-term goal for current and prospective ABBV stockholders. For the time being, it’s perfectly fine to buy shares at the current price point or wait for small dips to build your position. Just be sure to have an exit plan in place in case things don’t go as planned, which is always a possibility in the markets.
The Buyout That Changed Everything
For any serious aficionado of the biotechnology sector, there are a handful of mergers and acquisitions every year that are considered game changers. They have the potential to transform not only the companies involved, but the industry as a whole.
AbbVie’s acquisition of Allergan would most certainly qualify as one of these transformative acquisitions. After regulators approved the buyout, the acquisition was finalized and AbbVie became a substantially bigger company.
Does bigger necessarily mean better? Not always, but in this instance the addition to AbbVie’s already considerable pipeline has been warmly welcomed by virtually all stakeholders. Allergan was famous among biotech investors, and rightly so as the company’s flagship product, Botox, consistently drove strong revenues.
Besides, Allergan brings more to the table than Botox. As AbbVie elaborated upon finalizing the acquisition: “Allergan provides new growth opportunities in Neuroscience, with Botox® Therapeutics, Vraylar® and Ubrelvy™ and a global aesthetics business, with leading brands including Botox® and Juvederm®.”
A New Use for an Old Treatment
That’s a significant enhancement of AbbVie’s pipeline, which was already robust on its own. Yet the news only gets better from here as America’s most important pharmaceutical regulator just gave the nod of approval to use a well-known treatment in a new way.
You might think of Botox as just a way to treat wrinkles in the face. However, the U.S. Food and Drug Administration recently determined that there’s more to Botox than cosmetic procedures.
Specifically, the FDA approved AbbVie’s supplemental biologics license application allowing Botox to be prescribed for specified instances of the “signs and symptoms of detrusor (bladder muscle) overactivity associated with an underlying neurologic condition” in patients aged five through 17.
This regulatory approval should do much more for AbbVie than provide a new revenue stream for Botox. Just as significantly, it could enhance Botox’s profile as more than a cosmetic treatment. Now, Botox could gain a reputation as a treatment with real importance and substance in the medical community. That’s great for AbbVie’s reputation as well.
The Final Word on AbbVie Stock
Any bears and short-sellers could have a tough time fighting the progress of a bigger and better AbbVie. Thus, traders should prepare for higher prices in ABBV stock. The bulls won’t have much difficulty, if any, in knocking through the $125 level.
Louis Navellier had an unconventional start, as a grad student who accidentally built a market-beating stock system — with returns rivaling even Warren Buffett. In his latest feat, Louis discovered the “Master Key” to profiting from the biggest tech revolution of this (or any) generation. Louis Navellier may hold some of the aforementioned securities in one or more of his newsletters.
The post AbbVie Remains One of the Safest Pharma Investments You Can Make appeared first on InvestorPlace.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Specifically, the FDA approved AbbVie’s supplemental biologics license application allowing Botox to be prescribed for specified instances of the “signs and symptoms of detrusor (bladder muscle) overactivity associated with an underlying neurologic condition” in patients aged five through 17. InvestorPlace - Stock Market News, Stock Advice & Trading Tips When it comes to biotechnology market investing, sometimes it’s best just to de-risk your portfolio by sticking with well-known firms like AbbVie (NYSE:ABBV). There’s no perfectly safe investment, but among pharmaceutical plays, AbbVie stock involves less risk than many others in the sector. | InvestorPlace - Stock Market News, Stock Advice & Trading Tips When it comes to biotechnology market investing, sometimes it’s best just to de-risk your portfolio by sticking with well-known firms like AbbVie (NYSE:ABBV). There’s no perfectly safe investment, but among pharmaceutical plays, AbbVie stock involves less risk than many others in the sector. After regulators approved the buyout, the acquisition was finalized and AbbVie became a substantially bigger company. | InvestorPlace - Stock Market News, Stock Advice & Trading Tips When it comes to biotechnology market investing, sometimes it’s best just to de-risk your portfolio by sticking with well-known firms like AbbVie (NYSE:ABBV). AbbVie Stock at a Glance An argument could be made, based on the price action alone, that ABBV is a great novel coronavirus stock. As AbbVie elaborated upon finalizing the acquisition: “Allergan provides new growth opportunities in Neuroscience, with Botox® Therapeutics, Vraylar® and Ubrelvy™ and a global aesthetics business, with leading brands including Botox® and Juvederm®.” A New Use for an Old Treatment That’s a significant enhancement of AbbVie’s pipeline, which was already robust on its own. | InvestorPlace - Stock Market News, Stock Advice & Trading Tips When it comes to biotechnology market investing, sometimes it’s best just to de-risk your portfolio by sticking with well-known firms like AbbVie (NYSE:ABBV). Plus, there’s no shortage of trading volume when it comes to ABBV stock. After regulators approved the buyout, the acquisition was finalized and AbbVie became a substantially bigger company. |
24480.0 | 2020-07-08 00:00:00 UTC | Better Buy: AbbVie vs. Biogen | ABBV | https://www.nasdaq.com/articles/better-buy%3A-abbvie-vs.-biogen-2020-07-08 | nan | nan | AbbVie (NYSE: ABBV) and Biogen (NASDAQ: BIIB) are two drugmakers that have moved in opposite directions on the stock market of late. While AbbVie has rebounded nicely from the market crash since late March -- with its stock up by 11.7% year to date as of this writing -- shares of Biogen have lost altitude since early April or so, and are down by 10.7% since the beginning of the year.
As we will see below, Biogen has encountered some severe headwinds recently, which explains its poor stock-price performance. There's a chance that the company could recover from its recent woes, but could it actually outperform AbbVie moving forward? Let's dig into these companies' businesses and see which of the two stocks is the better pick right now.
ABBV data by YCharts
Why AbbVie looks like a buy at the moment
Fresh off its acquisition of Allergan -- which cost the company $63 billion and closed in May -- AbbVie has several things going its way. First, the company's blockbuster drug Humira, which treats several autoimmune disorders such as plaque psoriasis, is still generating growing revenue in the U.S. During the first quarter, Humira's U.S. revenue came in at $3.7 billion, representing a 13.7% year-over-year increase. True, Humira continues to lose steam in international markets, but that is precisely why AbbVie decided to acquire Allergan.
The acquisition helped diversify AbbVie's product lineup, most notably thanks to Allergan's Botox, a product line capable of generating well over $1 billion in annual revenue. During the fiscal year 2019, Botox Cosmetics' sales were $991.3 million, a 9.3% year-over-year increase. Meanwhile, Botox Therapeutics' sales came in at $1.7 billion, a rise of 6.1% compared with the year-ago period.
What's more, while Humira is currently losing steam in Europe due to competition from biosimilars, AbbVie believes that it's unlikely that we will see biosimilars for Botox anytime soon. Of course, the company has many other products to rely on as well. For instance, cancer drugs Venclexta and Imbruvica continue to generate growing sales. During the first quarter, the combined revenue of these two products was $1.5 billion, a 59.9% year-over-year increase.
Image source: Getty Images.
There's also Skyrizi, a treatment for moderate to severe plaque psoriasis that was approved last year, which brought in first-quarter revenue of $266 million.
With that said, though, there's one worry with AbbVie -- namely, that the company's acquisition of Humira raised its debt level significantly. However, the company has pledged to pay this debt as fast as possible with the "robust cash flow" generated by its strong lineup.
Given all these factors, I think AbbVie will continue outperforming the market, and I believe its stock is a buy today.
Will Biogen bounce back?
Biogen's current best-selling product is Tecfidera, which is used to treat multiple sclerosis (MS). During the first quarter, this drug brought in about $1.1 billion in revenue, a 10% increase compared with the year-ago period. Note that Biogen's total revenue for the first quarter was roughly $3.5 billion, which means Tecfidera alone accounted for about 30% of its revenue during the quarter. However, Biogen recently lost a patent lawsuit against Mylan over Tecfidera, which means sales of this MS drug could face generic competition soon. In other words, Biogen's most important cash cow at the moment could see its revenue decline in the coming quarters.
Furthermore, there's a lot of controversy surrounding aducanumab, a potential treatment for Alzheimer's disease (AD) that was regarded by many as Biogen's next blockbuster drug. At this point, whether this product will earn regulatory approval is anyone's guess. Note that Biogen has yet to submit aducanumab to the U.S. Food and Drug Administration (FDA) for review -- when it had initially said it would do so in early 2020. These two issues are the main reasons why Biogen's stock has been under pressure of late, but the biotech giant has a chance to recover. The company currently has a rich pipeline with about a dozen products in phase 3 testing, including another potential AD treatment called BAN2401.
While these products may not pay off within the next year or so, I do expect Biogen to eventually replenish its lineup and go back to its winning ways. While I think the company's stock remains risky at the moment, for those willing to jump on this opportunity to buy its stock for a discount, patience may be rewarded down the line.
Some financial metrics to consider
Biogen is currently the more efficient of these two companies. Biogen's current profit margin of 40.8% is much better than AbbVie's 24.8%. This trend has held constant over the past few years, with Biogen's profit margin consistently beating out that of AbbVie. Turning to their valuations, although Biogen's forward price-to-earnings (P/E) ratio of 8.1 compares favorably to that of AbbVie at 9.5, AbbVie is currently cheaper when taking into consideration forward sales growth.
AbbVie's forward price-to-earnings growth (PEG) ratio is about 0.1, compared with Biogen's 1.6. Biogen's debt-to-asset ratio of 22.8% is also much better than AbbVie's higher 73.5%, indicating that Biogen has a much more reasonable debt level. Lastly, let's not forget about AbbVie's dividend. The company currently offers a yield of 4.5% against the S&P 500 average of 2% -- with a healthy cash payout ratio of 48.3% -- and has raised its dividends by 131.4% over the past five years. Meanwhile, Biogen currently does not offer any dividends.
Which is the better buy?
Even with a lower debt level and a more efficient business, I think Biogen loses to AbbVie in this battle. Biogen's stock will remain volatile in the short run -- that is, until it solves the issues it is currently facing. Once those are in the rearview mirror, it may be worth buying Biogen's stock. By contrast, I expect AbbVie to continue growing its revenue and earnings, paying off its debt, and rewarding shareholders by way of strong and growing dividends from here on out. For that reason, I think AbbVie will perform better on the stock market than Biogen, which makes it the better of these two healthcare stocks to buy right now.
10 stocks we like better than Biogen
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Biogen wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of June 2, 2020
Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Biogen. The Motley Fool recommends Mylan. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie (NYSE: ABBV) and Biogen (NASDAQ: BIIB) are two drugmakers that have moved in opposite directions on the stock market of late. While AbbVie has rebounded nicely from the market crash since late March -- with its stock up by 11.7% year to date as of this writing -- shares of Biogen have lost altitude since early April or so, and are down by 10.7% since the beginning of the year. There's a chance that the company could recover from its recent woes, but could it actually outperform AbbVie moving forward? | By contrast, I expect AbbVie to continue growing its revenue and earnings, paying off its debt, and rewarding shareholders by way of strong and growing dividends from here on out. AbbVie (NYSE: ABBV) and Biogen (NASDAQ: BIIB) are two drugmakers that have moved in opposite directions on the stock market of late. While AbbVie has rebounded nicely from the market crash since late March -- with its stock up by 11.7% year to date as of this writing -- shares of Biogen have lost altitude since early April or so, and are down by 10.7% since the beginning of the year. | While AbbVie has rebounded nicely from the market crash since late March -- with its stock up by 11.7% year to date as of this writing -- shares of Biogen have lost altitude since early April or so, and are down by 10.7% since the beginning of the year. Biogen's debt-to-asset ratio of 22.8% is also much better than AbbVie's higher 73.5%, indicating that Biogen has a much more reasonable debt level. For that reason, I think AbbVie will perform better on the stock market than Biogen, which makes it the better of these two healthcare stocks to buy right now. | For that reason, I think AbbVie will perform better on the stock market than Biogen, which makes it the better of these two healthcare stocks to buy right now. AbbVie (NYSE: ABBV) and Biogen (NASDAQ: BIIB) are two drugmakers that have moved in opposite directions on the stock market of late. While AbbVie has rebounded nicely from the market crash since late March -- with its stock up by 11.7% year to date as of this writing -- shares of Biogen have lost altitude since early April or so, and are down by 10.7% since the beginning of the year. |
24481.0 | 2020-07-07 00:00:00 UTC | 4 Top Stock Trades for Wednesday: LVGO, WMT, ABBV, NVAX | ABBV | https://www.nasdaq.com/articles/4-top-stock-trades-for-wednesday%3A-lvgo-wmt-abbv-nvax-2020-07-07 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
After a strong trading day on Monday, investors used Tuesday as a way to digest the gains. Let’s look at a few top stock trades as we near mid-week.
Top Stock Trades for Tomorrow No. 1: Livongo (LVGO)
Click to Enlarge
Source: Chart courtesy of StockCharts.com
The only word that can describe Livongo’s (NASDAQ:LVGO) run at this point? Breathtaking.
Shares have surged over the past few months and did so again on Tuesday — rallying more than 20%. The move came on a strong dose of volume, too, of 15.5 million strong.
So, what now?
Obviously chasing the stock up here has its risks, as many investors may prefer to wait for a pullback. A dip down toward the $75 to $80 zone that is met with support could be a solid short-term buying opportunity.
10 Best ETFs for 2020: The Race Tightens With 'New Normal' Looming Ahead
Notice where Tuesday’s rally ran out of steam: right at the 261.8% extension near $95. If LVGO stock can clear this mark, first look to the $100 mark as the next upside target, followed by the 3-times range extension near $107.
Top Stock Trades for Tomorrow No. 2: Walmart (WMT)
Click to Enlarge
Source: Chart courtesy of StockCharts.com
Walmart (NYSE:WMT) shares erupted higher on Tuesday, tacking on nearly 7% on the day.
The stock continued to hold its 200-day moving average all through the month of June despite some lackluster price action.
Moreover, like LVGO, Walmart’s move comes on strong volume. It’s also propelling shares over the 50-day and 20-day moving averages. If it can hold above the $126 area, it puts the $132 range in play. Shares are not overbought, so if the stock can maintain momentum, there could certainly be upside left.
If it can’t hold the $126 level, though, look to see if the 50-day moving average holds as support. Bulls don’t want to see Walmart stock give up all of Tuesday’s gains.
Top Stock Trades for Tomorrow No. 3: AbbVie (ABBV)
Click to Enlarge
Source: Chart courtesy of StockCharts.com
Remember when we were looking at AbbVie (NYSE:ABBV) to make a nice move higher? Well, that has played out tremendously well, with shares briefly breaching $100 earlier in the day.
It’s been a slow, yet profitable rally over the past few months, but bulls have been rewarded. If the stock can clear and stay above $100, keep an eye on the 123.6% extension at $104.63, and potentially followed by the 138.2% extension up at $109.71.
4 California Stocks to Keep On Hold Until Post-Coronavirus
On the downside, however, I want to see the prior 52-week high from February hold as support — along with the 20-day moving average. Below could put a larger correction back in play, putting the $88 to $90 area on the table.
Top Stock Trades for Tomorrow No. 4: Novavax (NVAX)
Click to Enlarge
Source: Chart courtesy of StockCharts.com
What can we say about Novavax (NASDAQ:NVAX) at this point? This stock was trading for less than $5 at one point in early January. Now? Shares just eclipsed $100. From low to high, the stock has seen a rally of more than 2,500% — this year.
As you can see on the chart, this stock tends to make very similar patterns. That is, a big spike that’s met with lower highs and an eventual breakout over downtrend resistance (blue lines).
If that pattern starts to play out again, traders make look for another pop to the upside. Below the $85 to $90 area may give investors some concerns though — and rightfully so. This zone was resistance last month, and many bulls would like to see it act as support — provided NVAX trades there.
Bret Kenwell is the manager and author of Future Blue Chips and is on Twitter @BretKenwell. As of this writing, Bret did not hold a position in any of the aforementioned securities.
The post 4 Top Stock Trades for Wednesday: LVGO, WMT, ABBV, NVAX appeared first on InvestorPlace.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Click to Enlarge Source: Chart courtesy of StockCharts.com Remember when we were looking at AbbVie (NYSE:ABBV) to make a nice move higher? 3: AbbVie (ABBV) The post 4 Top Stock Trades for Wednesday: LVGO, WMT, ABBV, NVAX appeared first on InvestorPlace. | The post 4 Top Stock Trades for Wednesday: LVGO, WMT, ABBV, NVAX appeared first on InvestorPlace. 3: AbbVie (ABBV) Click to Enlarge Source: Chart courtesy of StockCharts.com Remember when we were looking at AbbVie (NYSE:ABBV) to make a nice move higher? | The post 4 Top Stock Trades for Wednesday: LVGO, WMT, ABBV, NVAX appeared first on InvestorPlace. 3: AbbVie (ABBV) Click to Enlarge Source: Chart courtesy of StockCharts.com Remember when we were looking at AbbVie (NYSE:ABBV) to make a nice move higher? | The post 4 Top Stock Trades for Wednesday: LVGO, WMT, ABBV, NVAX appeared first on InvestorPlace. 3: AbbVie (ABBV) Click to Enlarge Source: Chart courtesy of StockCharts.com Remember when we were looking at AbbVie (NYSE:ABBV) to make a nice move higher? |
24482.0 | 2020-07-07 00:00:00 UTC | AbbVie Stands to Benefit from Affluenza | ABBV | https://www.nasdaq.com/articles/abbvie-stands-to-benefit-from-affluenza-2020-07-07 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
For pharmaceutical giant AbbVie (NYSE:ABBV), the novel coronavirus couldn’t go away fast enough. Though AbbVie stock is obviously related to the suddenly in-demand healthcare space, the underlying company isn’t a play on the Covid-19 pandemic. In fact, the crisis hasn’t exactly helped its fundamental narrative.
Source: Piotr Swat / Shutterstock.com
That’s because ABBV’s pipeline mostly deals with chronic conditions. Additionally, it has invested heavily in addressing neurological disorders, such as Parkinson’s disease and Alzheimer’s disease. Also, AbbVie features a robust oncology department. In other words, it’s dealing with patients who have severe underlying conditions – exactly the demographic that faces the greatest risk to Covid-19 infections.
Therefore, it wasn’t much of a shock that management admitted that it anticipated a demand hit to their flagship drugs. With every incentive to stay home and avoid potential encounters with the coronavirus, AbbVie stock was all over the map during the first four months of this year.
However, up until late June, new daily infections hit a peak in early April according to the Centers for Disease Control and Prevention. Thus, state began opening certain businesses later that month and throughout May. With the coronavirus seemingly under control, investors began bidding up AbbVie stock.
Of course, this fundamental factor has again shifted directions. Around the middle of June, new cases started inching higher. By July 2, this daily tally breached the 55,000 mark, an all-time record and by a sizable margin.
Even more problematic for AbbVie stock is that hospitalizations are on the rise. According to the Washington Post, some state health officials have implemented protocols to determine which patients get ventilators. Again, hospitals are the last place you want to go, clouding ABBV’s revenue channels.
AbbVie Stock Is Disturbingly Relevant in the New Normal
In early May, AbbVie completed its buyout for Allergan in what management termed a “transformative” deal. When ABBV shelled out the $63 billion to close negotiations, it inarguably did so because of Botox, the blockbuster wrinkle treatment.
10 Best ETFs for 2020: The Race Tightens With 'New Normal' Looming Ahead
Sure, other considerations and synergies exist within the deal. But nothing rings up more growth potential than addressing “affluenza.”
Of course, affluenza is a type of pandemic that you want to nurture if you’re a stakeholder in AbbVie stock. Surprisingly, though, demand for Botox is very high, even in the midst of this unprecedented crisis. According to Allure.com contributor Brennan Kilbane, the rich apparently only care that their beauty products supply chain has been disrupted. This has led to “desperate” measures. Kilbane writes:
Severed from aesthetic maintenance rituals during the COVID-19 pandemic, many are seeing things unfamiliar to them — things like root growth and a loss of skin elasticity. They are looking older. But not if they can help it.
“I’ve been asked by a few patients to come out to the Hamptons and go house to house,” says Amy Wechsler, a dermatologist and psychiatrist, from her practice on Manhattan’s Upper East Side. “That makes no sense to me.” It’s simply dangerous to enter several different homes in the span of a few hours, Wechsler points out. “But people are feeling stressed out about the way they’re going to look, and women are worried that their Botox is going to wear off and their partner is going to see them in a way they haven’t.”
In other words, many rich folks would rather risk death than not look good. Ordinarily, you can look at this dynamic as a sign of class and mental dysfunction. But cynically, it’s incredibly beneficial to ABBV stock.
Welcome to the New Vice
And cynical is admittedly what I’ve become with my own investment philosophy as it relates to Covid-19. For instance, I’m attracted to Altria (NYSE:MO) because cigarettes represent a stress-mitigation platform. Granted, it’s not a healthy one. But at the end of the day, adults must make adult choices – and you can potentially profit from them.
In the same vein, RCI Hospitality (NASDAQ:RICK) is also appealing. During the Great Recession, the “hospitality” industry boomed as presumably discouraged gentlemen sought an outlet to ease their troubles. If we see another prolonged economic downturn, RICK could eventually pop higher.
Perhaps this is the new way to approach AbbVie stock. Before the pandemic, ABBV was a solid play on the pharmaceutical space. To be fair, it still is. But with Botox under its wings, it could benefit from the affluent person’s addiction to superficial beauty.
Is it distasteful? Absolutely. But a distasteful dollar is still a dollar. And there are many of those waiting for AbbVie to collect.
A former senior business analyst for Sony Electronics, Josh Enomoto has helped broker major contracts with Fortune Global 500 companies. Over the past several years, he has delivered unique, critical insights for the investment markets, as well as various other industries including legal, construction management, and healthcare. As of this writing, he is long Altria.
The post AbbVie Stands to Benefit from Affluenza appeared first on InvestorPlace.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | InvestorPlace - Stock Market News, Stock Advice & Trading Tips For pharmaceutical giant AbbVie (NYSE:ABBV), the novel coronavirus couldn’t go away fast enough. Though AbbVie stock is obviously related to the suddenly in-demand healthcare space, the underlying company isn’t a play on the Covid-19 pandemic. Source: Piotr Swat / Shutterstock.com That’s because ABBV’s pipeline mostly deals with chronic conditions. | InvestorPlace - Stock Market News, Stock Advice & Trading Tips For pharmaceutical giant AbbVie (NYSE:ABBV), the novel coronavirus couldn’t go away fast enough. With the coronavirus seemingly under control, investors began bidding up AbbVie stock. Though AbbVie stock is obviously related to the suddenly in-demand healthcare space, the underlying company isn’t a play on the Covid-19 pandemic. | InvestorPlace - Stock Market News, Stock Advice & Trading Tips For pharmaceutical giant AbbVie (NYSE:ABBV), the novel coronavirus couldn’t go away fast enough. Though AbbVie stock is obviously related to the suddenly in-demand healthcare space, the underlying company isn’t a play on the Covid-19 pandemic. AbbVie Stock Is Disturbingly Relevant in the New Normal In early May, AbbVie completed its buyout for Allergan in what management termed a “transformative” deal. | Even more problematic for AbbVie stock is that hospitalizations are on the rise. Perhaps this is the new way to approach AbbVie stock. InvestorPlace - Stock Market News, Stock Advice & Trading Tips For pharmaceutical giant AbbVie (NYSE:ABBV), the novel coronavirus couldn’t go away fast enough. |
24483.0 | 2020-07-07 00:00:00 UTC | 3 Best-Performing Dividend Aristocrats in the First Half of 2020: Are They Buys Now? | ABBV | https://www.nasdaq.com/articles/3-best-performing-dividend-aristocrats-in-the-first-half-of-2020%3A-are-they-buys-now-2020 | nan | nan | Claiming impressive track records of 25 or more consecutive years of dividend increases wasn't enough to translate to solid performances during the first half of 2020. Even with the overall market rebound in the second quarter, more than twice as many Dividend Aristocrats were in negative territory year to date after the first six months of 2020 than were up for the year.
But there were still some big winners among the group. Several even chalked up double-digit gains. Here are the three best-performing Dividend Aristocrats during the first half of the year.
Image source: Getty Images.
1. S&P Global
S&P Global (NYSE: SPGI) is one of only 24 S&P 500 index members to have increased its dividend for 47 consecutive years. And it was the top-performing Dividend Aristocrat in the first half of 2020, with a gain of nearly 21%.
Most financial stocks performed poorly as the COVID-19 pandemic negatively impacted the economy. S&P Global, however, was an exception to the rule. The company focuses on selling data and analytics to clients. Although its business model didn't totally insulate S&P Global from the overall beatdown in the financial services sector, its shares rebounded rapidly.
It's too soon to completely rule out headwinds for S&P Global resulting from the COVID-19 outbreak. A prolonged recession could hurt some of the company's clients and affect its new sales and subscription renewals. For now, though, S&P Global's business appears to be going full-steam ahead -- as is its dividend.
2. Lowe's
Lowe's (NYSE: LOW) ranks in the upper echelon of Dividend Aristocrats with a remarkable 57 consecutive years of dividend hikes. The home improvement retailer's stock performance was also among the best among the group during the first six months of the year, with Lowes' shares jumping nearly 13%.
The COVID-19 pandemic actually helped Lowe's. The company was declared an essential business and was able to keep its stores open across the country. Consumers who were stuck at home under shelter-in-place orders opted to embark on home-improvement projects. Lowe's reported 12% higher comparable-store sales in its fiscal first quarter, which ended on May 1, 2020, with rising profits.
CEO Marvin Ellison said in Lowe's quarterly update that the great performance continued beyond the end of the first quarter. However, the company has still suspended share repurchases because of the pandemic and doesn't expect to buy back any additional shares in 2020.
3. AbbVie
AbbVie (NYSE: ABBV) trailed Lowe's in terms of stock performance during the first half of the year with a gain of 11%. But the big pharma stock narrowly beat the home-improvement giant in total returns thanks to its strong dividend yield. Including its time as part of parent Abbott Labs (NYSE: ABT), AbbVie has increased its dividend for 47 years.
The solid first-half jump stemmed in part from AbbVie easily beating Wall Street's Q1 revenue and earnings estimates. AbbVie's top-selling drug Humira performed well. Several other drugs also picked up momentum, including new immunology drugs Rinvoq and Skyrizi and blood cancer drug Venclexta.
There were also other wins for AbbVie in the first half of 2020. Its acquisition of Allergan closed. The drugmaker scored a key patent litigation victory for Humira. It also inked a significant licensing and collaboration deal with GenMab.
Are they buys now?
I think that two of these three Dividend Aristocrats are still pretty good picks after their nice gains. The exception is S&P Global. I'm somewhat leery of S&P Global's valuation with shares trading at 33 times expected earnings. Lowe's and AbbVie, on the other hand, seem like solid picks. I like the long-term trends for home improvement. My view is that AbbVie will effectively navigate the loss of U.S. patent exclusivity for Humira.
10 stocks we like better than Lowe's
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Lowe's wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of June 2, 2020
Keith Speights owns shares of AbbVie. The Motley Fool recommends Lowe's. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The solid first-half jump stemmed in part from AbbVie easily beating Wall Street's Q1 revenue and earnings estimates. AbbVie AbbVie (NYSE: ABBV) trailed Lowe's in terms of stock performance during the first half of the year with a gain of 11%. Including its time as part of parent Abbott Labs (NYSE: ABT), AbbVie has increased its dividend for 47 years. | AbbVie AbbVie (NYSE: ABBV) trailed Lowe's in terms of stock performance during the first half of the year with a gain of 11%. See the 10 stocks *Stock Advisor returns as of June 2, 2020 Keith Speights owns shares of AbbVie. Including its time as part of parent Abbott Labs (NYSE: ABT), AbbVie has increased its dividend for 47 years. | AbbVie AbbVie (NYSE: ABBV) trailed Lowe's in terms of stock performance during the first half of the year with a gain of 11%. Including its time as part of parent Abbott Labs (NYSE: ABT), AbbVie has increased its dividend for 47 years. The solid first-half jump stemmed in part from AbbVie easily beating Wall Street's Q1 revenue and earnings estimates. | AbbVie AbbVie (NYSE: ABBV) trailed Lowe's in terms of stock performance during the first half of the year with a gain of 11%. Including its time as part of parent Abbott Labs (NYSE: ABT), AbbVie has increased its dividend for 47 years. The solid first-half jump stemmed in part from AbbVie easily beating Wall Street's Q1 revenue and earnings estimates. |
24484.0 | 2020-07-06 00:00:00 UTC | Royalty Pharma Stock Is Likely to Reach New Highs in the Coming Years | ABBV | https://www.nasdaq.com/articles/royalty-pharma-stock-is-likely-to-reach-new-highs-in-the-coming-years-2020-07-06 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Royalty Pharma (NASDAQ:RPRX) started trading on the NASDAQ June 16. It has been the largest initial public offering so far in 2020. Royalty Pharma offered 77.7 million shares, which was 7 million higher than initially planned. RPRX stock was priced at $28. The shares opened at $44 and on June 18, hit a high of 56.50. RPRX stock is currently shy of $49.
Source: Shutterstock
Therefore there has been considerable interest from retail and institutional investors alike. Today, I’ll take a look at the company to see if RPRX should belong in a long-term portfolio.
As the current COVID-19 pandemic has shown, Research & Development (R&D) is at the center of drug development. And developing a new prescription medicine is likely to cost well over $2 billion.
According to the Association of the British Pharmaceutical Industry (ABPI), “The global pharmaceutical industry invested over $1.36 trillion in R&D in the decade from 2007 to 2016 and forecasts predict an annual investment of $181 billion by 2022.”
The pharmaceutical industry faces monetary challenges as it develops new drugs. “Patent expiration, decreases in R&D productivity, and a general decline in profitability” also contribute to the long-term issues biopharma groups work to overcome. Therefore, many biopharma companies supplement their funding through royalty-based licenses.
7 American Manufacturing Stocks to Buy Before Recovery
The U.S. Food & Drug Administration (FDA) highlights that a drug patent lasts for 20 years. But about half of that time is, in general, spent to develop the drug. Put another way, drug development is a costly and lengthy process.
A Closer Look at RPRX Stock
Royalty Pharma partners directly “with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties.” And it also “acquires existing royalties from the original innovators.”
The company’s history goes back to 1996 when investment banker Pablo Legorreta founded the group and successfully initiated its business model.
According to a 2013 study by Andrew Lo and Sourya V. Naraharisetti of MIT:
“new alternative investment companies have emerged to bridge the biopharma funding gap by purchasing economic interests in drug royalty streams. Such purchases allow universities and biopharma companies to monetize their intellectual property, creating greater financial flexibility for them while giving investors an opportunity to participate in the life sciences industry at lower risk. Royalty Pharma is the largest of these drug royalty investment companies.”
The company currently holds a range of royalties which entitles Royalty Pharma to payments based directly on the top-line sales various therapies, including Imbruvica, Januvia, Kalydeco, Trikafta, Truvada, Tysabri and Xtandi. Some of the companies it partners with are AbbVie (NASDAQ:ABBV), Biogen (NASDAQ:BIIB), Johnson & Johnson (NYSE:JNJ), Merck (NYSE:MRK), and Vertex Pharmaceuticals (NASDAQ:VRTX).
According to a recent SEC filing, the company has a story of stable income and cash flow. In 2019, cash receipts were around $2 billion. It is likely that proceeds form the IPO will fund new royalty acquisitions for the group. And that would potentially mean shareholder value for investors in RPRX stock.
The Bottom Line on RPRX Stock
Over the past few decades, the pharmaceutical industry has been searching for alternative methods of financing for drug development. And that is where Royalty Pharma comes in.
Its recent IPO is regarded as one of the most interesting and potentially promising IPOs of recent months.
I’d continue to do due diligence on the group with the possibility of becoming an investor. Any upcoming weakness in the stock price may provide an opportunity for long-term investing in RPRX stock.
Tezcan Gecgil has worked in investment management for over two decades in the U.S. and U.K. In addition to formal higher education, including a Ph.D. degree, in the field, she has also completed all 3 levels of the Chartered Market Technician (CMT) examination. Her passion is for options trading based on technical analysis of fundamentally strong companies. She especially enjoys setting up weekly covered calls for income generation. As of this writing, Tezcan Gecgil holds covered calls on MRK (July 2 expiry).
The post Royalty Pharma Stock Is Likely to Reach New Highs in the Coming Years appeared first on InvestorPlace.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some of the companies it partners with are AbbVie (NASDAQ:ABBV), Biogen (NASDAQ:BIIB), Johnson & Johnson (NYSE:JNJ), Merck (NYSE:MRK), and Vertex Pharmaceuticals (NASDAQ:VRTX). According to a 2013 study by Andrew Lo and Sourya V. Naraharisetti of MIT: “new alternative investment companies have emerged to bridge the biopharma funding gap by purchasing economic interests in drug royalty streams. Such purchases allow universities and biopharma companies to monetize their intellectual property, creating greater financial flexibility for them while giving investors an opportunity to participate in the life sciences industry at lower risk. | Some of the companies it partners with are AbbVie (NASDAQ:ABBV), Biogen (NASDAQ:BIIB), Johnson & Johnson (NYSE:JNJ), Merck (NYSE:MRK), and Vertex Pharmaceuticals (NASDAQ:VRTX). InvestorPlace - Stock Market News, Stock Advice & Trading Tips Royalty Pharma (NASDAQ:RPRX) started trading on the NASDAQ June 16. A Closer Look at RPRX Stock Royalty Pharma partners directly “with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties.” And it also “acquires existing royalties from the original innovators.” The company’s history goes back to 1996 when investment banker Pablo Legorreta founded the group and successfully initiated its business model. | Some of the companies it partners with are AbbVie (NASDAQ:ABBV), Biogen (NASDAQ:BIIB), Johnson & Johnson (NYSE:JNJ), Merck (NYSE:MRK), and Vertex Pharmaceuticals (NASDAQ:VRTX). InvestorPlace - Stock Market News, Stock Advice & Trading Tips Royalty Pharma (NASDAQ:RPRX) started trading on the NASDAQ June 16. A Closer Look at RPRX Stock Royalty Pharma partners directly “with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties.” And it also “acquires existing royalties from the original innovators.” The company’s history goes back to 1996 when investment banker Pablo Legorreta founded the group and successfully initiated its business model. | Some of the companies it partners with are AbbVie (NASDAQ:ABBV), Biogen (NASDAQ:BIIB), Johnson & Johnson (NYSE:JNJ), Merck (NYSE:MRK), and Vertex Pharmaceuticals (NASDAQ:VRTX). InvestorPlace - Stock Market News, Stock Advice & Trading Tips Royalty Pharma (NASDAQ:RPRX) started trading on the NASDAQ June 16. And that would potentially mean shareholder value for investors in RPRX stock. |
24485.0 | 2020-07-05 00:00:00 UTC | Got $5,000? Buy These 3 High-Yield Dividend Stocks That Are Money Machines | ABBV | https://www.nasdaq.com/articles/got-%245000-buy-these-3-high-yield-dividend-stocks-that-are-money-machines-2020-07-05 | nan | nan | Wouldn't it be nice to invest in stocks and then simply sit back while the money flows in? You can do just that with dividend stocks.
Sure, some companies pay only puny dividends. Others are on such shaky ground that their dividends are in jeopardy. But there are stocks on the market that pay dividends that are both juicy and solid. If you've got $5,000 to invest, here are three high-yield dividend stocks that are flat-out money machines.
Image source: Getty Images.
1. AbbVie
Richard Nixon was beginning his second term when AbbVie's (NYSE: ABBV) streak of annual dividend hikes began. Very few companies can boast that they've increased their dividend for 47 years in a row. But AbbVie can. And since being spun off from Abbott Labs in 2013, AbbVie has raised its dividend by a whopping 195%. Today, AbbVie's dividend yields 4.8%.
The big drugmaker should be in great shape to keep those dividends coming. AbbVie recently picked up a big legal victory that should allow it hold onto its U.S. market share for top-selling drug Humira for a few more years. That should give the company's other products and pipeline candidates time to gain significant momentum.
Look for the most impressive sales growth to come from new immunology drugs Rinvoq and Skyrizi. Both drugs ranked among market researcher EvaluatePharma's top five new drug launches of 2019. AbbVie's blood cancer drugs Imbruvica and Venclexta will also be key drivers for the company's growth.
The company's acquisition of Allergan should also help ensure the continued stability of AbbVie's dividend. AbbVie picked up several great products with the deal, notably including the blockbuster Botox franchise and antipsychotic drug Vraylar.
2. Brookfield Infrastructure Partners
Brookfield Infrastructure Partners (NYSE: BIP) hasn't been around long enough to rival AbbVie when it comes to consecutive years of dividend increases. The company was founded in 2007. Since then, though, Brookfield's dividend has soared more than 720%. The dividend yield now stands at 4.7%.
As its name indicates, Brookfield Infrastructure Partners focuses on infrastructure assets. The company's assets include cell towers, data centers, electricity transmission lines, natural gas pipelines and storage facilities, railroads, ports, toll roads.
The main thing you'll want to know about Brookfield Infrastructure is that its dividends are arguably as stable as they come. Roughly 95% of the company's cash flows are regulated or contracted, largely insulating Brookfield from macroeconomic turbulence. Its infrastructure assets are also remarkably diversified across sectors and geographical regions.
But Brookfield Infrastructure isn't a boring no-growth kind of dividend stock. The company continually evaluates its assets, selling off the lower-performing ones to invest in infrastructure operations with higher growth potential. This strategy should enable Brookfield to deliver solid growth in addition to its attractive dividend payouts.
3. Innovative Industrial Partners
The newest company on our list didn't begin operations until 2016. However, Innovative Industrial Partners (NYSE: IIPR) has made income-seeking investors happy campers by boosting its dividend by more than 600% in only three years (it paid the first dividend in 2017). IIP's dividend currently yields 4.6%.
IIP achieved its success by addressing an unmet need. U.S. medical cannabis operators have limited availability to capital funding. IIP buys their facilities then leases the properties back to them. This gives the medical cannabis operators much-needed cash to fund operations and expand. And it gives IIP a steady source of revenue.
The company is organized as a real estate investment trust (REIT). This means that it must distribute at least 90% of its pre-tax income to shareholders as dividends. IIP's income has grown tremendously as it has added new properties, soaring nearly 250% year over year in its most recent quarter.
IIP now owns 58 medical cannabis properties in 15 states. That's an increase of 12 properties since the beginning of 2020. At this rate of expansion, the company could easily double its earnings -- and its dividend -- within the next couple of years.
10 stocks we like better than Brookfield Infrastructure Partners
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Brookfield Infrastructure Partners wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of June 2, 2020
Keith Speights owns shares of AbbVie, Brookfield Infrastructure Partners, and Innovative Industrial Properties. The Motley Fool owns shares of and recommends Innovative Industrial Properties. The Motley Fool recommends Brookfield Infrastructure Partners. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie recently picked up a big legal victory that should allow it hold onto its U.S. market share for top-selling drug Humira for a few more years. AbbVie picked up several great products with the deal, notably including the blockbuster Botox franchise and antipsychotic drug Vraylar. AbbVie Richard Nixon was beginning his second term when AbbVie's (NYSE: ABBV) streak of annual dividend hikes began. | Brookfield Infrastructure Partners Brookfield Infrastructure Partners (NYSE: BIP) hasn't been around long enough to rival AbbVie when it comes to consecutive years of dividend increases. See the 10 stocks *Stock Advisor returns as of June 2, 2020 Keith Speights owns shares of AbbVie, Brookfield Infrastructure Partners, and Innovative Industrial Properties. AbbVie Richard Nixon was beginning his second term when AbbVie's (NYSE: ABBV) streak of annual dividend hikes began. | Brookfield Infrastructure Partners Brookfield Infrastructure Partners (NYSE: BIP) hasn't been around long enough to rival AbbVie when it comes to consecutive years of dividend increases. See the 10 stocks *Stock Advisor returns as of June 2, 2020 Keith Speights owns shares of AbbVie, Brookfield Infrastructure Partners, and Innovative Industrial Properties. AbbVie Richard Nixon was beginning his second term when AbbVie's (NYSE: ABBV) streak of annual dividend hikes began. | But AbbVie can. AbbVie Richard Nixon was beginning his second term when AbbVie's (NYSE: ABBV) streak of annual dividend hikes began. And since being spun off from Abbott Labs in 2013, AbbVie has raised its dividend by a whopping 195%. |
24486.0 | 2020-07-03 00:00:00 UTC | 5 High-Yield Dividend Stocks to Watch | ABBV | https://www.nasdaq.com/articles/5-high-yield-dividend-stocks-to-watch-2020-07-03 | nan | nan | In a world of low interest rates, investors have had to become creative to find yield. One of the places they've found cash returns is in dividend stocks, particularly those that offer a relatively high payout. However, the higher the yield, the more risk investors face.
Fortunately, some high-yield dividend stocks remain well-positioned to sustain their dividends. The stocks below offer generous cash returns supported by growing businesses. The following companies should earn rising profits and bring further payout hikes over time.
Image source: Getty Images.
AbbVie
AbbVie (NYSE: ABBV) spent most of its history as a subsidiary of Abbott Laboratories before becoming an independent company in 2013. Consequently, it also benefits from a Dividend Aristocrat status that it gained from Abbott.
Its annual dividend, which now stands at $4.72 per share, yields about 4.8% as of Thursday's close. Moreover, this payout appears stable. Thanks to a dividend payout ratio just under 60%, the company looks positioned to sustain annual increases while having plenty of profit left over to invest in its drug pipeline.
The pipeline remains a significant concern. AbbVie stock benefited from a five-year bull run in most of the last decade. However, it spent 2018 and most of 2019 in decline as investors worried about where the company would find revenue as the patents on its blockbuster drug Humira began to expire across the world.
ABBV data by YCharts
AbbVie's prospects improved as it addressed that concern. The drugmaker's hematologic drugs Imbruvica and Venclexta have seen massive increases in revenue over the last year. Moreover, its takeover of Allergan should increase its offerings. Furthermore, with a forward P/E ratio just under 10, investors can buy this cash stream at a reasonable valuation.
AT&T
AT&T (NYSE: T) has struggled for years amid intense competition and costly buildouts. Also, its phone line and pay-TV businesses have fallen victim to changing technology. This has caused the company's stock to suffer. It sells at a forward P/E ratio of around 9.4 (as of Thursday's close) and trades at a price it first reached in the '90s!
T data by YCharts
The reticence about AT&T's stock is understandable. Its purchase of DirecTV and what is now WarnerMedia left the company with a long-term debt of $147.202 billion as of the last quarter.
However, the years of stagnation along with a Dividend Aristocrat status have taken the annual dividend to $2.08 per share, a yield of approximately 7%. Also, the dividend payout ratio measured against quarterly income amounts to almost 82%. While that may appear elevated, forecasts point to improving profits, which may significantly reduce that ratio.
Moreover, one of its costly investments could pay off for the company. Over the last few years, it has spent tens of billions on building a nationwide 5G network. As consumers move to 5G technology, AT&T will become only one of three providers of 5G service. This increases the likelihood of rising profits and increasing payouts for years to come.
Innovative Industrial Properties
Innovative Industrial Properties (NYSE: IIPR) is a real estate investment trust (REIT) that provides properties in the U.S. designed to facilitate the growth of cannabis. Since it doesn't produce or sell marijuana directly, it's not subject to the regulations affecting most of the industry.
Also, as a REIT, it must pay a dividend out of its net income to maintain that status. The current annual payout of $4.24 per share yields around 4.5%. This payout has increased every year since 2017.
Moreover, the company will more than likely have to raise dividends. In the most recent quarter, net income increased by 249% year over year, and revenue rose by 210%. Such increases have helped to fuel stock-price growth over the last few years.
IIPR data by YCharts
The growth trend should continue for the foreseeable future. According to Grandview Research, the compound annual growth rate (CAGR) of the marijuana industry is 18.1% globally. Also, with hemp legal in all 50 states, Innovative Industrial can operate anywhere in the country.
Moreover, in the previous quarter, it reported $1.12 per share in funds from operations (FFO).This would give the REIT a price-to-FFO ratio of about 21.1, assuming stable FFO income. Hence, the company offers a low-cost multiple considering its growth. This should continue to fuel both Innovative Industrial and its dividend for the foreseeable future.
IBM
International Business Machines (NYSE: IBM) recently hiked its dividend for the 25th straight year, making it the newest Dividend Aristocrat. Its current annual payout of $6.52 per share gives this stock a yield of 5.4%. Still, despite this generous payout, IBM stock still trades at a forward P/E ratio of just under 11.
Years of stagnating revenue and profits may help explain this low multiple. As of the time of this writing, IBM sells for almost 45% less than its peak in 2013.
IBM data by YCharts.
However, IBM bulls have a reason for optimism. The company appointed the leader of its cloud division, Arvind Krishna, as its new CEO in April. In Krishna's last quarter as the head of cloud computing, cloud revenue increased by 19% year over year. This occurred as overall revenue dropped by 3.4% from the same quarter last year. Both these results and Krishna's focus point to IBM becoming more of a cloud company.
Also, IBM's dividend payout ratio stands at about 64%. Though the dividend is not in trouble for now, this ratio indicates that IBM will need income growth to maintain payout hikes.
Nonetheless, with a more cloud-oriented focus, IBM can probably continue its dividend increases. Moreover, it could also inspire some long-awaited growth in the IBM stock price.
Prudential Financial
Prudential Financial (NYSE: PRU) provides wealth management and retirement products for individuals and institutions alike. The company has consistently increased its annual payout since 2008, topping $4 this year, and should have no trouble maintaining it. Even though its yield is over 7% today, its payout ratio is a manageable 57%.
However, the risk with this stock may come from the stock price. It's fallen by more than 30% over the last five years, with the coronavirus pandemic causing most of this drop. As a result, the forward P/E ratio now stands at around 6.4.
PRU data by YCharts
Despite Prudential's low P/E, investors shouldn't rely on significant multiple expansion for gains. However, earnings increased by an average of almost 7.1% per year over the last five years. Even though profit growth turned negative in the most recent earnings report, both Prudential's dividend and its stock price should register growth as the economy recovers.
10 stocks we like better than IBM
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and IBM wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of June 2, 2020
Will Healy owns shares of AbbVie and AT&T. The Motley Fool owns shares of and recommends Innovative Industrial Properties. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie AbbVie (NYSE: ABBV) spent most of its history as a subsidiary of Abbott Laboratories before becoming an independent company in 2013. AbbVie stock benefited from a five-year bull run in most of the last decade. ABBV data by YCharts AbbVie's prospects improved as it addressed that concern. | AbbVie AbbVie (NYSE: ABBV) spent most of its history as a subsidiary of Abbott Laboratories before becoming an independent company in 2013. AbbVie stock benefited from a five-year bull run in most of the last decade. ABBV data by YCharts AbbVie's prospects improved as it addressed that concern. | AbbVie AbbVie (NYSE: ABBV) spent most of its history as a subsidiary of Abbott Laboratories before becoming an independent company in 2013. AbbVie stock benefited from a five-year bull run in most of the last decade. ABBV data by YCharts AbbVie's prospects improved as it addressed that concern. | AbbVie AbbVie (NYSE: ABBV) spent most of its history as a subsidiary of Abbott Laboratories before becoming an independent company in 2013. AbbVie stock benefited from a five-year bull run in most of the last decade. ABBV data by YCharts AbbVie's prospects improved as it addressed that concern. |
24487.0 | 2020-07-02 00:00:00 UTC | AbbVie Is Cheap and Pays an Attractive Yield | ABBV | https://www.nasdaq.com/articles/abbvie-is-cheap-and-pays-an-attractive-yield-2020-07-02 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
AbbVie (NYSE:ABBV) stock is both cheap and has a very attractive dividend yield. In addition, this pharmaceutical company’s growth prospects are high, now that its purchase of Allergan is closed.
Source: Piotr Swat / Shutterstock.com
For example, the stock trades on a forward earnings ratio of just 9.2 times 2020 expected earnings. It is even lower with 2021 earnings prospects.
In addition, the $4.72 per share annual dividend is very attractive to most investors for several reasons. For one, the dividend yield for ABBV stock is much higher than the average stock.
Secondly, the dividend is likely to keep on growing at a nice pace. For example, on June 17 AbbVie declared a $1.18 quarterly dividend for the third time. After the fourth quarterly dividend at this rate, I suspect the company will raise the dividend in Q4. According to Seeking Alpha, AbbVie has had a 20.86% dividend growth rate annually on a compounded basis.
7 Utilities Stocks to Buy With Reassuring Dividends
Lastly, the dividend is still well covered by the company’s earnings. For example, Seeking Alpha‘s poll of 15 analysts’ estimates of 2020 is $10.46 per share. But the dividend rate right now is $4.72. So the dividend is more than 100% covered by earnings.
Why Is AbbVie Stock So Cheap?
AbbVie’s main revenue driver, up until its recent acquisition of Allergan, was Humira, a rheumatoid arthritis drug. It also acts as an anti-inflammatory drug for other conditions including Crohn’s disease, psoriasis, ulcerative colitis, etc. It is the world’s best-selling drug.
But adalimubab, the actual name of the drug, went off-patent in 2016. Recently, generic versions of the drug have become available.
The problem for AbbVie is that up until Q1 2020, Humira accounted for 54.5% of its revenue. AbbVie said its Q1 sales were $8.619 billion, up 10.7% year-over-year. But Humira sales were $4.703 billion, up 6.4%.
This is the most likely reason for AbbVie’s low valuation. It is too reliant on one drug and that drug is now off-patent. The market assumes that generic drugs will eventually overtake that revenue stream for AbbVie. But things are not as bad as that.
Why Investors Need Not Be So Worried
First of all, Humira does not go completely off-patent in the U.S., even though in some other countries this has happened. Its core U.S. patents went off-patent in 2016, but it has a “patent thicket” that extends its exclusivity to as late as 2034, according to one source. Another source says its exclusivity extends to 2023.
Second, the company will now have a much lower reliance on Humira. On May 8, AbbVie closed on its acquisition of Allergan for about $63 billion in cash and stock. Allergan made $3.6 billion in sales in its latest quarter and $378 million in profits.
So you can see that on a pro-forma combined basis, Humira will now account for a lower amount of total sales. They would total $12.2 billion on a combined basis in Q1. But Humira’s $4.7 billion would account for only 38.4%. Given that other drugs in the portfolio are likely growing faster than Humira, that portion will continue to fall.
So the risk is falling for the over-reliance on one drug. But some analysts point out that AbbVie’s other drugs and its pipeline are very attractive as growth drivers.
Valuing AbbVie Stock
Given that management clearly seems intent on growing its dividend, we can use this aspect of the return of capital to value AbbVie stock. Let’s assume the dividend next rises 10% next year, just like it did this year. That would put the annual dividend at $5.20 per share.
The historical dividend yield for AbbVie stock has been 4.22% over the past four years, according to Seeking Alpha. Therefore, by taking the $5.20 dividend per share and dividing it by 4.22%, the target price is $123.22 per share
That represents a significant gain over the current price of about $98. So not only is AbbVie stock cheap with an attractive dividend yield, but it also has good upside potential.
Mark Hake runs the Total Yield Value Guide which you can review here. As of this writing, Mark Hake, CFA does not hold a position in any of the aforementioned securities.
The post AbbVie Is Cheap and Pays an Attractive Yield appeared first on InvestorPlace.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie’s main revenue driver, up until its recent acquisition of Allergan, was Humira, a rheumatoid arthritis drug. So not only is AbbVie stock cheap with an attractive dividend yield, but it also has good upside potential. InvestorPlace - Stock Market News, Stock Advice & Trading Tips AbbVie (NYSE:ABBV) stock is both cheap and has a very attractive dividend yield. | InvestorPlace - Stock Market News, Stock Advice & Trading Tips AbbVie (NYSE:ABBV) stock is both cheap and has a very attractive dividend yield. According to Seeking Alpha, AbbVie has had a 20.86% dividend growth rate annually on a compounded basis. So not only is AbbVie stock cheap with an attractive dividend yield, but it also has good upside potential. | InvestorPlace - Stock Market News, Stock Advice & Trading Tips AbbVie (NYSE:ABBV) stock is both cheap and has a very attractive dividend yield. Valuing AbbVie Stock Given that management clearly seems intent on growing its dividend, we can use this aspect of the return of capital to value AbbVie stock. The historical dividend yield for AbbVie stock has been 4.22% over the past four years, according to Seeking Alpha. | According to Seeking Alpha, AbbVie has had a 20.86% dividend growth rate annually on a compounded basis. InvestorPlace - Stock Market News, Stock Advice & Trading Tips AbbVie (NYSE:ABBV) stock is both cheap and has a very attractive dividend yield. For one, the dividend yield for ABBV stock is much higher than the average stock. |
24488.0 | 2020-07-01 00:00:00 UTC | Best ETFs for 2020: The AdvisorShares Vice ETF Bets Big on Booze | ABBV | https://www.nasdaq.com/articles/best-etfs-for-2020%3A-the-advisorshares-vice-etf-bets-big-on-booze-2020-07-01 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
This article is a part of InvestorPlace.com’s Best ETFs for 2020 contest. The InvestorPlace Staff’s pick for the contest is the AdvisorShares Vice ETF (NASDAQ:ACT).
When I initially chose the AdvisorShares Vice ETF (NASDAQ:ACT) for InvestorPlace.com’s Best ETFs for 2020 contest, I expected it to float around where stands today on the leader board. In eighth place, it isn’t a winning pick, but it’s not a losing pick, either.
Since ACT is an actively managed exchange-traded fund, its managers can adapt to the ever-changing and outright bananas market conditions we’ve seen so far in 2020. It’s a convenient safety net to have, and one that ACT’s managers took advantage of this quarter.
ACT Portfolio manager Dan Ahrens commented in the fund’s May review: “[W]e can choose to hold extra cash when market conditions appear lousy and can choose to invest opportunistically in stocks of our choosing. During May, we increased holdings in the restaurant and bar stocks that we hold due to alcohol sales and enjoyed their nice bounce back.”
Although it’s down about 9% year-to-date, ACT gained 5.90% on its net asset value (NAV) and 5.88% on its market price for the month of May. Its holdings in “recession-resistant” areas like alcohol are still fairing well.
According to Nielsen, U.S. alcohol sales alone have “grown nearly 27%.” And that’s since the initial widespread lockdown in March, when consumers first flocked to stores to stock up their liquor cabinets.
Where ACT’s Top Holdings Stand Today
ACT’s current top five holdings are Thermo Fisher Scientific (NYSE:TMO), Boston Beer Company (NYSE:SAM), Abbvie (NYSE:ABBV), Abbott Labs (NYSE:ABT) and PerkinElmer (NYSE:PKI).
Of the fund’s 31 holdings, TMO and SAM are at the top, with the portfolio’s weight in these holdings at 7.79% and 7.35%, respectively. ABBV, which recently received an upgrade to “outperform” from “market perform” from analysts at Atlantic Equities, is in third with a portfolio weight of 6.65%.
9 Florida Stocks to Avoid as Coronavirus Rates Spike
TMO stock popped 3.29% on Tuesday, June 30. Thermo Fisher is one of the diagnostic makers that received Food and Drug Administration emergency use authorization to test for the novel coronavirus in March. Since then, they have been making over five million tests per week, but that number could increase.
At a Senate hearing Tuesday, Dr. Anthony Fauci stressed that if the country continues on its current trajectory, new cases of Covid-19 could reach 100,000 per day. Given that the recent spike in U.S. coronavirus cases is at around 40,000 a day, there will be significant demand for more tests from TMO.
As mentioned earlier, the No. 2 holding in the ACT ETF is Boston Beer. SAM stock is up almost 44% in 2020 thanks to the rise in alcohol sales as well as the spiked seltzer trend. Boston Beer is counting on spiked seltzer’s long-term popularity. The company has already released lemonade and ice cream versions of Truly Hard Seltzer this summer.
Earlier this month, RBC Capital Markets analyst Nik Modi said SAM stock will keep growing because of the strength of its Truly brand of hard seltzers. Modi has an “outperform” rating on the stock and a price target of $575.
Is ACT Still One of the Best ETFs to Buy This Year?
The fact that the AdvisorShares Vice ETF has an A rating from the MSCI ESG Fund doesn’t hurt, either. The rating measures the resiliency “of mutual funds and ETFs to long term risks and opportunities arising from environmental, social and governance (ESG) issues.” Ratings range from best (AAA) to worst (CCC).
With the healthcare and alcohol sectors currently carrying ACT through the various market cycles of 2020, the fund has a slight chance of improving its ranking in the Best ETFs contest. Even if it doesn’t move higher, this fund is just fine being safe at an average standing.
Anna Jacoby is a web editor for InvestorPlace.com. As of this writing, she did not hold a position in any of the aforementioned securities.
The post Best ETFs for 2020: The AdvisorShares Vice ETF Bets Big on Booze appeared first on InvestorPlace.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Where ACT’s Top Holdings Stand Today ACT’s current top five holdings are Thermo Fisher Scientific (NYSE:TMO), Boston Beer Company (NYSE:SAM), Abbvie (NYSE:ABBV), Abbott Labs (NYSE:ABT) and PerkinElmer (NYSE:PKI). ABBV, which recently received an upgrade to “outperform” from “market perform” from analysts at Atlantic Equities, is in third with a portfolio weight of 6.65%. According to Nielsen, U.S. alcohol sales alone have “grown nearly 27%.” And that’s since the initial widespread lockdown in March, when consumers first flocked to stores to stock up their liquor cabinets. | Where ACT’s Top Holdings Stand Today ACT’s current top five holdings are Thermo Fisher Scientific (NYSE:TMO), Boston Beer Company (NYSE:SAM), Abbvie (NYSE:ABBV), Abbott Labs (NYSE:ABT) and PerkinElmer (NYSE:PKI). ABBV, which recently received an upgrade to “outperform” from “market perform” from analysts at Atlantic Equities, is in third with a portfolio weight of 6.65%. The InvestorPlace Staff’s pick for the contest is the AdvisorShares Vice ETF (NASDAQ:ACT). | Where ACT’s Top Holdings Stand Today ACT’s current top five holdings are Thermo Fisher Scientific (NYSE:TMO), Boston Beer Company (NYSE:SAM), Abbvie (NYSE:ABBV), Abbott Labs (NYSE:ABT) and PerkinElmer (NYSE:PKI). ABBV, which recently received an upgrade to “outperform” from “market perform” from analysts at Atlantic Equities, is in third with a portfolio weight of 6.65%. ACT Portfolio manager Dan Ahrens commented in the fund’s May review: “[W]e can choose to hold extra cash when market conditions appear lousy and can choose to invest opportunistically in stocks of our choosing. | Where ACT’s Top Holdings Stand Today ACT’s current top five holdings are Thermo Fisher Scientific (NYSE:TMO), Boston Beer Company (NYSE:SAM), Abbvie (NYSE:ABBV), Abbott Labs (NYSE:ABT) and PerkinElmer (NYSE:PKI). ABBV, which recently received an upgrade to “outperform” from “market perform” from analysts at Atlantic Equities, is in third with a portfolio weight of 6.65%. The InvestorPlace Staff’s pick for the contest is the AdvisorShares Vice ETF (NASDAQ:ACT). |
24489.0 | 2020-07-01 00:00:00 UTC | 2 Biotech Stocks That Could Soar in 2020 | ABBV | https://www.nasdaq.com/articles/2-biotech-stocks-that-could-soar-in-2020-2020-07-01 | nan | nan | Stocks in the biotechnology sector have outperformed the broader market year to date. Despite the market volatility throughout this year, there are still good prospects in this sector, especially in small-cap biotechnology stocks. These companies are often selling at attractive prices, and their cutting-edge research could make investors wealthy in the long run.
If you have cash waiting to be put to work, you might want to take a look at these biotechnology stocks that are set to dominate in 2020 and beyond. Both companies are pioneers in their respective spaces and offer robust pipelines, with lead products nearing the middle of the drug-development process.
Let's take a closer look.
Image source: Getty Images.
Atara Biotherapeutics
Atara Biotherapeutics (NASDAQ: ATRA) is a hidden gem poised to move higher. Down 18% year to date, this T-cell immunotherapy specialist has a novel platform addressing Epstein-Barr-virus (EBV) T-cells that could be a game-changer in the development of therapies for patients with solid tumors, hematologic cancers, and autoimmune and viral diseases.
The science: Atara's platform leverages properties of EBV T-cells to treat a variety of EBV-associated diseases using engineered chimeric antigen receptors (CARs) and T-cell receptors (TCRs). Early studies of Atara's lead product candidate, tab-cel (tabelecleucel), have shown it to be effective in improving survival for patients with a deadly and ultra-rare form of cancer known as EBV-associated post-transplant lymphoproliferative disease (EBV+ PTLD). This product is currently in phase 3 of the drug-development process, and Atara is in the process of submitting a biologics license application (BLA) for tab-cel to the U.S. Food and Drug Administration (FDA) near the second half of 2020.
The potential: What is exciting about tab-cel is that it could be the first approved therapy for these ultra-rare diseases. Several companies such as Viracta Therapeutics, AlloVir, and Tessa Therapeutics are still in the early phases of development. If Atara stays ahead in the race to market, it could potentially have first-mover advantage in this space. Management sees plenty of expansion opportunities in the ultra-rare-disease market and has launched additional studies in a variety of EBV-associated diseases such as nasopharyngeal carcinoma (a type of throat cancer) and other cancers.
The promise of Atara's platform has investors bullish on the stock, with more than 87.8% of the shares held by institutional firms. The stock has a price-to-book ratio of 3.2, which is undervalued compared with peers including Heron Therapeutics (4.9) and Mirati Therapeutics (7.5) as well as the broader biotech sector (about 6). The stock is trading near the midpoint of its 52-week range and could easily move closer to its high of $21.45. There's plenty of upside in the long term based on Atara's unique capabilities and applicability in the EBV-associated ultra-rare-disease market.
Aprea Therapeutics
Aprea Therapeutics (NASDAQ: APRE) is another under-the-radar pick poised to excel in the long run. The stock is down 17% year to date. The company is developing novel cancer therapeutics that target p53, a protein expressed from the TP53 gene, a common mutation seen across a range of cancer types. These mutations are resistant to treatment and have poor overall survival rates, so a therapy that addresses them represents a major development in the treatment of cancer.
The science: Aprea has a promising lead product candidate known as eprenetapopt (APR-246) that is in phase 3 clinical trial development as a front-line treatment of TP53 mutant myelodysplastic syndromes (MDS, a type of blood cancer). The APR-246 therapy reactivates mutant and inactivated p53 protein to allow the immune system to effectively target and destroy cancer cells.
Early studies have shown APR-246 to be effective in combination with anticancer agents and safe in patients with blood cancers and solid tumors with mutations in the TP53 gene. Management believes that APR-246 has the potential to be a first-in-class therapy.
The potential: The MDS market is expected to grow at a compound annual growth rate (CAGR) of 5.5% and to reach 1.8 billion by 2025. There are an estimated 200,000 MDS patients worldwide, with 68,000 in the United States. Several companies are in the early and middle stages of drug development for MDS treatments, including AbbVie, argenx, Karyopharm Therapeutics, and Takeda Pharmaceuticals.
Aprea has an advantage among competitors, as it has received several designations for APR-246 from the FDA to expedite development, including orphan-drug and fast-track status for MDS. The company is on pace to report data at the end of 2020. Additionally, APR-246 has received an orphan drug designation from the European Medicines Agency for MDS, acute myeloid leukemia (AML), and ovarian cancer. Management plans to submit a New Drug Application (NDA) and Marketing Authorization Application (MAA) for the drug to the European Medicines Agency (EMA) in 2021.
Aprea's market value is $807 million, and the stock is nowhere near their 52-week high of $53.11. In the most recent quarter, 34 institutional investors increased their share holdings, and 13 opened new positions in Aprea Therapeutics. This suggests investors are bullish on the prospects of APR-246 and its potential to be commercialized. Aprea has a price-to-book ratio of 7.1, which is undervalued compared with peers including Karyopharm Therapeutics (8.1) and IGM Biosciences (9.4). Investors should consider buying shares of Aprea Therapeutics during the next dip as a long-term opportunity.
10 stocks we like better than Atara Biotherapeutics
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Atara Biotherapeutics wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of June 2, 2020
Amar Khatri has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Several companies are in the early and middle stages of drug development for MDS treatments, including AbbVie, argenx, Karyopharm Therapeutics, and Takeda Pharmaceuticals. Early studies of Atara's lead product candidate, tab-cel (tabelecleucel), have shown it to be effective in improving survival for patients with a deadly and ultra-rare form of cancer known as EBV-associated post-transplant lymphoproliferative disease (EBV+ PTLD). The science: Aprea has a promising lead product candidate known as eprenetapopt (APR-246) that is in phase 3 clinical trial development as a front-line treatment of TP53 mutant myelodysplastic syndromes (MDS, a type of blood cancer). | Several companies are in the early and middle stages of drug development for MDS treatments, including AbbVie, argenx, Karyopharm Therapeutics, and Takeda Pharmaceuticals. Early studies of Atara's lead product candidate, tab-cel (tabelecleucel), have shown it to be effective in improving survival for patients with a deadly and ultra-rare form of cancer known as EBV-associated post-transplant lymphoproliferative disease (EBV+ PTLD). The company is developing novel cancer therapeutics that target p53, a protein expressed from the TP53 gene, a common mutation seen across a range of cancer types. | Several companies are in the early and middle stages of drug development for MDS treatments, including AbbVie, argenx, Karyopharm Therapeutics, and Takeda Pharmaceuticals. The company is developing novel cancer therapeutics that target p53, a protein expressed from the TP53 gene, a common mutation seen across a range of cancer types. 10 stocks we like better than Atara Biotherapeutics When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. | Several companies are in the early and middle stages of drug development for MDS treatments, including AbbVie, argenx, Karyopharm Therapeutics, and Takeda Pharmaceuticals. Aprea Therapeutics Aprea Therapeutics (NASDAQ: APRE) is another under-the-radar pick poised to excel in the long run. The company is developing novel cancer therapeutics that target p53, a protein expressed from the TP53 gene, a common mutation seen across a range of cancer types. |
24490.0 | 2020-06-29 00:00:00 UTC | 4 Stocks to Buy With Dividends Yielding More Than 4% | ABBV | https://www.nasdaq.com/articles/4-stocks-to-buy-with-dividends-yielding-more-than-4-2020-06-30 | nan | nan | Stocks may have recovered most of what was lost in February and March, shortly after the novel coronavirus began to spread in the U.S., but few investors are naive enough to think the market and the economy are as strong as they were early this year. The recent bullishness is mostly founded on hopes for a quick recovery.
With that as a backdrop, it wouldn't be a terrible idea to take a step back and let dividends do some work while growth-oriented names figure out where they should truly be trading. You certainly deserve the mental break! Here's a rundown of four top dividend names, each of which currently yields more than 4% (versus the S&P 500's current average yield of just under 2%).
Image source: Getty Images.
Verizon's simplicity is its strength
Current dividend yield: 4.5%
There's nothing particularly riveting about telecommunication name Verizon Communications (NYSE: VZ). It owns and operates web portals Yahoo and AOL, but they're little more than pet projects now. Verizon is almost exclusively a communications name, and is setting itself up for more of the same going forward. It's upped up its capital spending budget this year by $500 million more than last year's planned expenditures, mostly to expand its 5G network that most customers will never see but will certainly be happy to plug into.
Verizon may be a bit on the boring side, but boring also means it's predictable. The company's revenue growth may be habitually in the single digits, but this year's expected (and typical) income of $4.75 per share is far more than enough to support the current annualized dividend payout of $2.46 per share.
The graphic below tells the tale, laying out not just Verizon's dividend history ($0.5775 per share in early 2017 to $0.6150 in early 2020), but earnings per share and revenue over those years (rising overall). The mean forecasts from analysts extends the trends of actual results already produced by the company. The advent of a combined Sprint and T-Mobile seemingly poses a threat to Verizon's dominance of the wireless space, but even before they were united the two companies weren't collectively able or planning to outspend Verizon.
Data sources: Thomson Reuters/Refinitiv. Chart by author.
AbbVie has its fair share of blockbusters
Current dividend yield: 4.9%
AbbVie (NYSE: ABBV) is among the several pharmaceutical names that have been caught up in the fervor linked to the race for a coronavirus vaccine. Although its HIV drug Kaletra was a bust as a treatment for COVID-19, it's still working with partners from the academic arena on a solution.
Potential for a coronavirus therapy alone is a terrible reason to make a bet on a stock, though. If this coronavirus goes away or eventually mutates, the work put into a current vaccine would not pan out. Then, after the pandemic ends, drug companies will be left with the portfolios and pipelines they built before the virus took hold.
Fortunately for AbbVie and its shareholders, the company's portfolio was already impressive. Its cancer-fighting drug Opdivo ranks as one of the world's 10-best-selling drugs, and Evaluate Pharma estimates that its Humira will hold its place as the world's best-selling drug ever through 2024. Even Humira's deteriorating patent protection won't necessarily mark the end of the franchise's value to AbbVie, which also co-owns Imbruvica with Johnson & Johnson. That's another top-10 drug.
It's the sort of product base that not only drives recurring revenue and earnings, but has helped drive 47 consecutive years' worth of dividend payout growth from AbbVie. The chart below puts the recent past and foreseeable future in perspective. Per-share earnings are about twice the amount being paid out in per-share dividends, leaving plenty of leftover income to invest in drugs that continue driving revenue growth...a virtuous cycle.
Data sources: Thomson Reuters/Refinitiv. Chart by author.
Investors have undervalued Duke Energy
Current dividend yield: 4.8%
It's not surprising to see a utility stock on a list of dividend payers to consider owning; they're ideal income-oriented companies simply because their customers have to pay their electricity bills every month. What's unusual about Duke Energy's (NYSE: DUK) earning a spot on this particular list is the fact that, more often than not, utility stocks perform like bonds, rising and falling so that their dividend yields reflect the prevailing interest rates at the time. Right now, interest rates remain near or even at record lows, but Duke's yield hasn't followed suit because its stock hasn't risen to push its yield downward. Just the opposite has been the case.
This is one of Mr. Market's mistakes that translates into opportunity for investors paying close attention to the situation. While Duke has and will encounter challenges stemming from the economic impact of the coronavirus pandemic -- like changing gas prices that alter its billing rates -- this is nothing new for the company. Nothing fundamental has changed about its business that generates recurring revenue. Ditto for its steady annualized earnings.
The graphic below visually makes this point. While changes to seasons prompt an ebb and flow in earnings and revenue, annualized, growth of both is reliable. Analysts are forecasting the same sort of dividend-driving growth going forward.
Data sources: Thomson Reuters/Refinitiv. Chart by author.
LyondellBasell isn't so tightly linked to energy prices
Current dividend yield: 6.6%
Add LyondellBasell (NYSE: LYB) to your list of buy-worthy dividend stocks presently paying out more than 4%. This chemical company currently yields 6.4%.
LyondellBasell shares haven't done particularly well this year, which is the key reason its yield is now so high. They're down nearly 30% from their February peak, thanks to the global coronavirus outbreak (and an April downgrade from Bank of America rooted in margin concerns), and are off by almost 40% from their November high. Investors have largely lumped the stock in with oil stocks and the chemical companies linked to the energy industry by virtue of supplying refiners and drillers with the consumables needed to extract oil and create fuel.
Connecting only those energy-related dots is a sizable mistake, though. Refining supplies accounted for about one-fourth of last year's sales, while oil intermediates and derivatives made up almost another one-fourth of its top line. Polymers and the olefins used to make plastics and some feedstocks make up about half of its business, and those markets' prices aren't quite as volatile as energy prices are. Usage of those plastic-making chemicals is even more consistent than their generally stable prices. Put it all together and what you've got is a misunderstood company that investors have unduly punished.
The revenue history and forecast shown in the chart below show a recent deterioration will likely persist through 2022 according to analysts' mean forecasts. That will likely prove a continued drag on per-share profits. But, even then, LyondellBasell is expected to keep earning more than its anticipated dividend payout once the coronavirus dust settles.
Data sources: Thomson Reuters/Refinitiv. Chart by author.
10 stocks we like better than Verizon Communications
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Verizon Communications wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of June 2, 2020
James Brumley has no position in any of the stocks mentioned. The Motley Fool recommends Duke Energy, Johnson & Johnson, and Verizon Communications. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie has its fair share of blockbusters Current dividend yield: 4.9% AbbVie (NYSE: ABBV) is among the several pharmaceutical names that have been caught up in the fervor linked to the race for a coronavirus vaccine. Fortunately for AbbVie and its shareholders, the company's portfolio was already impressive. Even Humira's deteriorating patent protection won't necessarily mark the end of the franchise's value to AbbVie, which also co-owns Imbruvica with Johnson & Johnson. | AbbVie has its fair share of blockbusters Current dividend yield: 4.9% AbbVie (NYSE: ABBV) is among the several pharmaceutical names that have been caught up in the fervor linked to the race for a coronavirus vaccine. Fortunately for AbbVie and its shareholders, the company's portfolio was already impressive. Even Humira's deteriorating patent protection won't necessarily mark the end of the franchise's value to AbbVie, which also co-owns Imbruvica with Johnson & Johnson. | AbbVie has its fair share of blockbusters Current dividend yield: 4.9% AbbVie (NYSE: ABBV) is among the several pharmaceutical names that have been caught up in the fervor linked to the race for a coronavirus vaccine. Fortunately for AbbVie and its shareholders, the company's portfolio was already impressive. Even Humira's deteriorating patent protection won't necessarily mark the end of the franchise's value to AbbVie, which also co-owns Imbruvica with Johnson & Johnson. | AbbVie has its fair share of blockbusters Current dividend yield: 4.9% AbbVie (NYSE: ABBV) is among the several pharmaceutical names that have been caught up in the fervor linked to the race for a coronavirus vaccine. Fortunately for AbbVie and its shareholders, the company's portfolio was already impressive. Even Humira's deteriorating patent protection won't necessarily mark the end of the franchise's value to AbbVie, which also co-owns Imbruvica with Johnson & Johnson. |
24491.0 | 2020-06-29 00:00:00 UTC | HIV treatment found to have no benefit for hospitalised COVID-19 patients in trial | ABBV | https://www.nasdaq.com/articles/hiv-treatment-found-to-have-no-benefit-for-hospitalised-covid-19-patients-in-trial-2020-06 | nan | nan | Adds quote, detail, background
LONDON, June 29 (Reuters) - A combination of antiviral drugs used to treat HIV had no beneficial effect in patients hospitalised with COVID-19 in a large-scale randomised trial, British scientists said on Monday.
Scientists running the RECOVERY trial at the University of Oxford said that the results "convincingly rule out any meaningful mortality benefit of lopinavir-ritonavir in the hospitalised COVID-19 patients we studied."
The scientists found no difference in mortality, length of hospital stay or the risk of being put on a ventilator, when they compared 1,596 patients given lopinavir-ritonavir with 3,376 patients in a control group.
AbbVie Inc's ABBV.N Kaletra is a combination of the drugs lopinavir and ritonavir, used together to fight HIV. The company had increased its supplies while it was determining whether it can be used to treat COVID-19.
"These preliminary results show that for patients hospitalised with COVID-19 and not on a ventilator, lopinavir-ritonavir is not an effective treatment," Peter Horby, chief investigator for the trial, said.
The scientists were unable to draw conclusions about the effectiveness of the drug combination in patients on ventilators because of the difficulty of administering it.
Lopinavir-ritonavir is also being studied in a trial by the World Health Organization.
The Oxford-based RECOVERY trial has been examining the effectiveness of six possible COVID-19 treatments, enrolling 11,800 patients in all.
The arm of the trial studying dexamethasone, a steroid, found it reduced the death rate of patients that required oxygen. Another arm found the malaria drug hydroxychloroquine, touted by U.S. President Donald Trump, had no benefit.
(Reporting by Alistair Smout Editing by Franklin Paul and Peter Graff)
((alistair.smout@thomsonreuters.com; +44 207 542 7064; Reuters Messaging: alistair.smout.thomsonreuters.com@reuters.net))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie Inc's ABBV.N Kaletra is a combination of the drugs lopinavir and ritonavir, used together to fight HIV. Adds quote, detail, background LONDON, June 29 (Reuters) - A combination of antiviral drugs used to treat HIV had no beneficial effect in patients hospitalised with COVID-19 in a large-scale randomised trial, British scientists said on Monday. Scientists running the RECOVERY trial at the University of Oxford said that the results "convincingly rule out any meaningful mortality benefit of lopinavir-ritonavir in the hospitalised COVID-19 patients we studied." | AbbVie Inc's ABBV.N Kaletra is a combination of the drugs lopinavir and ritonavir, used together to fight HIV. Adds quote, detail, background LONDON, June 29 (Reuters) - A combination of antiviral drugs used to treat HIV had no beneficial effect in patients hospitalised with COVID-19 in a large-scale randomised trial, British scientists said on Monday. Scientists running the RECOVERY trial at the University of Oxford said that the results "convincingly rule out any meaningful mortality benefit of lopinavir-ritonavir in the hospitalised COVID-19 patients we studied." | AbbVie Inc's ABBV.N Kaletra is a combination of the drugs lopinavir and ritonavir, used together to fight HIV. Adds quote, detail, background LONDON, June 29 (Reuters) - A combination of antiviral drugs used to treat HIV had no beneficial effect in patients hospitalised with COVID-19 in a large-scale randomised trial, British scientists said on Monday. Scientists running the RECOVERY trial at the University of Oxford said that the results "convincingly rule out any meaningful mortality benefit of lopinavir-ritonavir in the hospitalised COVID-19 patients we studied." | AbbVie Inc's ABBV.N Kaletra is a combination of the drugs lopinavir and ritonavir, used together to fight HIV. Adds quote, detail, background LONDON, June 29 (Reuters) - A combination of antiviral drugs used to treat HIV had no beneficial effect in patients hospitalised with COVID-19 in a large-scale randomised trial, British scientists said on Monday. Scientists running the RECOVERY trial at the University of Oxford said that the results "convincingly rule out any meaningful mortality benefit of lopinavir-ritonavir in the hospitalised COVID-19 patients we studied." |
24492.0 | 2020-06-29 00:00:00 UTC | Canada federal court dismisses drugmakers' plea challenging drug price rules | ABBV | https://www.nasdaq.com/articles/canada-federal-court-dismisses-drugmakers-plea-challenging-drug-price-rules-2020-06-29 | nan | nan | June 29 (Reuters) - The federal court of Canada on Monday dismissed a plea by drugmakers challenging the Canadian government's new regulations aimed at lowering prices of patented drugs that could potentially lead them to lose billions over a decade.
The court struck down one part of the new regulation, finding that using certain payments to third parties to determine a drug's regulated price went beyond the government's authority, but upheld the bulk of the rules.
Canada published the final regulations in August last year, despite strong opposition from drug companies. The lawsuit was filed in federal court and is led by Innovative Medicines Canada (IMC), which represents major drugmakers in the country.
The new rules will save money for patients, employers and insurers including the government at the expense of drug company profits.
The Canadian reforms could spill into the drugmakers' most lucrative market, the United States, where policymakers have suggested importing less expensive Canadian drugs or basing some prices on drug costs in other countries, including Canada.
The plaintiffs included the Canadian units of Pfizer Inc PFE.N, AbbVie Corp ABBV.N, Amgen Inc AMGN.O, Bristol Myers Squibb Co BMY.N, AstraZeneca Plc AZN.L, Novartis AG NOVN.S and Eli Lilly and Co LLY.N.
The new regulations, which take into account cost-effectiveness of medicines and their impact on government budgets, apply only to drugs approved by Health Canada.
The regulations which were to go into force on July 1, have been deferred until Jan. 1, 2021.
FACTBOX-Details of Canada's biggest drug pricing overhaul in decades
(Reporting by Dania Nadeem in Bengaluru; Editing by Shounak Dasgupta)
((Dania.Nadeem@thomsonreuters.com; within U.S. +1 646 223 8780, outside U.S. +91 80 6182 3463;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The plaintiffs included the Canadian units of Pfizer Inc PFE.N, AbbVie Corp ABBV.N, Amgen Inc AMGN.O, Bristol Myers Squibb Co BMY.N, AstraZeneca Plc AZN.L, Novartis AG NOVN.S and Eli Lilly and Co LLY.N. June 29 (Reuters) - The federal court of Canada on Monday dismissed a plea by drugmakers challenging the Canadian government's new regulations aimed at lowering prices of patented drugs that could potentially lead them to lose billions over a decade. The lawsuit was filed in federal court and is led by Innovative Medicines Canada (IMC), which represents major drugmakers in the country. | The plaintiffs included the Canadian units of Pfizer Inc PFE.N, AbbVie Corp ABBV.N, Amgen Inc AMGN.O, Bristol Myers Squibb Co BMY.N, AstraZeneca Plc AZN.L, Novartis AG NOVN.S and Eli Lilly and Co LLY.N. The court struck down one part of the new regulation, finding that using certain payments to third parties to determine a drug's regulated price went beyond the government's authority, but upheld the bulk of the rules. The new rules will save money for patients, employers and insurers including the government at the expense of drug company profits. | The plaintiffs included the Canadian units of Pfizer Inc PFE.N, AbbVie Corp ABBV.N, Amgen Inc AMGN.O, Bristol Myers Squibb Co BMY.N, AstraZeneca Plc AZN.L, Novartis AG NOVN.S and Eli Lilly and Co LLY.N. June 29 (Reuters) - The federal court of Canada on Monday dismissed a plea by drugmakers challenging the Canadian government's new regulations aimed at lowering prices of patented drugs that could potentially lead them to lose billions over a decade. The court struck down one part of the new regulation, finding that using certain payments to third parties to determine a drug's regulated price went beyond the government's authority, but upheld the bulk of the rules. | The plaintiffs included the Canadian units of Pfizer Inc PFE.N, AbbVie Corp ABBV.N, Amgen Inc AMGN.O, Bristol Myers Squibb Co BMY.N, AstraZeneca Plc AZN.L, Novartis AG NOVN.S and Eli Lilly and Co LLY.N. June 29 (Reuters) - The federal court of Canada on Monday dismissed a plea by drugmakers challenging the Canadian government's new regulations aimed at lowering prices of patented drugs that could potentially lead them to lose billions over a decade. The court struck down one part of the new regulation, finding that using certain payments to third parties to determine a drug's regulated price went beyond the government's authority, but upheld the bulk of the rules. |
24493.0 | 2020-06-27 00:00:00 UTC | 3 Top Pharma Stocks to Buy in a Recession | ABBV | https://www.nasdaq.com/articles/3-top-pharma-stocks-to-buy-in-a-recession-2020-06-27 | nan | nan | We've officially been in a recession in the U.S. since February, according to the National Bureau of Economic Research. Some pundits think that the economy will rebound quickly, and many stock traders appear to be in that camp, considering how the equities market has climbed back from its steep February-March plunge over the subsequent three months. Other experts, though, are predicting that it's going to take a lot longer for the economy to recover. They anticipate lingering high unemployment rates and the real possibility that fall will bring new waves of COVID-19 outbreaks across the country.
Regardless of how long this recession lasts, investing in big pharma stocks could be a smart move. Large drugmakers typically have significant financial flexibility to weather economic storms. They sell products that people need regardless of how the economy is performing.
But which pharma stocks are the top picks to own in a recession? Here are three that especially stand out, listed in alphabetical order.
Image source: Getty Images.
1. AbbVie
Arguably the most attractive thing about AbbVie (NYSE: ABBV) is its outstanding dividend, which currently yields close to 4.9%. Including the time that it was part of Abbott Labs, AbbVie claims an impressive track record of 47 consecutive years of dividend increases. That should give investors confidence that the company will prioritize its dividend even during challenging economic periods.
Of course, what makes AbbVie's nice dividends possible is the strong cash flow generated by its top drugs. Humira remains the biggest moneymaker for now. But the immunology drug already faces biosimilar competition in Europe and will in the U.S. beginning in 2023.
AbbVie has several products that it thinks can pick up the slack as Humira's sales fall. Cancer drugs Imbruvica and Venclexta continue to enjoy strong sales momentum. And the company's new immunology drugs, Rinvoq and Skyrizi, appear to be poised to take the baton from Humira.
In addition, AbbVie's recent acquisition of Allergan brought the blockbuster Botox franchise into its lineup, as well as a long list of other drugs. That will significantly reduce its revenue reliance on Humira.
2. Bristol Myers Squibb
Bristol Myers Squibb (NYSE: BMY) is another big pharmaceutical company that has benefited from a key acquisition. Its buyout of Celgene in late 2019 has dramatically transformed its product lineup and pipeline.
Drugs including blood thinner Eliquis and cancer immunotherapy Opdivo were already tremendously successful for Bristol Myers Squibb before it acquired Celgene. Now, three other big blockbusters have been added to its lineup: Revlimid, Pomalyst/Imnovid, and Abraxane. The Celgene deal also brought it several recently approved drugs that should be big winners, including multiple sclerosis drug Zeposia and Reblozyl, which treats anemia in beta-thalassemia and myelodysplastic syndromes.
Bristol Myers Squibb's pipeline is deeper after the Celgene transaction as well. The company hopes to soon win regulatory approvals for CAR-T therapies ide-cel and liso-cel. It has more than 50 late-stage programs, over 30 of which are pursuing additional indications for Opdivo either as a monotherapy or in combination with other drugs.
The pharma company's current product lineup and pipeline should enable it to deliver strong earnings growth over the next few years. Bristol Myers Squibb also offers an attractive dividend that currently yields around 3.1%.
3. Eli Lilly
Eli Lilly (NYSE: LLY) has, perhaps surprisingly, become one of the top stocks to watch in the race to develop treatments for COVID-19. The company is conducting early-stage clinical studies of two antibody therapies. It's evaluating experimental drug LY3127804 in treating COVID-19 patients with pneumonia. And Lilly's rheumatoid arthritis drug Olumiant is in late-stage testing for treating COVID-19.
But Eli Lilly is better known for its drugs targeting other diseases. Diabetes drugs Jardiance and Trulicity continue to rake in billions of dollars each year. It's is a major player in immunology with Olumiant and Taltz. It's also an oncology leader with cancer drugs Cyramza and Verzenio, both of which are likely on the way to generating blockbuster sales.
Verzenio could become Lilly's biggest oncology winner: The company reported overwhelmingly positive results earlier this month from a phase 3 study of the drug as a treatment for early-stage breast cancer. Lilly also recently won FDA approval for Retevmo in treating lung and thyroid cancer. In addition, the company's pipeline includes promising late-stage candidates targeting osteoarthritic pain, atopic dermatitis, and psoriasis.
Wall Street analysts expect Lilly to generate average annual earnings growth of close to 13.5% over the next few years. The drugmaker also pays a dividend that yields north of 1.8%.
Good recession plays
AbbVie, Bristol Myers Squibb, and Eli Lilly aren't totally immune to the effects of a recession. The stocks could sink somewhat with any major market downturn caused by an economic decline. It's also possible that their sales could be impacted if patients lose their jobs and can't afford to pay for their prescription drugs. However, I think that all three stocks will hold up better than most during a recession -- especially a prolonged one.
10 stocks we like better than Bristol Myers Squibb
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Bristol Myers Squibb wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of June 2, 2020
Keith Speights owns shares of AbbVie and Bristol Myers Squibb. The Motley Fool owns shares of and recommends Bristol Myers Squibb. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie Arguably the most attractive thing about AbbVie (NYSE: ABBV) is its outstanding dividend, which currently yields close to 4.9%. Including the time that it was part of Abbott Labs, AbbVie claims an impressive track record of 47 consecutive years of dividend increases. Of course, what makes AbbVie's nice dividends possible is the strong cash flow generated by its top drugs. | Good recession plays AbbVie, Bristol Myers Squibb, and Eli Lilly aren't totally immune to the effects of a recession. AbbVie Arguably the most attractive thing about AbbVie (NYSE: ABBV) is its outstanding dividend, which currently yields close to 4.9%. Including the time that it was part of Abbott Labs, AbbVie claims an impressive track record of 47 consecutive years of dividend increases. | See the 10 stocks *Stock Advisor returns as of June 2, 2020 Keith Speights owns shares of AbbVie and Bristol Myers Squibb. AbbVie Arguably the most attractive thing about AbbVie (NYSE: ABBV) is its outstanding dividend, which currently yields close to 4.9%. Including the time that it was part of Abbott Labs, AbbVie claims an impressive track record of 47 consecutive years of dividend increases. | In addition, AbbVie's recent acquisition of Allergan brought the blockbuster Botox franchise into its lineup, as well as a long list of other drugs. Good recession plays AbbVie, Bristol Myers Squibb, and Eli Lilly aren't totally immune to the effects of a recession. AbbVie Arguably the most attractive thing about AbbVie (NYSE: ABBV) is its outstanding dividend, which currently yields close to 4.9%. |
24494.0 | 2020-06-26 00:00:00 UTC | AbbVie: FDA Issues Complete Response Letter To BLA For Abicipar Pegol | ABBV | https://www.nasdaq.com/articles/abbvie%3A-fda-issues-complete-response-letter-to-bla-for-abicipar-pegol-2020-06-26 | nan | nan | (RTTNews) - Allergan, an AbbVie Company (ABBV), and Molecular Partners announced the FDA has issued a Complete Response Letter to the Biologics License Application for Abicipar pegol, an investigational DARPin therapy for patients with neovascular age-related macular degeneration.
The Response Letter indicates that the rate of intraocular inflammation observed following administration of Abicipar pegol 2mg/0.05 mL results in an unfavorable benefit-risk ratio in the treatment of neovascular (wet) age-related macular degeneration. AbbVie plans to meet with the FDA to discuss the comments and decide next steps.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - Allergan, an AbbVie Company (ABBV), and Molecular Partners announced the FDA has issued a Complete Response Letter to the Biologics License Application for Abicipar pegol, an investigational DARPin therapy for patients with neovascular age-related macular degeneration. AbbVie plans to meet with the FDA to discuss the comments and decide next steps. The Response Letter indicates that the rate of intraocular inflammation observed following administration of Abicipar pegol 2mg/0.05 mL results in an unfavorable benefit-risk ratio in the treatment of neovascular (wet) age-related macular degeneration. | (RTTNews) - Allergan, an AbbVie Company (ABBV), and Molecular Partners announced the FDA has issued a Complete Response Letter to the Biologics License Application for Abicipar pegol, an investigational DARPin therapy for patients with neovascular age-related macular degeneration. AbbVie plans to meet with the FDA to discuss the comments and decide next steps. The Response Letter indicates that the rate of intraocular inflammation observed following administration of Abicipar pegol 2mg/0.05 mL results in an unfavorable benefit-risk ratio in the treatment of neovascular (wet) age-related macular degeneration. | (RTTNews) - Allergan, an AbbVie Company (ABBV), and Molecular Partners announced the FDA has issued a Complete Response Letter to the Biologics License Application for Abicipar pegol, an investigational DARPin therapy for patients with neovascular age-related macular degeneration. AbbVie plans to meet with the FDA to discuss the comments and decide next steps. The Response Letter indicates that the rate of intraocular inflammation observed following administration of Abicipar pegol 2mg/0.05 mL results in an unfavorable benefit-risk ratio in the treatment of neovascular (wet) age-related macular degeneration. | (RTTNews) - Allergan, an AbbVie Company (ABBV), and Molecular Partners announced the FDA has issued a Complete Response Letter to the Biologics License Application for Abicipar pegol, an investigational DARPin therapy for patients with neovascular age-related macular degeneration. AbbVie plans to meet with the FDA to discuss the comments and decide next steps. The Response Letter indicates that the rate of intraocular inflammation observed following administration of Abicipar pegol 2mg/0.05 mL results in an unfavorable benefit-risk ratio in the treatment of neovascular (wet) age-related macular degeneration. |
24495.0 | 2020-06-26 00:00:00 UTC | FDA Rejects AbbVie's Macular Degeneration Drug Abicipar Pegol | ABBV | https://www.nasdaq.com/articles/fda-rejects-abbvies-macular-degeneration-drug-abicipar-pegol-2020-06-26 | nan | nan | One of the potential growth drivers from AbbVie's (NYSE: ABBV) acquisition of Allergan was just shot down by the Food and Drug Administration. The agency issued a complete response letter (the FDA's euphemism for a rejection) for AbbVie's abicipar pegol, which Allergan and Switzerland-based Molecular Partners were developing for wet age-related macular degeneration.
The FDA decided the benefits of abicipar pegol didn't outweigh the side effects. Specifically, the agency is worried about the high number of patients who had inflammation in their eyes. In two phase 3 clinical trials, 15.1% to 15.7% of patients had inflammation in their eyes, compared with 0% to 0.6% of patients treated with Roche's (OTC: RHHBY) Lucentis.
The drugmaker plans to meet with the FDA to discuss the decision. "We are committed to working with the FDA to determine the appropriate next steps for abicipar pegol," Michael Robinson, vice president and global therapeutic area head for ophthalmology at AbbVie, said in a statement.
Image source: Getty Images.
Abicipar pegol certainly has substantial potential, given that Regeneron Pharmaceuticals' (NASDAQ: REGN) Eylea, which treats wet age-related macular degeneration and related eye diseases, generated $4.6 billion in sales last year in the U.S. alone.
At this point, AbbVie's best hope might be to try to get the drug approved for patients with advanced cases of the disease, where the risk of having inflammation would be more justified given that the risk of doing nothing would eventually result in blindness.
Investors appear to be shaking off the news, with shares down just 1% at 1:13 p.m. EDT, less than the decline in the broader markets.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of June 2, 2020
Brian Orelli and The Motley Fool have no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The agency issued a complete response letter (the FDA's euphemism for a rejection) for AbbVie's abicipar pegol, which Allergan and Switzerland-based Molecular Partners were developing for wet age-related macular degeneration. "We are committed to working with the FDA to determine the appropriate next steps for abicipar pegol," Michael Robinson, vice president and global therapeutic area head for ophthalmology at AbbVie, said in a statement. One of the potential growth drivers from AbbVie's (NYSE: ABBV) acquisition of Allergan was just shot down by the Food and Drug Administration. | The agency issued a complete response letter (the FDA's euphemism for a rejection) for AbbVie's abicipar pegol, which Allergan and Switzerland-based Molecular Partners were developing for wet age-related macular degeneration. One of the potential growth drivers from AbbVie's (NYSE: ABBV) acquisition of Allergan was just shot down by the Food and Drug Administration. "We are committed to working with the FDA to determine the appropriate next steps for abicipar pegol," Michael Robinson, vice president and global therapeutic area head for ophthalmology at AbbVie, said in a statement. | The agency issued a complete response letter (the FDA's euphemism for a rejection) for AbbVie's abicipar pegol, which Allergan and Switzerland-based Molecular Partners were developing for wet age-related macular degeneration. 10 stocks we like better than AbbVie When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. One of the potential growth drivers from AbbVie's (NYSE: ABBV) acquisition of Allergan was just shot down by the Food and Drug Administration. | * David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! One of the potential growth drivers from AbbVie's (NYSE: ABBV) acquisition of Allergan was just shot down by the Food and Drug Administration. The agency issued a complete response letter (the FDA's euphemism for a rejection) for AbbVie's abicipar pegol, which Allergan and Switzerland-based Molecular Partners were developing for wet age-related macular degeneration. |
24496.0 | 2020-06-26 00:00:00 UTC | Molecular Partners's AbbVie-partnered eye drug gets FDA safety snub | ABBV | https://www.nasdaq.com/articles/molecular-partnerss-abbvie-partnered-eye-drug-gets-fda-safety-snub-2020-06-26 | nan | nan | ZURICH, June 26 (Reuters) - Swiss drugmaker Molecular Partners MOLN.S has suffered a setback after the U.S. Food and Drug Administration said the company's abicipar product for a blindness-causing eye disease had an unfavorable risk-benefit profile due to inflammation.
Molecular Partners, which with abicipar was aiming for its first commercial product, has partnered on the medicine for macular degeneration with AbbVie ABBV.N unit Allergan, and has been hoping a successful launch would help bring in milestone payments to help fund the Swiss company's other projects.
"AbbVie plans to meet with the FDA to discuss their comments and determine next steps," a statement on Molecular Partners' website said.
(Reporting by John Miller, editing by John Revill)
((J.Miller@thomsonreuters.com; +41 58 306 7734; Reuters Messaging: j.miller.thomsonreuters.com@reuters.net))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Molecular Partners, which with abicipar was aiming for its first commercial product, has partnered on the medicine for macular degeneration with AbbVie ABBV.N unit Allergan, and has been hoping a successful launch would help bring in milestone payments to help fund the Swiss company's other projects. "AbbVie plans to meet with the FDA to discuss their comments and determine next steps," a statement on Molecular Partners' website said. ZURICH, June 26 (Reuters) - Swiss drugmaker Molecular Partners MOLN.S has suffered a setback after the U.S. Food and Drug Administration said the company's abicipar product for a blindness-causing eye disease had an unfavorable risk-benefit profile due to inflammation. | Molecular Partners, which with abicipar was aiming for its first commercial product, has partnered on the medicine for macular degeneration with AbbVie ABBV.N unit Allergan, and has been hoping a successful launch would help bring in milestone payments to help fund the Swiss company's other projects. "AbbVie plans to meet with the FDA to discuss their comments and determine next steps," a statement on Molecular Partners' website said. ZURICH, June 26 (Reuters) - Swiss drugmaker Molecular Partners MOLN.S has suffered a setback after the U.S. Food and Drug Administration said the company's abicipar product for a blindness-causing eye disease had an unfavorable risk-benefit profile due to inflammation. | Molecular Partners, which with abicipar was aiming for its first commercial product, has partnered on the medicine for macular degeneration with AbbVie ABBV.N unit Allergan, and has been hoping a successful launch would help bring in milestone payments to help fund the Swiss company's other projects. "AbbVie plans to meet with the FDA to discuss their comments and determine next steps," a statement on Molecular Partners' website said. ZURICH, June 26 (Reuters) - Swiss drugmaker Molecular Partners MOLN.S has suffered a setback after the U.S. Food and Drug Administration said the company's abicipar product for a blindness-causing eye disease had an unfavorable risk-benefit profile due to inflammation. | Molecular Partners, which with abicipar was aiming for its first commercial product, has partnered on the medicine for macular degeneration with AbbVie ABBV.N unit Allergan, and has been hoping a successful launch would help bring in milestone payments to help fund the Swiss company's other projects. "AbbVie plans to meet with the FDA to discuss their comments and determine next steps," a statement on Molecular Partners' website said. ZURICH, June 26 (Reuters) - Swiss drugmaker Molecular Partners MOLN.S has suffered a setback after the U.S. Food and Drug Administration said the company's abicipar product for a blindness-causing eye disease had an unfavorable risk-benefit profile due to inflammation. |
24497.0 | 2020-06-26 00:00:00 UTC | Molecular Partners hopes for COVID-19 rebound after eye drug failure | ABBV | https://www.nasdaq.com/articles/molecular-partners-hopes-for-covid-19-rebound-after-eye-drug-failure-2020-06-26 | nan | nan | By John Miller
ZURICH, June 26 (Reuters) - Molecular Partners MOLN.S aims to test its COVID-19 drug candidate on people later this year, Chief Executive Patrick Amstutz said on Friday, as the Swiss company hopes that project will help it recover from the failure of its eye drug abicipar.
The U.S. Food and Drug Administration declined to approve the drug for macular degeneration, citing concerns over high rates of inflammation that tarnished its risk-benefit profile.
Molecular Partners signed a deal in 2011 that made it eligible to future payments of up to around $1.5 billion from its partner AbbVie ABBV.N, but only if the drug was a success.
Amstutz, who called the FDA snub of abicipar a "very disappointing moment", said Molecular Partners remains well-financed into the second half of 2021, despite the fact that a big milestone payment now will not come.
Investors took fright, with the company's stock losing 40% by 0715 GMT.
In April, Molecular Partners initiated an COVID-19 program for one of its other drug candidates, and now expects to start human trials in the second half of the year.
Given abicipar's uncertain future -- AbbVie has pledged further talks with U.S. regulators -- the experimental drug against the new coronavirus has emerged as Molecular Partner's best hope for a quick rebound.
"We're now in preclinical trials, and to our knowledge, we have one of the most-potent anti-COVID drugs," Amstutz told reporters and analysts on a call.
He said his company still has options for securing additional financing, including more partnering, and never considered the hoped-for AbbVie payments as part of its long-term planning to keep Molecular Partners afloat.
To cut outflows the Schlieren-based company will reduce investments in two experimental molecules, one drug against multiple myeloma in a Phase 2 trial and another, earlier-stage drug against HER2-positive tumors. It will instead focus on the COVID-19 project as well as an oncology partnership with Amgen AMGN.O, Amstutz said.
(Reporting by John Miller; editing by David Evans)
((J.Miller@thomsonreuters.com; +41 58 306 7734; Reuters Messaging: j.miller.thomsonreuters.com@reuters.net))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Given abicipar's uncertain future -- AbbVie has pledged further talks with U.S. regulators -- the experimental drug against the new coronavirus has emerged as Molecular Partner's best hope for a quick rebound. Molecular Partners signed a deal in 2011 that made it eligible to future payments of up to around $1.5 billion from its partner AbbVie ABBV.N, but only if the drug was a success. He said his company still has options for securing additional financing, including more partnering, and never considered the hoped-for AbbVie payments as part of its long-term planning to keep Molecular Partners afloat. | Given abicipar's uncertain future -- AbbVie has pledged further talks with U.S. regulators -- the experimental drug against the new coronavirus has emerged as Molecular Partner's best hope for a quick rebound. Molecular Partners signed a deal in 2011 that made it eligible to future payments of up to around $1.5 billion from its partner AbbVie ABBV.N, but only if the drug was a success. He said his company still has options for securing additional financing, including more partnering, and never considered the hoped-for AbbVie payments as part of its long-term planning to keep Molecular Partners afloat. | Molecular Partners signed a deal in 2011 that made it eligible to future payments of up to around $1.5 billion from its partner AbbVie ABBV.N, but only if the drug was a success. Given abicipar's uncertain future -- AbbVie has pledged further talks with U.S. regulators -- the experimental drug against the new coronavirus has emerged as Molecular Partner's best hope for a quick rebound. He said his company still has options for securing additional financing, including more partnering, and never considered the hoped-for AbbVie payments as part of its long-term planning to keep Molecular Partners afloat. | Molecular Partners signed a deal in 2011 that made it eligible to future payments of up to around $1.5 billion from its partner AbbVie ABBV.N, but only if the drug was a success. Given abicipar's uncertain future -- AbbVie has pledged further talks with U.S. regulators -- the experimental drug against the new coronavirus has emerged as Molecular Partner's best hope for a quick rebound. He said his company still has options for securing additional financing, including more partnering, and never considered the hoped-for AbbVie payments as part of its long-term planning to keep Molecular Partners afloat. |
24498.0 | 2020-06-26 00:00:00 UTC | IVW, ABBV, CHTR, COST: Large Outflows Detected at ETF | ABBV | https://www.nasdaq.com/articles/ivw-abbv-chtr-cost%3A-large-outflows-detected-at-etf-2020-06-26 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares S&P 500 Growth ETF (Symbol: IVW) where we have detected an approximate $103.3 million dollar outflow -- that's a 0.4% decrease week over week (from 134,650,000 to 134,150,000). Among the largest underlying components of IVW, in trading today AbbVie Inc (Symbol: ABBV) is off about 1.2%, Charter Communications Inc (Symbol: CHTR) is down about 0.8%, and Costco Wholesale Corp (Symbol: COST) is relatively unchanged. For a complete list of holdings, visit the IVW Holdings page » The chart below shows the one year price performance of IVW, versus its 200 day moving average:
Looking at the chart above, IVW's low point in its 52 week range is $140.84 per share, with $211.496 as the 52 week high point — that compares with a last trade of $203.42. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ».
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs experienced notable outflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of IVW, in trading today AbbVie Inc (Symbol: ABBV) is off about 1.2%, Charter Communications Inc (Symbol: CHTR) is down about 0.8%, and Costco Wholesale Corp (Symbol: COST) is relatively unchanged. For a complete list of holdings, visit the IVW Holdings page » The chart below shows the one year price performance of IVW, versus its 200 day moving average: Looking at the chart above, IVW's low point in its 52 week range is $140.84 per share, with $211.496 as the 52 week high point — that compares with a last trade of $203.42. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of IVW, in trading today AbbVie Inc (Symbol: ABBV) is off about 1.2%, Charter Communications Inc (Symbol: CHTR) is down about 0.8%, and Costco Wholesale Corp (Symbol: COST) is relatively unchanged. For a complete list of holdings, visit the IVW Holdings page » The chart below shows the one year price performance of IVW, versus its 200 day moving average: Looking at the chart above, IVW's low point in its 52 week range is $140.84 per share, with $211.496 as the 52 week high point — that compares with a last trade of $203.42. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). | Among the largest underlying components of IVW, in trading today AbbVie Inc (Symbol: ABBV) is off about 1.2%, Charter Communications Inc (Symbol: CHTR) is down about 0.8%, and Costco Wholesale Corp (Symbol: COST) is relatively unchanged. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares S&P 500 Growth ETF (Symbol: IVW) where we have detected an approximate $103.3 million dollar outflow -- that's a 0.4% decrease week over week (from 134,650,000 to 134,150,000). For a complete list of holdings, visit the IVW Holdings page » The chart below shows the one year price performance of IVW, versus its 200 day moving average: Looking at the chart above, IVW's low point in its 52 week range is $140.84 per share, with $211.496 as the 52 week high point — that compares with a last trade of $203.42. | Among the largest underlying components of IVW, in trading today AbbVie Inc (Symbol: ABBV) is off about 1.2%, Charter Communications Inc (Symbol: CHTR) is down about 0.8%, and Costco Wholesale Corp (Symbol: COST) is relatively unchanged. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares S&P 500 Growth ETF (Symbol: IVW) where we have detected an approximate $103.3 million dollar outflow -- that's a 0.4% decrease week over week (from 134,650,000 to 134,150,000). For a complete list of holdings, visit the IVW Holdings page » The chart below shows the one year price performance of IVW, versus its 200 day moving average: Looking at the chart above, IVW's low point in its 52 week range is $140.84 per share, with $211.496 as the 52 week high point — that compares with a last trade of $203.42. |
24499.0 | 2020-06-25 00:00:00 UTC | August 7th Options Now Available For AbbVie (ABBV) | ABBV | https://www.nasdaq.com/articles/august-7th-options-now-available-for-abbvie-abbv-2020-06-25 | nan | nan | Investors in AbbVie Inc (Symbol: ABBV) saw new options begin trading today, for the August 7th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV options chain for the new August 7th contracts and identified one put and one call contract of particular interest.
The put contract at the $91.50 strike price has a current bid of $1.39. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $91.50, but will also collect the premium, putting the cost basis of the shares at $90.11 (before broker commissions). To an investor already interested in purchasing shares of ABBV, that could represent an attractive alternative to paying $95.56/share today.
Because the $91.50 strike represents an approximate 4% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 63%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 1.52% return on the cash commitment, or 12.89% annualized — at Stock Options Channel we call this the YieldBoost.
Below is a chart showing the trailing twelve month trading history for AbbVie Inc, and highlighting in green where the $91.50 strike is located relative to that history:
Turning to the calls side of the option chain, the call contract at the $96.50 strike price has a current bid of $1.13. If an investor was to purchase shares of ABBV stock at the current price level of $95.56/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock at $96.50. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 2.17% if the stock gets called away at the August 7th expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if ABBV shares really soar, which is why looking at the trailing twelve month trading history for AbbVie Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ABBV's trailing twelve month trading history, with the $96.50 strike highlighted in red:
Considering the fact that the $96.50 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 53%. On our website under the contract detail page for this contract, Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 1.18% boost of extra return to the investor, or 10.04% annualized, which we refer to as the YieldBoost.
The implied volatility in the put contract example is 55%, while the implied volatility in the call contract example is 43%.
Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 252 trading day closing values as well as today's price of $95.56) to be 34%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com.
Top YieldBoost Calls of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Of course, a lot of upside could potentially be left on the table if ABBV shares really soar, which is why looking at the trailing twelve month trading history for AbbVie Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ABBV's trailing twelve month trading history, with the $96.50 strike highlighted in red: Considering the fact that the $96.50 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in AbbVie Inc (Symbol: ABBV) saw new options begin trading today, for the August 7th expiration. | Below is a chart showing ABBV's trailing twelve month trading history, with the $96.50 strike highlighted in red: Considering the fact that the $96.50 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in AbbVie Inc (Symbol: ABBV) saw new options begin trading today, for the August 7th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV options chain for the new August 7th contracts and identified one put and one call contract of particular interest. | Below is a chart showing the trailing twelve month trading history for AbbVie Inc, and highlighting in green where the $91.50 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $96.50 strike price has a current bid of $1.13. Below is a chart showing ABBV's trailing twelve month trading history, with the $96.50 strike highlighted in red: Considering the fact that the $96.50 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in AbbVie Inc (Symbol: ABBV) saw new options begin trading today, for the August 7th expiration. | At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV options chain for the new August 7th contracts and identified one put and one call contract of particular interest. Below is a chart showing ABBV's trailing twelve month trading history, with the $96.50 strike highlighted in red: Considering the fact that the $96.50 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in AbbVie Inc (Symbol: ABBV) saw new options begin trading today, for the August 7th expiration. |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.